No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, d3uytA_, 1.0000, 0.00, 1.000, 287, 287, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
2, d4hnfB_, 0.9821, 0.85, 1.000, 290, 287, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
3, d3uzpA_, 0.9816, 0.86, 1.000, 292, 287, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
4, d5w4wA_, 0.9769, 0.89, 1.000, 291, 286, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
5, d5w4wB_, 0.9756, 0.92, 1.000, 291, 286, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
6, d5w4wD_, 0.9749, 0.86, 1.000, 287, 285, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
7, d4kbkB_, 0.9734, 0.81, 1.000, 289, 284, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
8, d4kb8B_, 0.9707, 0.79, 1.000, 285, 283, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
9, d3uysD_, 0.9705, 0.80, 1.000, 284, 283, CRYSTAL STRUCTURE OF APO HUMAN CK1D
10, d5fqdF_, 0.9700, 1.15, 0.767, 294, 287, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
11, d4kbaB_, 0.9696, 0.82, 1.000, 285, 283, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
12, d5fqdC_, 0.9694, 1.16, 0.767, 294, 287, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
13, d4hnfA_, 0.9686, 1.17, 1.000, 289, 287, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
14, d3uysC_, 0.9677, 0.78, 1.000, 286, 282, CRYSTAL STRUCTURE OF APO HUMAN CK1D
15, d4twcB_, 0.9665, 1.14, 0.993, 292, 284, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
16, d5mqvC_, 0.9660, 1.07, 0.996, 288, 285, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
17, d1ckjB_, 0.9658, 1.13, 1.000, 293, 286, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
18, d4kbkA_, 0.9639, 0.79, 1.000, 283, 281, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
19, d1eh4B_, 0.9639, 1.19, 0.573, 293, 286, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
20, d4twcA_, 0.9631, 1.34, 0.990, 293, 286, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
21, d1ckjA_, 0.9627, 1.36, 1.000, 296, 287, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
22, d5x17A_, 0.9603, 1.20, 1.000, 290, 285, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
23, d1eh4A_, 0.9603, 1.25, 0.566, 293, 286, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
24, d4hgtA_, 0.9600, 1.13, 0.996, 283, 283, CRYSTAL STRUCTURE OF CK1D WITH COMPOUND 13
25, d5mqvA_, 0.9596, 1.07, 1.000, 286, 283, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
26, d3sv0A_, 0.9596, 1.34, 0.787, 294, 287, CRYSTAL STRUCTURE OF CASEIN KINASE-1 LIKE PROTEIN IN PLANT
27, d4tn6A_, 0.9595, 1.31, 1.000, 292, 286, CK1D IN COMPLEX WITH INHIBITOR
28, d4kbcA_, 0.9595, 0.99, 1.000, 288, 282, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
29, d5mqvB_, 0.9590, 1.15, 1.000, 287, 284, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
30, d5x17B_, 0.9584, 1.24, 1.000, 289, 285, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
31, d5mqvF_, 0.9582, 1.10, 0.993, 286, 283, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
32, d5w4wC_, 0.9570, 0.88, 1.000, 284, 280, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
33, d4tw9A_, 0.9564, 1.28, 0.989, 290, 283, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
34, d3uysA_, 0.9561, 0.90, 1.000, 281, 280, CRYSTAL STRUCTURE OF APO HUMAN CK1D
35, d4tw9B_, 0.9560, 1.15, 0.989, 289, 281, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
36, d4kbkD_, 0.9551, 0.84, 1.000, 281, 279, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
37, d2izuA_, 0.9547, 1.30, 0.592, 297, 284, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
38, d2csnA_, 0.9544, 1.42, 0.577, 293, 286, BINARY COMPLEX OF CASEIN KINASE-1 WITH CKI7
39, d3uytB_, 0.9533, 1.34, 1.000, 286, 286, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
40, d5mqvD_, 0.9528, 1.31, 1.000, 287, 284, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
41, d3uytC_, 0.9528, 1.11, 1.000, 286, 282, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
42, d4nt4A1, 0.9526, 1.47, 0.582, 299, 285, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF GILGAMESH ISOFORM I FROM DROSOPHILA MELANOGASTER
43, d1csnA_, 0.9526, 1.45, 0.573, 293, 286, BINARY COMPLEX OF CASEIN KINASE-1 WITH MGATP
44, d4g17A1, 0.9522, 1.69, 0.598, 301, 286, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-TERT-BUTYLPHENYL)AMINO]-1H- BENZIMIDAZOLE-6-CARBONITRILE
45, d4hokI_, 0.9518, 1.30, 0.972, 291, 284, CRYSTAL STRUCTURE OF APO CK1E
46, d2iztA_, 0.9516, 1.34, 0.595, 296, 284, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
47, d5mqvE_, 0.9515, 1.33, 1.000, 287, 284, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
48, d4hokM_, 0.9511, 1.54, 0.972, 291, 287, CRYSTAL STRUCTURE OF APO CK1E
49, d2chlA_, 0.9509, 1.52, 0.594, 298, 286, STRUCTURE OF CASEIN KINASE 1 GAMMA 3
50, d4hgsA1, 0.9507, 1.71, 0.598, 301, 286, CRYSTAL STRUCTURE OF CK1GS WITH COMPOUND 13
51, d4tn6B_, 0.9506, 1.44, 0.979, 285, 282, CK1D IN COMPLEX WITH INHIBITOR
52, d3uysB_, 0.9504, 0.87, 1.000, 279, 278, CRYSTAL STRUCTURE OF APO HUMAN CK1D
53, d5ih5A_, 0.9502, 1.05, 1.000, 286, 280, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A
54, d4hglA1, 0.9501, 1.72, 0.598, 301, 286, CRYSTAL STRUCTURE OF CK1G3 WITH COMPOUND 1
55, d4g16A1, 0.9496, 1.74, 0.594, 301, 286, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-{[3-(TRIFLUOROMETHYL)PYRIDIN2- YL]OXY}PHENYL)AMINO]-1H-BENZIMIDAZOLE-6-CARBONITRILE
56, d5ih4A_, 0.9491, 1.08, 1.000, 286, 280, HUMAN CASEIN KINASE 1 ISOFORM DELTA APO (KINASE DOMAIN)
57, d5ih6A_, 0.9488, 1.09, 1.000, 286, 280, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A DERIVATIVE
58, d5x18A_, 0.9487, 1.58, 0.538, 294, 286, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
59, d4hokO_, 0.9480, 1.30, 0.972, 290, 283, CRYSTAL STRUCTURE OF APO CK1E
60, d4hokU_, 0.9476, 1.22, 0.972, 289, 282, CRYSTAL STRUCTURE OF APO CK1E
61, d2izrA_, 0.9471, 1.71, 0.593, 298, 285, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
62, d4jjrA_, 0.9468, 0.87, 0.996, 284, 277, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
63, d4hokE_, 0.9468, 1.42, 0.972, 291, 284, CRYSTAL STRUCTURE OF APO CK1E
64, d4kbkC_, 0.9467, 0.79, 1.000, 280, 276, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
65, d1ckiA_, 0.9466, 1.16, 1.000, 292, 280, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
66, d2izsA_, 0.9459, 1.80, 0.591, 298, 286, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
67, d4hokW_, 0.9455, 1.36, 0.972, 289, 283, CRYSTAL STRUCTURE OF APO CK1E
68, d4hokS_, 0.9450, 1.29, 0.972, 286, 282, CRYSTAL STRUCTURE OF APO CK1E
69, d2c47D1, 0.9444, 1.16, 0.584, 289, 279, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
70, d4hniA_, 0.9435, 1.33, 0.972, 284, 282, CRYSTAL STRUCTURE OF CK1E IN COMPLEX WITH PF4800567
71, d1ckiB_, 0.9434, 1.11, 1.000, 286, 279, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
72, d4hokA_, 0.9427, 1.40, 0.972, 290, 283, CRYSTAL STRUCTURE OF APO CK1E
73, d2c47B_, 0.9422, 1.24, 0.581, 289, 279, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
74, d4hokQ_, 0.9411, 1.43, 0.972, 290, 283, CRYSTAL STRUCTURE OF APO CK1E
75, d4hokK_, 0.9410, 1.45, 0.972, 290, 283, CRYSTAL STRUCTURE OF APO CK1E
76, d4hokG_, 0.9408, 1.43, 0.972, 290, 283, CRYSTAL STRUCTURE OF APO CK1E
77, d4kb8D_, 0.9404, 1.06, 0.993, 278, 276, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
78, d4kb8C_, 0.9396, 0.80, 1.000, 277, 274, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
79, d3uzpB_, 0.9395, 1.44, 0.996, 284, 282, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
80, d4hokC_, 0.9391, 1.45, 0.972, 289, 283, CRYSTAL STRUCTURE OF APO CK1E
81, d2c47A_, 0.9391, 1.23, 0.579, 288, 278, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
82, d4kbaC_, 0.9379, 0.84, 1.000, 277, 274, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
83, d5x18B_, 0.9355, 1.81, 0.542, 294, 286, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
84, d4hniB_, 0.9347, 1.37, 0.968, 284, 280, CRYSTAL STRUCTURE OF CK1E IN COMPLEX WITH PF4800567
85, d4jjrB_, 0.9325, 1.12, 0.993, 283, 276, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
86, d4kbaD_, 0.9316, 0.83, 1.000, 274, 272, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
87, d4hgtB_, 0.9309, 1.28, 0.971, 280, 277, CRYSTAL STRUCTURE OF CK1D WITH COMPOUND 13
88, d2cmwA_, 0.9306, 1.59, 0.568, 294, 280, STRUCTURE OF HUMAN CASEIN KINASE 1 GAMMA-1 IN COMPLEX WITH 2-(2-HYDROXYETHYLAMINO)-6-(3-CHLOROANILINO)-9- ISOPROPYLPURINE (CASP TARGET)
89, d4kbcB_, 0.9298, 1.60, 0.978, 277, 276, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
90, d2c47C_, 0.9295, 1.21, 0.578, 282, 275, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
91, d4nfmA_, 0.9161, 1.80, 0.375, 293, 280, HUMAN TAU TUBULIN KINASE 1 (TTBK1)
92, d4nfnA_, 0.9099, 1.90, 0.375, 293, 280, HUMAN TAU TUBULIN KINASE 1 (TTBK1) COMPLEXED WITH 3-({5-[(4-AMINO-4- METHYLPIPERIDIN-1-YL)METHYL]PYRROLO[21-F][124]TRIAZIN-4-YL}AMINO)- 5-BROMOPHENOL
93, d4btjA_, 0.9089, 1.73, 0.378, 292, 278, TTBK1 IN COMPLEX WITH ATP
94, d4btmA_, 0.9088, 1.74, 0.378, 292, 278, TTBK1 IN COMPLEX WITH INHIBITOR
95, d4btmB_, 0.9078, 1.80, 0.384, 293, 279, TTBK1 IN COMPLEX WITH INHIBITOR
96, d4btjB_, 0.9074, 1.82, 0.380, 293, 279, TTBK1 IN COMPLEX WITH ATP
97, d4btkA_, 0.9057, 1.53, 0.376, 287, 274, TTBK1 IN COMPLEX WITH INHIBITOR
98, d3uytD_, 0.8985, 0.97, 1.000, 268, 264, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
99, d4kb8A_, 0.8933, 0.74, 1.000, 265, 260, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
100, d4kbaA_, 0.8851, 0.78, 1.000, 263, 258, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
101, d6bu6B_, 0.8603, 2.09, 0.293, 307, 270, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
102, d6bu6D_, 0.8600, 2.18, 0.290, 318, 272, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
103, d6bp0B_, 0.8578, 2.01, 0.295, 304, 268, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
104, d5ukfA_, 0.8573, 2.28, 0.289, 322, 273, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
105, d6bu6A_, 0.8572, 2.28, 0.289, 322, 273, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
106, d6bruA_, 0.8565, 2.37, 0.292, 322, 274, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
107, d3op5A_, 0.8556, 2.31, 0.286, 320, 273, HUMAN VACCINIA-RELATED KINASE 1
108, d5uvfC_, 0.8531, 2.02, 0.303, 301, 267, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
109, d3op5B_, 0.8514, 2.25, 0.277, 319, 271, HUMAN VACCINIA-RELATED KINASE 1
110, d6bruD_, 0.8511, 2.21, 0.297, 311, 269, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
111, d6bp0D_, 0.8506, 2.24, 0.297, 311, 269, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
112, d3op5C_, 0.8502, 2.08, 0.292, 308, 267, HUMAN VACCINIA-RELATED KINASE 1
113, d6bruB_, 0.8501, 2.00, 0.297, 301, 266, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
114, d6btwB_, 0.8477, 2.04, 0.297, 301, 266, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
115, d5ukfC_, 0.8471, 2.23, 0.279, 317, 269, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
116, d3op5D_, 0.8469, 2.04, 0.297, 302, 266, HUMAN VACCINIA-RELATED KINASE 1
117, d6btwD_, 0.8461, 2.20, 0.300, 307, 267, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
118, d5uvfA_, 0.8454, 2.32, 0.293, 317, 270, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
119, d6bp0A_, 0.8452, 2.31, 0.293, 317, 270, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
120, d6btwA_, 0.8449, 2.31, 0.293, 317, 270, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
121, d5uvfB_, 0.8438, 2.22, 0.280, 316, 268, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
122, d6bruC_, 0.8408, 2.22, 0.281, 315, 267, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
123, d6bu6C_, 0.8404, 2.23, 0.281, 315, 267, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
124, d6bp0C_, 0.8396, 2.28, 0.287, 315, 268, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
125, d5uvfD_, 0.8391, 2.09, 0.299, 296, 264, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
126, d6btwC_, 0.8384, 2.31, 0.287, 315, 268, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
127, d4bcpA1, 0.8023, 2.56, 0.193, 297, 259, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
128, d3thbA_, 0.8022, 2.74, 0.183, 287, 263, STRUCTURE OF PLK1 KINASE DOMAIN IN COMPLEX WITH A BENZOLACTAM-DERIVED INHIBITOR
129, d4bcoA1, 0.8020, 2.56, 0.193, 297, 259, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
130, d4w8eA_, 0.8013, 2.70, 0.218, 290, 262, STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF-06645342)
131, d4a4lA_, 0.8010, 2.75, 0.183, 290, 263, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 5-(2-AMINO-PYRIMIDIN-4-YL)-1H-PYRROLE INHIBITOR
132, d4eonA1, 0.8002, 2.55, 0.189, 297, 259, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
133, d4a4oA_, 0.8002, 2.77, 0.183, 290, 263, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 2- (2-AMINO-PYRIMIDIN-4-YL)-1567-TETRAHYDRO-PYRROLOPYRIDIN- 4-ONE INHIBITOR
134, d1oiyC1, 0.8001, 2.45, 0.191, 295, 257, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
135, d4eosC1, 0.7997, 2.47, 0.187, 295, 257, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
136, d4eonC1, 0.7995, 2.53, 0.186, 296, 258, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
137, d2iw8A1, 0.7995, 2.52, 0.182, 296, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
138, d5cyiC1, 0.7994, 2.47, 0.191, 295, 257, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
139, d2yacA_, 0.7994, 2.76, 0.183, 290, 263, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH NMS-P937
140, d2g9xA2, 0.7994, 2.60, 0.193, 297, 259, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
141, d4ogrI_, 0.7991, 2.91, 0.184, 318, 266, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
142, d4eoiC1, 0.7989, 2.47, 0.191, 295, 257, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
143, d5lmkA1, 0.7987, 2.61, 0.193, 295, 259, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
144, d4eorA1, 0.7987, 2.53, 0.190, 292, 258, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
145, d3dogA1, 0.7987, 2.61, 0.189, 296, 259, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
146, d5cyiA1, 0.7986, 2.54, 0.190, 297, 258, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
147, d1h1sC1, 0.7986, 2.48, 0.191, 295, 257, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
148, d3kb7A_, 0.7985, 2.78, 0.183, 289, 263, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
149, d4u8zA_, 0.7982, 2.70, 0.206, 289, 262, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06447475)
150, d4eolC1, 0.7981, 2.53, 0.190, 296, 258, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
151, d2owbA_, 0.7981, 2.73, 0.183, 294, 262, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
152, d4imyE_, 0.7980, 2.76, 0.186, 313, 263, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
153, d4eolA1, 0.7980, 2.55, 0.190, 293, 258, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
154, d3fc2A_, 0.7979, 2.78, 0.183, 293, 263, PLK1 IN COMPLEX WITH BI6727
155, d5nevA1, 0.7978, 2.44, 0.191, 294, 256, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
156, d4eokC1, 0.7978, 2.54, 0.198, 296, 258, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
157, d4j53A_, 0.7977, 2.79, 0.183, 293, 263, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH TAK-960
158, d1oiuA1, 0.7976, 2.54, 0.190, 293, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
159, d3ddqA1, 0.7975, 2.64, 0.189, 295, 259, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
160, d2iw9A2, 0.7975, 2.54, 0.190, 292, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
161, d2biyA_, 0.7975, 2.72, 0.193, 287, 259, STRUCTURE OF PDK1-S241A MUTANT KINASE DOMAIN
162, d4eokA1, 0.7974, 2.56, 0.190, 292, 258, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
163, d1h1qC1, 0.7974, 2.50, 0.191, 295, 257, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
164, d1oguA1, 0.7971, 2.55, 0.190, 293, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
165, d4eopC1, 0.7970, 2.50, 0.191, 295, 257, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
166, d3miaA_, 0.7970, 3.05, 0.184, 324, 267, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH ATP-BOUND HUMAN P-TEFB
167, d1h1sA1, 0.7970, 2.49, 0.191, 295, 257, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
168, d4w8dA_, 0.7969, 2.73, 0.206, 289, 262, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06454589).
169, d4qmqA_, 0.7969, 2.63, 0.212, 289, 260, MST3 IN COMPLEX WITH CP-673451
170, d4qmmA_, 0.7968, 2.70, 0.211, 288, 261, MST3 IN COMPLEX WITH AT-9283 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]- 1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
171, d4cfmA1, 0.7968, 2.50, 0.191, 295, 257, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
172, d2rkuA_, 0.7968, 2.79, 0.183, 294, 263, STRUCTURE OF PLK1 IN COMPLEX WITH BI2536
173, d4j52A_, 0.7967, 2.79, 0.183, 293, 263, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A PYRIMIDODIAZEPINONE INHIBITOR
174, d3ddpA1, 0.7967, 2.57, 0.186, 296, 258, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
175, d2g9xC2, 0.7967, 2.67, 0.193, 273, 259, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
176, d5nevC1, 0.7966, 2.50, 0.195, 295, 257, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
177, d4or5F_, 0.7966, 3.08, 0.180, 324, 267, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
178, d1oi9A1, 0.7966, 2.50, 0.191, 294, 257, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
179, d5ta6A_, 0.7965, 2.80, 0.183, 294, 263, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR.
180, d3bhuA1, 0.7963, 2.65, 0.189, 295, 259, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
181, d3mi9A_, 0.7962, 3.13, 0.179, 328, 268, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB
182, d3ddpC1, 0.7961, 2.63, 0.189, 297, 259, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
183, d1h1qA1, 0.7961, 2.51, 0.191, 295, 257, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
184, d4eopA1, 0.7960, 2.56, 0.190, 294, 258, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
185, d2uzlC_, 0.7960, 2.51, 0.191, 295, 257, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
186, d2cchC2, 0.7958, 2.53, 0.187, 295, 257, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
187, d2c6tA_, 0.7958, 2.53, 0.191, 295, 257, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
188, d1oiyA1, 0.7958, 2.51, 0.191, 292, 257, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
189, d4ogrA_, 0.7957, 3.03, 0.190, 314, 269, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
190, d4cfwC1, 0.7957, 2.52, 0.191, 295, 257, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
191, d1oi9C1, 0.7957, 2.50, 0.191, 295, 257, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
192, d4rqvA_, 0.7956, 2.73, 0.189, 288, 259, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS2
193, d4b6lA_, 0.7955, 2.78, 0.214, 281, 262, DISCOVERY OF ORAL POLO-LIKE KINASE (PLK) INHIBITORS WITH ENHANCED SELECTIVITY PROFILE USING RESIDUE TARGETED DRUG DESIGN
194, d1h1rA1, 0.7955, 2.54, 0.191, 295, 257, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
195, d2uzlA_, 0.7954, 2.52, 0.191, 295, 257, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
196, d2hy81_, 0.7954, 2.87, 0.217, 293, 263, PAK1 COMPLEX WITH ST2001
197, d5lvlA_, 0.7953, 2.71, 0.189, 285, 259, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND PS653 BOUND TO THE ATP-BINDING SITE
198, d3bhtA2, 0.7953, 2.66, 0.189, 295, 259, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
199, d4cfnA1, 0.7952, 2.57, 0.190, 293, 258, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
200, d1fvvA_, 0.7952, 2.67, 0.193, 298, 259, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
201, d3a7iA_, 0.7951, 2.76, 0.210, 286, 262, HUMAN MST3 KINASE IN COMPLEX WITH ADENINE
202, d2uzeA_, 0.7951, 2.52, 0.191, 295, 257, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
203, d2iw6C2, 0.7951, 2.49, 0.187, 294, 256, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
204, d4qmyA_, 0.7950, 2.77, 0.210, 287, 262, MST3 IN COMPLEX WITH STAUROSPORINE
205, d4qmxA_, 0.7950, 2.76, 0.210, 287, 262, MST3 IN COMPLEX WITH SARACATINIB
206, d3qhrC1, 0.7950, 2.53, 0.191, 295, 257, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
207, d3qhrA1, 0.7950, 2.53, 0.191, 295, 257, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
208, d4xx9A_, 0.7949, 2.74, 0.189, 288, 259, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RF4
209, d4bcoC1, 0.7949, 2.54, 0.191, 268, 257, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
210, d2uzdA_, 0.7949, 2.54, 0.187, 295, 257, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
211, d3qhwC1, 0.7948, 2.53, 0.187, 295, 257, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
212, d4eoiA1, 0.7947, 2.58, 0.190, 293, 258, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
213, d4qmoA_, 0.7946, 2.75, 0.206, 288, 262, MST3 IN COMPLEX WITH IMIDAZOLO-OXINDOLE PKR INHIBITOR C16
214, d3qhwA1, 0.7946, 2.53, 0.187, 295, 257, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
215, d4qmvA_, 0.7945, 2.66, 0.212, 288, 260, MST3 IN COMPLEX WITH PF-03814735 N-{2-[(1S4R)-6-{[4- (CYCLOBUTYLAMINO)-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL]AMINO}-1234- TETRAHYDRO-14-EPIMINONAPHTHALEN-9-YL]-2-OXOETHYL}ACETAMIDE
216, d1oguC1, 0.7944, 2.55, 0.191, 269, 257, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
217, d4qmzA_, 0.7943, 2.77, 0.210, 286, 262, MST3 IN COMPLEX WITH SUNITINIB
218, d4eosA1, 0.7943, 2.58, 0.186, 293, 258, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
219, d4ct2A_, 0.7943, 2.73, 0.197, 277, 259, HUMAN PDK1-PKCZETA KINASE CHIMERA
220, d2iw6A1, 0.7942, 2.49, 0.191, 291, 256, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
221, d2cchA2, 0.7942, 2.55, 0.191, 295, 257, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
222, d1h1rC1, 0.7942, 2.55, 0.191, 295, 257, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
223, d4nw6A1, 0.7941, 2.72, 0.178, 296, 259, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 27
224, d4qmpA_, 0.7940, 2.73, 0.211, 289, 261, MST3 IN COMPLEX WITH CDK1/2 INHIBITOR III 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
225, d4nw5A1, 0.7940, 2.71, 0.178, 296, 259, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 8
226, d4eooC1, 0.7940, 2.55, 0.191, 295, 257, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
227, d2uzeC_, 0.7940, 2.54, 0.191, 295, 257, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
228, d4ct1A_, 0.7938, 2.73, 0.197, 283, 259, HUMAN PDK1-PKCZETA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS315 BOUND TO THE PIF-POCKET
229, d3rcjA_, 0.7937, 2.69, 0.190, 281, 258, RAPID PREPARATION OF TRIAZOLYL SUBSTITUTED NH-HETEROCYCLIC KINASE INHIBITORS VIA ONE-POT SONOGASHIRA COUPLING TMS-DEPROTECTION CUAAC SEQUENCE
230, d3my5A1, 0.7937, 2.68, 0.193, 294, 259, CDK2/CYCLINA IN COMPLEX WITH DRB
231, d5mrdA_, 0.7936, 2.73, 0.193, 283, 259, HUMAN PDK1-PKCIOTA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS267 BOUND TO THE PIF-POCKET
232, d4rqkA_, 0.7936, 2.76, 0.189, 285, 259, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS1
233, d4qmuA_, 0.7936, 2.78, 0.210, 286, 262, MST3 IN COMPLEX WITH JNJ-7706621 4-({5-AMINO-1-[(26-DIFLUOROPHENYL) CARBONYL]-1H-124-TRIAZOL-3-YL}AMINO)BENZENESULFONAMIDE
234, d4cfvA1, 0.7935, 2.69, 0.193, 297, 259, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
235, d3orxC_, 0.7935, 2.68, 0.198, 283, 258, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
236, d3bhvA1, 0.7935, 2.68, 0.193, 295, 259, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
237, d2c5oA_, 0.7935, 2.61, 0.190, 296, 258, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
238, d4qnaA_, 0.7934, 2.79, 0.210, 284, 262, MST3 IN COMPLEX WITH 2-(46-DIAMINO-135-TRIAZIN-2-YL)PHENOL
239, d4or5A_, 0.7934, 3.15, 0.180, 319, 267, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
240, d3orxD_, 0.7934, 2.69, 0.198, 282, 258, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
241, d1p5eA1, 0.7934, 2.55, 0.191, 295, 257, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
242, d4fx3C_, 0.7933, 2.69, 0.193, 298, 259, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
243, d1pkdA1, 0.7933, 2.56, 0.191, 295, 257, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
244, d1gy3A_, 0.7933, 2.55, 0.191, 295, 257, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
245, d5lvnA_, 0.7932, 2.76, 0.189, 283, 259, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENOSINE BOUND TO THE ATP- BINDING SITE
246, d4eojA1, 0.7932, 2.68, 0.197, 293, 259, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
247, d3orxA_, 0.7932, 2.69, 0.198, 283, 258, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
248, d4bcnA1, 0.7931, 2.62, 0.190, 295, 258, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
249, d2wmbA1, 0.7931, 2.56, 0.187, 295, 257, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
250, d3hrfA_, 0.7930, 2.76, 0.189, 284, 259, CRYSTAL STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN ALLOSTERIC ACTIVATOR BOUND TO THE PIF-POCKET
251, d3d5uA_, 0.7930, 2.79, 0.198, 288, 262, CRYSTAL STRUCTURE OF A WILDTYPE POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN.
252, d1h26A1, 0.7930, 2.55, 0.191, 295, 257, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
253, d5lvmA_, 0.7929, 2.73, 0.189, 283, 259, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENINE BOUND TO THE ATP- BINDING SITE
254, d3iw4C_, 0.7929, 2.74, 0.177, 332, 260, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
255, d2ou7A_, 0.7929, 2.80, 0.183, 292, 262, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
256, d4imyA_, 0.7928, 3.15, 0.184, 314, 266, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
257, d5ta8A_, 0.7927, 2.84, 0.183, 294, 263, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR
258, d4qmwA_, 0.7927, 2.79, 0.202, 286, 262, MST3 IN COMPLEX WITH PP-121 1-CYCLOPENTYL-3-(1H-PYRROLO[23- B]PYRIDIN-5-YL)-1H-PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
259, d4cfuA1, 0.7927, 2.70, 0.193, 295, 259, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
260, d3d5wA_, 0.7927, 2.70, 0.208, 284, 260, CRYSTAL STRUCTURE OF A PHOSPHORYLATED POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH ADP.
261, d3bhuC1, 0.7927, 2.57, 0.191, 269, 257, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
262, d3a8xA1, 0.7927, 2.76, 0.165, 331, 260, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
263, d2wevA_, 0.7927, 2.61, 0.190, 296, 258, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
264, d2bkzC2, 0.7927, 2.69, 0.193, 297, 259, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
265, d4bcmA1, 0.7926, 2.56, 0.191, 292, 257, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
266, d2xikA_, 0.7926, 2.77, 0.218, 288, 262, STRUCTURE OF HUMAN YSK1 (YEAST SPS1-STE20-RELATED KINASE 1)
267, d2c5pA_, 0.7926, 2.61, 0.186, 296, 258,  
268, d2bkzA2, 0.7926, 2.69, 0.193, 298, 259, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
269, d2whaA_, 0.7925, 2.62, 0.190, 296, 258,  
270, d1gy3C_, 0.7925, 2.57, 0.191, 295, 257, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
271, d1h1pA1, 0.7924, 2.58, 0.195, 295, 257, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
272, d5ackA_, 0.7923, 2.73, 0.189, 286, 259, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND 7 BOUND TO THE PIF-POCKET
273, d3a8xB1, 0.7923, 2.72, 0.166, 325, 259, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
274, d2x1nA_, 0.7923, 2.62, 0.190, 296, 258, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
275, d5lvoA_, 0.7921, 2.73, 0.189, 285, 259, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PSE10 BOUND TO THE PIF-POCKET
276, d5if1A_, 0.7921, 2.71, 0.193, 298, 259, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
277, d4eoqA1, 0.7921, 2.61, 0.190, 293, 258, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
278, d4eomA1, 0.7921, 2.62, 0.190, 294, 258, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
279, d1jstC_, 0.7921, 2.64, 0.190, 297, 258, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
280, d4a06A_, 0.7920, 2.74, 0.190, 282, 258, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS114 BOUND TO THE PIF-POCKET
281, d2v22A_, 0.7919, 2.62, 0.194, 296, 258, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
282, d4qmsA_, 0.7917, 2.80, 0.206, 283, 262, MST3 IN COMPLEX WITH DASATINIB
283, d4bcgA_, 0.7917, 2.93, 0.186, 312, 263, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
284, d2wxvA1, 0.7917, 2.73, 0.193, 298, 259, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
285, d2uueA_, 0.7917, 2.62, 0.190, 296, 258, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
286, d1vywA1, 0.7917, 2.71, 0.193, 298, 259, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
287, d4eomC1, 0.7916, 2.59, 0.191, 271, 257, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
288, d1q8zB_, 0.7916, 2.89, 0.219, 364, 260, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
289, d4bckA1, 0.7915, 2.63, 0.190, 296, 258, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
290, d2whbA_, 0.7915, 2.63, 0.194, 296, 258, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
291, d2c5tA_, 0.7915, 2.63, 0.190, 296, 258,  
292, d1h27A1, 0.7915, 2.56, 0.191, 295, 257, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
293, d2uzbA_, 0.7914, 2.57, 0.198, 295, 257, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
294, d1urcA_, 0.7914, 2.63, 0.186, 296, 258, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
295, d4i6hA_, 0.7913, 2.87, 0.163, 285, 263, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE ALPHA-SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
296, d4cfwA1, 0.7913, 2.65, 0.190, 297, 258, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
297, d1h1pC1, 0.7913, 2.59, 0.195, 295, 257, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
298, d2wxvC1, 0.7912, 2.71, 0.193, 298, 259, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
299, d4eooA1, 0.7910, 2.63, 0.190, 292, 258, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
300, d2c4gC2, 0.7910, 2.73, 0.193, 298, 259, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
301, d2c5oC_, 0.7909, 2.64, 0.190, 296, 258, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
302, d1okuC_, 0.7909, 2.65, 0.190, 296, 258,  
303, d3iw4B_, 0.7908, 2.71, 0.178, 325, 259, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
304, d2x1nC_, 0.7908, 2.64, 0.190, 296, 258, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
305, d2c5vC_, 0.7908, 2.65, 0.190, 296, 258, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
306, d2c5vA_, 0.7908, 2.64, 0.190, 296, 258, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
307, d4fx3A_, 0.7907, 2.75, 0.189, 298, 259, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
308, d2whaC_, 0.7907, 2.65, 0.190, 296, 258,  
309, d3my1A_, 0.7906, 2.94, 0.183, 314, 263, STRUCTURE OF CDK9/CYCLINT1 IN COMPLEX WITH DRB
310, d2c5xA_, 0.7906, 2.63, 0.186, 296, 258, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
311, d1urcC_, 0.7906, 2.65, 0.190, 296, 258, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
312, d1h28C1, 0.7906, 2.61, 0.191, 295, 257, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
313, d4i5pA_, 0.7905, 2.77, 0.172, 284, 261, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
314, d3zh8A_, 0.7905, 2.99, 0.170, 318, 264, A NOVEL SMALL MOLECULE APKC INHIBITOR
315, d2c5nA_, 0.7905, 2.64, 0.190, 296, 258, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
316, d1okuA_, 0.7905, 2.64, 0.190, 296, 258,  
317, d1e9hC1, 0.7905, 2.58, 0.191, 295, 257, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
318, d4ii5A_, 0.7904, 2.61, 0.191, 295, 257, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
319, d3orxB_, 0.7904, 2.68, 0.195, 280, 257, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
320, d3iw4A_, 0.7904, 2.77, 0.177, 330, 260, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
321, d4ii5C_, 0.7903, 2.61, 0.191, 295, 257, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
322, d3tnwA1, 0.7903, 2.66, 0.190, 294, 258, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
323, d3bhtC1, 0.7903, 2.54, 0.187, 269, 256, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
324, d1finA_, 0.7903, 2.74, 0.193, 298, 259, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
325, d3zh8B_, 0.7902, 3.00, 0.174, 317, 264, A NOVEL SMALL MOLECULE APKC INHIBITOR
326, d3ckxA_, 0.7902, 2.79, 0.206, 276, 262, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24) IN COMPLEX WITH STAUROSPORINE
327, d4i3zA_, 0.7901, 2.62, 0.191, 295, 257, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
328, d2uzbC_, 0.7901, 2.60, 0.198, 292, 257, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
329, d2cciA2, 0.7901, 2.58, 0.191, 295, 257, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
330, d2c6tC_, 0.7901, 2.59, 0.195, 295, 257, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
331, d2bpmA2, 0.7901, 2.73, 0.193, 298, 259, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
332, d4qmtA_, 0.7900, 2.82, 0.210, 284, 262, MST3 IN COMPLEX WITH HESPERADIN
333, d4eoqC1, 0.7900, 2.60, 0.191, 271, 257, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
334, d4eojC1, 0.7900, 2.59, 0.195, 278, 257, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
335, d4qmnA_, 0.7899, 2.84, 0.214, 283, 262, MST3 IN COMPLEX WITH BOSUTINIB
336, d2wpaA1, 0.7899, 2.75, 0.189, 298, 259, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
337, d2wmaA1, 0.7899, 2.61, 0.187, 295, 257, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
338, d1ol1C_, 0.7899, 2.67, 0.194, 296, 258, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
339, d4i3zC_, 0.7898, 2.63, 0.191, 295, 257, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
340, d1qmzC1, 0.7897, 2.60, 0.191, 295, 257, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
341, d2whbC_, 0.7896, 2.65, 0.194, 296, 258, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
342, d1ol1A_, 0.7896, 2.64, 0.186, 296, 258, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
343, d4i6fA_, 0.7895, 2.84, 0.164, 285, 262, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
344, d1qmzA1, 0.7894, 2.60, 0.191, 295, 257, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
345, d4i6bA_, 0.7893, 2.79, 0.172, 285, 261, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
346, d1ol2A_, 0.7892, 2.66, 0.194, 296, 258, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
347, d1e9hA_, 0.7892, 2.61, 0.191, 295, 257, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
348, d4bcnC1, 0.7891, 2.53, 0.188, 293, 255, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
349, d1vywC1, 0.7891, 2.74, 0.193, 298, 259, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
350, d4imyC_, 0.7890, 2.93, 0.179, 310, 262, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
351, d2jedA_, 0.7890, 2.81, 0.205, 324, 259, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
352, d1q99B_, 0.7890, 2.91, 0.219, 364, 260, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
353, d2wpaC1, 0.7889, 2.74, 0.193, 298, 259, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
354, d2wihA1, 0.7889, 2.76, 0.193, 298, 259, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
355, d2jd5B_, 0.7889, 2.91, 0.219, 360, 260, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
356, d1uv5A_, 0.7888, 3.00, 0.192, 348, 261, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 6-BROMOINDIRUBIN-3 -OXIME
357, d3f5xA_, 0.7887, 2.75, 0.193, 297, 259, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
358, d1p5eC1, 0.7887, 2.61, 0.191, 295, 257, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
359, d6aywB_, 0.7886, 2.90, 0.196, 293, 260, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
360, d5if1C_, 0.7886, 2.65, 0.194, 296, 258, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
361, d4a07A_, 0.7886, 2.74, 0.190, 282, 258, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS171 BOUND TO THE PIF-POCKET
362, d2cciC2, 0.7886, 2.63, 0.187, 295, 257, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
363, d4cfnC1, 0.7885, 2.52, 0.188, 293, 255, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
364, d4aw0A_, 0.7885, 2.75, 0.194, 283, 258, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS182 BOUND TO THE PIF-POCKET
365, d3rwqA_, 0.7885, 2.65, 0.196, 283, 255, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
366, d3bhvC1, 0.7885, 2.63, 0.191, 269, 257, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
367, d3f5xC_, 0.7884, 2.75, 0.193, 298, 259, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
368, d1fvvC_, 0.7884, 2.75, 0.193, 298, 259, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
369, d2wmbC1, 0.7883, 2.54, 0.192, 265, 255, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
370, d2c4gA2, 0.7883, 2.78, 0.193, 297, 259, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
371, d1pkdC1, 0.7883, 2.63, 0.191, 295, 257, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
372, d1h28A1, 0.7883, 2.61, 0.191, 295, 257, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
373, d4cfuC1, 0.7882, 2.62, 0.191, 269, 257, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
374, d1okwA_, 0.7882, 2.66, 0.190, 296, 258, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
375, d1h1wA_, 0.7882, 2.66, 0.192, 284, 255, HIGH RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PDK1 CATALYTIC DOMAIN
376, d3lq5A_, 0.7881, 2.65, 0.163, 307, 258, STRUCTURE OF CDK9/CYCLINT IN COMPLEX WITH S-CR8
377, d2v22C_, 0.7881, 2.68, 0.190, 296, 258, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
378, d5veeA_, 0.7880, 2.85, 0.184, 289, 261, PAK4 KINASE DOMAIN IN COMPLEX WITH FRAX486
379, d3a7jA_, 0.7879, 2.84, 0.210, 286, 262, HUMAN MST3 KINASE IN COMPLEX WITH MNADP
380, d2jedB1, 0.7879, 2.79, 0.201, 315, 259, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
381, d2uueC_, 0.7878, 2.69, 0.190, 296, 258, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
382, d2c5pC_, 0.7878, 2.69, 0.190, 296, 258,  
383, d4bchA_, 0.7877, 2.75, 0.193, 308, 259, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
384, d3eidA_, 0.7877, 2.68, 0.195, 292, 257, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
385, d4bcmC1, 0.7876, 2.55, 0.188, 293, 255, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
386, d1zrzA_, 0.7876, 2.78, 0.163, 310, 258, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF ATYPICAL PROTEIN KINASE C-IOTA
387, d1uvrA_, 0.7876, 2.68, 0.196, 284, 255, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-8
388, d1stcE_, 0.7876, 2.75, 0.215, 334, 256, CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH STAUROSPORINE
389, d3zrkB_, 0.7875, 3.12, 0.195, 348, 262, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
390, d2bpmC2, 0.7875, 2.76, 0.193, 298, 259, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
391, d2uzdC_, 0.7874, 2.64, 0.195, 295, 257, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
392, d2c5tC_, 0.7874, 2.69, 0.190, 296, 258,  
393, d2c5nC_, 0.7873, 2.70, 0.190, 296, 258, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
394, d3q53A_, 0.7872, 2.89, 0.219, 291, 260, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN IN COMPLEX WITH ATP
395, d3db6A_, 0.7872, 2.87, 0.198, 287, 262, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 902
396, d3a8wA1, 0.7872, 2.68, 0.167, 323, 257, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
397, d2iw9C2, 0.7872, 2.57, 0.192, 267, 255, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
398, d2i40A_, 0.7872, 2.65, 0.195, 291, 256, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
399, d1h27C1, 0.7872, 2.62, 0.191, 290, 257, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
400, d4eorC1, 0.7871, 2.57, 0.192, 269, 255, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
401, d1q4lB_, 0.7871, 3.03, 0.195, 337, 261, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
402, d1q4lA_, 0.7871, 3.02, 0.195, 342, 261, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
403, d1jstA_, 0.7871, 2.70, 0.190, 297, 258, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
404, d5vloB_, 0.7870, 2.92, 0.196, 293, 260, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
405, d2i40C_, 0.7870, 2.72, 0.194, 296, 258, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
406, d3dogC1, 0.7869, 2.51, 0.189, 266, 254, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
407, d2wfyA_, 0.7869, 2.63, 0.191, 295, 257, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
408, d1q97B_, 0.7868, 2.85, 0.220, 361, 259, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
409, d3zrlB_, 0.7867, 3.14, 0.202, 347, 262, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
410, d2wihC1, 0.7867, 2.76, 0.193, 298, 259, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
411, d4o0tA_, 0.7865, 2.91, 0.217, 292, 263, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
412, d2wevC_, 0.7864, 2.72, 0.190, 296, 258, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
413, d5lmkC1, 0.7863, 2.54, 0.193, 264, 254, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
414, d5dh3B_, 0.7863, 2.96, 0.186, 283, 264, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
415, d3ddqC1, 0.7862, 2.51, 0.189, 265, 254, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
416, d5li1A1, 0.7859, 2.69, 0.163, 329, 257, STRUCTURE OF A PAR3-INHIBITORY PEPTIDE BOUND TO PKCIOTA CORE KINASE DOMAIN
417, d3a7gB_, 0.7859, 2.86, 0.210, 290, 262, HUMAN MST3 KINASE
418, d2wfyC_, 0.7859, 2.69, 0.190, 296, 258, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
419, d1j1bA_, 0.7858, 3.05, 0.195, 354, 261, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
420, d1h25A1, 0.7858, 2.52, 0.189, 292, 254, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
421, d4bcpC1, 0.7857, 2.51, 0.189, 266, 254, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
422, d3zrmB_, 0.7857, 3.06, 0.195, 347, 261, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
423, d4dawA_, 0.7855, 2.98, 0.214, 293, 262, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH THE RUTHENIUM PHTHALIMIDE COMPLEX
424, d2gcdA_, 0.7855, 2.75, 0.212, 308, 260, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
425, d4ogrE_, 0.7852, 3.13, 0.169, 310, 267, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
426, d4o0xA1, 0.7852, 2.96, 0.186, 289, 263, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
427, d2gcdB_, 0.7852, 2.75, 0.212, 308, 260, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
428, d2iw8C2, 0.7851, 2.55, 0.189, 264, 254, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
429, d1okwC_, 0.7851, 2.71, 0.190, 296, 258, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
430, d3zh8C_, 0.7850, 2.92, 0.172, 312, 261, A NOVEL SMALL MOLECULE APKC INHIBITOR
431, d1q41B_, 0.7850, 3.05, 0.195, 343, 261, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
432, d1pyxB_, 0.7849, 3.06, 0.195, 338, 261, GSK-3 BETA COMPLEXED WITH AMP-PNP
433, d5f94A_, 0.7848, 3.14, 0.191, 346, 262, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
434, d5deyA_, 0.7848, 3.00, 0.213, 295, 263, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
435, d1oiuC1, 0.7848, 2.55, 0.193, 264, 254, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
436, d4nm0A1, 0.7847, 3.07, 0.195, 355, 261, CRYSTAL STRUCTURE OF PEPTIDE INHIBITOR-FREE GSK-3/AXIN COMPLEX
437, d4cfmC1, 0.7847, 2.52, 0.194, 265, 253, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
438, d1q5kA_, 0.7847, 3.04, 0.192, 345, 261, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
439, d5dfpA_, 0.7846, 3.02, 0.214, 292, 262, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND FRAX1036
440, d4nstA_, 0.7846, 3.12, 0.221, 322, 263, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
441, d2o5kA1, 0.7846, 3.06, 0.195, 350, 261, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A BENZOIMIDAZOL INHIBITOR
442, d1h26C1, 0.7846, 2.59, 0.192, 266, 255, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
443, d2c5xC_, 0.7845, 2.72, 0.194, 296, 258, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
444, d1q8zA_, 0.7845, 2.61, 0.236, 354, 254, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
445, d6aywA_, 0.7844, 2.93, 0.196, 293, 260, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
446, d5vedA_, 0.7842, 2.92, 0.187, 289, 262, PAK4 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
447, d3i4bB_, 0.7842, 3.06, 0.195, 347, 261, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
448, d1q3wB_, 0.7842, 3.06, 0.195, 341, 261, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
449, d3hrcA_, 0.7841, 2.71, 0.192, 279, 255, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ATP
450, d1j1bB_, 0.7841, 3.06, 0.192, 364, 261, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
451, d4figA_, 0.7840, 2.82, 0.192, 292, 261, CATALYTIC DOMAIN OF HUMAN PAK4
452, d4bcjA_, 0.7840, 2.86, 0.193, 309, 259, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
453, d3sayB_, 0.7840, 3.05, 0.196, 347, 260, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
454, d1j1cA_, 0.7840, 3.06, 0.195, 354, 261, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
455, d1bx6A_, 0.7840, 2.80, 0.211, 337, 256, CRYSTAL STRUCTURE OF THE POTENT NATURAL PRODUCT INHIBITOR BALANOL IN COMPLEX WITH THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
456, d6babD_, 0.7839, 2.96, 0.196, 291, 260, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
457, d5f94B_, 0.7839, 3.16, 0.191, 349, 262, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
458, d4qmlA_, 0.7839, 2.90, 0.210, 280, 262, MST3 IN COMPLEX WITH AMP-PNP
459, d4figB_, 0.7839, 2.82, 0.192, 292, 261, CATALYTIC DOMAIN OF HUMAN PAK4
460, d3m1sB_, 0.7839, 3.06, 0.195, 349, 261, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
461, d4eqcA1, 0.7838, 3.01, 0.214, 292, 262, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN IN COMPLEX WITH FRAX597 INHIBITOR
462, d3sayA_, 0.7838, 3.05, 0.196, 347, 260, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
463, d2cjmC_, 0.7838, 2.63, 0.195, 294, 256, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
464, d1okyA_, 0.7838, 2.61, 0.194, 281, 253, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
465, d3tnwC_, 0.7837, 2.51, 0.186, 291, 253, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
466, d5dewA_, 0.7836, 3.06, 0.213, 295, 263, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
467, d5li9A1, 0.7834, 2.72, 0.168, 328, 256, STRUCTURE OF A NUCLEOTIDE-BOUND FORM OF PKCIOTA CORE KINASE DOMAIN
468, d5dh3A_, 0.7834, 2.99, 0.186, 287, 264, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
469, d4q9zB_, 0.7834, 3.04, 0.195, 308, 261, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
470, d1ol2C_, 0.7834, 2.75, 0.194, 296, 258, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
471, d3du8A_, 0.7833, 3.08, 0.195, 336, 261, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
472, d4bciA_, 0.7832, 2.77, 0.198, 308, 257, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
473, d3pvwA2, 0.7832, 2.97, 0.214, 343, 262, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD103A)
474, d3ocbA_, 0.7832, 2.85, 0.213, 315, 258, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
475, d2i0eA_, 0.7832, 2.70, 0.171, 326, 257, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
476, d1pyxA_, 0.7832, 3.07, 0.192, 343, 261, GSK-3 BETA COMPLEXED WITH AMP-PNP
477, d1h8fB_, 0.7832, 3.07, 0.195, 350, 261, GLYCOGEN SYNTHASE KINASE 3 BETA.
478, d4j71B_, 0.7831, 3.05, 0.196, 347, 260, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
479, d1yhwA_, 0.7831, 3.02, 0.218, 293, 262, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH ONE POINT MUTATIONS (K299R)
480, d1yhvA_, 0.7831, 3.02, 0.218, 293, 262, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH TWO POINT MUTATIONS (K299R T423E)
481, d1o9uA_, 0.7831, 3.05, 0.196, 349, 260, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE
482, d4bcfA_, 0.7830, 2.72, 0.195, 307, 257, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
483, d1unlB_, 0.7830, 2.54, 0.175, 292, 252, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
484, d1h8fA_, 0.7830, 3.08, 0.195, 352, 261, GLYCOGEN SYNTHASE KINASE 3 BETA.
485, d4j71A_, 0.7829, 3.06, 0.196, 347, 260, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
486, d3my5C1, 0.7829, 2.56, 0.193, 265, 254, CDK2/CYCLINA IN COMPLEX WITH DRB
487, d1q99A_, 0.7829, 2.62, 0.232, 354, 254, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
488, d3q3bB_, 0.7828, 3.10, 0.195, 341, 261, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
489, d5f9eB_, 0.7827, 2.91, 0.196, 293, 260, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
490, d3l1sB_, 0.7827, 3.06, 0.195, 330, 261, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
491, d1h24A1, 0.7827, 2.57, 0.193, 292, 254, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
492, d1q41A_, 0.7826, 3.07, 0.192, 339, 261, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
493, d1j1cB_, 0.7826, 3.08, 0.192, 364, 261, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
494, d4pteB_, 0.7825, 3.10, 0.192, 347, 261, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
495, d3zrmA_, 0.7825, 3.09, 0.204, 344, 260, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
496, d1rekA_, 0.7825, 2.75, 0.215, 336, 256, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 8
497, d4cxaA_, 0.7824, 3.16, 0.224, 329, 263, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
498, d1okvA_, 0.7824, 2.67, 0.187, 295, 257, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
499, d1i09B_, 0.7824, 3.08, 0.195, 341, 261, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
500, d5acbC_, 0.7823, 2.96, 0.222, 324, 261, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
501, d4ra4A_, 0.7823, 2.86, 0.181, 317, 259, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE C ALPHA IN COMPLEX WITH COMPOUND 28 ((R)-6-((3S4S)-13-DIMETHYL-PIPERIDIN-4-YL)-7-(2-FLUORO- PHENYL)-4-METHYL-210-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
502, d3m1sA_, 0.7823, 3.08, 0.192, 348, 261, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
503, d3i4bA_, 0.7823, 3.08, 0.192, 359, 261, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
504, d1u5qA_, 0.7823, 2.80, 0.212, 308, 260, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
505, d3zrkA_, 0.7822, 3.11, 0.192, 345, 261, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
506, d2jgzA_, 0.7822, 2.39, 0.192, 288, 250, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B
507, d4afjB_, 0.7821, 3.05, 0.197, 346, 259, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
508, d4achB_, 0.7821, 3.10, 0.195, 350, 261, GSK3B IN COMPLEX WITH INHIBITOR
509, d3q3bA_, 0.7821, 3.10, 0.192, 344, 261, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
510, d1howA_, 0.7821, 2.69, 0.217, 346, 254, THE X-RAY CRYSTAL STRUCTURE OF SKY1P AN SR PROTEIN KINASE IN YEAST
511, d5efqA_, 0.7820, 3.11, 0.210, 321, 262, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
512, d4o0vA1, 0.7820, 3.00, 0.183, 289, 263, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
513, d3a7fA_, 0.7820, 2.66, 0.207, 283, 256, HUMAN MST3 KINASE
514, d2x39A_, 0.7820, 2.97, 0.212, 316, 259, STRUCTURE OF 4-AMINO-N-(4-CHLOROBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE BOUND TO PKB
515, d1rejA_, 0.7820, 2.79, 0.211, 333, 256, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 1
516, d4bcqC1, 0.7819, 2.55, 0.190, 291, 253, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
517, d4nstC_, 0.7818, 3.13, 0.221, 317, 262, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
518, d4achA_, 0.7818, 3.11, 0.195, 350, 261, GSK3B IN COMPLEX WITH INHIBITOR
519, d2jldB_, 0.7818, 3.09, 0.195, 349, 261, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
520, d5hlpB_, 0.7817, 2.99, 0.205, 335, 259, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
521, d4bckC1, 0.7817, 2.54, 0.190, 291, 253, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
522, d5ukfD_, 0.7816, 1.97, 0.299, 268, 244, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
523, d5hlnB_, 0.7816, 3.03, 0.196, 346, 260, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
524, d1svhA_, 0.7816, 2.81, 0.211, 335, 256, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 8
525, d1bkxA_, 0.7816, 2.81, 0.207, 337, 256, A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND ADENOSINE FURTHER DEFINES CONFORMATIONAL FLEXIBILITY
526, d5hlpA_, 0.7815, 3.02, 0.205, 337, 259, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
527, d4pteA_, 0.7815, 3.05, 0.192, 341, 260, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
528, d4nm5A1, 0.7815, 3.14, 0.195, 360, 261, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 C-MOTIF
529, d3zrlA_, 0.7815, 3.06, 0.204, 345, 260, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
530, d2q0nA_, 0.7815, 2.98, 0.190, 293, 263, STRUCTURE OF HUMAN P21 ACTIVATING KINASE 4 (PAK4) IN COMPLEX WITH A CONSENSUS PEPTIDE
531, d1xh8A_, 0.7815, 2.82, 0.211, 337, 256, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
532, d5f95A_, 0.7814, 3.10, 0.195, 345, 261, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
533, d3a7hB_, 0.7814, 2.93, 0.210, 290, 262, HUMAN MST3 KINASE IN COMPLEX WITH ATP
534, d4o0yA1, 0.7813, 3.02, 0.190, 289, 263, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
535, d4nusA_, 0.7813, 3.03, 0.185, 301, 259, RSK2 N-TERMINAL KINASE IN COMPLEX WITH LJH685
536, d3q52A_, 0.7813, 3.05, 0.210, 292, 262, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN
537, d2ow3B_, 0.7813, 3.08, 0.204, 351, 260, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
538, d1u5qB_, 0.7812, 2.80, 0.212, 308, 260, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
539, d1finC_, 0.7812, 2.87, 0.193, 298, 259, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
540, d4ptcB_, 0.7811, 3.17, 0.191, 347, 262, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
541, d3sd0B_, 0.7811, 3.12, 0.195, 349, 261, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
542, d3o7lD_, 0.7811, 2.89, 0.207, 333, 256, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
543, d3l9mA_, 0.7811, 2.74, 0.208, 338, 255, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
544, d3gb2A_, 0.7811, 3.07, 0.192, 340, 260, GSK3BETA INHIBITOR COMPLEX
545, d2gniA_, 0.7811, 2.78, 0.219, 338, 256, PKA FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR FASUDIL (HA1077)
546, d1q5kB_, 0.7811, 3.09, 0.192, 344, 261, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
547, d5hlnA_, 0.7810, 3.06, 0.200, 346, 260, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
548, d4iq6B_, 0.7810, 3.12, 0.195, 332, 261, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
549, d3pupA_, 0.7810, 3.10, 0.192, 346, 261, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
550, d2gnjA_, 0.7810, 2.80, 0.215, 335, 256, PKA THREE FOLD MUTANT MODEL OF RHO-KINASE WITH Y-27632
551, d1szmA_, 0.7809, 2.72, 0.201, 317, 254, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
552, d1q3wA_, 0.7809, 3.11, 0.192, 344, 261, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
553, d5k5nB_, 0.7808, 2.84, 0.199, 334, 256, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
554, d4q9zA1, 0.7808, 3.00, 0.204, 330, 260, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
555, d4acdA_, 0.7808, 3.11, 0.195, 350, 261, GSK3B IN COMPLEX WITH INHIBITOR
556, d3pupB_, 0.7808, 3.10, 0.192, 347, 261, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
557, d3l9lA_, 0.7808, 2.85, 0.211, 338, 256, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
558, d3krwA2, 0.7808, 3.05, 0.206, 349, 262, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (SOAK)
559, d1q8yB_, 0.7808, 2.81, 0.219, 357, 256, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
560, d5l2wA1, 0.7807, 2.53, 0.191, 296, 251, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK2/CYCLINE AND DINACICLIB.
561, d4acgA_, 0.7807, 3.12, 0.195, 350, 261, GSK3B IN COMPLEX WITH INHIBITOR
562, d1uu7A_, 0.7807, 2.72, 0.198, 280, 253, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-2
563, d4un0C_, 0.7806, 3.07, 0.221, 308, 262, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
564, d3du8B_, 0.7806, 3.10, 0.192, 339, 261, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
565, d5ho7A_, 0.7805, 2.58, 0.195, 280, 251, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
566, d5f95B_, 0.7805, 3.13, 0.192, 338, 261, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
567, d4ptcA_, 0.7805, 3.11, 0.195, 342, 261, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
568, d4acgB_, 0.7805, 3.11, 0.195, 350, 261, GSK3B IN COMPLEX WITH INHIBITOR
569, d1q3dB_, 0.7805, 3.10, 0.195, 339, 261, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
570, d4nm7A1, 0.7804, 3.16, 0.195, 354, 261, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 E-MOTIF
571, d3l9mB_, 0.7804, 2.85, 0.207, 336, 256, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
572, d5efqC_, 0.7803, 3.13, 0.210, 325, 262, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
573, d4u45A_, 0.7803, 2.81, 0.195, 289, 257, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
574, d3fxzA_, 0.7803, 3.03, 0.218, 292, 261, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX LAMBDA-FL172
575, d3f7zB1, 0.7803, 3.11, 0.196, 338, 260, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
576, d4u44A_, 0.7802, 2.88, 0.198, 286, 258, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
577, d3mv5A_, 0.7802, 2.89, 0.217, 315, 258, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
578, d4ptgB_, 0.7801, 3.12, 0.192, 332, 261, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
579, d3mvhA_, 0.7801, 2.99, 0.212, 311, 259, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
580, d2ow3A_, 0.7801, 3.13, 0.204, 346, 260, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
581, d1okvC_, 0.7801, 2.78, 0.190, 296, 258, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
582, d4j1rC_, 0.7800, 3.00, 0.205, 344, 259, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
583, d2uw9A_, 0.7800, 2.99, 0.208, 316, 259, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH 4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
584, d2i0eB_, 0.7800, 2.74, 0.171, 300, 257, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
585, d2gfcA_, 0.7800, 2.80, 0.215, 335, 256, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
586, d4ptgA_, 0.7799, 3.13, 0.192, 333, 261, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
587, d4j1rB_, 0.7799, 3.00, 0.205, 346, 259, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
588, d4accA_, 0.7799, 3.12, 0.195, 350, 261, GSK3B IN COMPLEX WITH INHIBITOR
589, d3f7zA1, 0.7799, 3.03, 0.197, 338, 259, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
590, d3cqwA_, 0.7799, 2.81, 0.214, 318, 257, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
591, d2wipC1, 0.7798, 2.59, 0.190, 291, 253, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
592, d2jldA_, 0.7798, 3.11, 0.192, 349, 261, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
593, d2jdoA_, 0.7798, 2.81, 0.214, 314, 257, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
594, d1u5rA_, 0.7798, 2.82, 0.212, 308, 260, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
595, d4fijA_, 0.7797, 3.00, 0.186, 291, 263, CATALYTIC DOMAIN OF HUMAN PAK4
596, d4acdB_, 0.7797, 3.12, 0.195, 350, 261, GSK3B IN COMPLEX WITH INHIBITOR
597, d2jdvA_, 0.7797, 2.80, 0.199, 334, 256, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH A-443654
598, d3tn8A_, 0.7796, 2.72, 0.195, 304, 256, CDK9/CYCLIN T IN COMPLEX WITH CAN508
599, d3sc1A_, 0.7796, 2.59, 0.195, 278, 251, NOVEL ISOQUINOLONE PDK1 INHIBITORS DISCOVERED THROUGH FRAGMENT-BASED LEAD DISCOVERY
600, d3nx8A_, 0.7796, 2.84, 0.211, 333, 256, HUMAN CAMP DEPENDENT PROTEIN KINASE IN COMPLEX WITH PHENOL
601, d1xh5A_, 0.7796, 2.85, 0.211, 335, 256, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
602, d2ojfE_, 0.7795, 2.85, 0.214, 336, 257, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
603, d1r0eB_, 0.7795, 3.12, 0.195, 344, 261, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
604, d3ocbB_, 0.7794, 2.90, 0.213, 319, 258, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
605, d1xh9A_, 0.7794, 2.80, 0.211, 336, 256, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
606, d5vloA_, 0.7793, 2.87, 0.191, 290, 257, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
607, d4ra5B_, 0.7793, 3.10, 0.195, 310, 261, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
608, d4jdiA_, 0.7793, 3.01, 0.191, 289, 262, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
609, d3juhA_, 0.7793, 2.90, 0.178, 334, 258, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
610, d1xhaA_, 0.7793, 2.85, 0.211, 348, 256, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
611, d1h24C1, 0.7793, 2.63, 0.197, 292, 254, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
612, d3l9lB_, 0.7792, 2.85, 0.211, 337, 256, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
613, d1ymiA_, 0.7792, 2.91, 0.178, 334, 258,  
614, d1smhA_, 0.7792, 2.83, 0.207, 348, 256, PROTEIN KINASE A VARIANT COMPLEX WITH COMPLETELY ORDERED N- TERMINAL HELIX
615, d1r0eA_, 0.7792, 3.12, 0.195, 344, 261, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
616, d3bw5A_, 0.7791, 2.92, 0.178, 334, 258,  
617, d2jd5A_, 0.7791, 2.63, 0.237, 353, 253, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
618, d1u5rB_, 0.7791, 2.81, 0.212, 308, 260, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
619, d1q8wA_, 0.7791, 2.83, 0.204, 334, 255, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR FASUDIL (HA-1077)
620, d4j1rA_, 0.7790, 3.01, 0.205, 343, 259, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
621, d2xchA_, 0.7790, 2.61, 0.195, 278, 251, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
622, d2uzuE_, 0.7790, 2.86, 0.214, 336, 257, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
623, d2oh0E_, 0.7790, 2.86, 0.214, 336, 257, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
624, d2jdtA_, 0.7790, 2.85, 0.207, 334, 256, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
625, d2f7eE_, 0.7790, 2.85, 0.214, 336, 257, PKA COMPLEXED WITH (S)-2-(1H-INDOL-3-YL)-1-(5-ISOQUINOLIN-6- YL-PYRIDIN-3-YLOXYMETHYL-ETYLAMINE
626, d4j1rD_, 0.7789, 3.01, 0.205, 345, 259, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
627, d2rkpA_, 0.7788, 2.90, 0.171, 334, 258,  
628, d2f7xE_, 0.7788, 2.86, 0.214, 336, 257, PROTEIN KINASE A BOUND TO (S)-2-(1H-INDOL-3-YL)-1-[5-((E)-2- PYRIDIN-4-YL-VINYL)-PYRIDIN-3-YLOXYMETHYL]-ETHYLAMINE
629, d1q3dA_, 0.7788, 3.14, 0.195, 339, 261, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
630, d5vefA_, 0.7787, 2.99, 0.179, 289, 262, PAK4 KINASE DOMAIN IN COMPLEX WITH FASUDIL
631, d3krxA2, 0.7787, 2.99, 0.211, 349, 261, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (CO-CRYSTAL)
632, d3a8wB1, 0.7787, 2.69, 0.169, 324, 254, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
633, d2uzwE_, 0.7787, 2.89, 0.210, 336, 257, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
634, d5f9eA1, 0.7786, 2.92, 0.201, 331, 259, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
635, d4qo9B_, 0.7786, 3.00, 0.202, 285, 262, MST3 IN COMPLEX WITH DANUSERTIB
636, d3pvuA2, 0.7786, 3.03, 0.214, 340, 262, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD101)
637, d3otuA_, 0.7786, 2.67, 0.194, 276, 253, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR JS30
638, d1jbpE_, 0.7786, 2.83, 0.207, 339, 256, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE COMPLEXED WITH A SUBSTRATE PEPTIDE ADP AND DETERGENT
639, d2uw7A_, 0.7785, 2.86, 0.207, 335, 256, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
640, d5i0bA_, 0.7783, 2.97, 0.187, 288, 262, STRUCTURE OF PAK4
641, d4l67A_, 0.7783, 3.02, 0.175, 289, 263, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF PAK4
642, d4afjA_, 0.7783, 3.09, 0.197, 342, 259, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
643, d3nayB_, 0.7783, 2.63, 0.195, 278, 251, PDK1 IN COMPLEX WITH INHIBITOR MP6
644, d2wipA1, 0.7783, 2.69, 0.189, 293, 254, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
645, d2c1bA_, 0.7783, 2.85, 0.211, 335, 256, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ( 4R2S)-5 -(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2- YLMETHANESULFONYL)ISOQUINOLINE
646, d1unlA_, 0.7783, 2.58, 0.175, 292, 252, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
647, d5nqcA_, 0.7781, 2.87, 0.171, 331, 257, CK2ALPHA IN COMPLEX WITH NMR154
648, d5hngA_, 0.7781, 2.63, 0.195, 280, 251, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
649, d4gv1A1, 0.7781, 2.93, 0.213, 328, 258, PKB ALPHA IN COMPLEX WITH AZD5363
650, d3sd0A_, 0.7781, 3.21, 0.195, 350, 262, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
651, d3p0mA_, 0.7781, 2.84, 0.211, 335, 256, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
652, d5ukfB_, 0.7780, 1.85, 0.311, 265, 241, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
653, d2gnfA_, 0.7780, 2.85, 0.215, 339, 256, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH Y- 27632
654, d4ra5A1, 0.7779, 2.95, 0.197, 331, 259, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
655, d2gnhA_, 0.7779, 2.84, 0.215, 338, 256, PKA FIVE FOLD MUTANT MODEL OF RHO-KINASE WITH H1152P
656, d2gngA_, 0.7779, 2.86, 0.215, 338, 256, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE
657, d1ydrE_, 0.7779, 2.85, 0.211, 334, 256, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H7 PROTEIN KINASE INHIBITOR 1-(5- ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE
658, d4accB_, 0.7778, 3.14, 0.195, 350, 261, GSK3B IN COMPLEX WITH INHIBITOR
659, d3mfuA_, 0.7778, 3.13, 0.204, 302, 260, CASK-4M CAM KINASE DOMAIN AMPPNP-MN2+
660, d3dndA_, 0.7778, 2.86, 0.211, 334, 256, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
661, d2c1aA_, 0.7778, 2.86, 0.211, 335, 256, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL)AMIDE
662, d1fmoE_, 0.7778, 2.79, 0.199, 336, 256, CRYSTAL STRUCTURE OF A POLYHISTIDINE-TAGGED RECOMBINANT CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH THE PEPTIDE INHIBITOR PKI(5-24) AND ADENOSINE
663, d3nayA_, 0.7777, 2.64, 0.195, 278, 251, PDK1 IN COMPLEX WITH INHIBITOR MP6
664, d2vn9B_, 0.7777, 3.03, 0.192, 301, 260, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
665, d5uq2A_, 0.7776, 2.85, 0.190, 296, 258, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
666, d5bmsA1, 0.7776, 3.01, 0.191, 289, 262, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 4 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
667, d4fihA_, 0.7776, 3.01, 0.176, 291, 262, CATALYTIC DOMAIN OF HUMAN PAK4 WITH QKFTGLPRQW PEPTIDE
668, d3l1sA_, 0.7776, 3.01, 0.193, 336, 259, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
669, d3f88A_, 0.7776, 3.03, 0.197, 340, 259, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
670, d3mfsA_, 0.7775, 3.05, 0.205, 303, 259, CASK-4M CAM KINASE DOMAIN AMPPNP
671, d3blrA_, 0.7775, 2.70, 0.191, 300, 256, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH FLAVOPIRIDOL
672, d2uztA_, 0.7775, 2.90, 0.210, 336, 257, PKA STRUCTURES OF AKT INDAZOLE-PYRIDINE INHIBITORS
673, d2uvxA_, 0.7775, 2.85, 0.207, 335, 256, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 7-AZAINDOLE
674, d1ydsE_, 0.7775, 2.86, 0.211, 334, 256, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H8 PROTEIN KINASE INHIBITOR [N-(2-METHYLAMINO)ETHYL]-5- ISOQUINOLINESULFONAMIDE
675, d1vebA_, 0.7775, 2.85, 0.211, 338, 256, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 5
676, d4otdA_, 0.7774, 2.88, 0.202, 334, 258, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN
677, d4ks7A_, 0.7774, 3.00, 0.191, 286, 262, PAK6 KINASE DOMAIN IN COMPLEX WITH PF-3758309
678, d4jdhA_, 0.7774, 3.07, 0.183, 289, 263, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
679, d2erzE_, 0.7774, 2.86, 0.211, 334, 256, CRYSTAL STRUCTURE OF C-AMP DEPENDENT KINASE (PKA) BOUND TO HYDROXYFASUDIL
680, d4o0rA_, 0.7773, 3.02, 0.198, 293, 262, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
681, d2uzvA_, 0.7773, 2.87, 0.214, 336, 257, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
682, d1sveA_, 0.7773, 2.86, 0.211, 341, 256, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 1
683, d4jdkA_, 0.7772, 3.06, 0.179, 288, 263, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
684, d3cquA_, 0.7772, 2.99, 0.212, 318, 259, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
685, d3blhA1, 0.7772, 2.65, 0.197, 291, 254, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1
686, d3agmA_, 0.7772, 2.84, 0.215, 337, 256, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-670
687, d2vo7A_, 0.7772, 2.86, 0.207, 335, 256, STRUCTURE OF PKA COMPLEXED WITH 4-(4-CHLOROBENZYL)-1-(7H- PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN-4-YLAMINE
688, d2vo0A_, 0.7772, 2.85, 0.203, 340, 256, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
689, d5he2A2, 0.7771, 3.00, 0.211, 353, 261, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224406
690, d1q61A_, 0.7771, 2.86, 0.207, 335, 256, PKA TRIPLE MUTANT MODEL OF PKB
691, d1cmkE_, 0.7771, 2.92, 0.207, 348, 256, CRYSTAL STRUCTURES OF THE MYRISTYLATED CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE REVEAL OPEN AND CLOSED CONFORMATIONS
692, d4cjyC_, 0.7770, 2.94, 0.212, 303, 260,  
693, d2vn9A_, 0.7770, 3.03, 0.192, 301, 260, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
694, d3ow4A_, 0.7769, 2.86, 0.214, 317, 257, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
695, d1svgA_, 0.7769, 2.86, 0.211, 338, 256, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 4
696, d1re8A_, 0.7769, 2.83, 0.215, 337, 256, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 2
697, d1i09A_, 0.7769, 3.08, 0.196, 338, 260, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
698, d4eklA_, 0.7768, 2.82, 0.218, 329, 257, AKT1 WITH GDC0068
699, d3oogA_, 0.7768, 2.87, 0.211, 333, 256, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH A SMALL FRAGMENT
700, d1ydtE_, 0.7767, 2.87, 0.211, 334, 256, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H89 PROTEIN KINASE INHIBITOR N-[2- (4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE
701, d3dneA_, 0.7766, 2.86, 0.215, 336, 256, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
702, d2gu8A_, 0.7766, 2.86, 0.211, 335, 256, DISCOVERY OF 2-PYRIMIDYL-5-AMIDOTHIOPHENES AS NOVEL AND POTENT INHIBITORS FOR AKT: SYNTHESIS AND SAR STUDIES
703, d3pooA_, 0.7765, 2.86, 0.211, 331, 256, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
704, d3eidC_, 0.7765, 2.75, 0.195, 290, 256, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
705, d2xh5A_, 0.7765, 2.98, 0.213, 316, 258, STRUCTURE OF 4-(4-TERT-BUTYLBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDIN-4-AMINE BOUND TO PKB
706, d2f7zE_, 0.7765, 2.91, 0.210, 336, 257, PROTEIN KINASE A BOUND TO (R)-1-(1H-INDOL-3-YLMETHYL)-2-(2- PYRIDIN-4-YL-[17]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE
707, d1atpE_, 0.7765, 2.83, 0.195, 334, 256, 2.2 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH MNATP AND A PEPTIDE INHIBITOR
708, d4cfvC1, 0.7764, 2.51, 0.191, 263, 251, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
709, d3aglB_, 0.7764, 2.86, 0.215, 335, 256, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
710, d2gnlA_, 0.7764, 2.87, 0.215, 338, 256, PKA THREEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR H- 1152P
711, d1jluE_, 0.7764, 2.86, 0.211, 337, 256, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PHOSPHORYLATED SUBSTRATE PEPTIDE AND DETERGENT
712, d3h30A_, 0.7763, 2.90, 0.171, 333, 257, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
713, d3f88B_, 0.7763, 3.15, 0.196, 340, 260, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
714, d2vo3A_, 0.7763, 2.81, 0.204, 334, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
715, d2vnyA_, 0.7763, 2.84, 0.200, 334, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)AMINE
716, d2vnwA_, 0.7763, 2.81, 0.204, 334, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)METHANAMINE
717, d2cjmA_, 0.7763, 2.57, 0.190, 285, 252, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
718, d1o6kA_, 0.7763, 3.00, 0.201, 317, 259, STRUCTURE OF ACTIVATED FORM OF PKB KINASE DOMAIN S474D WITH GSK3 PEPTIDE AND AMP-PNP
719, d4jdjA_, 0.7762, 3.08, 0.179, 288, 263, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
720, d4crsA1, 0.7762, 2.87, 0.195, 329, 257, HUMAN PROTEIN KINASE N2 (PKN2 PRKCL2) IN COMPLEX WITH ATPGAMMAS
721, d3juhB_, 0.7762, 2.98, 0.178, 334, 258, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
722, d2uw4A_, 0.7762, 2.81, 0.204, 334, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-(5-METHYL- 1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
723, d2jdrA_, 0.7762, 2.83, 0.218, 316, 257, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH THE INHIBITOR A- 443654
724, d1o6lA_, 0.7762, 3.01, 0.201, 316, 259, CRYSTAL STRUCTURE OF AN ACTIVATED AKT/PROTEIN KINASE B (PKB-PIF CHIMERA) TERNARY COMPLEX WITH AMP-PNP AND GSK3 PEPTIDE
725, d1ctpE_, 0.7762, 2.94, 0.203, 332, 256, STRUCTURE OF THE MAMMALIAN CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND AN INHIBITOR PEPTIDE DISPLAYS AN OPEN CONFORMATION
726, d3mftA_, 0.7761, 3.15, 0.204, 302, 260, CASK-4M CAM KINASE DOMAIN MN2+
727, d3e8cF_, 0.7761, 2.88, 0.211, 341, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
728, d3e8cD_, 0.7761, 2.88, 0.211, 344, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
729, d3e8cB_, 0.7761, 2.88, 0.211, 344, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
730, d3blqA_, 0.7761, 2.54, 0.187, 295, 252, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH ATP
731, d2xckA_, 0.7761, 2.65, 0.195, 275, 251, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
732, d2wmaC1, 0.7761, 2.69, 0.189, 264, 254, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
733, d4krcA_, 0.7760, 2.69, 0.183, 297, 252, CRYSTAL STRUCTURE OF PHO85-PCL10-ATP-GAMMA-S COMPLEX
734, d3e8cC_, 0.7760, 2.88, 0.211, 341, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
735, d3e8cA_, 0.7760, 2.89, 0.211, 341, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
736, d1xh6A_, 0.7760, 2.85, 0.215, 331, 256, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
737, d1q8tA_, 0.7760, 2.88, 0.211, 338, 256, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH RHO-KINASE INHIBITOR Y-27632
738, d5k5nA_, 0.7759, 2.91, 0.199, 331, 256, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
739, d4o22A1, 0.7759, 2.85, 0.208, 333, 255, BINARY COMPLEX OF METAL-FREE PKAC WITH SP20.
740, d4ae6A_, 0.7759, 2.96, 0.210, 319, 257, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
741, d3o0gA_, 0.7759, 2.48, 0.176, 289, 250, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
742, d3h30B_, 0.7759, 2.90, 0.171, 333, 257, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
743, d3e8cE_, 0.7759, 2.88, 0.211, 336, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
744, d1xh4A_, 0.7759, 2.85, 0.208, 334, 255, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
745, d3iopA_, 0.7758, 2.58, 0.196, 275, 250, PDK-1 IN COMPLEX WITH THE INHIBITOR COMPOUND-8I
746, d2v7oA1, 0.7758, 3.02, 0.185, 297, 259, CRYSTAL STRUCTURE OF HUMAN CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE II GAMMA
747, d2uw3A_, 0.7758, 2.82, 0.204, 334, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 5-METHYL-4- PHENYL-1H-PYRAZOLE
748, d1q8uA_, 0.7758, 2.88, 0.211, 341, 256, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR H-1152P
749, d4otgA_, 0.7757, 2.99, 0.197, 322, 259, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH LESTAURTINIB
750, d3rwpA_, 0.7757, 2.61, 0.200, 277, 250, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
751, d3nuuA_, 0.7757, 2.56, 0.197, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT11
752, d3h9oA_, 0.7757, 2.54, 0.192, 275, 250, PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK-1) IN COMPLEX WITH COMPOUND 9
753, d2qurA_, 0.7757, 2.86, 0.211, 338, 256, CRYSTAL STRUCTURE OF F327A/K285P MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
754, d4ks8A_, 0.7756, 2.95, 0.192, 286, 260, PAK6 KINASE DOMAIN IN COMPLEX WITH SUNITINIB
755, d3pscA2, 0.7756, 2.97, 0.170, 344, 259, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
756, d3mfrA_, 0.7756, 3.16, 0.204, 302, 260, CASK-4M CAM KINASE DOMAIN NATIVE
757, d3e8eI_, 0.7755, 2.89, 0.211, 345, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
758, d5he1A2, 0.7754, 3.04, 0.207, 342, 261, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224062
759, d4aw1A_, 0.7754, 2.63, 0.190, 283, 252, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS210 BOUND TO THE PIF-POCKET
760, d1xh7A_, 0.7754, 2.85, 0.204, 337, 255, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
761, d3ambA_, 0.7753, 2.89, 0.211, 340, 256, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR VX- 680
762, d4yxrA_, 0.7752, 2.86, 0.215, 334, 256, CRYSTAL STRUCTURE OF PKA IN COMPLEX WITH INHIBITOR.
763, d3orxE_, 0.7752, 2.61, 0.204, 274, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
764, d1apmE_, 0.7752, 2.82, 0.195, 338, 256, 2.0 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PEPTIDE INHIBITOR AND DETERGENT
765, d3orzB_, 0.7751, 2.66, 0.199, 278, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
766, d3l9nA_, 0.7751, 2.85, 0.204, 332, 255, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 27
767, d3c0hB_, 0.7751, 3.32, 0.179, 300, 263, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
768, d2uw0A_, 0.7751, 2.86, 0.200, 334, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  6-(4-(4-(4- CHLORO-PHENYL)-PIPERIDIN-4-YL)-PHENYL)-9H-PURINE
769, d5ho8A_, 0.7750, 2.57, 0.201, 278, 249, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
770, d3orzD_, 0.7750, 2.66, 0.199, 278, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
771, d3fy0A_, 0.7750, 3.07, 0.218, 292, 261, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX DW1
772, d3e8eP_, 0.7750, 2.90, 0.211, 341, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
773, d3ag9B_, 0.7750, 2.90, 0.203, 317, 256, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
774, d5ax9C_, 0.7749, 2.75, 0.197, 282, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
775, d2uw6A_, 0.7749, 2.85, 0.200, 334, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (S)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
776, d2uvyA_, 0.7749, 2.86, 0.200, 333, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH METHYL-(4-(9H- PURIN-6-YL)-BENZYL)-AMINE
777, d3c0iA_, 0.7748, 3.08, 0.197, 298, 259, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P212121 FORM
778, d2f57B1, 0.7748, 3.04, 0.188, 293, 261, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
779, d1q62A_, 0.7748, 2.88, 0.207, 336, 256, PKA DOUBLE MUTANT MODEL OF PKB
780, d1q24A_, 0.7748, 2.84, 0.195, 335, 256, PKA DOUBLE MUTANT MODEL OF PKB IN COMPLEX WITH MGATP
781, d4iq6A_, 0.7747, 3.12, 0.193, 324, 259, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
782, d5he0A2, 0.7746, 3.03, 0.215, 346, 261, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG215022
783, d3c0gA_, 0.7746, 3.31, 0.183, 309, 263, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
784, d4njdA1, 0.7745, 3.07, 0.186, 289, 263, STRUCTURE OF P21-ACTIVATED KINASE 4 WITH A NOVEL INHIBITOR KY-04031
785, d3amaA_, 0.7745, 2.88, 0.211, 342, 256, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR JNJ- 7706621
786, d2vo6A_, 0.7744, 2.86, 0.204, 335, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4- CHLOROBENZYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YLAMINE
787, d1okzA_, 0.7744, 2.58, 0.197, 276, 249, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH UCN-01
788, d3d5xA_, 0.7743, 2.76, 0.200, 279, 255, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH WORTMANNIN.
789, d3nuyA_, 0.7742, 2.59, 0.197, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT17
790, d2xuuA_, 0.7742, 3.09, 0.188, 301, 260, CRYSTAL STRUCTURE OF A DAP-KINASE 1 MUTANT
791, d4k18A_, 0.7741, 2.81, 0.196, 277, 255, STRUCTURE OF PIM-1 KINASE BOUND TO 5-(4-CYANOBENZYL)-N-(4- FLUOROPHENYL)-7-HYDROXYPYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
792, d2uw8A_, 0.7741, 2.88, 0.204, 334, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-CHLORO- PHENYL)-2-PHENYL-ETHYLAMINE
793, d1xjdA_, 0.7741, 2.72, 0.206, 280, 252, CRYSTAL STRUCTURE OF PKC-THETA COMPLEXED WITH STAUROSPORINE AT 2A RESOLUTION
794, d1h25C1, 0.7741, 2.61, 0.190, 277, 252, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
795, d4bcqA1, 0.7740, 2.56, 0.187, 289, 251, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
796, d3qklA_, 0.7740, 3.07, 0.212, 317, 259, SPIROCHROMANE AKT INHIBITORS
797, d3idbA_, 0.7740, 2.89, 0.211, 341, 256, CRYSTAL STRUCTURE OF (108-268)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
798, d2jdsA_, 0.7740, 2.86, 0.208, 334, 255, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A- 443654
799, d3c0hA_, 0.7739, 3.30, 0.179, 300, 263, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
800, d1q97A_, 0.7739, 2.68, 0.226, 351, 252, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
801, d3nusA_, 0.7737, 2.60, 0.197, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT8
802, d3fwqB_, 0.7737, 2.98, 0.171, 334, 258, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
803, d2uw5A_, 0.7737, 2.85, 0.208, 333, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (R)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
804, d4krdA_, 0.7736, 2.62, 0.184, 294, 250, CRYSTAL STRUCTURE OF PHO85-PCL10 COMPLEX
805, d3ow4B_, 0.7736, 2.90, 0.214, 317, 257, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
806, d3orxG_, 0.7736, 2.60, 0.205, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
807, d3e87B_, 0.7736, 3.04, 0.201, 321, 259, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
808, d3e87A_, 0.7736, 3.04, 0.201, 321, 259, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
809, d3bhhB1, 0.7736, 2.95, 0.184, 288, 256, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
810, d4pnkA2, 0.7735, 3.05, 0.207, 350, 261, G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GSK180736A
811, d3mvjE_, 0.7735, 2.92, 0.211, 334, 256, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
812, d3e8eE_, 0.7735, 2.92, 0.211, 341, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
813, d2uvzA_, 0.7735, 2.86, 0.204, 334, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH C-PHENYL-C-(4-( 9H-PURIN-6-YL)-PHENYL)-METHYLAMINE
814, d2r7bA_, 0.7735, 2.60, 0.197, 274, 249, CRYSTAL STRUCTURE OF THE PHOSPHOINOSITIDE-DEPENDENT KINASE- 1 (PDK-1)CATALYTIC DOMAIN BOUND TO A DIBENZONAPHTHYRIDINE INHIBITOR
815, d1q8yA_, 0.7735, 2.67, 0.226, 351, 252, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
816, d4ntsB_, 0.7734, 2.97, 0.207, 341, 256, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
817, d3e8eB_, 0.7734, 2.92, 0.211, 337, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
818, d6babA_, 0.7733, 3.11, 0.188, 290, 261, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
819, d4qo9A_, 0.7733, 3.05, 0.203, 280, 261, MST3 IN COMPLEX WITH DANUSERTIB
820, d3ionA_, 0.7733, 2.61, 0.197, 274, 249, PDK1 IN COMPLEX WITH COMPOUND 8H
821, d2cdzA_, 0.7733, 3.01, 0.192, 289, 261, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH CGP74514A
822, d4zy4A_, 0.7732, 3.16, 0.202, 288, 262, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
823, d3e8eA_, 0.7732, 2.92, 0.211, 341, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
824, d2bcjA3, 0.7732, 2.96, 0.174, 348, 258, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GALPHA-Q AND GBETAGAMMA SUBUNITS
825, d3qamE_, 0.7731, 2.90, 0.211, 348, 256, CRYSTAL STRUCTURE OF GLU208ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
826, d2x4zA1, 0.7731, 3.03, 0.184, 289, 261, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH PF-03758309
827, d2eufB_, 0.7731, 2.71, 0.187, 282, 252, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLIN IN COMPLEX WITH THE INHIBITOR PD0332991
828, d3fjqE_, 0.7730, 2.85, 0.199, 334, 256, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA IN COMPLEX WITH PEPTIDE INHIBITOR PKI ALPHA (6-25)
829, d3d0eB_, 0.7730, 3.03, 0.201, 322, 259, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
830, d3a7gA_, 0.7730, 3.04, 0.218, 289, 262, HUMAN MST3 KINASE
831, d1cdkB_, 0.7730, 2.85, 0.195, 342, 256, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
832, d4j7bA_, 0.7729, 2.71, 0.206, 284, 253, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
833, d3q9wA_, 0.7729, 2.81, 0.175, 328, 252, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 8.5
834, d3d0eA_, 0.7729, 3.03, 0.201, 322, 259, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
835, d5kbqA_, 0.7728, 3.08, 0.198, 289, 262, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
836, d3orzC_, 0.7728, 2.65, 0.200, 276, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
837, d3cikA2, 0.7728, 3.05, 0.196, 347, 260, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
838, d3c13A_, 0.7728, 2.87, 0.178, 328, 253, LOW PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
839, d1uu3A_, 0.7728, 2.62, 0.201, 276, 249, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH LY333531
840, d4j7bD_, 0.7727, 2.66, 0.206, 281, 252, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
841, d3orxF_, 0.7727, 2.61, 0.205, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
842, d3bqcA_, 0.7727, 2.88, 0.178, 328, 253, HIGH PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
843, d1ym7C3, 0.7727, 3.09, 0.173, 346, 260, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
844, d5cspA_, 0.7726, 2.76, 0.179, 327, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
845, d3qcxA_, 0.7726, 2.54, 0.193, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-{2- AMINO-6-[(3R)-3-METHYL-4-MORPHOLINYL]-4-PYRIMIDINYL}-1H-INDAZOL-3- AMINE
846, d3orxH_, 0.7726, 2.61, 0.205, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
847, d1rdqE_, 0.7726, 2.91, 0.207, 340, 256, HYDROLYSIS OF ATP IN THE CRYSTAL OF Y204A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
848, d3ow3A_, 0.7725, 2.92, 0.211, 334, 256, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
849, d3mvjA_, 0.7725, 2.88, 0.195, 334, 256, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
850, d3e8eL_, 0.7725, 2.92, 0.211, 336, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
851, d2cpkE_, 0.7725, 2.87, 0.208, 333, 255, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CYCLIC ADENOSINE MONOPHOSPHATE-DEPENDENT PROTEIN KINASE
852, d1omwA3, 0.7725, 3.00, 0.178, 344, 259, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN G PROTEIN-COUPLED RECEPTOR KINASE 2 AND HETEROTRIMERIC G PROTEIN BETA 1 AND GAMMA 2 SUBUNITS
853, d5ukmA2, 0.7724, 3.02, 0.193, 353, 259, BOVINE GRK2 IN COMPLEX WITH HUMAN GBETAGAMMA SUBUNITS AND CCG258208 (14AS)
854, d4appA1, 0.7724, 3.03, 0.183, 290, 262, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH (S)-N-(5-(3-BENZYL-1-METHYLPIPERAZINE-4- CARBONYL)-66-DIMETHYL-1456-TETRAHYDROPYRROLO(34-C) PYRAZOL-3-YL)-3-PHENOXYBENZAMIDE
855, d3orzA_, 0.7724, 2.66, 0.200, 276, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
856, d3c0gB_, 0.7724, 3.31, 0.176, 320, 262, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
857, d2pe0A_, 0.7724, 2.62, 0.201, 275, 249, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 5-HYDROXY-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-13-DIHYDRO- INDOL-2-ONE COMPLEX
858, d1uu8A_, 0.7724, 2.62, 0.197, 277, 249, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-1
859, d1j3hB_, 0.7724, 2.91, 0.208, 327, 255, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
860, d5csvA_, 0.7722, 2.78, 0.179, 327, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 6 BOUND
861, d4o21A_, 0.7722, 2.88, 0.208, 333, 255, PRODUCT COMPLEX OF METAL-FREE PKAC ATP-GAMMA-S AND SP20.
862, d5acbD_, 0.7721, 2.98, 0.225, 319, 258, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
863, d3qalE_, 0.7721, 2.89, 0.195, 339, 256, CRYSTAL STRUCTURE OF ARG280ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
864, d3e88B_, 0.7721, 3.04, 0.201, 319, 259, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
865, d3e88A_, 0.7721, 3.04, 0.201, 319, 259, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
866, d2pe2A_, 0.7721, 2.55, 0.193, 275, 249, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 3-{5-[2-OXO-5-UREIDO-12-DIHYDRO-INDOL-(3Z)-YLIDENEMETHYL]-1H- PYRROL-3-YL}-N-(2-PIPERIDIN-1-YL-ETHYL)-BENZAMIDE COMPLEX
867, p4ib5A_, 0.7720, 3.07, 0.178, 331, 258, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
868, d3qkkA_, 0.7720, 2.91, 0.214, 326, 257, SPIROCHROMANE AKT INHIBITORS
869, d3qcsA_, 0.7720, 2.55, 0.193, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-[2- AMINO-6-(4-MORPHOLINYL)-4-PYRIMIDINYL]-1H-INDAZOL-3-AMINE
870, d3nunA_, 0.7720, 2.56, 0.193, 278, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH LEAD COMPOUND
871, d4x6rA_, 0.7719, 2.87, 0.208, 347, 255, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
872, d4wbbB_, 0.7719, 2.91, 0.208, 334, 255, SINGLE TURNOVER AUTOPHOSPHORYLATION CYCLE OF THE PKA RIIB HOLOENZYME
873, d5h9bA_, 0.7718, 2.92, 0.201, 269, 254, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/AMPPN
874, d3qcyA_, 0.7718, 2.57, 0.202, 275, 248, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 4-[2- AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-N-PHENYL-2- MORPHOLINECARBOXAMIDE
875, d3mb6A_, 0.7718, 2.89, 0.182, 329, 253, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (CPA)
876, d1z5mA_, 0.7718, 2.63, 0.197, 275, 249, CRYSTAL STRUCTURE OF N1-[3-[[5-BROMO-2-[[3-[(1-PYRROLIDINYLCARBONYL) AMINO]PHENYL]AMINO]-4-PYRIMIDINYL]AMINO]PROPYL]-22- DIMETHYLPROPANEDIAMIDE COMPLEXED WITH HUMAN PDK1
877, d3qcqA_, 0.7717, 2.55, 0.193, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-(3- AMINO-1H-INDAZOL-6-YL)-N4-ETHYL-24-PYRIMIDINEDIAMINE
878, d2pe1A_, 0.7717, 2.57, 0.193, 275, 249, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) {2-OXO-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-23-DIHYDRO-1H- INDOL-5-YL}-UREA {BX-517} COMPLEX
879, d4zk5A_, 0.7715, 3.04, 0.198, 286, 258, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
880, d4obpA_, 0.7715, 3.06, 0.198, 285, 258, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
881, d4md7E_, 0.7715, 3.01, 0.176, 332, 255, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
882, d3qd3A_, 0.7715, 2.57, 0.193, 278, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL {(3R6S)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-6-METHYL-3-PIPERIDINYL}CARBAMATE
883, d1xqzA_, 0.7715, 2.85, 0.196, 277, 255, CRYSTAL STRUCTURE OF HPIM-1 KINASE AT 2.1 A RESOLUTION
884, d1ym7D3, 0.7714, 3.06, 0.177, 340, 260, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
885, d1u7eA_, 0.7714, 2.92, 0.211, 338, 256,  
886, d4md7G_, 0.7713, 3.02, 0.176, 332, 255, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
887, d4ae9A_, 0.7713, 2.90, 0.208, 321, 255, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
888, d2x7fB_, 0.7713, 2.81, 0.192, 288, 255, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
889, p5ooiA_, 0.7712, 2.95, 0.176, 329, 255, STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
890, d4b4lA_, 0.7712, 3.16, 0.188, 299, 261, CRYSTAL STRUCTURE OF AN ARD DAP-KINASE 1 MUTANT
891, d3fhiA_, 0.7712, 2.92, 0.211, 336, 256, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN THE CATALYTIC AND REGULATORY (RI{ALPHA}) SUBUNITS OF PKA
892, d1zltA_, 0.7712, 2.98, 0.215, 272, 256, CRYSTAL STRUCTURE OF CHK1 COMPLEXED WITH A HYMENALDISINE ANALOG
893, d3owlA_, 0.7711, 2.89, 0.185, 330, 254, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
894, p4md8E_, 0.7710, 3.01, 0.172, 332, 256, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
895, d4e4mB_, 0.7709, 3.24, 0.197, 296, 264, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
896, d3e8dB_, 0.7709, 3.06, 0.201, 317, 259, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
897, d3e8dA_, 0.7709, 3.06, 0.201, 315, 259, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
898, d1ym7A3, 0.7709, 3.09, 0.192, 347, 261, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
899, d4md7F_, 0.7708, 3.01, 0.176, 332, 255, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
900, d4e4mD_, 0.7708, 3.23, 0.197, 296, 264, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
901, d1ym7B3, 0.7708, 3.09, 0.192, 347, 261, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
902, d1w98A2, 0.7708, 2.68, 0.195, 296, 251, THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E
903, d1gngB_, 0.7708, 3.34, 0.201, 355, 264, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
904, d4rllA_, 0.7706, 2.92, 0.177, 329, 254, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
905, p4md8G_, 0.7706, 3.01, 0.172, 332, 256, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
906, d1gngA_, 0.7706, 3.21, 0.200, 348, 260, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
907, d5motA_, 0.7705, 2.81, 0.179, 328, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0627 BOUND
908, d5d7aC_, 0.7705, 2.86, 0.188, 286, 255, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
909, p4jqeA_, 0.7705, 2.94, 0.153, 369, 255, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH AMPPN
910, p5omyA_, 0.7704, 3.01, 0.172, 332, 256, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
911, d5e8uA1, 0.7704, 3.23, 0.198, 303, 262, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F)
912, d5mohA_, 0.7703, 2.72, 0.179, 326, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0583 BOUND.
913, d4gmyA_, 0.7703, 3.26, 0.193, 298, 264, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH 26-DICHLORO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
914, d3v5wA2, 0.7703, 3.05, 0.197, 355, 259, HUMAN G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH SOLUBLE GBETAGAMMA SUBUNITS AND PAROXETINE
915, d3tnpF_, 0.7703, 2.90, 0.208, 334, 255, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
916, d3tnpC_, 0.7703, 2.90, 0.208, 334, 255, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
917, d3q9yA_, 0.7703, 2.84, 0.178, 327, 253, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 8.5
918, d3qc4A_, 0.7702, 2.78, 0.194, 276, 252, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
919, d3ofmA_, 0.7702, 2.98, 0.180, 325, 255, STRUCTURE OF A HUMAN CK2ALPHA PRIME THE PARALOG ISOFORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM HOMO SAPIENS
920, d1cdkA_, 0.7702, 2.87, 0.195, 342, 256, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
921, d5d7aA_, 0.7701, 2.91, 0.184, 289, 256, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
922, d3a7hA_, 0.7701, 3.07, 0.218, 289, 262, HUMAN MST3 KINASE IN COMPLEX WITH ATP
923, d2pvrA_, 0.7701, 2.84, 0.178, 328, 253, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 (C- TERMINAL DELETION MUTANT 1-335) IN COMPLEX WITH TWO SULFATE IONS
924, d2ckeD_, 0.7701, 3.20, 0.188, 300, 261, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
925, d1na7A_, 0.7701, 2.86, 0.178, 326, 253, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2
926, d2a2aD_, 0.7700, 3.16, 0.192, 303, 260, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
927, d5ugbA_, 0.7699, 3.36, 0.177, 307, 265, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN IN COMPLEX WITH 4-(4-{[2- {[(3S)-1-ACETYLPYRROLIDIN-3-YL]AMINO}-9-(PROPAN-2-YL)-9H-PURIN-6- YL]AMINO}PHENYL)-1-METHYLPIPERAZIN-1-IUM
928, d4e4mA_, 0.7699, 3.29, 0.193, 296, 264, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
929, d3q9xB_, 0.7699, 2.93, 0.173, 330, 254, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
930, d2j0iA_, 0.7699, 3.15, 0.186, 289, 263, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
931, d5ax9A_, 0.7698, 2.79, 0.197, 282, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
932, d4e4mE_, 0.7698, 3.29, 0.193, 296, 264, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
933, d1l3rE_, 0.7698, 2.88, 0.212, 338, 255, CRYSTAL STRUCTURE OF A TRANSITION STATE MIMIC OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
934, d4tl0A_, 0.7697, 3.16, 0.180, 300, 261, CRYSTAL STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 WITH A CRUCIAL PHOSPHOMIMICKING MUTATION
935, d4x6qC_, 0.7695, 2.90, 0.208, 334, 255, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
936, p4md8H_, 0.7695, 3.03, 0.172, 331, 256, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
937, d3q9zB_, 0.7695, 3.16, 0.174, 332, 259, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
938, p5oulA_, 0.7694, 2.86, 0.178, 327, 253, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 9
939, p4md8F_, 0.7694, 3.05, 0.176, 332, 256, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
940, d4md7H_, 0.7694, 3.19, 0.178, 330, 259, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
941, d3rpsA_, 0.7694, 3.14, 0.171, 334, 257, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
942, p5os8A_, 0.7693, 2.86, 0.178, 327, 253, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 11
943, d5m4cA_, 0.7693, 2.98, 0.173, 329, 255, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER LOW-SALT CONDITIONS
944, d3qkmA_, 0.7693, 2.93, 0.214, 329, 257, SPIROCYCLIC SULFONAMIDES AS AKT INHIBITORS
945, d2qcsA_, 0.7693, 2.91, 0.208, 335, 255, A COMPLEX STRUCTURE BETWEEN THE CATALYTIC AND REGULATORY SUBUNIT OF PROTEIN KINASE A THAT REPRESENTS THE INHIBITED STATE
946, d5e8xA_, 0.7692, 3.21, 0.207, 304, 261, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F) IN COMPLEX WITH STAUROSPORINE
947, d3tnqB_, 0.7692, 2.94, 0.208, 331, 255, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
948, d3owjA_, 0.7692, 2.97, 0.177, 328, 254, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A PYRIDOCARBAZOLE DERIVATIVE INHIBITOR
949, d2ckeC_, 0.7692, 3.17, 0.188, 300, 260, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
950, d1uu9A_, 0.7692, 2.63, 0.198, 276, 248, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-3
951, d5h8bA_, 0.7691, 3.00, 0.176, 331, 255, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
952, d5cvfA_, 0.7691, 2.87, 0.178, 325, 253, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
953, d4jiaA_, 0.7691, 3.27, 0.193, 298, 264, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 9
954, d3o7lB_, 0.7691, 2.86, 0.194, 326, 253, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
955, d2a2aC_, 0.7691, 3.17, 0.188, 303, 260, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
956, p5otzA_, 0.7690, 2.85, 0.178, 327, 253, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 1
957, d3rp0C_, 0.7690, 2.93, 0.177, 329, 254,  
958, d2w4kA_, 0.7690, 3.15, 0.188, 301, 260, X-RAY STRUCTURE OF A DAP-KINASE 2-302
959, d1pjkA_, 0.7690, 2.87, 0.178, 331, 253, CRYSTAL STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
960, d1j91B_, 0.7690, 3.04, 0.169, 327, 255, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
961, d5hkmA_, 0.7689, 2.62, 0.198, 272, 248, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
962, d5he3A2, 0.7687, 3.11, 0.211, 346, 261, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224411
963, d4ythA_, 0.7687, 3.18, 0.206, 287, 262, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
964, d3lxpA_, 0.7687, 3.15, 0.225, 285, 262, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
965, d5n1vA_, 0.7686, 2.98, 0.176, 331, 255, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
966, p4nh1B_, 0.7686, 3.03, 0.176, 332, 255, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
967, d3oxtA_, 0.7686, 2.93, 0.195, 335, 256, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
968, d3idcA_, 0.7686, 2.89, 0.199, 341, 256, CRYSTAL STRUCTURE OF (102-265)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
969, d3bhhA1, 0.7686, 3.02, 0.180, 287, 255, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
970, d1ds5B_, 0.7686, 3.05, 0.169, 328, 255, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
971, d3pe1A_, 0.7685, 2.86, 0.178, 327, 253, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-4945
972, p4nh1A_, 0.7684, 3.03, 0.176, 330, 255, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
973, d2oxyA_, 0.7684, 3.02, 0.169, 327, 255, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
974, p4md9P_, 0.7683, 2.93, 0.173, 328, 254, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
975, d3q04A_, 0.7683, 2.91, 0.173, 328, 254, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 8.5
976, d3pe2A_, 0.7683, 2.88, 0.178, 327, 253, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR CX-5011
977, d3ngaB_, 0.7683, 3.01, 0.176, 331, 255, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
978, d2ckeA_, 0.7683, 3.21, 0.192, 301, 261, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
979, d5uklA2, 0.7681, 3.13, 0.200, 353, 260, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG222886 (14BD)
980, d4x2gA1, 0.7681, 3.31, 0.210, 302, 262, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
981, d2ckeB_, 0.7681, 3.30, 0.191, 300, 262, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
982, d2x7fC_, 0.7680, 2.74, 0.186, 285, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
983, d5h8eA_, 0.7679, 3.02, 0.173, 331, 255, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
984, d2oxyB_, 0.7679, 3.02, 0.169, 327, 255, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
985, d5n1vB_, 0.7678, 3.00, 0.173, 331, 255, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
986, d3fwqA_, 0.7678, 3.14, 0.178, 334, 258, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
987, d2qvsE_, 0.7678, 3.08, 0.207, 323, 256, CRYSTAL STRUCTURE OF TYPE IIA HOLOENZYME OF CAMP-DEPENDENT PROTEIN KINASE
988, d4x2fA1, 0.7677, 3.31, 0.206, 302, 262, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
989, d5e8wA1, 0.7676, 3.23, 0.211, 302, 261, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH STAUROSPORINE
990, d5d7aB_, 0.7676, 2.93, 0.184, 286, 256, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
991, d3qa0B_, 0.7676, 2.95, 0.173, 330, 254, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
992, d5oorA_, 0.7675, 2.90, 0.209, 273, 254, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH STAUROSPORINE
993, d4x2nA1, 0.7675, 3.19, 0.208, 302, 260, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
994, d3r0tA_, 0.7675, 2.89, 0.174, 327, 253, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-5279
995, d3nszA_, 0.7675, 2.78, 0.179, 327, 252, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH AMPPN
996, d3bwjA_, 0.7675, 2.96, 0.208, 338, 255, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR LEAD COMPOUND ARC-1034
997, d2yabA_, 0.7675, 3.14, 0.196, 299, 260, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
998, d2yaaA_, 0.7675, 3.23, 0.195, 300, 261, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
999, p4md9L_, 0.7674, 2.97, 0.177, 328, 254, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1000, d4ll5A_, 0.7674, 2.75, 0.198, 268, 252, CRYSTAL STRUCTURE OF PIM-1 IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
1001, d3wikA_, 0.7674, 3.00, 0.173, 334, 254, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND10 COMPLEX
1002, d2a2aA_, 0.7674, 3.19, 0.188, 304, 260, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
1003, d5ctpB_, 0.7673, 2.79, 0.179, 327, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
1004, d2oi4X_, 0.7673, 2.78, 0.194, 275, 253, CRYSTAL STRUCTURE OF HUMAN PIM1 IN COMPLEX WITH FLUORINATED RUTHENIUM PYRIDOCARBAZOLE
1005, d2gs6A2, 0.7673, 3.35, 0.174, 308, 265, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AN ATP ANALOG-PEPTIDE CONJUGATE
1006, d5cu4A_, 0.7672, 2.87, 0.178, 327, 253, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
1007, d5ct0A_, 0.7672, 2.80, 0.179, 326, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
1008, d4x2kA1, 0.7672, 3.32, 0.210, 302, 262, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
1009, d4x2jA1, 0.7672, 3.32, 0.210, 302, 262, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
1010, p4md9M_, 0.7672, 3.07, 0.176, 331, 256, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1011, d4hyiA_, 0.7672, 2.95, 0.216, 269, 255, X-RAY CRYSTAL STRUCTURE OF COMPOUND 40 BOUND TO HUMAN CHK1 KINASE DOMAIN
1012, d2ydiA_, 0.7672, 3.06, 0.211, 279, 256, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
1013, d2bujA1, 0.7672, 2.70, 0.183, 283, 251, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
1014, d1fotA_, 0.7672, 2.97, 0.185, 299, 254, STRUCTURE OF THE UNLIGANDED CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT FROM SACCHAROMYCES CEREVISIAE
1015, d5mmfA_, 0.7671, 2.79, 0.179, 326, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
1016, d5cx9A_, 0.7671, 2.79, 0.179, 328, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
1017, d5cquA_, 0.7671, 2.88, 0.182, 328, 253, MONOCLINIC COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
1018, d4fbxA_, 0.7671, 3.17, 0.171, 333, 257, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT CRYSTALLIZED IN THE PRESENCE OF A BISUBSTRATE INHIBITOR
1019, p5otyA_, 0.7670, 2.88, 0.178, 327, 253, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH CAM4712
1020, d5cu6A_, 0.7670, 2.88, 0.178, 327, 253, CRYSTAL STRUCTURE OF CK2ALPHA
1021, d5t1hA_, 0.7669, 3.03, 0.176, 331, 255, CRYSTAL STRUCTURE OF CK2
1022, d5ax9B_, 0.7669, 2.63, 0.200, 274, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
1023, d4uv0A_, 0.7669, 3.08, 0.188, 300, 260, STRUCTURE OF A SEMISYNTHETIC PHOSPHORYLATED DAPK
1024, d4qteA_, 0.7669, 2.67, 0.216, 348, 250, STRUCTURE OF ERK2 IN COMPLEX WITH VTX-11E 4-{2-[(2-CHLORO-4- FLUOROPHENYL)AMINO]-5-METHYLPYRIMIDIN-4-YL}-N-[(1S)-1-(3- CHLOROPHENYL)-2-HYDROXYETHYL]-1H-PYRROLE-2-CARBOXAMIDE
1025, d4bxbA_, 0.7669, 2.88, 0.182, 328, 253,  
1026, d4aqcA_, 0.7669, 3.34, 0.201, 289, 264, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
1027, d2j2iB_, 0.7669, 2.75, 0.198, 273, 252, CRYSTAL STRUCTURE OF THE HUMAB PIM1 IN COMPLEX WITH LY333531
1028, d1m17A_, 0.7669, 3.36, 0.174, 312, 264, EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE DOMAIN WITH 4-ANILINOQUINAZOLINE INHIBITOR ERLOTINIB
1029, d5xgnA_, 0.7668, 3.25, 0.192, 302, 261, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
1030, p5n9kA_, 0.7668, 2.97, 0.177, 329, 254, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF107 (5)
1031, d5mmrA_, 0.7668, 2.81, 0.179, 326, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
1032, d5kwhA_, 0.7668, 3.03, 0.173, 331, 255, CRYSTAL STRUCTURE OF CK2
1033, d5ig1A_, 0.7668, 3.16, 0.201, 300, 259, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
1034, d4jx3A_, 0.7668, 2.88, 0.193, 274, 254, CRYSTAL STRUCTURE OF PIM1 KINASE
1035, d3qa0A_, 0.7668, 3.01, 0.176, 330, 255, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
1036, d2yabB_, 0.7668, 3.22, 0.195, 299, 261, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
1037, d2a2aB_, 0.7668, 3.21, 0.188, 303, 260, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
1038, d1lr4A_, 0.7668, 3.06, 0.169, 327, 255, ROOM TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
1039, d5xdkA_, 0.7667, 3.47, 0.185, 307, 265, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH CO-1686
1040, d5cu0A_, 0.7667, 2.82, 0.179, 327, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
1041, d4gihA1, 0.7667, 3.12, 0.215, 287, 260, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}BENZAMIDE
1042, d3qd4A_, 0.7667, 2.62, 0.198, 276, 247, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL{(3R5R)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-5-METHYL-3-PIPERIDINYL}CARBAMATE
1043, d3f3zA_, 0.7667, 2.93, 0.211, 271, 256, CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840 IN PRESENCE OF INDIRUBIN E804
1044, d1ia8A_, 0.7667, 3.06, 0.219, 272, 256, THE 1.7 A CRYSTAL STRUCTURE OF HUMAN CELL CYCLE CHECKPOINT KINASE CHK1
1045, d5kgkA_, 0.7666, 2.76, 0.194, 273, 252, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 3-(4-METHOXYPHENYL)-1~{H}- PYRAZOL-5-AMINE
1046, d5clpB_, 0.7666, 2.78, 0.175, 327, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
1047, p4md9G_, 0.7666, 2.98, 0.181, 329, 254, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1048, d2w1iB_, 0.7666, 3.23, 0.198, 284, 263, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
1049, d1xwsA_, 0.7666, 2.75, 0.198, 273, 252, CRYSTAL STRUCTURE OF THE HUMAN PIM1 KINASE DOMAIN
1050, d2yaaB_, 0.7665, 3.20, 0.192, 299, 260, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
1051, d2y0aA_, 0.7665, 3.19, 0.188, 300, 260, STRUCTURE OF DAPK1 CONSTRUCT RESIDUES 1-304
1052, d2x2kA1, 0.7665, 3.05, 0.167, 284, 257, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
1053, d4cxaC_, 0.7664, 3.03, 0.223, 330, 256, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
1054, d3rp0B_, 0.7664, 2.95, 0.177, 329, 254,  
1055, d2bzhB_, 0.7664, 2.87, 0.197, 275, 254, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
1056, d5cqwA_, 0.7663, 3.01, 0.176, 331, 255, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
1057, p4md9E_, 0.7663, 2.98, 0.177, 329, 254, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1058, d3rvgA_, 0.7663, 3.06, 0.205, 285, 259, CRYSTALS STRUCTURE OF JAK2 WITH A 1-AMINO-5H-PYRIDO[43-B]INDOL-4- CARBOXAMIDE INHIBITOR
1059, d2w1iA_, 0.7663, 3.23, 0.198, 284, 263, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
1060, d1j91A_, 0.7663, 3.01, 0.169, 327, 254, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
1061, p5v61A_, 0.7662, 2.74, 0.220, 348, 250, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP2
1062, d5l3aA_, 0.7662, 3.31, 0.197, 290, 264, FRAGMENT-BASED DISCOVERY OF 6-ARYLINDAZOLE JAK INHIBITORS
1063, d4ivaA_, 0.7662, 3.29, 0.193, 290, 264, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-[(8AS)- 2-[(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(8AH)- YL]CYCLOHEXANECARBONITRILE
1064, p4ib5C_, 0.7662, 3.30, 0.181, 332, 260, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
1065, d5u6iA_, 0.7661, 2.73, 0.216, 339, 250, DISCOVERY OF MLI-2 AN ORALLY AVAILABLE AND SELECTIVE LRRK2 INHIBITOR THAT REDUCES BRAIN KINASE ACTIVITY
1066, d5fg8A_, 0.7661, 3.09, 0.195, 269, 256, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
1067, p4md9K_, 0.7661, 2.93, 0.177, 328, 254, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1068, d4ditA_, 0.7661, 3.17, 0.195, 328, 257, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A IMIDAZOPYRIDINE INHIBITOR
1069, d4as0A_, 0.7661, 2.79, 0.194, 273, 252, CYCLOMETALATED PHTHALIMIDES AS PROTEIN KINASE INHIBITORS
1070, p3zuvC_, 0.7661, 2.71, 0.220, 357, 250, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
1071, d1ds5C_, 0.7661, 3.20, 0.162, 328, 259, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1072, d5cf5B1, 0.7660, 3.32, 0.197, 292, 264, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
1073, d4bxaA_, 0.7660, 3.01, 0.176, 331, 255,  
1074, d3f2aA_, 0.7660, 2.97, 0.184, 276, 255, CRYSTAL STRUCTURE OF HUMAN PIM-1 IN COMPLEX WITH DAPPA
1075, d3c4eA_, 0.7660, 2.75, 0.194, 273, 252, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
1076, d5mp8A_, 0.7659, 2.73, 0.179, 325, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1077, d5movA_, 0.7659, 2.79, 0.183, 325, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0633 BOUND
1078, d5cf5A1, 0.7659, 3.25, 0.202, 286, 263, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
1079, d4fv7A_, 0.7659, 2.66, 0.217, 342, 249, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E94
1080, d2x8dA_, 0.7659, 3.07, 0.211, 279, 256, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
1081, d2gdoA_, 0.7659, 2.99, 0.208, 269, 255, 4-(AMINOALKYLAMINO)-3-BENZIMIDAZOLE-QUINOLINONES AS POTENT CHK1 INHIBITORS
1082, d1yxsA_, 0.7659, 2.90, 0.193, 274, 254, CRYSTAL STRUCTURE OF KINASE PIM1 WITH P123M MUTATION
1083, d1lp4A_, 0.7659, 3.15, 0.163, 327, 258, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 WITH MG-AMPPNP
1084, d1j3hA_, 0.7659, 2.98, 0.197, 329, 254, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
1085, d1dawA_, 0.7659, 3.15, 0.163, 327, 258, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-AMPPNP
1086, d5m56A_, 0.7658, 2.98, 0.177, 331, 254, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
1087, d5m4fA_, 0.7658, 3.11, 0.176, 330, 255, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER LOW-SALT CONDITIONS
1088, d3c4eB_, 0.7658, 2.75, 0.194, 273, 252, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
1089, d1fq1B_, 0.7658, 2.92, 0.191, 295, 256, CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) IN COMPLEX WITH PHOSPHO-CDK2
1090, d4ntsA_, 0.7657, 2.98, 0.185, 341, 254, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
1091, d2bikB_, 0.7657, 2.77, 0.187, 272, 252, HUMAN PIM1 PHOSPHORYLATED ON SER261
1092, d1xo2B_, 0.7657, 2.69, 0.187, 289, 251, CRYSTAL STRUCTURE OF A HUMAN CYCLIN-DEPENDENT KINASE 6 COMPLEX WITH A FLAVONOL INHIBITOR FISETIN
1093, d5mo8A_, 0.7655, 2.82, 0.179, 325, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1094, p4md9H_, 0.7655, 2.96, 0.181, 328, 254, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1095, d4gj2A1, 0.7655, 3.13, 0.215, 287, 260, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
1096, d3qd0A_, 0.7655, 2.55, 0.194, 274, 247, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH (2R5S)- 1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-6-METHYL-N- PHENYL-3-PIPERIDINECARBOXAMIDE
1097, d3q32A_, 0.7655, 3.25, 0.202, 291, 263, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
1098, d3ngaA_, 0.7655, 3.21, 0.181, 331, 259, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
1099, d3axwA_, 0.7655, 3.01, 0.177, 329, 254, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA COMPLEXED WITH A POTENT INHIBITOR
1100, d1jwhA_, 0.7655, 2.93, 0.174, 336, 253, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
1101, d5nhvA_, 0.7654, 2.69, 0.216, 345, 250, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
1102, d4qtbB_, 0.7654, 2.68, 0.216, 348, 250, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
1103, d4e1zA_, 0.7654, 3.17, 0.215, 288, 260, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
1104, d2f57A1, 0.7654, 3.05, 0.178, 290, 259, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
1105, d1ds5A_, 0.7654, 3.16, 0.163, 328, 258, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1106, d6babB_, 0.7653, 2.94, 0.194, 285, 253, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1107, d5hg5A_, 0.7653, 3.44, 0.180, 302, 266, EGFR (L858R T790M V948R) IN COMPLEX WITH N-{3-[(2-{[4-(4- METHYLPIPERAZIN-1-YL)PHENYL]AMINO}-7H-PYRROLO[23-D]PYRIMIDIN-4-YL) OXY]PHENYL}PROP-2-ENAMIDE
1108, d4grbA_, 0.7653, 2.87, 0.179, 327, 252, CASEIN KINASE 2 (CK2) BOUND TO INHIBITOR
1109, d3kxhA_, 0.7653, 3.03, 0.165, 326, 254, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR (2-DYMETHYLAMMINO-4567-TETRABROMOBENZOIMIDAZOL-1YL- ACETIC ACID (K66)
1110, d3aglA_, 0.7653, 2.98, 0.215, 338, 256, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
1111, d5moeA_, 0.7652, 2.80, 0.183, 325, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1112, d5h8eB_, 0.7652, 3.05, 0.173, 331, 255, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
1113, d1ql6A_, 0.7652, 2.72, 0.168, 281, 250, THE CATALYTIC MECHANISM OF PHOSPHORYLASE KINASE PROBED BY MUTATIONAL STUDIES
1114, d5nhhA_, 0.7651, 2.77, 0.215, 348, 251, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
1115, d5mo6A_, 0.7651, 2.76, 0.179, 325, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1116, d5ke0A_, 0.7651, 2.71, 0.216, 340, 250, DISCOVERY OF 1-1H-PYRAZOLO 43-C PYRIDINE-6-YL UREA INHIBITORS OF EXTRACELLULAR SIGNAL REGULATED KINASE ERK FOR THE TREATMENT OF CANCERS
1117, d5cu0B_, 0.7651, 2.79, 0.179, 325, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
1118, d5aepA_, 0.7651, 3.24, 0.198, 287, 263, NOVEL PYRROLE CARBOXAMIDE INHIBITORS OF JAK2 AS POTENTIAL TREATMENT OF MYELOPROLIFERATIVE DISORDERS
1119, d1ywvA_, 0.7651, 2.83, 0.194, 274, 253, CRYSTAL STRUCTURES OF PROTO-ONCOGENE KINASE PIM1: A TARGET OF ABERRANT SOMATIC HYPERMUTATIONS IN DIFFUSE LARGE CELL LYMPHOMA
1120, p5v62A_, 0.7650, 2.78, 0.220, 349, 250, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP3
1121, d5dgzA_, 0.7650, 2.87, 0.194, 273, 253, DISCOVERY OF 35-SUBSTITUTED 6-AZAINDAZOLES AS POTENT PAN-PIM INHIBITORS
1122, d4qygB_, 0.7650, 2.96, 0.213, 264, 254, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
1123, d3at2A_, 0.7650, 3.07, 0.176, 334, 255, CRYSTAL STRUCTURE OF CK2ALPHA
1124, d2cgxA_, 0.7650, 2.90, 0.217, 265, 254, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
1125, d1zysA_, 0.7650, 3.04, 0.212, 271, 255, CO-CRYSTAL STRUCTURE OF CHECKPOINT KINASE CHK1 WITH A PYRROLO-PYRIDINE INHIBITOR
1126, d1lpuA_, 0.7650, 3.17, 0.163, 327, 258, LOW TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
1127, d5v82A_, 0.7649, 2.93, 0.193, 273, 254, PIM1 KINASE IN COMPLEX WITH CPD17 (1-(6-(44-DIFLUOROPIPERIDIN-3-YL) PYRIDIN-2-YL)-6-(6-METHYLPYRAZIN-2-YL)-1H-PYRAZOLO[43-C]PYRIDINE)
1128, d5kgiA_, 0.7649, 2.81, 0.194, 273, 252, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR 2-[34-BIS(CHLORANYL) PHENOXY]ETHANAMINE
1129, p4lfiA_, 0.7649, 3.13, 0.151, 370, 258, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1130, d3q9zA_, 0.7649, 3.21, 0.178, 332, 259, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
1131, d3naxA_, 0.7649, 2.81, 0.174, 278, 253, PDK1 IN COMPLEX WITH INHIBITOR MP7
1132, p4lfiB_, 0.7648, 3.13, 0.151, 371, 258, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1133, d4giiA1, 0.7648, 3.17, 0.215, 287, 261, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
1134, d4a7cA_, 0.7648, 2.79, 0.187, 273, 252, CRYSTAL STRUCTURE OF PIM1 KINASE WITH ETP46546
1135, d3wowA_, 0.7648, 3.05, 0.176, 334, 255, CRYSTAL STRUCTURE OF HUMAN CK2A WITH AMPPNP
1136, d2xj0A_, 0.7648, 2.87, 0.194, 274, 253, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-4 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
1137, d2ivsA_, 0.7648, 3.04, 0.167, 284, 257, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
1138, d1ds5D_, 0.7648, 3.17, 0.163, 328, 258, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1139, d5mpjA_, 0.7647, 2.84, 0.175, 326, 252, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
1140, d5imeA1, 0.7647, 2.99, 0.203, 279, 256, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
1141, d4qygA_, 0.7647, 2.83, 0.218, 264, 252, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
1142, d4gj3A1, 0.7647, 3.14, 0.215, 287, 260, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
1143, d3e63A_, 0.7647, 3.29, 0.208, 290, 264, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
1144, p3e3bX_, 0.7647, 2.99, 0.181, 334, 254, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2ALPHA PRIME WITH A POTENT INDAZOLE-DERIVATIVE INHIBITOR
1145, d2zoqB_, 0.7647, 2.71, 0.216, 351, 250, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
1146, d5nhoA_, 0.7646, 2.71, 0.216, 343, 250, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
1147, d4zimB1, 0.7646, 3.35, 0.193, 292, 264, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
1148, d4rpvA_, 0.7646, 2.79, 0.194, 273, 252, CO-CRYSTAL STRUCTURE OF PIM1 WITH COMPOUND 3
1149, d2bdwB_, 0.7646, 3.14, 0.201, 309, 259, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
1150, d1vjyA_, 0.7646, 3.20, 0.208, 299, 260, CRYSTAL STRUCTURE OF A NAPHTHYRIDINE INHIBITOR OF HUMAN TGF- BETA TYPE I RECEPTOR
1151, d5kgdA_, 0.7645, 2.81, 0.194, 273, 252, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-PYRIDIN-3-YL-1~{H}- BENZIMIDAZOLE
1152, d5b0xA_, 0.7645, 3.02, 0.177, 329, 254, CRYSTAL STRUCTURE OF THE CK2A/BENZOIC ACID DERIVATIVE COMPLEX
1153, d4x0mA1, 0.7645, 3.35, 0.206, 302, 262, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
1154, d4mbiA_, 0.7645, 2.90, 0.197, 274, 254, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
1155, d4kwpA_, 0.7645, 3.09, 0.179, 329, 257, CRYSTAL STRUCTURE OF HUMAN CK2-ALPHA IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR (K164) AT 1.25 A RESOLUTION
1156, d4jx7A_, 0.7645, 2.91, 0.193, 274, 254, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR 2-[(TRANS- 4-AMINOCYCLOHEXYL)AMINO]-4-{[3-(TRIFLUOROMETHYL) PHENYL]AMINO}PYRIDO[43-D]PYRIMIDIN-5(6H)-ONE
1157, d3w2qA1, 0.7645, 3.44, 0.174, 306, 265, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH HKI-272
1158, d3c4eC_, 0.7645, 2.77, 0.194, 272, 252, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
1159, d5telA_, 0.7644, 2.93, 0.193, 273, 254, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
1160, d5mo7B_, 0.7644, 2.78, 0.175, 325, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1161, d5flfD_, 0.7644, 3.06, 0.205, 290, 259, DISEASE LINKED MUTATION IN FGFR
1162, d5cx9B_, 0.7644, 2.78, 0.183, 325, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
1163, d4n6yA_, 0.7644, 2.81, 0.183, 273, 252, PIM1 COMPLEXED WITH A PHENYLCARBOXAMIDE
1164, d4fzaB1, 0.7644, 3.12, 0.198, 280, 257, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX
1165, d3owkA_, 0.7644, 3.09, 0.183, 330, 257, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
1166, d2ya9A_, 0.7644, 3.15, 0.181, 299, 260, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
1167, d2gs2A_, 0.7644, 3.49, 0.177, 305, 266, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN
1168, d5opuA_, 0.7643, 2.79, 0.211, 261, 251, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
1169, d5c1qB_, 0.7643, 2.78, 0.194, 273, 252, SERINE/THREONINE-PROTEIN KINASE PIM-1
1170, d4i23A_, 0.7643, 3.39, 0.171, 304, 263, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH DACOMITINIB (SOAKED)
1171, d4ckiA1, 0.7643, 3.03, 0.168, 288, 256, CRYSTAL STRUCTURE OF ONCOGENIC RET TYROSINE KINASE M918T BOUND TO ADENOSINE
1172, p3u9cA_, 0.7643, 3.16, 0.178, 331, 258, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
1173, d2o3pA_, 0.7643, 2.93, 0.193, 274, 254, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETIN
1174, d5v60A_, 0.7642, 2.76, 0.220, 347, 250, PHOSPHO-ERK2 BOUND TO AMP-PCP
1175, d5mo5B_, 0.7642, 2.79, 0.179, 325, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1176, d5kgeA_, 0.7642, 2.90, 0.194, 273, 253, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 5-(34-DICHLOROPHENYL)- 1~{H}-PYRAZOL-3-AMINE
1177, d5dhjA_, 0.7642, 2.88, 0.194, 273, 253, PIM1 IN COMPLEX WITH CPD4 (3-METHYL-5-(PYRIDIN-3-YL)-1H-PYRAZOLO[34- C]PYRIDINE)
1178, d4k1bA_, 0.7642, 2.89, 0.194, 273, 253, STRUCTURE OF PIM-1 KINASE BOUND TO N-(5-(2-FLUOROPHENYL)-1H-PYRROLO[2 3-B]PYRIDIN-3-YL)-5-((((3R4R)-3-FLUOROPIPERIDIN-4-YL)METHYL)AMINO) PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
1179, d3u87A_, 0.7642, 3.10, 0.183, 329, 257, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
1180, d3rpsB_, 0.7642, 3.20, 0.171, 334, 257, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
1181, d3kxnA_, 0.7642, 3.15, 0.163, 327, 258, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR TETRAIODOBENZIMIDAZOLE (K88)
1182, d3e62A_, 0.7642, 3.29, 0.205, 291, 264, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
1183, d5mmrB_, 0.7641, 2.78, 0.183, 325, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
1184, d5m56B_, 0.7641, 3.17, 0.176, 328, 256, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
1185, d4qyeA_, 0.7641, 2.98, 0.217, 271, 254, CHK1 KINASE DOMAIN IN COMPLEX WITH DIARYLPYRAZINE COMPOUND 1
1186, d4f08A_, 0.7641, 3.30, 0.209, 288, 263, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
1187, d4d0xA_, 0.7641, 3.29, 0.205, 291, 264, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
1188, d2xiyA_, 0.7641, 2.98, 0.181, 273, 254, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-2 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
1189, d2wotA_, 0.7641, 3.23, 0.208, 303, 260, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
1190, d2wotA1, 0.7641, 3.23, 0.208, 301, 260, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
1191, d2o64A_, 0.7641, 2.93, 0.193, 274, 254, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETAGETIN
1192, d1yxuC_, 0.7641, 2.79, 0.194, 272, 252, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
1193, d5mmfB_, 0.7640, 2.78, 0.179, 325, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
1194, d5cf4B_, 0.7640, 3.35, 0.197, 291, 264, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
1195, d4ytiA_, 0.7640, 3.23, 0.198, 284, 262, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
1196, d4mblA_, 0.7640, 2.83, 0.198, 274, 253, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
1197, d4f08B_, 0.7640, 3.29, 0.205, 288, 263, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
1198, p3zuvA_, 0.7640, 2.74, 0.220, 357, 250, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
1199, p3u9cB_, 0.7640, 3.17, 0.178, 331, 258, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
1200, d5hg8A_, 0.7639, 3.44, 0.185, 300, 265, EGFR (L858R T790M V948R) IN COMPLEX WITH N-[3-({2-[(1-METHYL-1H- PYRAZOL-4-YL)AMINO]-7H-PYRROLO[23-D]PYRIMIDIN-4-YL}OXY)PHENYL]PROP- 2-ENAMIDE
1201, d5flfB_, 0.7639, 3.11, 0.204, 292, 260, DISEASE LINKED MUTATION IN FGFR
1202, d4ubaB_, 0.7639, 3.11, 0.172, 333, 256, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
1203, d4li5A1, 0.7639, 3.46, 0.175, 303, 263, EGFR-K IN COMPLEX WITH N-[3-[[5-CHLORO-4-(1H-INDOL-3-YL)PYRIMIDIN-2- YL]AMINO]-4-METHOXY-PHENYL] PROP-2-ENAMIDE
1204, d4alvA_, 0.7639, 2.96, 0.193, 274, 254, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
1205, d3vc4A_, 0.7639, 2.89, 0.194, 274, 253, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
1206, d2o63A_, 0.7639, 2.92, 0.197, 274, 254, CRYSTAL STRUCTURE OF PIM1 WITH MYRICETIN
1207, d2hxqA_, 0.7639, 2.98, 0.216, 272, 255, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2
1208, d2erkA_, 0.7639, 2.74, 0.220, 351, 250, PHOSPHORYLATED MAP KINASE ERK2
1209, d2bzjA_, 0.7639, 2.79, 0.198, 273, 252, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU3
1210, d2a27A_, 0.7639, 3.17, 0.177, 304, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1211, d1yxuB_, 0.7639, 2.79, 0.194, 273, 252, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
1212, d5cu2A_, 0.7638, 2.95, 0.180, 328, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
1213, d3mb7A_, 0.7638, 3.20, 0.182, 330, 258, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (AMR)
1214, d2welA_, 0.7638, 2.97, 0.196, 304, 255, CRYSTAL STRUCTURE OF SU6656-BOUND CALCIUM/CALMODULIN- DEPENDENT PROTEIN KINASE II DELTA IN COMPLEX WITH CALMODULIN
1215, d2a27C_, 0.7638, 3.17, 0.177, 303, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1216, d1yxvA_, 0.7638, 2.95, 0.193, 274, 254, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH 34-DIHYDROXY-1- METHYLQUINOLIN-2(1H)-ONE
1217, d5hd7A_, 0.7637, 2.71, 0.212, 347, 250, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT MUTANT SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
1218, d4wsyA_, 0.7637, 2.89, 0.194, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIAZOLAMINE-INDAZOLE INHIBITOR.
1219, d4py1A_, 0.7637, 3.17, 0.215, 289, 261, CRYSTAL STRUCTURE OF TYK2 IN COMPLEX WITH COMPOUND 15 6-((25- DIMETHOXYPHENYL)THIO)-3-(1-METHYL-1H-PYRAZOL-4-YL)-[124]TRIAZOLO[4 3-B]PYRIDAZINE
1220, d3r01A_, 0.7637, 2.88, 0.194, 274, 253, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
1221, d1xr1A_, 0.7637, 3.06, 0.196, 277, 255, CRYSTAL STRUCTURE OF HPIM-1 KINASE IN COMPLEX WITH AMP-PNP AT 2.1 A RESOLUTION
1222, d4medA_, 0.7636, 2.89, 0.186, 272, 253, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE DERIVATIVES
1223, d4k0yA_, 0.7636, 2.95, 0.193, 274, 254, STRUCTURE OF PIM-1 KINASE BOUND TO N-(4-FLUOROPHENYL)-7-HYDROXY-5- (PIPERIDIN-4-YL)PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
1224, d4gfmA_, 0.7636, 3.27, 0.202, 289, 263, JAK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
1225, d3mvjB_, 0.7636, 2.95, 0.185, 320, 254, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
1226, d2o65A_, 0.7636, 2.84, 0.198, 274, 253, CRYSTAL STRUCTURE OF PIM1 WITH PENTAHYDROXYFLAVONE
1227, d2a27F_, 0.7636, 3.17, 0.177, 303, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1228, d5texA_, 0.7635, 2.94, 0.193, 274, 254, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
1229, d5op5A_, 0.7635, 2.76, 0.212, 259, 250, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
1230, d5nhlA_, 0.7635, 2.72, 0.216, 345, 250, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
1231, d5e90A1, 0.7635, 3.30, 0.204, 300, 260, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249F S280T Y282FS287NA350CL352F) IN COMPLEX WITH 3-AMINO-6- [4-(2- HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL]PYRAZINE-2- CARBOXAMIDE
1232, d4xh6A_, 0.7635, 2.90, 0.198, 273, 253, CRYSTAL STRUCTURE OF PROTO-ONCOGENE KINASE PIM1 BOUND TO HISPIDULIN
1233, d4wrsA_, 0.7635, 2.89, 0.194, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AZASPIRO PYRAZINYL-INDAZOLE INHIBITOR.
1234, d4ji9A_, 0.7635, 3.20, 0.203, 284, 261, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
1235, d3qc4B1, 0.7635, 2.78, 0.196, 268, 250, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
1236, d3jyaA_, 0.7635, 2.87, 0.194, 274, 253, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
1237, d2a27G_, 0.7635, 3.17, 0.177, 303, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1238, d1yxxA_, 0.7635, 2.95, 0.193, 274, 254, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH (3E)-3-[(4- HYDROXYPHENYL)IMINO]-1H-INDOL-2(3H)-ONE
1239, d1m2qA_, 0.7635, 3.17, 0.167, 327, 258, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO-XANTEN-9- ONE/CK2 KINASE COMPLEX
1240, d5mo8B_, 0.7634, 2.79, 0.179, 324, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1241, d5cvhA_, 0.7634, 2.79, 0.179, 327, 251, CRYSTAL STRUCTURE OF CK2ALPHA
1242, d2a27H_, 0.7634, 3.17, 0.177, 304, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1243, d2a27D_, 0.7634, 3.17, 0.177, 304, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1244, d5mowA1, 0.7633, 2.72, 0.184, 326, 250, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1245, d4hyhA_, 0.7633, 2.95, 0.209, 263, 254, X-RAY CRYSTAL STRUCTURE OF COMPOUND 39 BOUND TO HUMAN CHK1 KINASE DOMAIN
1246, d4ewhA_, 0.7633, 2.98, 0.215, 274, 256, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
1247, d4dgoA_, 0.7633, 3.17, 0.163, 325, 258, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH TYRPHOSTIN AG99
1248, d2xixA_, 0.7633, 3.00, 0.181, 272, 254, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-1 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
1249, d1yxuA_, 0.7633, 2.80, 0.194, 273, 252, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
1250, d5nhjA_, 0.7632, 2.73, 0.216, 345, 250, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
1251, d4rvkA_, 0.7632, 3.00, 0.209, 264, 254, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 8: N-[3-(6-CYANO-9H- PYRROLO[23-B:54-C ]DIPYRIDIN-3-YL)PHENYL]ACETAMIDE
1252, d3fl5A_, 0.7632, 3.14, 0.163, 324, 257, PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR QUINALIZARIN
1253, d3eyhA_, 0.7632, 3.23, 0.208, 285, 260, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
1254, d2a27E_, 0.7632, 3.18, 0.177, 303, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1255, d4rlkA_, 0.7631, 3.19, 0.163, 327, 258, CRYSTAL STRUCTURE OF Z. MAYS CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
1256, d3r00A_, 0.7631, 2.97, 0.193, 274, 254, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
1257, d2ya9B_, 0.7631, 3.15, 0.193, 299, 259, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
1258, d2xzsA_, 0.7631, 3.19, 0.188, 301, 260, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
1259, d2cgvA_, 0.7631, 2.88, 0.217, 264, 253, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
1260, d6b16A_, 0.7630, 3.28, 0.215, 285, 261, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
1261, d5oopA_, 0.7630, 2.87, 0.218, 261, 252, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMP-PNP
1262, d5nhpA_, 0.7630, 2.72, 0.216, 338, 250, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
1263, d5dwrA_, 0.7630, 2.90, 0.182, 273, 253, IDENTIFICATION OF N-(4-((1R3S5S)-3-AMINO-5-METHYLCYCLOHEXYL)PYRIDIN- 3-YL)-6-(26-DIFLUOROPHENYL)-5-FLUOROPICOLINAMIDE (PIM447) A POTENT AND SELECTIVE PROVIRAL INSERTION SITE OF MOLONEY MURINE LEUKEMIA (PIM) 12 AND 3 KINASE INHIBITOR IN CLINICAL TRIALS FOR HEMATOLOGICAL MALIGNANCIES
1264, d4qyhB_, 0.7630, 2.99, 0.209, 264, 254, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
1265, d4jq8A_, 0.7630, 3.25, 0.185, 303, 260, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4B
1266, d4dgmA_, 0.7630, 3.17, 0.163, 326, 258, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR APIGENIN
1267, d4anmA1, 0.7630, 3.16, 0.163, 327, 258, COMPLEX OF CK2 WITH A CDC7 INHIBITOR
1268, d3q32B1, 0.7630, 3.41, 0.192, 293, 265, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
1269, d3nlbA_, 0.7630, 2.88, 0.210, 261, 252, NOVEL KINASE PROFILE HIGHLIGHTS THE TEMPORAL BASIS OF CONTEXT DEPENDENT CHECKPOINT PATHWAYS TO CELL DEATH
1270, d3jpvA_, 0.7630, 2.91, 0.194, 273, 253, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A PYRROLO[23- A]CARBAZOLE LIGAND
1271, d2zoqA_, 0.7630, 2.73, 0.216, 351, 250, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
1272, d2j5eA_, 0.7630, 3.47, 0.185, 309, 265, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 13-JAB
1273, d5modB_, 0.7629, 2.80, 0.183, 324, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1274, d5h8bB_, 0.7629, 3.18, 0.178, 331, 258, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
1275, d4qyyA_, 0.7629, 2.72, 0.220, 337, 250, DISCOVERY OF NOVEL DUAL MECHANISM ERK INHIBITORS BY AFFINITY SELECTION SCREENING OF AN INACTIVE KINASE STATE
1276, d4n70A_, 0.7629, 2.91, 0.182, 274, 253, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
1277, p4fi1A_, 0.7629, 3.15, 0.151, 371, 258, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
1278, d3jxwA_, 0.7629, 2.89, 0.194, 274, 253, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
1279, d2brbA_, 0.7629, 3.01, 0.216, 272, 255, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
1280, d2br1A_, 0.7629, 2.99, 0.216, 272, 255, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
1281, d5mowB_, 0.7628, 2.81, 0.183, 324, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1282, d5cf6B1, 0.7628, 3.34, 0.198, 288, 263, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
1283, p4mwhA_, 0.7628, 3.15, 0.151, 371, 258, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
1284, d4iaaA_, 0.7628, 2.83, 0.183, 272, 252, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE
1285, d4f09A_, 0.7628, 3.35, 0.193, 288, 264, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
1286, d2brnA_, 0.7628, 3.01, 0.212, 268, 255, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
1287, d1phkA_, 0.7628, 2.82, 0.171, 277, 251, TWO STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHORYLASE KINASE: AN ACTIVE PROTEIN KINASE COMPLEXED WITH NUCLEOTIDE SUBSTRATE-ANALOGUE AND PRODUCT
1288, p6g97A_, 0.7627, 2.76, 0.216, 344, 250, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1289, d5kwhB_, 0.7627, 3.18, 0.178, 331, 258, CRYSTAL STRUCTURE OF CK2
1290, d4wt6A_, 0.7627, 2.81, 0.194, 273, 252, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIADIAZOLAMINE-INDOLE INHIBITOR.
1291, d3q6wA1, 0.7627, 3.05, 0.176, 293, 256, STRUCTURE OF DUALLY-PHOSPHORYLATED MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG WITH SPECIFICITY FOR THE ACTIVATED RECEPTOR
1292, d2a27B_, 0.7627, 3.17, 0.177, 303, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1293, d5cf6A_, 0.7626, 3.23, 0.203, 285, 261, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
1294, d4riyD_, 0.7626, 3.42, 0.179, 297, 262, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
1295, d4ftiA_, 0.7626, 2.96, 0.221, 270, 253, CRYSTAL STRUCTURE OF THE CHK1
1296, d4aluA_, 0.7626, 2.98, 0.189, 274, 254, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
1297, d5toeA_, 0.7625, 2.96, 0.197, 272, 254, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
1298, d3q9xA_, 0.7625, 3.16, 0.178, 330, 258, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
1299, d2broA_, 0.7625, 3.11, 0.215, 272, 256, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
1300, d5modA_, 0.7624, 2.96, 0.180, 327, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1301, d4dtkA_, 0.7624, 2.92, 0.194, 273, 253, NOVEL AND SELECTIVE PAN-PIM KINASE INHIBITOR
1302, d3u87B_, 0.7624, 3.10, 0.175, 329, 257, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
1303, d2jiuA_, 0.7624, 3.37, 0.183, 303, 263, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
1304, d2ivtA1, 0.7624, 3.05, 0.168, 283, 256, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
1305, d1ungA_, 0.7624, 2.62, 0.169, 288, 248, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
1306, d1dayA_, 0.7624, 3.25, 0.162, 327, 259, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-GMPPNP
1307, d5oq5A_, 0.7623, 2.88, 0.230, 265, 252, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
1308, d4zy5A_, 0.7623, 3.19, 0.197, 283, 259, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
1309, d4rc4A_, 0.7623, 2.85, 0.183, 272, 252, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
1310, d4j96B_, 0.7623, 3.16, 0.173, 305, 260, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
1311, d3bgpA_, 0.7623, 2.94, 0.182, 272, 253, HUMAN PIM-1 COMPLEXED WITH A BENZOISOXAZOLE INHIBITOR VX1
1312, d2bziB_, 0.7623, 2.91, 0.186, 272, 253, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU2
1313, d5xvuB_, 0.7622, 2.87, 0.190, 321, 252, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
1314, p5owlB_, 0.7622, 3.18, 0.174, 332, 259, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
1315, d5cqwB_, 0.7622, 3.23, 0.181, 331, 259, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
1316, d4dglC_, 0.7622, 3.04, 0.177, 334, 254, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
1317, d3w8lA_, 0.7622, 2.93, 0.178, 326, 253, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
1318, d3c4eD_, 0.7622, 2.92, 0.194, 273, 253, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
1319, d2xizA_, 0.7622, 3.00, 0.181, 273, 254, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-3 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
1320, d2hxlA_, 0.7622, 3.01, 0.220, 272, 255, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1
1321, p5n9nA_, 0.7621, 3.12, 0.179, 329, 257, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF85 (4A)
1322, p5n9lA_, 0.7621, 3.12, 0.179, 329, 257, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE DIBENZOFURAN INHIBITOR TF (4B)
1323, d5em8A_, 0.7621, 3.30, 0.176, 303, 262, EGFR KINASE DOMAIN WITH PYRIDONE COMPOUND 13: 4-[(2-METHOXYPHENYL) AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2-OXIDANYLIDENE-1~{H}- PYRIDINE-3-CARBOXAMIDE
1324, d4xhkB_, 0.7621, 2.85, 0.183, 269, 252, PIM1 KINASE IN COMPLEX WITH COMPOUND 1S
1325, d4ubaA_, 0.7621, 3.25, 0.181, 333, 259, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
1326, d3krrA1, 0.7621, 3.33, 0.197, 290, 264, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT QUINOXALINE ATP SITE INHIBITOR
1327, d2hogA_, 0.7621, 3.04, 0.217, 272, 254, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 20
1328, d5j79A_, 0.7620, 3.10, 0.170, 283, 259, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
1329, d4i41A_, 0.7620, 2.86, 0.183, 272, 252, CRYSTAL STRUCTURE OF HUMAN SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE
1330, p4gubA_, 0.7620, 3.00, 0.182, 329, 253, CASEIN KINASE II BOUND TO INHIBITOR
1331, d2xj2A_, 0.7620, 3.00, 0.181, 273, 254, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1332, d5ku8A_, 0.7619, 3.05, 0.173, 328, 254, CRYSTAL STRUCTURE OF CK2
1333, d5kggA_, 0.7619, 2.86, 0.194, 273, 252, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-(5-CHLORANYL-1~{H}-INDOL- 3-YL)ETHANAMINE
1334, d5iisA_, 0.7619, 2.86, 0.183, 273, 252, DESIGN SYNTHESIS AND STRUCTURE ACTIVITY RELATIONSHIP OF POTENT PAN- PIM KINASE INHIBITORS DERIVED FROM THE PYRIDYL-AMIDE SCAFFOLD
1335, d4rblA_, 0.7619, 2.80, 0.183, 271, 251, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
1336, d3kxmA_, 0.7619, 3.17, 0.163, 326, 258, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR K74
1337, d2objA_, 0.7619, 2.87, 0.183, 272, 252, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH INHIBITOR
1338, d1yxuD_, 0.7619, 2.93, 0.194, 273, 253, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
1339, d1m2pA_, 0.7619, 3.20, 0.163, 325, 258, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO- ANTHRAQUINONE/CK2 KINASE COMPLEX
1340, p6gdqA_, 0.7618, 2.69, 0.217, 339, 249, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1341, p6g93A_, 0.7618, 2.70, 0.217, 343, 249, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1342, d5mo5A_, 0.7618, 2.91, 0.181, 326, 254, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1343, d3we8A_, 0.7618, 2.82, 0.198, 273, 252, PIM-1 KINASE IN COMPLEX WITH RUTHENIUM-BASED INHIBITOR
1344, d5usqA_, 0.7617, 3.19, 0.213, 299, 258, ALK-5 KINASE INHIBITOR COMPLEX
1345, d5kcxA_, 0.7617, 2.91, 0.198, 272, 253, PIM-1 KINASE IN COMPLEX WITH A SELECTIVE N-SUBSTITUTED 7-AZAINDOLE INHIBITOR
1346, d4zimA_, 0.7617, 3.32, 0.195, 285, 262, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
1347, d4fsnA_, 0.7617, 3.03, 0.205, 270, 254, CRYSTAL STRUCTURE OF THE CHK1
1348, d3b2tA_, 0.7617, 3.27, 0.172, 288, 261, STRUCTURE OF PHOSPHOTRANSFERASE
1349, d5ipjA_, 0.7616, 2.94, 0.194, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A QUINAZOLINONE-PYRROLOPYRROLONE INHIBITOR.
1350, d5eolA_, 0.7616, 2.95, 0.194, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A MACROCYCLIC QUINOXALINE-PYRROLODIHYDROPIPERIDINONE INHIBITOR
1351, d4ty1A_, 0.7616, 2.92, 0.194, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AMINOOXADIAZOLE-INDOLE INHIBITOR.
1352, d4jrvA_, 0.7616, 3.30, 0.180, 300, 261, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4C
1353, d4iwdA1, 0.7616, 3.09, 0.171, 295, 257, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-8033 ANALOG
1354, d4rvtA_, 0.7615, 3.06, 0.196, 281, 255, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
1355, p4md9F_, 0.7615, 3.14, 0.183, 327, 257, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1356, d4bxaB_, 0.7615, 3.15, 0.174, 331, 258,  
1357, d4bbeC_, 0.7615, 3.29, 0.195, 288, 262, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
1358, d2brmA_, 0.7615, 2.97, 0.209, 263, 254, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
1359, d1nvqA_, 0.7615, 3.06, 0.209, 264, 254, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/UCN-01
1360, d5t1hB_, 0.7614, 3.20, 0.178, 331, 258, CRYSTAL STRUCTURE OF CK2
1361, d3wilA_, 0.7614, 3.13, 0.183, 331, 257, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND3 COMPLEX
1362, d3warA_, 0.7614, 3.27, 0.178, 334, 259, CRYSTAL STRUCTURE OF HUMAN CK2A
1363, d3tkiA_, 0.7614, 2.98, 0.225, 272, 253, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S25
1364, d3bwfA_, 0.7614, 2.84, 0.194, 273, 252, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH AN OSMIUM COMPOUND
1365, d1om1A_, 0.7614, 3.18, 0.163, 325, 258, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH IQA
1366, d5mo6B_, 0.7613, 2.93, 0.181, 324, 254, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1367, d5ku8B_, 0.7613, 3.21, 0.178, 331, 258, CRYSTAL STRUCTURE OF CK2
1368, d5cu3A_, 0.7613, 2.82, 0.179, 325, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
1369, d5cu2B_, 0.7613, 2.93, 0.185, 325, 254, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
1370, d5ctpA_, 0.7613, 2.92, 0.185, 324, 254, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
1371, d4bbfA_, 0.7613, 3.32, 0.195, 288, 262, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
1372, d4bbeD_, 0.7613, 3.29, 0.195, 288, 262, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
1373, d4bbeA_, 0.7613, 3.29, 0.195, 288, 262, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
1374, d3rp0A_, 0.7613, 3.13, 0.179, 329, 257,  
1375, d3ikaA_, 0.7613, 3.32, 0.192, 310, 261, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
1376, d2x7fA_, 0.7613, 2.74, 0.203, 276, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
1377, d1zohA_, 0.7613, 3.19, 0.163, 326, 258, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
1378, d5flfA_, 0.7612, 3.09, 0.205, 296, 258, DISEASE LINKED MUTATION IN FGFR
1379, d5e8sA1, 0.7612, 3.29, 0.208, 299, 259, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (WT)
1380, d4rixD_, 0.7612, 3.36, 0.176, 297, 261, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
1381, d3kckA_, 0.7612, 3.23, 0.203, 285, 261, A NOVEL CHEMOTYPE OF KINASE INHIBITORS
1382, d1jwhB_, 0.7612, 3.08, 0.176, 335, 255, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
1383, d5tq8A_, 0.7611, 3.55, 0.203, 291, 266, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
1384, d5cf4A_, 0.7611, 3.21, 0.204, 283, 260, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
1385, d4rc2A_, 0.7611, 2.87, 0.183, 272, 252, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
1386, d4bbfD_, 0.7611, 3.31, 0.195, 288, 262, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
1387, d3w2oA1, 0.7611, 3.46, 0.181, 304, 265, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH TAK-285
1388, d3r04A_, 0.7611, 2.81, 0.195, 271, 251, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
1389, d2b7aA_, 0.7611, 3.25, 0.203, 284, 261, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
1390, d1jamA_, 0.7611, 3.19, 0.163, 327, 258, CRYSTAL STRUCTURE OF APO-FORM OF Z. MAYS CK2 PROTEIN KINASE ALPHA SUBUNIT
1391, d5turA_, 0.7610, 2.95, 0.194, 270, 253, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
1392, d5ct0B_, 0.7610, 2.94, 0.181, 326, 254, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
1393, d4qyhA_, 0.7610, 2.88, 0.218, 264, 252, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
1394, d4bbeB_, 0.7610, 3.30, 0.195, 288, 262, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
1395, d2xj1A_, 0.7610, 3.02, 0.181, 273, 254, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INIBITOR
1396, d1zoeA_, 0.7610, 3.18, 0.163, 325, 258, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
1397, d5opvA_, 0.7609, 2.92, 0.211, 261, 251, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
1398, d5mo7A_, 0.7609, 2.99, 0.180, 327, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1399, d5hd4A_, 0.7609, 2.75, 0.220, 347, 250, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT WILD TYPE SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
1400, d5e8zA1, 0.7609, 3.20, 0.213, 300, 258, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 3- AMINO-6-[4-(2-HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3- YL]PYRAZINE-2-CARBOXAMIDE
1401, d4rvmA_, 0.7609, 2.95, 0.209, 264, 253, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 19
1402, d3u4uA_, 0.7609, 3.00, 0.184, 327, 255, CASEIN KINASE 2 IN COMPLEX WITH AZ-INHIBITOR
1403, d5cf8A1, 0.7608, 3.22, 0.200, 284, 260, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
1404, d4qyfA_, 0.7608, 2.95, 0.209, 269, 253, CHK1 KINASE DOMAIN IN COMPLEX WITH AMINOPYRAZINE COMPOUND 13
1405, d4ewhB_, 0.7608, 2.98, 0.216, 273, 255, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
1406, d4bbfB_, 0.7608, 3.29, 0.198, 288, 262, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
1407, d3tjcA_, 0.7608, 3.27, 0.199, 284, 261, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
1408, d3bgzA_, 0.7608, 2.88, 0.183, 267, 252, HUMAN PIM-1 KINASE IN COMPLEX WITH DIPHENYL INDOLE INHIBITOR VX3
1409, d5mpjB_, 0.7607, 2.95, 0.185, 324, 254, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
1410, p4ib5B_, 0.7607, 3.25, 0.182, 329, 258, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
1411, d4ftuA_, 0.7607, 3.06, 0.205, 270, 254, CRYSTAL STRUCTURE OF THE CHK1
1412, d3lxnA_, 0.7607, 3.13, 0.216, 287, 259, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
1413, d2oxdA_, 0.7607, 3.12, 0.163, 325, 257, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE K17 K22 AND K32 INHIBITORS
1414, d2hy0A_, 0.7607, 3.03, 0.217, 272, 254, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 22
1415, d4u42A_, 0.7606, 3.09, 0.196, 282, 255, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
1416, d3vbyA_, 0.7606, 2.81, 0.195, 267, 251, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
1417, d3pvgA_, 0.7606, 3.18, 0.163, 326, 257, CRYSTAL STRUCTURE OF Z. MAYS CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMO-1-CARBOXYMETHYLBENZIMIDAZOLE (K68)
1418, d3kxjA_, 0.7606, 3.18, 0.163, 326, 257,  
1419, d3iecB_, 0.7606, 2.71, 0.217, 313, 249, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
1420, p3be9A_, 0.7606, 3.17, 0.163, 327, 257, STRUCTURE-BASED DESIGN AND SYNTHESIS OF NOVEL MACROCYCLIC PYRAZOLO[15-A] [135]TRIAZINE COMPOUNDS AS POTENT INHIBITORS OF PROTEIN KINASE CK2 AND THEIR ANTICANCER ACTIVITIES
1421, d2cgwA_, 0.7606, 2.89, 0.222, 262, 252, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
1422, d5ig1B_, 0.7605, 3.30, 0.211, 304, 261, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
1423, d3dcvA_, 0.7605, 2.94, 0.182, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM1 KINASE COMPLEXED WITH 4-(4- HYDROXY-3-METHYL-PHENYL)-6-PHENYLPYRIMIDIN-2(1H)-ONE
1424, d5usyB_, 0.7604, 3.21, 0.196, 287, 260, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
1425, d5op7A_, 0.7604, 2.88, 0.210, 261, 252, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
1426, d5h8gA_, 0.7604, 2.91, 0.179, 324, 251, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7B
1427, d5cvgA_, 0.7604, 2.81, 0.181, 326, 249, CRYSTAL STRUCTURE OF CK2ALPHA WITH A NOVEL CLOSED CONFORMATION OF THE AD LOOP
1428, d3t9iA_, 0.7604, 2.91, 0.175, 273, 252, PIM1 COMPLEXED WITH A NOVEL 36-DISUBSTITUTED INDOLE AT 2.6 ANG RESOLUTION
1429, d2xzsB_, 0.7604, 3.27, 0.188, 293, 260, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
1430, d1yi4A_, 0.7604, 2.82, 0.183, 267, 251, STRUCTURE OF PIM-1 BOUND TO ADENOSINE
1431, p6g9aA_, 0.7603, 2.73, 0.217, 341, 249, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1432, d5moeB_, 0.7603, 2.88, 0.182, 323, 253, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1433, d5diaA_, 0.7603, 2.96, 0.194, 273, 253, PIM1 IN COMPLEX WITH CPD36 ((1S3S)-N1-(6-(5-(PYRIDIN-3-YL)-1H- PYRAZOLO[34-C]PYRIDIN-3-YL)PYRIDIN-2-YL)CYCLOHEXANE-13-DIAMINE)
1434, d5cshA_, 0.7603, 2.93, 0.181, 324, 254, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
1435, d4hgeA_, 0.7603, 3.28, 0.202, 284, 262, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
1436, d3rp0D_, 0.7603, 3.15, 0.179, 329, 257,  
1437, d2zjwA_, 0.7603, 3.06, 0.181, 332, 254, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH ELLAGIC ACID
1438, d1f0qA_, 0.7603, 3.22, 0.163, 329, 258, CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT OF PROTEIN KINASE CK2 IN COMPLEX WITH THE NUCLEOTIDE COMPETITIVE INHIBITOR EMODIN
1439, p6ehuA_, 0.7602, 2.98, 0.178, 327, 253, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
1440, d5xvuC_, 0.7602, 2.95, 0.190, 321, 253, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
1441, d5tq3B_, 0.7602, 3.40, 0.198, 285, 262, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
1442, d4qp1B_, 0.7602, 2.72, 0.221, 343, 249, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
1443, d3vbtA_, 0.7602, 2.81, 0.195, 267, 251, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
1444, d3r7oA1, 0.7602, 3.09, 0.176, 295, 256, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG
1445, d3r02A_, 0.7602, 2.83, 0.195, 271, 251, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
1446, d2qc6A_, 0.7602, 3.09, 0.165, 326, 254, PROTEIN KINASE CK2 IN COMPLEX WITH DBC
1447, p2pvnA_, 0.7602, 3.17, 0.163, 327, 257, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1448, d4rc3A_, 0.7601, 2.83, 0.187, 271, 251, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
1449, d4mtaA_, 0.7601, 2.95, 0.194, 273, 253, CRYSTAL STRUCTURE OF PIM-1 KINASE DOMAIN IN COMPLEX WITH 2-METHYL-5- PHENYLFURAN-3-CARBOXYLIC ACID
1450, d4ckjA1, 0.7601, 3.12, 0.167, 287, 257, CRYSTAL STRUCTURE OF RET TYROSINE KINASE DOMAIN BOUND TO ADENOSINE
1451, d4aqcB_, 0.7601, 3.35, 0.198, 295, 263, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
1452, d3e64A_, 0.7601, 3.34, 0.201, 291, 264, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
1453, d2oxxA_, 0.7601, 3.20, 0.163, 325, 258, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
1454, d5e8tA1, 0.7600, 3.25, 0.208, 300, 259, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D)
1455, d3q4zA1, 0.7600, 3.08, 0.171, 281, 257, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
1456, d2cguA_, 0.7600, 2.88, 0.218, 263, 252, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
1457, d1sykB_, 0.7600, 3.06, 0.189, 323, 254, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
1458, d5xvuA_, 0.7599, 2.93, 0.190, 321, 253, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
1459, d5cvhB_, 0.7599, 2.95, 0.185, 324, 254, CRYSTAL STRUCTURE OF CK2ALPHA
1460, d4e6qA_, 0.7599, 3.36, 0.197, 296, 264, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
1461, d4bbfC_, 0.7599, 3.35, 0.198, 288, 263, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
1462, d1zogA_, 0.7599, 3.21, 0.163, 325, 258, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES
1463, d1nvsA_, 0.7599, 3.09, 0.209, 264, 254, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/SB218078
1464, d2ivuA1, 0.7598, 3.11, 0.172, 283, 256, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR ZD6474
1465, d1yhsA_, 0.7598, 2.83, 0.183, 267, 251, CRYSTAL STRUCTURE OF PIM-1 BOUND TO STAUROSPORINE
1466, d1sykA_, 0.7598, 3.04, 0.189, 348, 254, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
1467, d1h4lB_, 0.7598, 2.40, 0.181, 278, 243, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
1468, d5op2A_, 0.7597, 2.96, 0.209, 263, 253, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
1469, d5ootA_, 0.7597, 2.87, 0.211, 260, 251, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
1470, d3pzhA_, 0.7597, 3.18, 0.163, 327, 257, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH EMODIN AT 1.92 A RESOLUTION
1471, d2j6mA_, 0.7597, 3.29, 0.181, 306, 260, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AEE788
1472, d1h4lA_, 0.7597, 2.46, 0.180, 278, 244, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
1473, d5ui0B_, 0.7596, 3.17, 0.170, 304, 259, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
1474, d3kxgA_, 0.7596, 3.17, 0.163, 326, 257, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 34567-PENTABROMO-1H-INDAZOLE (K64)
1475, d3at4A_, 0.7596, 3.14, 0.183, 331, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVERTIVE
1476, d1nvrA_, 0.7596, 3.00, 0.209, 264, 253, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/STAUROSPORINE
1477, d1m14A_, 0.7596, 3.27, 0.185, 307, 260, TYROSINE KINASE DOMAIN FROM EPIDERMAL GROWTH FACTOR RECEPTOR
1478, d5j95A_, 0.7595, 3.15, 0.195, 284, 256, MAP4K4 IN COMPLEX WITH INHIBITOR
1479, d4lm5A_, 0.7595, 2.79, 0.200, 264, 250, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH 2-{4-[(3-AMINOPROPYL) AMINO]QUINAZOLIN-2-YL}PHENOL (RESULTING FROM DISPLACEMENT OF SKF86002)
1480, d4ft7A_, 0.7595, 3.07, 0.209, 270, 254, CRYSTAL STRUCTURE OF THE CHK1
1481, d3w2pA1, 0.7595, 3.49, 0.177, 307, 265, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 2
1482, d3vbxA_, 0.7595, 2.83, 0.195, 268, 251, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
1483, d2wtkC1, 0.7595, 2.55, 0.183, 261, 246, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
1484, d4ji9B_, 0.7594, 3.40, 0.198, 288, 263, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
1485, d4dgnA_, 0.7594, 3.18, 0.163, 325, 257, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR LUTEOLIN
1486, p2pvmA_, 0.7594, 3.19, 0.163, 327, 257, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1487, d5ui0A_, 0.7593, 3.16, 0.170, 301, 259, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
1488, d3pwdA_, 0.7593, 3.21, 0.163, 327, 258, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH NBC (Z1)
1489, d3dfcB1, 0.7593, 3.08, 0.193, 276, 254, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH AMPPNP
1490, d2c3lA_, 0.7593, 2.97, 0.226, 265, 252, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
1491, d5o13A_, 0.7592, 2.93, 0.183, 270, 252, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
1492, d5d9kB_, 0.7592, 2.78, 0.181, 280, 248, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
1493, d4riwD_, 0.7592, 3.44, 0.179, 297, 262, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
1494, d4e6qB_, 0.7592, 3.38, 0.193, 296, 264, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
1495, d4d0wA_, 0.7592, 3.28, 0.206, 289, 262, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
1496, d3vbvA_, 0.7592, 2.84, 0.195, 268, 251, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
1497, d3eqrA_, 0.7592, 3.11, 0.230, 270, 257, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
1498, d3e5aA_, 0.7592, 2.86, 0.196, 264, 250, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH VX-680 AND TPX2
1499, d3bgqA_, 0.7592, 2.89, 0.179, 272, 252, HUMAN PIM-1 KINASE IN COMPLEX WITH AN TRIAZOLO PYRIDAZINE INHIBITOR VX2
1500, d2f2cB_, 0.7592, 2.73, 0.181, 280, 248, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLINWITH THE INHIBITOR AMINOPURVALANOL
1501, d4jr3A_, 0.7591, 3.35, 0.184, 303, 261, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 3G
1502, d4bzoA_, 0.7591, 2.91, 0.183, 272, 252, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO- PYRAZINONE INHIBITOR
1503, d3fupA_, 0.7591, 3.30, 0.207, 284, 261, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
1504, d3at3A_, 0.7591, 3.14, 0.183, 332, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVATIVE
1505, d5oq8A_, 0.7590, 2.94, 0.214, 261, 252, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
1506, d3gu8A1, 0.7590, 3.01, 0.193, 276, 254, CRYSTAL STRUCTURE OF DAPKL93G WITH N6-CYCLOPENTYLADENOSINE
1507, d5tq5A_, 0.7589, 3.60, 0.203, 291, 266, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
1508, d5cxhA1, 0.7589, 3.04, 0.195, 273, 257, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT ORALLY BIOAVAILABLE THIAZOLE INHIBITOR
1509, d1zwsD_, 0.7589, 3.16, 0.187, 278, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1510, d5cwzA_, 0.7588, 2.96, 0.194, 284, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
1511, d4alwA_, 0.7588, 3.06, 0.193, 273, 254, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
1512, d3jy9A_, 0.7588, 3.23, 0.192, 282, 260, JANUS KINASE 2 INHIBITORS
1513, d5cf8B1, 0.7587, 3.30, 0.199, 287, 261, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
1514, d3eygA_, 0.7587, 3.21, 0.209, 280, 258, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
1515, d2y7jA_, 0.7587, 2.77, 0.193, 284, 249, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1516, d1yi3A_, 0.7587, 2.86, 0.183, 267, 251, CRYSTAL STRUCTURE OF PIM-1 BOUND TO LY294002
1517, d4zy6A_, 0.7586, 3.33, 0.208, 284, 260, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
1518, d4ytfA_, 0.7586, 3.28, 0.195, 283, 261, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
1519, d4ft9A_, 0.7586, 3.03, 0.206, 270, 253, CRYSTAL STRUCTURE OF THE CHK1
1520, d3w8lB_, 0.7586, 3.02, 0.178, 326, 253, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
1521, d2x2mA1, 0.7586, 3.01, 0.161, 281, 254, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
1522, d2vz6A1, 0.7586, 3.14, 0.191, 285, 256, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
1523, d2itpA_, 0.7586, 3.29, 0.177, 305, 260, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AEE788
1524, d2eb2A_, 0.7586, 3.35, 0.169, 305, 261, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (G719S)
1525, d5walA1, 0.7585, 3.26, 0.215, 285, 261, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
1526, d5flfC_, 0.7585, 3.20, 0.204, 283, 260, DISEASE LINKED MUTATION IN FGFR
1527, d4ytcA_, 0.7585, 3.30, 0.191, 284, 262, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
1528, d4gvjA1, 0.7585, 3.23, 0.215, 288, 260, TYK2 (JH1) IN COMPLEX WITH ADENOSINE DI-PHOSPHATE
1529, d3ag9A_, 0.7585, 3.07, 0.181, 323, 254, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
1530, d5hu3A_, 0.7584, 3.06, 0.194, 266, 253, DROSOPHILA CAMKII-D136N IN COMPLEX WITH A PHOSPHORYLATED FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
1531, d4n6zA_, 0.7584, 2.90, 0.183, 272, 252, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
1532, p2pvhA_, 0.7584, 3.20, 0.163, 327, 257, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1533, d2ojgA_, 0.7584, 2.75, 0.220, 337, 250, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH NN-DIMETHYL-4-(4- PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
1534, d1yxtA_, 0.7584, 3.05, 0.193, 274, 254, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMPPNP
1535, d4qtbA_, 0.7583, 2.92, 0.209, 351, 254, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
1536, d4ae6B_, 0.7583, 3.04, 0.190, 321, 253, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
1537, d1yrpB_, 0.7583, 2.98, 0.190, 275, 252, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
1538, d1yrpA_, 0.7583, 2.98, 0.190, 275, 252, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
1539, d5usyA_, 0.7582, 3.26, 0.196, 287, 260, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
1540, d5cs6A_, 0.7582, 2.96, 0.175, 327, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
1541, d4ft3A_, 0.7582, 2.96, 0.214, 269, 252, CRYSTAL STRUCTURE OF THE CHK1
1542, d3gu4A1, 0.7582, 3.09, 0.193, 276, 254, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP
1543, d5wevA_, 0.7581, 3.24, 0.189, 293, 259, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
1544, d4yc3A1, 0.7581, 2.86, 0.201, 294, 249, CDK1/CYCLINB1/CKS2 APO
1545, d4jq7A_, 0.7581, 3.24, 0.181, 303, 260, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 2A
1546, d4j98B_, 0.7581, 3.13, 0.174, 304, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
1547, p6gihA_, 0.7580, 3.00, 0.182, 324, 253, CRYSTAL STRUCTURE OF CK2ALPHA WITH CAM187 BOUND 
1548, p6g8xA_, 0.7580, 2.73, 0.221, 338, 249, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1549, d5tq3A_, 0.7580, 3.33, 0.200, 282, 260, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
1550, d5eg3A_, 0.7580, 3.34, 0.172, 301, 261, CRYSTAL STRUCTURE OF THE ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH THE CSH2 DOMAIN OF PHOSPHOLIPASE C GAMMA (PLCGAMMA)
1551, d4hgeB_, 0.7580, 3.34, 0.202, 288, 262, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
1552, d4fv3A_, 0.7580, 2.74, 0.221, 346, 249, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK6
1553, d2ojjA_, 0.7580, 2.77, 0.220, 344, 250, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-N-(1-(3- CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
1554, d1zwsF_, 0.7580, 3.17, 0.191, 278, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1555, p6ehuB_, 0.7579, 3.10, 0.180, 327, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
1556, d5f1zA1, 0.7579, 3.15, 0.233, 280, 258, STRUCTURE OF TYK2 WITH INHIBITOR 16: 3-AZANYL-5-[(2~{S})-3- METHYLBUTAN-2-YL]-7-[1-METHYL-5-(2-OXIDANYLPROPAN-2-YL)PYRAZOL-3-YL]- 1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
1557, d5d9kA_, 0.7579, 2.83, 0.181, 280, 248, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
1558, d4fsrA_, 0.7579, 2.98, 0.214, 269, 252, CRYSTAL STRUCTURE OF THE CHK1
1559, d3vbqA_, 0.7579, 2.95, 0.194, 271, 252, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
1560, d3tjcB_, 0.7579, 3.36, 0.198, 287, 262, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
1561, d2xa4B_, 0.7579, 3.23, 0.205, 275, 258, INHIBITORS OF JAK2 KINASE DOMAIN
1562, d2itqA_, 0.7579, 3.21, 0.178, 300, 259, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AFN941
1563, d4u43A_, 0.7578, 3.12, 0.195, 287, 257, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
1564, d4c2vA_, 0.7578, 2.74, 0.187, 270, 251, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
1565, d4bznA_, 0.7578, 2.92, 0.183, 272, 252, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO(12-A) PYRAZINONE INHIBITOR
1566, d1oecA_, 0.7578, 3.07, 0.176, 280, 256, FGFR2 KINASE DOMAIN
1567, d1jkkA_, 0.7578, 3.10, 0.193, 277, 254, 2.4A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MG.
1568, d5nguA_, 0.7577, 2.75, 0.217, 339, 249, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
1569, d1zwsG_, 0.7577, 3.17, 0.191, 278, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1570, d1yvjA_, 0.7577, 3.21, 0.232, 288, 259, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN IN COMPLEX WITH A STAUROSPORINE ANALOGUE
1571, d5kziA_, 0.7576, 2.99, 0.194, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN IMIDAZOPYRIDAZINE INHIBITOR.
1572, d3eqrB_, 0.7576, 2.88, 0.217, 271, 253, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
1573, d4j96A_, 0.7575, 3.18, 0.174, 302, 259, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
1574, d1f5qA_, 0.7575, 3.09, 0.177, 296, 254, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
1575, d3iecD_, 0.7574, 2.66, 0.219, 311, 247, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
1576, d3iecC_, 0.7574, 2.68, 0.219, 311, 247, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
1577, d3gubA1, 0.7574, 3.00, 0.190, 276, 252, CRYSTAL STRUCTURE OF DAPKL93G COMPLEXED WITH N6-(2- PHENYLETHYL)ADENOSINE
1578, d3erkA_, 0.7574, 2.85, 0.216, 350, 250, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/SB220025
1579, d4wnpC_, 0.7573, 2.92, 0.236, 271, 250, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
1580, d4e6dA_, 0.7573, 3.25, 0.204, 286, 260, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
1581, d3bceB_, 0.7573, 3.40, 0.170, 286, 259, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
1582, d5di1A_, 0.7572, 2.99, 0.194, 285, 253, MAP4K4 IN COMPLEX WITH AN INHIBITOR
1583, d3iokA_, 0.7572, 3.26, 0.203, 285, 261, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
1584, d3fupB_, 0.7572, 3.38, 0.195, 287, 262, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
1585, d3ehaA1, 0.7572, 3.06, 0.194, 275, 253, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH AMPPNP
1586, d2yexA_, 0.7572, 2.94, 0.210, 269, 252, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
1587, d1wvxA_, 0.7572, 2.97, 0.190, 275, 253, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
1588, d4l3lA_, 0.7571, 3.03, 0.190, 291, 252, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN (ZINC ANOMALOUS)
1589, d3lpbB1, 0.7571, 3.17, 0.202, 283, 258, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
1590, d3gu5A1, 0.7571, 3.11, 0.193, 276, 254, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP-MG2+
1591, d2yakA_, 0.7571, 3.08, 0.192, 277, 255, STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 (DAPK1) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OSV)
1592, d2c3kA_, 0.7571, 2.92, 0.215, 262, 251, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
1593, d3kk8A_, 0.7570, 3.19, 0.198, 283, 258, CAMKII SUBSTRATE COMPLEX A
1594, d3gu7A1, 0.7570, 3.11, 0.193, 276, 254, CRYSTAL STRUCTURE OF DAPKQ23V-ADP-MG2+
1595, d1ig1A_, 0.7570, 3.11, 0.193, 280, 254, 1.8A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MN.
1596, p6g9hA_, 0.7569, 2.77, 0.221, 343, 249, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1597, d5cavA_, 0.7569, 3.19, 0.181, 306, 259, EGFR KINASE DOMAIN WITH COMPOUND 41A
1598, d3tjdA_, 0.7569, 3.32, 0.181, 284, 260, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
1599, d3jy0A_, 0.7569, 3.16, 0.193, 275, 254, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
1600, d6bkuA1, 0.7568, 2.65, 0.207, 264, 246, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO GSK650394
1601, d5opbA_, 0.7568, 2.96, 0.213, 262, 253, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH INDAZOLE LRRK2 INHIBITOR
1602, d2pwlB_, 0.7568, 3.06, 0.191, 286, 256, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
1603, p2pvkA_, 0.7568, 3.21, 0.163, 327, 257, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1604, d2ojiA_, 0.7568, 2.80, 0.220, 344, 250, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
1605, d5m4iA_, 0.7567, 3.31, 0.172, 331, 256, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
1606, d2y7jC_, 0.7567, 2.77, 0.193, 284, 249, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1607, d2b7aB_, 0.7567, 3.38, 0.198, 287, 262, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
1608, d1zwsB_, 0.7567, 3.16, 0.195, 278, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1609, d4xrlA_, 0.7566, 2.76, 0.221, 337, 249, CRYSTAL STRUCTURE AT ROOM TEMPERATURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1610, d4txcA_, 0.7566, 3.01, 0.193, 276, 254, CRYSTAL STRUCTURE OF DAPK1 KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
1611, d3pp0B_, 0.7566, 3.38, 0.169, 296, 261, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
1612, p2pvjA_, 0.7566, 3.22, 0.163, 326, 257, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1613, d5opsA_, 0.7565, 2.78, 0.214, 258, 248, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
1614, d4p7eA_, 0.7565, 3.37, 0.203, 281, 261, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
1615, d3iecA_, 0.7565, 2.69, 0.219, 311, 247, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
1616, d1zwsH_, 0.7565, 3.18, 0.191, 278, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1617, d1zwsA_, 0.7565, 3.18, 0.191, 278, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1618, d4u40A_, 0.7564, 3.13, 0.194, 295, 258, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
1619, d4fv2A_, 0.7564, 2.77, 0.221, 344, 249, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK5
1620, d6babC_, 0.7563, 3.15, 0.180, 284, 256, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1621, d5uyjA1, 0.7563, 2.75, 0.206, 279, 248, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
1622, d5friA1, 0.7563, 3.34, 0.208, 299, 259, ALK5 IN COMPLEX WITHA AN N-(4-ANILINO-2-PYRIDYL)ACETAMIDE INHIBITOR.
1623, d4zzoA_, 0.7563, 2.75, 0.217, 339, 249, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
1624, d4j95B_, 0.7563, 3.10, 0.175, 282, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
1625, d1jksA_, 0.7563, 3.12, 0.193, 280, 254, 1.5A X-RAY STRUCTURE OF APO FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
1626, d5u6bB1, 0.7562, 2.99, 0.176, 289, 255, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
1627, d5m4uA_, 0.7562, 3.19, 0.180, 332, 256, ORTHORHOMBIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
1628, d5lwnA_, 0.7562, 3.42, 0.200, 290, 265, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 5 (FM409)
1629, d4j99B_, 0.7562, 3.10, 0.175, 291, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
1630, d3nz0A1, 0.7562, 3.25, 0.225, 283, 258, NON-PHOSPHORYLATED TYK2 KINASE WITH CMP6
1631, d5nhfA_, 0.7561, 2.78, 0.221, 339, 249, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
1632, d5mp8B_, 0.7561, 2.91, 0.187, 323, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1633, d5lwmA_, 0.7561, 3.42, 0.200, 290, 265, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 4 (FM381)
1634, d4hvgA_, 0.7561, 3.27, 0.223, 281, 260, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-2-HYDROXY-12-DIMETHYL-PROPYL)- AMIDE
1635, d4fszA_, 0.7561, 3.03, 0.210, 268, 252, CRYSTAL STRUCTURE OF THE CHK1
1636, d4dglD_, 0.7561, 3.17, 0.179, 328, 257, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
1637, d5vuaB_, 0.7560, 2.86, 0.196, 270, 250, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
1638, d4wnpA_, 0.7560, 2.92, 0.231, 273, 251, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
1639, d3gu6A1, 0.7559, 3.13, 0.193, 276, 254, CRYSTAL STRUCTURE OF DAPKQ23V-ADP
1640, d1jklA_, 0.7559, 3.13, 0.193, 280, 254, 1.6A X-RAY STRUCTURE OF BINARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE
1641, d5u6bD1, 0.7558, 3.00, 0.176, 289, 255, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
1642, d5tq4A_, 0.7558, 3.56, 0.194, 290, 263, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
1643, d5hibA_, 0.7558, 3.50, 0.163, 314, 263, EGFR KINASE DOMAIN MUTANT TMLR WITH A PYRAZOLOPYRIMIDINE INHIBITOR
1644, d4e6dB_, 0.7558, 3.32, 0.203, 286, 261, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
1645, d2y7jB_, 0.7558, 2.80, 0.193, 281, 249, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1646, d2x0gA_, 0.7558, 3.30, 0.185, 318, 260, X-RAY STRUCTURE OF A DAP-KINASE CALMODULIN COMPLEX
1647, d2gphA_, 0.7558, 2.84, 0.220, 345, 250, DOCKING MOTIF INTERACTIONS IN THE MAP KINASE ERK2
1648, d5ar5A_, 0.7557, 3.18, 0.170, 284, 259, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
1649, d4yo4A1, 0.7557, 3.04, 0.194, 276, 252, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT PHTHALAZINE
1650, d3eh9A1, 0.7557, 2.96, 0.195, 274, 251, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH ADP
1651, d1gjoA_, 0.7557, 3.09, 0.176, 280, 256, THE FGFR2 TYROSINE KINASE DOMAIN
1652, d3qyiA_, 0.7556, 2.81, 0.221, 346, 249,  
1653, d3dgkA1, 0.7556, 3.14, 0.193, 276, 254, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN
1654, d1iasB_, 0.7556, 3.33, 0.212, 324, 260, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
1655, d5ugxA_, 0.7555, 3.08, 0.175, 297, 257, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
1656, d5cu3B_, 0.7555, 2.99, 0.181, 324, 254, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
1657, d4xneA_, 0.7555, 2.76, 0.221, 344, 249, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1658, p2pvlA_, 0.7555, 3.22, 0.163, 327, 257, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1659, d2phkA_, 0.7555, 3.08, 0.179, 277, 252, THE CRYSTAL STRUCTURE OF A PHOSPHORYLASE KINASE PEPTIDE SUBSTRATE COMPLEX: KINASE SUBSTRATE RECOGNITION
1660, d4lmuA_, 0.7554, 2.80, 0.201, 265, 249, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH THE INHIBITOR QUERCETIN (RESULTING FROM DISPLACEMENT OF SKF86002)
1661, d3io7A_, 0.7554, 3.25, 0.196, 282, 260, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
1662, d3bceC_, 0.7554, 3.51, 0.169, 286, 261, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
1663, d3a99A_, 0.7554, 3.04, 0.198, 273, 252, STRUCTURE OF PIM-1 KINASE CRYSTALLIZED IN THE PRESENCE OF P27KIP1 CARBOXY-TERMINAL PEPTIDE
1664, d1zwsC_, 0.7554, 3.18, 0.191, 278, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1665, d5ukkA2, 0.7553, 3.27, 0.196, 348, 260, HUMAN GRK2 IN COMPLEX WITH HUMAN G-BETA-GAMMA SUBUNITS AND CCG211998 (14AK)
1666, d2itwA_, 0.7553, 3.38, 0.180, 300, 261, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AFN941
1667, d4ub7A_, 0.7552, 3.28, 0.165, 334, 255, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26) SHOWING AN EXTREME DISTORTION OF THE ATP-BINDING LOOP COMBINED WITH A PI-HALOGEN BOND
1668, d4j99C_, 0.7552, 3.12, 0.175, 291, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
1669, d4fuxA_, 0.7552, 2.77, 0.217, 342, 249, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E75
1670, p6g91A_, 0.7551, 2.77, 0.217, 344, 249, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1671, d5cwzB_, 0.7551, 3.02, 0.181, 284, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
1672, d3uixA_, 0.7551, 2.81, 0.201, 266, 249, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1673, d3f5uA1, 0.7551, 3.09, 0.194, 275, 253, CRYSTAL STRUCTURE OF THE DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH AMPPNP AND MG2+
1674, d4ypdA1, 0.7550, 3.05, 0.194, 276, 252, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT 4-METHYLPYRIDAZINE
1675, d4c61B_, 0.7550, 3.23, 0.202, 274, 257, INHIBITORS OF JAK2 KINASE DOMAIN
1676, d3f5gA1, 0.7550, 3.09, 0.194, 275, 253, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH ADP AND MG2+
1677, d3comA_, 0.7550, 3.03, 0.191, 264, 256, CRYSTAL STRUCTURE OF MST1 KINASE
1678, d5uy6A1, 0.7549, 2.73, 0.206, 280, 247, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
1679, d5e8yA_, 0.7549, 3.26, 0.163, 298, 257, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH STAUROSPORINE
1680, d4xp2A_, 0.7549, 2.76, 0.217, 337, 249, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1681, d3gqiA_, 0.7549, 3.25, 0.205, 304, 259, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
1682, d1koaA2, 0.7549, 3.44, 0.169, 350, 260, TWITCHIN KINASE FRAGMENT (C.ELEGANS) AUTOREGULATED PROTEIN KINASE AND IMMUNOGLOBULIN DOMAINS
1683, d5cy3A1, 0.7548, 3.11, 0.199, 274, 256, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT AND ORALLY BIOAVAILABLE BENZISOTHIAZOLE INHIBITOR
1684, d4zzmA_, 0.7548, 2.82, 0.217, 344, 249, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
1685, d4xp3A_, 0.7548, 2.77, 0.217, 339, 249, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1686, d3tjdB_, 0.7548, 3.42, 0.198, 287, 262, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
1687, d1unhA_, 0.7548, 2.36, 0.178, 276, 241, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
1688, d3ot3A_, 0.7547, 2.91, 0.208, 259, 250, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22K BOUND TO HUMAN CHK1 KINASE DOMAIN
1689, d1wvwA_, 0.7547, 3.01, 0.186, 275, 253, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
1690, d1rw8A_, 0.7547, 3.30, 0.217, 301, 258, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH ATP SITE INHIBITOR
1691, d1erkA_, 0.7547, 2.86, 0.220, 357, 250, STRUCTURE OF SIGNAL-REGULATED KINASE
1692, d4xj0B_, 0.7546, 2.85, 0.221, 338, 249, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
1693, d2e9uA_, 0.7546, 3.01, 0.219, 269, 251, STRUCTURE OF H-CHK1 COMPLEXED WITH A780125
1694, d2e9oA_, 0.7546, 3.05, 0.214, 269, 252, STRUCTURE OF H-CHK1 COMPLEXED WITH AA582939
1695, d1m2rA_, 0.7546, 3.27, 0.163, 327, 258, CRYSTAL STRUCTURE OF 58-DI-AMINO-14-DI-HYDROXY- ANTHRAQUINONE/CK2 KINASE COMPLEX
1696, d5oq6A_, 0.7545, 2.86, 0.221, 257, 249, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
1697, d4zznA_, 0.7545, 2.78, 0.217, 338, 249, HUMAN ERK2 IN COMPLEX WITH AN INHIBITOR
1698, d2vz6B1, 0.7545, 3.26, 0.194, 288, 258, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
1699, d4s34A_, 0.7544, 2.81, 0.216, 343, 250, ERK2 (I84A) IN COMPLEX WITH AMP-PNP
1700, d2x2lA1, 0.7544, 3.09, 0.169, 282, 254, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
1701, d2qhmA_, 0.7544, 2.92, 0.212, 268, 250, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2A
1702, d5umoA_, 0.7543, 2.82, 0.220, 347, 250, STRUCTURE OF EXTRACELLULAR SIGNAL-REGULATED KINASE
1703, d5op4A_, 0.7543, 2.84, 0.213, 259, 249, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDINE LRRK2 INHIBITOR
1704, d4l3jA_, 0.7543, 3.08, 0.190, 291, 252, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN
1705, d2ivvA1, 0.7543, 3.02, 0.170, 277, 253, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR PP1
1706, p6g9nA_, 0.7542, 2.80, 0.221, 344, 249, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1707, p6g9mA_, 0.7542, 2.80, 0.221, 341, 249, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1708, d4zp5A_, 0.7542, 3.14, 0.196, 284, 255, MAP4K4 IN COMPLEX WITH INHIBITOR
1709, d4riyB_, 0.7542, 3.37, 0.182, 293, 258, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
1710, d4ic7A_, 0.7542, 3.02, 0.225, 355, 253, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
1711, d4erkA_, 0.7542, 2.84, 0.220, 350, 250, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/OLOMOUCINE
1712, d4enxA_, 0.7542, 2.92, 0.196, 266, 250, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH INHIBITOR (2E5Z)-2- (2-CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-NITROBENZYLIDENE)THIAZOLIDIN-4- ONE
1713, d3bceA_, 0.7542, 3.48, 0.169, 285, 260, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
1714, d2pk9A_, 0.7542, 2.84, 0.190, 287, 247, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
1715, d3vjoA_, 0.7541, 3.40, 0.173, 298, 260, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH AMPPNP.
1716, d3ug2A_, 0.7541, 3.42, 0.172, 299, 261, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH GEFITINIB
1717, d3comB_, 0.7541, 3.07, 0.179, 279, 257, CRYSTAL STRUCTURE OF MST1 KINASE
1718, d1tvoA_, 0.7541, 2.84, 0.220, 350, 250, THE STRUCTURE OF ERK2 IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
1719, d4fv1A_, 0.7540, 2.79, 0.221, 342, 249, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK4
1720, d4asxA1, 0.7540, 2.94, 0.202, 295, 253, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
1721, d3vjnA_, 0.7540, 3.27, 0.174, 297, 258, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH AMPPNP.
1722, d2w4jA_, 0.7540, 3.19, 0.193, 276, 254, X-RAY STRUCTURE OF A DAP-KINASE 2-277
1723, d4s33A_, 0.7539, 2.81, 0.220, 347, 250, ERK2 R65S MUTANT COMPLEXED WITH AMP-PNP
1724, d1unhB_, 0.7539, 2.36, 0.178, 276, 241, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
1725, d3eqpB_, 0.7538, 3.20, 0.233, 270, 257, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
1726, d3tkhA_, 0.7537, 3.00, 0.223, 269, 251, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S01
1727, d3kcfB_, 0.7537, 3.21, 0.209, 324, 258, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
1728, d2ywpA_, 0.7537, 3.06, 0.214, 269, 252, CRYSTAL STRUCTURE OF CHK1 WITH A UREA INHIBITOR
1729, d1u59A1, 0.7537, 3.29, 0.174, 276, 258, CRYSTAL STRUCTURE OF THE ZAP-70 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1730, p6ge0A_, 0.7536, 2.77, 0.222, 343, 248, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1731, d2wouA_, 0.7536, 3.20, 0.215, 299, 256, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
1732, d2wouA1, 0.7536, 3.20, 0.215, 297, 256, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
1733, d2fgaA_, 0.7536, 3.06, 0.218, 269, 252,  
1734, d2e9nA_, 0.7536, 3.08, 0.218, 269, 252, STRUCTURE OF H-CHK1 COMPLEXED WITH A767085
1735, d1zwsE_, 0.7536, 3.21, 0.191, 278, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1736, d5lcjA_, 0.7535, 2.79, 0.217, 345, 249, IN-GEL ACTIVITY-BASED PROTEIN PROFILING OF A CLICKABLE COVALENT ERK 1/2 INHIBITOR
1737, d4wnpD_, 0.7535, 3.01, 0.235, 272, 251, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
1738, d4qp3B_, 0.7535, 2.80, 0.222, 331, 248, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
1739, d3bhyA1, 0.7535, 3.11, 0.190, 267, 252, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH A BETA-CARBOLINE LIGAND
1740, d1golA_, 0.7535, 2.90, 0.216, 357, 250, COORDINATES OF RAT MAP KINASE ERK2 WITH AN ARGININE MUTATION AT POSITION 52
1741, p6g9dA_, 0.7534, 2.81, 0.221, 345, 249, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1742, d5oprA_, 0.7534, 2.86, 0.213, 258, 249, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIDINE LRRK2 INHIBITOR
1743, d5ar2B_, 0.7534, 3.27, 0.166, 285, 259, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
1744, d4rixB_, 0.7534, 3.35, 0.178, 293, 258, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
1745, d2pwlA_, 0.7534, 3.06, 0.192, 284, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
1746, d5av3A_, 0.7533, 3.13, 0.194, 275, 253, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF IODIDE IONS.
1747, d4j95C_, 0.7533, 3.09, 0.176, 281, 256, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
1748, d3qywA_, 0.7533, 2.78, 0.217, 340, 249, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1749, p4jr7A_, 0.7532, 3.15, 0.153, 367, 255, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1750, d2xa4A_, 0.7532, 3.05, 0.201, 276, 254, INHIBITORS OF JAK2 KINASE DOMAIN
1751, d5vubB_, 0.7531, 2.87, 0.197, 269, 249, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
1752, p5owlA_, 0.7531, 3.30, 0.179, 331, 257, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
1753, d3we4A_, 0.7531, 3.15, 0.194, 286, 252, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRIMIDINE DERIVATIVE PF-4708671 2-{[4-(5-ETHYLPYRIMIDIN-4-YL)PIPERAZIN-1- YL]METHYL}-5-(TRIFLUOROMETHYL)-1H-BENZIMIDAZOLE
1754, d1iasC_, 0.7531, 3.35, 0.208, 330, 260, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
1755, d4d1sA_, 0.7530, 3.11, 0.199, 280, 256, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
1756, d3zmmB_, 0.7530, 3.25, 0.202, 274, 257, INHIBITORS OF JAK2 KINASE DOMAIN
1757, d6brcB_, 0.7529, 2.78, 0.206, 260, 247, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
1758, d4wnpB_, 0.7529, 2.98, 0.231, 272, 251, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
1759, d4fsyA_, 0.7529, 3.04, 0.207, 267, 251, CRYSTAL STRUCTURE OF THE CHK1
1760, d2yerA_, 0.7529, 2.95, 0.211, 268, 251, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
1761, d1iasE_, 0.7529, 3.21, 0.209, 330, 258, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
1762, d5oq7A_, 0.7528, 2.90, 0.224, 259, 250, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
1763, d5o11A_, 0.7528, 2.95, 0.180, 268, 250, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
1764, d4s2zA_, 0.7528, 2.83, 0.220, 346, 250, ERK2 INTRINSICALLY ACTIVE MUTANT R65S
1765, d4ftjA_, 0.7528, 2.93, 0.225, 266, 249, CRYSTAL STRUCTURE OF THE CHK1
1766, d4ft0A_, 0.7528, 2.98, 0.216, 266, 250, CRYSTAL STRUCTURE OF THE CHK1
1767, d1iasD_, 0.7528, 3.40, 0.211, 330, 261, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
1768, d4s32A_, 0.7527, 2.82, 0.220, 346, 250, CRYSTAL STRUCTURE OF ERK2 AMP-PNP COMPLEX
1769, d4pf4A1, 0.7527, 3.17, 0.193, 277, 254, 1.1A X-RAY STRUCTURE OF THE APO CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE 1 AA 1-277
1770, d4iz5D_, 0.7527, 2.86, 0.221, 347, 249, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
1771, d4iz5C_, 0.7527, 2.86, 0.221, 347, 249, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
1772, d4g6oA_, 0.7527, 2.72, 0.219, 339, 247, CRYSTAL STRUCTURE OF THE ERK2
1773, p4f9bA_, 0.7527, 3.49, 0.213, 318, 258, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND PHA767491
1774, d4ae9B_, 0.7527, 3.05, 0.187, 321, 252, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
1775, d2psqA_, 0.7527, 3.17, 0.183, 287, 257, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
1776, d6brcA1, 0.7526, 2.78, 0.206, 263, 247, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
1777, d5uhnA_, 0.7526, 3.18, 0.175, 282, 257, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
1778, d5j79B_, 0.7526, 3.12, 0.164, 277, 256, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
1779, d4iz5B_, 0.7526, 2.86, 0.221, 347, 249, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
1780, d4iz5A_, 0.7526, 2.86, 0.221, 347, 249, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
1781, d4g5jA_, 0.7526, 3.24, 0.172, 307, 256, CRYSTAL STRUCTURE OF EGFR KINASE IN COMPLEX WITH BIBW2992
1782, d3ri1A_, 0.7526, 3.17, 0.183, 285, 257, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
1783, d3pjcA_, 0.7526, 3.64, 0.228, 286, 263, CRYSTAL STRUCTURE OF JAK3 COMPLEXED WITH A POTENT ATP SITE INHIBITOR SHOWING HIGH SELECTIVITY WITHIN THE JANUS KINASE FAMILY
1784, d2z7lA_, 0.7526, 2.73, 0.219, 329, 247, UNPHOSPHORYLATED MITOGEN ACTIVATED PROTEIN KINASE ERK2 IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN 2-YL]AMINO}PHENYL)ACETIC ACID
1785, d2c30A_, 0.7525, 3.21, 0.185, 289, 259, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 6
1786, d5j9yA_, 0.7524, 3.48, 0.181, 300, 260, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1B
1787, d2r0uA_, 0.7524, 3.00, 0.211, 269, 251, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 54
1788, d5u94A_, 0.7523, 2.42, 0.216, 263, 241, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PASTA KINASE PKNB IN COMPLEX WITH THE POTENTIAL THERAPUTIC KINASE INHIBITOR GSK690693.
1789, d4p7eB_, 0.7523, 3.49, 0.198, 285, 262, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
1790, d3kcfC_, 0.7523, 3.35, 0.208, 330, 260, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
1791, d5f20A_, 0.7522, 3.12, 0.231, 274, 255, STRUCTURE OF TYK2 WITH INHIBITOR 4: 3-AZANYL-5-(2-METHYLPHENYL)-7-(1- METHYLPYRAZOL-3-YL)-1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
1792, d5auvA_, 0.7522, 3.13, 0.194, 275, 253, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH APIGENIN.
1793, d4fsuA_, 0.7522, 3.04, 0.207, 260, 251, CRYSTAL STRUCTURE OF THE CHK1
1794, d3tzmA_, 0.7522, 3.21, 0.208, 295, 255, TGF-BETA RECEPTOR TYPE 1 IN COMPLEX WITH SB431542
1795, d3ha6A1, 0.7522, 2.72, 0.194, 262, 248, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH TPX2 AND COMPOUND 10
1796, d2qhnA_, 0.7522, 2.95, 0.212, 268, 250, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1A
1797, d5hq0A1, 0.7521, 2.76, 0.199, 289, 246, TERNARY COMPLEX OF HUMAN PROTEINS CDK1 CYCLIN B AND CKS2 BOUND TO AN INHIBITOR
1798, d4y72A1, 0.7521, 2.76, 0.199, 289, 246, HUMAN CDK1/CYCLINB1/CKS2 WITH INHIBITOR
1799, d4qp1A_, 0.7521, 2.83, 0.221, 342, 249, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
1800, d4j98A_, 0.7521, 3.21, 0.174, 304, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
1801, d4g6nA_, 0.7521, 2.80, 0.221, 341, 249, CRYSTAL STRUCTURE OF THE ERK2
1802, d4enyA_, 0.7521, 2.90, 0.193, 261, 249, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH (2E5Z)-2-(2- CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-METHOXYBENZYLIDENE)THIAZOLIDIN-4- ONE
1803, d3ug1A_, 0.7521, 3.27, 0.175, 296, 257, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN THE APO FORM
1804, d5av2A_, 0.7520, 3.14, 0.194, 275, 253, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF BROMIDE IONS.
1805, d3dlsD_, 0.7520, 3.08, 0.179, 284, 252, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
1806, d3bhhD1, 0.7520, 3.07, 0.182, 285, 253, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
1807, d5vucB_, 0.7519, 2.89, 0.197, 269, 249, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
1808, d5auyA_, 0.7519, 3.14, 0.194, 275, 253, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH MORIN.
1809, d4xj0A_, 0.7519, 2.88, 0.221, 345, 249, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
1810, d4wkqA1, 0.7519, 3.26, 0.175, 294, 257, 1.85 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN WITH GEFITINIB
1811, d4s31A_, 0.7519, 2.84, 0.220, 347, 250, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 1 WTERK2 AT 1.45A
1812, d3socB1, 0.7519, 2.94, 0.202, 294, 252, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
1813, d5av1A_, 0.7518, 3.14, 0.194, 275, 253, CRYSTAL STRUCTURE OF DAPK1 IN THE PRESENCE OF BROMIDE IONS.
1814, d4aguB_, 0.7518, 2.33, 0.209, 276, 239, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
1815, d3uodA_, 0.7518, 2.90, 0.195, 266, 251, AURORA A IN COMPLEX WITH RPM1693
1816, d3r63A_, 0.7518, 2.84, 0.220, 347, 250, STRUCTURE OF ERK2 (SPE) MUTANT (S246E)
1817, d5cshB_, 0.7517, 2.96, 0.183, 323, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
1818, d2bfyA_, 0.7517, 2.75, 0.157, 270, 249, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
1819, d1py5A_, 0.7517, 3.36, 0.212, 301, 259, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH INHIBITOR
1820, d5auxA_, 0.7516, 3.13, 0.194, 275, 253, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH KAEMPFEROL.
1821, d4j97B_, 0.7516, 3.06, 0.181, 283, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
1822, d3up2A_, 0.7516, 2.83, 0.196, 266, 250, AURORA A IN COMPLEX WITH RPM1686
1823, d4aguC_, 0.7515, 2.37, 0.209, 278, 239, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
1824, d3kcfE_, 0.7515, 3.39, 0.207, 330, 261, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
1825, d3dlsA_, 0.7515, 3.07, 0.179, 285, 252, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
1826, d2aypA_, 0.7515, 2.97, 0.223, 268, 251, CRYSTAL STRUCTURE OF CHK1 WITH AN INDOL INHIBITOR
1827, d5up3A_, 0.7514, 2.64, 0.225, 258, 244, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
1828, d4qp2B_, 0.7514, 2.83, 0.222, 329, 248, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
1829, d1szmB_, 0.7514, 2.97, 0.183, 320, 251, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
1830, p6gdmA_, 0.7513, 2.79, 0.222, 341, 248, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1831, d3lpbA_, 0.7513, 3.34, 0.205, 278, 258, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
1832, d1iasA_, 0.7513, 3.35, 0.208, 330, 260, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
1833, d6bqpA1, 0.7511, 2.75, 0.203, 262, 246, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CRENOLANIB
1834, d3ri1B_, 0.7511, 3.24, 0.182, 283, 258, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
1835, d5oryA_, 0.7510, 2.97, 0.195, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1836, d5hx8A_, 0.7510, 3.38, 0.205, 291, 259, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
1837, d5av0A_, 0.7510, 3.14, 0.194, 275, 253, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH 73 4 - TRIHYDROXYISOFLAVONE.
1838, d4aguA_, 0.7510, 2.38, 0.209, 277, 239, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
1839, p3zu7A_, 0.7510, 3.00, 0.216, 344, 250, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE MAP KINASE ERK2
1840, d3umwA_, 0.7510, 2.86, 0.202, 264, 248, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDAZOL-3-YL)METHYLENE]-6-METHOXY-7-(PIPERAZIN-1-YLMETHYL)BENZOFURAN- 3(2H)-ONE
1841, d2pvfA_, 0.7510, 3.15, 0.176, 285, 256, CRYSTAL STRUCTURE OF TYROSINE PHOSPHORYLATED ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH ATP ANALOG AND SUBSTRATE PEPTIDE
1842, d5v24B_, 0.7509, 2.73, 0.216, 263, 245, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
1843, d1xbcA1, 0.7509, 3.19, 0.198, 267, 257, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH STAUROSPORIN
1844, d5v19B_, 0.7508, 2.83, 0.220, 260, 246, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
1845, d4qp6B_, 0.7508, 2.83, 0.222, 334, 248, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
1846, d4hvhA_, 0.7508, 3.23, 0.226, 278, 257, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-2-HYDROXY-12-DIMETHYL-PROPYL
1847, d3uo5A_, 0.7508, 2.99, 0.194, 267, 252, AURORA A IN COMPLEX WITH YL1-038-31
1848, d3u9nA_, 0.7508, 2.86, 0.218, 257, 248, X-RAY CRYSTAL STRUCTURE OF COMPOUND 1 BOUND TO HUMAN CHK1 KINASE DOMAIN
1849, d5ortA_, 0.7507, 2.97, 0.195, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1850, d5orrA_, 0.7507, 2.97, 0.195, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1851, d5dt3A_, 0.7507, 2.89, 0.195, 263, 251, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
1852, d4fttA_, 0.7507, 3.03, 0.204, 266, 250, CRYSTAL STRUCTURE OF THE CHK1
1853, d6bleA1, 0.7506, 2.79, 0.211, 263, 247, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CP673451
1854, d4xozA_, 0.7506, 2.86, 0.217, 341, 249, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1855, p6g92A_, 0.7505, 2.85, 0.221, 343, 249, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1856, d4rioA_, 0.7505, 3.45, 0.223, 285, 260, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE CARBOXAMIDE INHIBITOR
1857, d4i6qA_, 0.7505, 3.24, 0.226, 277, 257, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-PHENOXY-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-1-CYCLOPROPYL-ETHYL)-AMIDE
1858, d2x8eA_, 0.7505, 2.80, 0.223, 259, 247, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
1859, d5lckA_, 0.7504, 2.79, 0.218, 345, 248, A CLICKABLE COVALENT ERK 1/2 INHIBITOR
1860, d4wnmA1, 0.7504, 3.19, 0.195, 269, 257, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT TRIAZOLOPYRIDINE INHIBITOR
1861, d4riwB_, 0.7504, 3.49, 0.185, 293, 259, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
1862, d4g5pA_, 0.7504, 3.34, 0.181, 299, 260, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
1863, d2psqB_, 0.7504, 3.27, 0.181, 286, 259, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
1864, d2brgA_, 0.7504, 2.90, 0.213, 257, 249, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
1865, d5orwA_, 0.7503, 2.93, 0.196, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1866, d4gt3A_, 0.7503, 2.86, 0.221, 347, 249, ATP-BOUND FORM OF THE ERK2 KINASE
1867, d2fumB_, 0.7503, 2.37, 0.217, 262, 240, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
1868, d2b54A_, 0.7503, 3.02, 0.176, 298, 250, HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2)COMPLEXED WITH DIN- 232305
1869, d1kobB_, 0.7503, 3.60, 0.174, 352, 259, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
1870, d5uglA_, 0.7502, 3.15, 0.179, 285, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
1871, d5osdA_, 0.7502, 2.97, 0.195, 266, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1872, d5orxA_, 0.7502, 2.93, 0.196, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1873, d5dnrA_, 0.7502, 2.87, 0.192, 264, 250, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P41212
1874, d4k33A_, 0.7502, 3.22, 0.195, 293, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 3 (FGFR3) KINASE DOMAIN HARBORING THE K650E MUTATION A GAIN-OF-FUNCTION MUTATION RESPONSIBLE FOR THANATOPHORIC DYSPLASIA TYPE II AND SPERMATOCYTIC SEMINOMA
1875, d2f4jA_, 0.7502, 3.55, 0.202, 287, 262, STRUCTURE OF THE KINASE DOMAIN OF AN IMATINIB-RESISTANT ABL MUTANT IN COMPLEX WITH THE AURORA KINASE INHIBITOR VX-680
1876, p4fmqA_, 0.7501, 2.98, 0.220, 350, 250, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
1877, d2itxA_, 0.7501, 3.42, 0.181, 307, 260, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AMP- PNP
1878, d2ghgA1, 0.7501, 2.97, 0.216, 269, 250, H-CHK1 COMPLEXED WITH A431994
1879, d5uoxA_, 0.7500, 2.74, 0.216, 263, 245, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
1880, d5oroA_, 0.7500, 2.98, 0.195, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1881, d5e1eA_, 0.7500, 3.38, 0.202, 279, 258, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
1882, d3dlsE_, 0.7500, 3.13, 0.174, 282, 253, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
1883, d2c3jA_, 0.7500, 2.83, 0.214, 257, 248, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
1884, d1u4dB_, 0.7500, 2.97, 0.236, 262, 250, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
1885, d5orzA_, 0.7499, 2.97, 0.195, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1886, d5orvA_, 0.7499, 2.93, 0.196, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1887, d5autA_, 0.7499, 3.11, 0.194, 274, 252, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH ANS.
1888, d3ztxA_, 0.7499, 2.89, 0.187, 269, 251, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
1889, d2bujB1, 0.7499, 3.01, 0.183, 277, 251, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
1890, d5e1eB_, 0.7498, 3.42, 0.205, 280, 259, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
1891, d4ic7D_, 0.7498, 3.01, 0.226, 353, 252, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
1892, d5tr6A1, 0.7497, 3.22, 0.202, 268, 257, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
1893, d5osfA_, 0.7497, 2.98, 0.195, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1894, d5oq7B_, 0.7497, 2.83, 0.227, 256, 247, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
1895, d5e91A_, 0.7497, 3.27, 0.172, 297, 256, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH 3-AMINO-6-[4-(2- HYDROXYETHYL)PHENYL]-N-[4- (MORPHOLIN-4-YL)PYRIDIN-3-YL] PYRAZINE-2-CARBOXAMIDE
1896, d5dn3A_, 0.7497, 2.75, 0.194, 264, 248, AURORA A IN COMPLEX WITH ATP AND AA35.
1897, d4l42A_, 0.7497, 2.99, 0.198, 299, 248, CRYSTAL STRUCTURES OF HUMAN P70S6K1-PIF
1898, d3ue4A_, 0.7497, 3.27, 0.205, 270, 258, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
1899, d2clqA_, 0.7497, 2.80, 0.223, 263, 247, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
1900, d1xbaA1, 0.7497, 3.19, 0.198, 265, 257, CRYSTAL STRUCTURE OF APO SYK TYROSINE KINASE DOMAIN
1901, d5tozA_, 0.7496, 3.36, 0.229, 278, 258, JAK3 WITH COVALENT INHIBITOR PF-06651600
1902, d4s30A_, 0.7496, 2.83, 0.217, 342, 249, ERK2 INTRINSICALLY ACTIVE MUTANT (I84A)
1903, d5orpA_, 0.7495, 2.98, 0.195, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1904, d4b8mA_, 0.7495, 2.89, 0.187, 270, 251, AURORA B KINASE IN COMPLEX WITH VX-680
1905, d3qyzA_, 0.7495, 2.87, 0.221, 339, 249, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1906, d2y7jD_, 0.7495, 2.88, 0.193, 281, 249, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1907, d2jitA_, 0.7495, 3.34, 0.165, 299, 260, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
1908, d1ol5A_, 0.7495, 2.69, 0.194, 263, 247, STRUCTURE OF AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288 AND BOUND TO TPX2 1-43
1909, d1kobA_, 0.7495, 3.67, 0.173, 352, 260, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
1910, d5wo4A_, 0.7494, 3.41, 0.205, 292, 259, JAK1 COMPLEXED WITH COMPOUND 28
1911, d5os1A_, 0.7494, 2.98, 0.195, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1912, d5ornA_, 0.7494, 2.98, 0.195, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1913, d3mdyA_, 0.7494, 3.22, 0.199, 320, 256, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
1914, d5os5A_, 0.7493, 2.98, 0.195, 267, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1915, d4j97A_, 0.7493, 3.12, 0.173, 282, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
1916, d4gfgA1, 0.7493, 3.16, 0.195, 273, 257, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R9021
1917, d3vbwA_, 0.7493, 2.80, 0.186, 264, 247, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
1918, d3r83A_, 0.7493, 3.09, 0.171, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-92
1919, d3qziA_, 0.7493, 3.29, 0.160, 294, 256, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-126
1920, d2fumA_, 0.7493, 2.46, 0.216, 263, 241, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
1921, d1ykrA_, 0.7493, 3.01, 0.172, 298, 250, CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINE INHIBITOR
1922, d5oseA_, 0.7492, 2.99, 0.195, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1923, d4fuyA_, 0.7492, 2.90, 0.218, 329, 248, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK2
1924, d3zewA_, 0.7492, 3.00, 0.143, 269, 252, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
1925, d3vf8A_, 0.7492, 3.23, 0.198, 265, 257, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH PYRAZOLYLBENZIMIDAZOLE INHIBITOR 416
1926, d3dlsC_, 0.7492, 2.99, 0.171, 281, 251, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
1927, d2py3B_, 0.7492, 3.10, 0.173, 284, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
1928, d5os3A_, 0.7491, 2.98, 0.195, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1929, d5os0A_, 0.7491, 2.99, 0.195, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1930, d5k3yB_, 0.7491, 2.78, 0.149, 277, 249, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
1931, d5d9lA_, 0.7491, 2.98, 0.189, 299, 249, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BIS-PHENOL PYRAZOLE
1932, d5auzA_, 0.7491, 3.13, 0.194, 274, 252, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH GENISTEIN.
1933, d5ar5B_, 0.7491, 3.01, 0.170, 279, 253, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
1934, d4uxlA_, 0.7491, 3.25, 0.172, 288, 256, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH PF-06463922
1935, d4rx7A1, 0.7491, 3.13, 0.191, 270, 256, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR
1936, d4gh2A_, 0.7491, 3.00, 0.213, 266, 249, CRYSTAL STRUCTURE OF THE CHK1
1937, d3eqpA_, 0.7491, 3.23, 0.219, 268, 256, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
1938, d3dlsF_, 0.7491, 3.12, 0.179, 281, 252, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
1939, d1y57A3, 0.7491, 3.18, 0.207, 285, 256, STRUCTURE OF UNPHOSPHORYLATED C-SRC IN COMPLEX WITH AN INHIBITOR
1940, d4xrjA_, 0.7490, 2.88, 0.217, 344, 249, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1941, d4wnoA_, 0.7490, 3.08, 0.231, 272, 251, STRUCTURE OF ULK1 BOUND TO AN INHIBITOR
1942, d4e20A_, 0.7490, 3.27, 0.230, 282, 257, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
1943, d3ppzA_, 0.7490, 2.83, 0.217, 264, 249, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1944, d2b53A_, 0.7490, 3.04, 0.171, 294, 252, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN- 234325
1945, d5orsA_, 0.7489, 2.98, 0.195, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1946, d5k3yA_, 0.7489, 2.78, 0.157, 267, 249, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
1947, d4qt1A_, 0.7489, 3.18, 0.230, 277, 256, JAK3 KINASE DOMAIN IN COMPLEX WITH 1-[(3S)-1-ISOBUTYLSULFONYL-3- PIPERIDYL]-3-(5H-PYRROLO[23-B]PYRAZIN-2-YL)UREA
1948, d4ft5A_, 0.7489, 3.01, 0.197, 265, 249, CRYSTAL STRUCTURE OF THE CHK1
1949, d3qrtA_, 0.7489, 3.05, 0.182, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC2-55
1950, d3qqlA_, 0.7489, 3.27, 0.169, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR L3
1951, d2vgoB_, 0.7489, 2.90, 0.175, 277, 252, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
1952, d2vgoA_, 0.7489, 2.91, 0.187, 268, 251, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
1953, d5av4A_, 0.7488, 3.03, 0.196, 274, 250, CRYSTAL STRUCTURE OF DAPK1-GENISTEIN COMPLEX IN THE PRESENCE OF BROMIDE IONS.
1954, d4bicB_, 0.7488, 2.71, 0.233, 259, 245, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
1955, d3uo4A_, 0.7488, 2.81, 0.197, 266, 249, AURORA A IN COMPLEX WITH RPM1680
1956, d3kcfD_, 0.7488, 3.34, 0.208, 330, 259, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
1957, d5lqfA1, 0.7487, 2.70, 0.202, 284, 243, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
1958, d4j97C_, 0.7487, 3.10, 0.185, 283, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
1959, d4i0sA1, 0.7487, 3.02, 0.202, 263, 253, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(6- CHLORO-1-METHYL-1H-INDAZOL-3-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID ISOPROPYLAMIDE
1960, d2j0lA_, 0.7487, 3.12, 0.200, 274, 255, CRYSTAL STRUCTURE OF A THE ACTIVE CONFORMATION OF THE KINASE DOMAIN OF FOCAL ADHESION KINASE WITH A PHOSPHORYLATED ACTIVATION LOOP.
1961, d5gtzA_, 0.7486, 3.45, 0.186, 317, 258, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH JTS-1-39
1962, d4qpaA_, 0.7486, 2.87, 0.222, 331, 248, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
1963, d3nizA1, 0.7486, 3.28, 0.179, 284, 251, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH ADP BOUND.
1964, d2r7iC_, 0.7486, 2.96, 0.174, 321, 247, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1965, d2e9vB_, 0.7486, 2.97, 0.224, 268, 250, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
1966, d5w5oM_, 0.7485, 3.19, 0.167, 276, 257, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1967, d5os6A_, 0.7485, 2.99, 0.199, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1968, d5o12A_, 0.7485, 2.83, 0.174, 264, 247, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
1969, d5ci7A_, 0.7485, 3.00, 0.232, 276, 250, STRUCTURE OF ULK1 BOUND TO A SELECTIVE INHIBITOR
1970, d4asxB1, 0.7485, 3.17, 0.202, 296, 253, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
1971, d3r1qA_, 0.7485, 3.26, 0.160, 294, 256, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-102
1972, d3kcfA_, 0.7485, 3.42, 0.208, 328, 260, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
1973, d2bfyB_, 0.7485, 2.85, 0.144, 278, 250, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
1974, d2bfxA_, 0.7485, 2.92, 0.187, 269, 251, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
1975, d5ng0B_, 0.7484, 3.01, 0.163, 282, 252, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
1976, d5auuA_, 0.7484, 3.14, 0.194, 274, 252, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH LUTEOLIN.
1977, d4deeA_, 0.7484, 2.98, 0.195, 271, 251, AURORA A IN COMPLEX WITH ADP
1978, d3r28A_, 0.7484, 3.37, 0.160, 294, 257, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-140
1979, d2z60A1, 0.7484, 3.50, 0.203, 280, 261, CRYSTAL STRUCTURE OF THE T315I MUTANT OF ABL KINASE BOUND WITH PPY-A
1980, d2e9vA_, 0.7484, 2.97, 0.224, 268, 250, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
1981, d2a0cX_, 0.7484, 3.14, 0.170, 294, 253, HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II A NOVEL 269- TRISUBSTITUTED PURINE CYCLIN-DEPENDENT KINASE INHIBITOR
1982, p6g9jA_, 0.7483, 2.79, 0.223, 347, 247, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1983, d5jznA_, 0.7483, 2.84, 0.202, 268, 247, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
1984, d4o0sA_, 0.7483, 2.94, 0.196, 265, 250, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
1985, d3q4tB1, 0.7483, 2.94, 0.203, 293, 251, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
1986, d3dqwD_, 0.7483, 3.20, 0.203, 276, 256, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
1987, d2bvaB_, 0.7483, 2.93, 0.167, 274, 252, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
1988, d5uorB_, 0.7482, 2.64, 0.230, 262, 243, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
1989, d4e5wA1, 0.7482, 3.44, 0.201, 291, 259, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
1990, d3dlsB_, 0.7482, 3.15, 0.179, 280, 252, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
1991, d2fysA_, 0.7482, 3.02, 0.217, 348, 249, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
1992, d4rvlA_, 0.7481, 2.97, 0.206, 258, 248, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 7: 3-(2- HYDROXYPHENYL)-9H-PYRROLO[23-B:54-C ]DIPYRIDINE-6-CARBONITRILE
1993, d4fv0A_, 0.7481, 2.82, 0.222, 341, 248, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK3
1994, d4bibB_, 0.7481, 2.60, 0.222, 258, 243, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
1995, d3rniA_, 0.7481, 3.15, 0.185, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-3-86
1996, d3nyxA1, 0.7481, 3.33, 0.219, 285, 260, NON-PHOSPHORYLATED TYK2 JH1 DOMAIN WITH QUINOLINE-THIADIAZOLE- THIOPHENE INHIBITOR
1997, d2py3A_, 0.7481, 3.13, 0.173, 282, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
1998, d1pmeA_, 0.7481, 2.74, 0.220, 333, 246, STRUCTURE OF PENTA MUTANT HUMAN ERK2 MAP KINASE COMPLEXED WITH A SPECIFIC INHIBITOR OF HUMAN P38 MAP KINASE
1999, d5w5oO_, 0.7480, 3.17, 0.168, 276, 256, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2000, d5os4A_, 0.7480, 3.00, 0.195, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2001, d5cxzA1, 0.7480, 3.22, 0.199, 267, 256, SYK CATALYTIC DOMAIN COMPLEXED WITH NAPHTHYRIDINE INHIBITOR
2002, d5c26A1, 0.7480, 3.11, 0.196, 271, 255, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 1
2003, d5auwA_, 0.7480, 3.04, 0.196, 274, 250, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH QUERCETIN.
2004, d3vf9A_, 0.7480, 3.26, 0.198, 265, 257, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 027
2005, d3dqwA_, 0.7480, 3.18, 0.207, 278, 256, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
2006, d5w5oL_, 0.7479, 3.14, 0.169, 275, 255, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2007, d5clpA_, 0.7479, 2.96, 0.184, 322, 250, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
2008, d4xp0A_, 0.7479, 2.78, 0.219, 336, 247, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
2009, d4mygA_, 0.7479, 2.71, 0.218, 335, 243, MAPK13 ACTIVE FORM
2010, d4debA_, 0.7479, 2.92, 0.196, 264, 250, AURORA A IN COMPLEX WITH RK2-17-01
2011, d4deaA_, 0.7479, 2.94, 0.195, 266, 251, AURORA A IN COMPLEX WITH YL1-038-18
2012, d3f69B_, 0.7479, 3.11, 0.214, 282, 252, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
2013, d1m52B_, 0.7479, 3.40, 0.208, 272, 259, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
2014, d4qpaB_, 0.7478, 2.89, 0.221, 345, 249, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
2015, d4j99D_, 0.7478, 3.01, 0.183, 281, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
2016, d4fsmA_, 0.7478, 3.01, 0.205, 265, 249, CRYSTAL STRUCTURE OF THE CHK1
2017, d4c2wA_, 0.7478, 2.82, 0.153, 268, 249, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
2018, d3pj8A1, 0.7478, 3.13, 0.176, 287, 250, STRUCTURE OF CDK2 IN COMPLEX WITH A PYRAZOLO[43-D]PYRIMIDINE BIOISOSTERE OF ROSCOVITINE.
2019, d3dqwC_, 0.7478, 3.19, 0.199, 275, 256, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
2020, d3bhhC1, 0.7478, 3.10, 0.179, 284, 252, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2021, d4l45A_, 0.7477, 3.10, 0.190, 317, 248, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389E
2022, d3r1sA_, 0.7477, 3.30, 0.169, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-127
2023, d1wzyA_, 0.7477, 2.96, 0.216, 350, 250, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A PYRAZOLOPYRIDAZINE DERIVATIVE
2024, d1oplA3, 0.7477, 3.34, 0.201, 291, 259, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
2025, d5e92A_, 0.7476, 3.24, 0.160, 298, 256, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH AMPPNP
2026, d5dr2A1, 0.7476, 2.98, 0.195, 263, 251, AURORA A KINASE IN COMPLEX WITH AA30 AND ATP IN SPACE GROUP P6122
2027, d4hvdA_, 0.7476, 3.24, 0.230, 276, 256, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-122-TRIMETHYL-PROPYL)-AMIDE
2028, p4h3qA_, 0.7476, 2.90, 0.225, 352, 249, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
2029, d5m44A_, 0.7475, 3.12, 0.171, 329, 252, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
2030, d4z16B_, 0.7475, 3.28, 0.223, 276, 256, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
2031, d4izaA_, 0.7475, 2.97, 0.225, 346, 249, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
2032, d3dqwB_, 0.7475, 3.19, 0.203, 278, 256, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
2033, d2z8cA1, 0.7475, 3.07, 0.202, 297, 253, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN-2- YL]AMINO}PHENYL)ACETIC ACID
2034, d6bqqA1, 0.7474, 2.85, 0.206, 269, 247, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH BI2526
2035, d5khwB_, 0.7474, 3.47, 0.205, 276, 259, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
2036, d5khwA_, 0.7474, 3.45, 0.205, 276, 259, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
2037, d4xg6A1, 0.7474, 3.10, 0.181, 270, 254, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2038, d5w5oJ_, 0.7473, 3.17, 0.169, 275, 255, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2039, d5ghvB_, 0.7473, 3.04, 0.194, 265, 253, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2040, d5aneA_, 0.7473, 3.02, 0.172, 294, 250, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-METHOXY-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
2041, d4xg5B_, 0.7473, 3.04, 0.194, 265, 253,  
2042, d4l46A_, 0.7473, 3.13, 0.184, 317, 250, CRYSTAL STRUCTURES OF HUMAN P70S6K1-WT
2043, d4ftcA_, 0.7473, 3.02, 0.205, 266, 249, CRYSTAL STRUCTURE OF THE CHK1
2044, d3pxrA_, 0.7473, 3.20, 0.169, 294, 254, APO CDK2 CRYSTALLIZED FROM JEFFAMINE
2045, d3b2tB_, 0.7473, 3.10, 0.174, 287, 253, STRUCTURE OF PHOSPHOTRANSFERASE
2046, d2r7iD_, 0.7473, 3.06, 0.175, 322, 251, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2047, d4l44A_, 0.7472, 3.08, 0.192, 321, 250, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM II)
2048, d4bn1A_, 0.7472, 2.78, 0.198, 261, 248, CRYSTAL STRUCTURE OF V174M MUTANT OF AURORA-A KINASE
2049, d4bidB_, 0.7472, 2.68, 0.217, 258, 244, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2050, d3raiA_, 0.7472, 3.30, 0.165, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-160
2051, d3qzhA_, 0.7472, 3.32, 0.160, 294, 256, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-124
2052, d3qxoA_, 0.7472, 3.19, 0.169, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-84
2053, d2r7iB_, 0.7472, 3.07, 0.175, 322, 251, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2054, d2clxA_, 0.7472, 3.15, 0.170, 293, 253, 4-ARYLAZO-35-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY CRYSTAL STRUCTURE IN COMPLEX WITH CDK2 SELECTIVITY AND CELLULAR EFFECTS
2055, d1wvyA_, 0.7472, 3.11, 0.194, 273, 253, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
2056, d4bicA_, 0.7471, 2.84, 0.228, 260, 246, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2057, d3lfqA_, 0.7471, 3.05, 0.173, 289, 249, CRYSTAL STRUCTURE OF CDK2 WITH SAR60 AN AMINOINDAZOLE TYPE INHIBITOR
2058, d2r7iA_, 0.7471, 3.06, 0.179, 322, 251, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2059, d3r6xA_, 0.7470, 3.24, 0.169, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-158
2060, d3mdyC_, 0.7470, 3.32, 0.207, 320, 256, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
2061, d2vrxA_, 0.7470, 2.92, 0.187, 268, 251, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
2062, d1jktA_, 0.7470, 3.25, 0.185, 276, 254, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2063, d5jznB_, 0.7469, 2.81, 0.203, 266, 246, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
2064, d4k77A_, 0.7469, 3.36, 0.195, 282, 257, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
2065, d4fl1A_, 0.7469, 3.21, 0.195, 268, 257, STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF THE SYK ACTIVATION SWITCH
2066, d3qx2A_, 0.7469, 3.21, 0.165, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-190
2067, d3lxlA_, 0.7469, 3.47, 0.233, 281, 258, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
2068, d5w5oH_, 0.7468, 3.18, 0.169, 275, 255, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2069, d5ghvA_, 0.7468, 3.04, 0.194, 265, 253, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2070, d5cwzC_, 0.7468, 2.75, 0.202, 271, 247, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
2071, d4xg5A_, 0.7468, 3.04, 0.194, 265, 253,  
2072, d4j8nC_, 0.7468, 2.97, 0.195, 266, 251, AURORA A KINASE APO
2073, d4fyoA1, 0.7468, 3.06, 0.202, 263, 253, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH N-{(S)-1- [7-(34-DIMETHOXY-PHENYLAMINO)-THIAZOLO[54-D]PYRIMIDIN-5-YL]- PYRROLIDIN-3-YL}-TEREPHTHALAMIC ACID
2074, d5amnA1, 0.7467, 3.15, 0.170, 282, 253, THE DISCOVERY OF 2-SUBSTITUTED PHENOL QUINAZOLINES AS POTENT AND SELECTIVE RET KINASE INHIBITORS
2075, d3lfsA_, 0.7467, 3.15, 0.172, 290, 250, CRYSTAL STRUCTURE OF CDK2 WITH SAR37 AN AMINOINDAZOLE TYPE INHIBITOR
2076, d3e3pA_, 0.7467, 3.27, 0.177, 337, 254, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
2077, d4j8nB_, 0.7466, 2.97, 0.195, 266, 251, AURORA A KINASE APO
2078, d4ivbA1, 0.7466, 3.40, 0.205, 290, 258, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
2079, d5mjbB_, 0.7465, 3.24, 0.148, 278, 257, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
2080, d5eykB_, 0.7465, 2.82, 0.153, 275, 249, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
2081, d4j8nD_, 0.7465, 2.97, 0.195, 265, 251, AURORA A KINASE APO
2082, d3rk9A_, 0.7465, 3.20, 0.185, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-2-74
2083, d3qx4A_, 0.7465, 3.24, 0.161, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-78
2084, d2brhA_, 0.7465, 2.99, 0.213, 257, 249, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
2085, d5orlA_, 0.7464, 2.91, 0.197, 264, 249, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2086, d4rssA_, 0.7464, 3.19, 0.191, 269, 257, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE SYK WITH AN INHIBITOR
2087, d4j8nA_, 0.7464, 2.98, 0.195, 266, 251, AURORA A KINASE APO
2088, d3pa3A_, 0.7464, 2.95, 0.217, 259, 249, X-RAY CRYSTAL STRUCTURE OF COMPOUND 70 BOUND TO HUMAN CHK1 KINASE DOMAIN
2089, d5w5oP_, 0.7463, 3.17, 0.169, 275, 255, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2090, d5w5oD_, 0.7463, 3.18, 0.169, 275, 255, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2091, d4bhnB_, 0.7463, 2.69, 0.217, 257, 244, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2092, d3royA_, 0.7463, 3.36, 0.160, 294, 256, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-154
2093, d3r7eA_, 0.7463, 3.21, 0.165, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-67
2094, d3hmmA_, 0.7463, 3.15, 0.202, 293, 253, STRUCTURE OF ALK5 + GW855857
2095, d2g2hB_, 0.7463, 3.46, 0.201, 272, 259, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
2096, d4utdA_, 0.7462, 3.11, 0.194, 266, 252, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP IN AN ACTIVE CONFORMATION
2097, d4cegA_, 0.7462, 2.96, 0.196, 264, 250, CRYSTAL STRUCTURE OF AURORA A 122-403 C290A C393A BOUND TO ADP
2098, d4bieB_, 0.7462, 2.67, 0.226, 257, 243, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2099, d3r73A_, 0.7462, 3.37, 0.160, 294, 256, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-164
2100, p2gmxA_, 0.7462, 2.96, 0.212, 357, 250, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
2101, d1opkA3, 0.7462, 3.37, 0.205, 291, 259, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
2102, d1ol7A_, 0.7462, 2.85, 0.197, 261, 249, STRUCTURE OF HUMAN AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288
2103, d1b6cD_, 0.7462, 3.42, 0.208, 326, 259, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
2104, d3r8pA_, 0.7461, 3.15, 0.170, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-6
2105, d3qwkA_, 0.7461, 3.08, 0.190, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-150
2106, d3qwjA_, 0.7461, 3.22, 0.161, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-142
2107, d4ftrA_, 0.7460, 2.94, 0.215, 258, 247, CRYSTAL STRUCTURE OF THE CHK1
2108, d3qtwA_, 0.7460, 3.38, 0.171, 294, 257, CDK2 IN COMPLEX WITH INHIBITOR RC-2-13
2109, d2v7aA_, 0.7460, 3.26, 0.210, 269, 257, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
2110, d1m52A_, 0.7460, 3.34, 0.210, 271, 257, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
2111, d5w5oC_, 0.7459, 3.18, 0.169, 275, 255, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2112, d4dedA_, 0.7459, 2.89, 0.197, 265, 249, AURORA A IN COMPLEX WITH YL1-038-21
2113, d3wf8A_, 0.7459, 3.18, 0.192, 287, 250, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 2-OXO-2-[(4-SULFAMOYLPHENYL)AMINO]ETHYL 78910- TETRAHYDRO-6H-CYCLOHEPTA[B]QUINOLINE-11-CARBOXYLATE
2114, d5w5oE_, 0.7458, 3.18, 0.165, 275, 255, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2115, d5lqfD1, 0.7458, 2.83, 0.202, 282, 243, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
2116, d5dlsA_, 0.7458, 2.87, 0.227, 257, 247, IDENTIFICATION OF NOVEL IN VIVO ACTIVE CHK1 INHIBITORS UTILIZING STRUCTURE GUIDED DRUG DESIGN
2117, d4u41A_, 0.7458, 3.22, 0.198, 275, 253, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
2118, d4nifE_, 0.7458, 2.98, 0.222, 348, 248, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
2119, d4nifB_, 0.7458, 2.98, 0.222, 349, 248, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
2120, d3rm6A_, 0.7458, 3.24, 0.181, 293, 254, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-80
2121, d3nrmA_, 0.7458, 2.93, 0.197, 263, 249, IMIDAZO[12-A]PYRAZINE-BASED AURORA KINASE INHIBITORS
2122, d3ma3A_, 0.7458, 2.89, 0.182, 266, 247, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A NAPHTHO-DIFURAN LIGAND
2123, d5tt7A1, 0.7457, 3.12, 0.188, 270, 255, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
2124, d4xg4A_, 0.7457, 3.06, 0.198, 264, 252, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2125, d4c62A_, 0.7457, 3.07, 0.198, 273, 252, INHIBITORS OF JAK2 KINASE DOMAIN
2126, d3r1yA_, 0.7457, 3.27, 0.169, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-134
2127, d3qqkA_, 0.7457, 3.23, 0.173, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR L4
2128, d3pp0A_, 0.7457, 3.39, 0.181, 286, 259, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
2129, d2q0bB_, 0.7457, 3.11, 0.170, 282, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
2130, d4fswA_, 0.7456, 2.96, 0.206, 265, 248, CRYSTAL STRUCTURE OF THE CHK1
2131, d3qtzA_, 0.7456, 3.30, 0.172, 294, 256, CDK2 IN COMPLEX WITH INHIBITOR RC-2-36
2132, d2ds1A_, 0.7456, 3.07, 0.173, 290, 249, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
2133, d1pw2A_, 0.7456, 3.07, 0.176, 294, 250, APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2
2134, d4i5cB1, 0.7455, 3.43, 0.205, 290, 258, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
2135, d3wf9A_, 0.7455, 3.20, 0.192, 287, 250, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 1-OXO-1-[(4-SULFAMOYLPHENYL)AMINO]PROPAN-2-YL-2-METHYL-1 234-TETRAHYDROACRIDINE-9-CARBOXYLATE
2136, d1hckA_, 0.7455, 3.19, 0.170, 294, 253, HUMAN CYCLIN-DEPENDENT KINASE 2
2137, d5w5oK_, 0.7454, 3.22, 0.168, 275, 256, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2138, d4k77B_, 0.7454, 3.40, 0.202, 280, 258, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
2139, d4ivdB_, 0.7454, 3.41, 0.202, 280, 258, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
2140, d4hviA_, 0.7454, 3.29, 0.223, 274, 256, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-1-METHYL-2-OXO-2-PIPERIDIN-1-YL- ETHYL)-AMIDE
2141, d4ez3A_, 0.7454, 3.10, 0.187, 294, 252, CDK2 IN COMPLEX WITH NSC 134199
2142, d3ue4B_, 0.7454, 3.20, 0.204, 268, 255, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
2143, d5w5oI_, 0.7453, 3.15, 0.169, 275, 254, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2144, d5ttvA_, 0.7453, 3.49, 0.221, 280, 258, JAK3 WITH COVALENT INHIBITOR 6
2145, d5c27A1, 0.7453, 3.12, 0.177, 271, 254, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 2
2146, d4rx8A1, 0.7453, 3.19, 0.199, 266, 256, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR2
2147, d4lynA_, 0.7453, 3.01, 0.189, 287, 249, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH (2S)-N-(5-(((5-TERT-BUTYL-13-OXAZOL-2-YL)METHYL)SULFANYL)-13- THIAZOL-2-YL)-2-PHENYLPROPANAMIDE
2148, d4c62B_, 0.7453, 3.22, 0.197, 271, 254, INHIBITORS OF JAK2 KINASE DOMAIN
2149, d3rk7A_, 0.7453, 3.34, 0.172, 294, 256, CDK2 IN COMPLEX WITH INHIBITOR RC-2-71
2150, d3jvrA_, 0.7453, 2.93, 0.215, 258, 246, CHARACTERIZATION OF THE CHK1 ALLOSTERIC INHIBITOR BINDING SITE
2151, d2qohB2, 0.7453, 3.49, 0.212, 280, 260, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
2152, d4ivbB_, 0.7452, 3.41, 0.202, 280, 258, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
2153, d1f5qC_, 0.7452, 3.04, 0.185, 288, 249, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
2154, d5tq6A_, 0.7451, 3.28, 0.203, 274, 256, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
2155, d4kd1A_, 0.7451, 3.18, 0.170, 298, 253, CDK2 IN COMPLEX WITH DINACICLIB
2156, d3umxA_, 0.7451, 2.83, 0.203, 261, 246, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDOL-3-YL)METHYLENE]-7-(AZEPAN-1-YLMETHYL)-6-HYDROXYBENZOFURAN- 3(2H)-ONE
2157, d3lfnA_, 0.7451, 2.98, 0.172, 285, 250, CRYSTAL STRUCTURE OF CDK2 WITH SAR57 AN AMINOINDAZOLE TYPE INHIBITOR
2158, d3kf4A_, 0.7451, 3.59, 0.211, 281, 261, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
2159, d2clqB_, 0.7451, 2.77, 0.220, 259, 245, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
2160, d5tq7A_, 0.7450, 3.39, 0.202, 275, 257, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
2161, d2ydkA_, 0.7450, 3.07, 0.214, 263, 252, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
2162, d5hx8B_, 0.7449, 3.43, 0.190, 279, 258, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
2163, d4erwA_, 0.7449, 2.97, 0.188, 292, 250, CDK2 IN COMPLEX WITH STAUROSPORINE
2164, d4e4nA1, 0.7449, 3.41, 0.195, 290, 257, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
2165, p3vuhA_, 0.7449, 2.75, 0.221, 355, 244, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M3 IN MAP KINASE JNK1
2166, d3up7A_, 0.7449, 2.89, 0.193, 264, 249, AURORA A IN COMPLEX WITH YL1-038-09
2167, d3clyA_, 0.7449, 3.50, 0.170, 289, 259, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAINS TRAPPED IN TRANS-PHOSPHORYLATION REACTION
2168, d1hclA_, 0.7449, 3.20, 0.170, 294, 253, HUMAN CYCLIN-DEPENDENT KINASE 2
2169, d5w5oA_, 0.7448, 3.14, 0.169, 275, 254, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2170, d4twpB_, 0.7448, 3.25, 0.211, 271, 256, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
2171, d4e4nB_, 0.7448, 3.42, 0.202, 280, 258, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
2172, p3vugA_, 0.7448, 2.77, 0.221, 356, 244, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
2173, d3qtxA_, 0.7448, 3.27, 0.176, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR RC-2-35
2174, d4ixpA_, 0.7447, 3.00, 0.222, 334, 248, CRYSTAL STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK)
2175, d4bieA_, 0.7447, 2.71, 0.222, 257, 243, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2176, p3vuiA_, 0.7447, 2.76, 0.221, 355, 244, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
2177, d3r7vA_, 0.7447, 3.22, 0.165, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-9
2178, d2xmyA_, 0.7447, 3.27, 0.161, 295, 254, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
2179, d1qpjA_, 0.7447, 3.08, 0.202, 265, 253, CRYSTAL STRUCTURE OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH STAUROSPORINE.
2180, d5w5oF_, 0.7446, 3.20, 0.169, 275, 255, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2181, d4zy5B_, 0.7446, 3.26, 0.226, 287, 252, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
2182, d4oboA_, 0.7446, 3.37, 0.200, 275, 255, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
2183, d3rjcA_, 0.7446, 3.25, 0.185, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR L4-12
2184, d3qu0A_, 0.7446, 3.30, 0.172, 294, 256, CDK2 IN COMPLEX WITH INHIBITOR RC-2-38
2185, d3e3pB_, 0.7446, 3.33, 0.176, 337, 255, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
2186, d5w5oB_, 0.7445, 3.20, 0.169, 275, 255, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2187, d5ar4B_, 0.7445, 3.12, 0.157, 279, 254, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
2188, d4obqA_, 0.7445, 3.16, 0.199, 275, 251, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
2189, d4ivcB_, 0.7445, 3.42, 0.202, 280, 258, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
2190, d4gvaA_, 0.7445, 2.90, 0.217, 345, 249, ADP-BOUND FORM OF THE ERK2 KINASE
2191, d3qruA_, 0.7445, 3.22, 0.185, 295, 254, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-12
2192, d3qqfA_, 0.7445, 3.22, 0.174, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR L1
2193, d3pa4A_, 0.7445, 2.94, 0.218, 257, 248, X-RAY CRYSTAL STRUCTURE OF COMPOUND 2A BOUND TO HUMAN CHK1 KINASE DOMAIN
2194, d2vgpA_, 0.7445, 2.81, 0.181, 265, 248, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
2195, d2v7aB_, 0.7445, 3.24, 0.210, 268, 257, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
2196, d1b6cB_, 0.7445, 3.45, 0.208, 326, 259, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
2197, d4zogB_, 0.7444, 3.31, 0.207, 268, 256, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
2198, d3sa0A_, 0.7444, 2.85, 0.222, 354, 248, COMPLEX OF ERK2 WITH NORATHYRIOL
2199, d3rpvA_, 0.7444, 3.27, 0.176, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR RC-2-88
2200, d1b6cF_, 0.7444, 3.43, 0.208, 326, 259, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
2201, d4lqmA_, 0.7443, 3.52, 0.162, 305, 259, EGFR L858R IN COMPLEX WITH PD168393
2202, d4c61A_, 0.7443, 3.05, 0.199, 272, 251, INHIBITORS OF JAK2 KINASE DOMAIN
2203, d3zmmA_, 0.7443, 3.09, 0.198, 273, 252, INHIBITORS OF JAK2 KINASE DOMAIN
2204, d5wo4B_, 0.7442, 3.45, 0.202, 280, 258, JAK1 COMPLEXED WITH COMPOUND 28
2205, d5w5oG_, 0.7442, 3.25, 0.168, 275, 256, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2206, d4ftaA_, 0.7442, 3.02, 0.206, 264, 248, CRYSTAL STRUCTURE OF THE CHK1
2207, d4dfnA1, 0.7442, 3.19, 0.191, 268, 256, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH AN ADAMANTYLPYRAZINE INHIBITOR
2208, d3rpoA_, 0.7442, 3.25, 0.165, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-156
2209, d4l43A_, 0.7441, 2.94, 0.195, 316, 246, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM I)
2210, d4iz7A_, 0.7441, 2.78, 0.224, 344, 246, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
2211, d3zepA_, 0.7441, 3.20, 0.226, 274, 252, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
2212, d3r7yA_, 0.7441, 3.20, 0.170, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-88
2213, d3kulB_, 0.7441, 3.20, 0.165, 271, 255, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
2214, d2exmA_, 0.7441, 3.18, 0.170, 298, 253, HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE
2215, d1y91A_, 0.7441, 3.10, 0.187, 286, 251, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
2216, d5os2A_, 0.7440, 2.89, 0.198, 261, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2217, d5byyA_, 0.7440, 2.87, 0.231, 338, 247, ERK5 IN COMPLEX WITH SMALL MOLECULE
2218, d4bgqA_, 0.7440, 2.77, 0.199, 276, 246, CRYSTAL STRUCTURE OF THE HUMAN CDKL5 KINASE DOMAIN
2219, d3wf6A_, 0.7440, 3.14, 0.197, 277, 249, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-INDOL-3-YL)-36- DIHYDROPYRIDIN-1(2H)-YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
2220, d3rm7A_, 0.7440, 3.19, 0.170, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-91
2221, d3r9dA_, 0.7440, 3.26, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-2-135
2222, p2gmxB_, 0.7440, 2.93, 0.217, 357, 249, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
2223, d2e9pA_, 0.7440, 3.12, 0.215, 269, 251, STRUCTURE OF H-CHK1 COMPLEXED WITH A771129
2224, d1pxiA_, 0.7440, 3.19, 0.170, 294, 253, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(25-DICHLORO-THIOPHEN-3-YL)-PYRIMIDIN-2- YLAMINE
2225, d4n0sA_, 0.7439, 2.87, 0.222, 348, 248, COMPLEX OF ERK2 WITH CAFFEIC ACID
2226, d4ez7A1, 0.7439, 2.97, 0.198, 298, 247, CDK2 IN COMPLEX WITH STAUROSPORINE AND 2 MOLECULES OF 8-ANILINO-1- NAPHTHALENE SULFONIC ACID
2227, d4b8mB_, 0.7439, 3.13, 0.175, 279, 252, AURORA B KINASE IN COMPLEX WITH VX-680
2228, d3wf5A_, 0.7439, 3.16, 0.197, 277, 249, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-BENZIMIDAZOL-2-YL)PIPERIDIN-1- YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
2229, p3vudA_, 0.7439, 2.78, 0.221, 355, 244, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
2230, d1b6cH_, 0.7439, 3.46, 0.208, 326, 259, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
2231, d4jajA_, 0.7438, 3.06, 0.195, 265, 251, CRYSTAL STRUCTURE OF AURORA KINASE A IN COMPLEX WITH BENZO[C][1 8]NAPHTHYRIDIN-6(5H)-ONE
2232, d4c2vB_, 0.7438, 3.02, 0.175, 280, 251, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
2233, d3ad6A_, 0.7438, 3.14, 0.201, 272, 254, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2234, d4jikA_, 0.7437, 2.85, 0.215, 256, 246, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22A (R)-2-(4-CHLOROPHENYL)-8- (PIPERIDIN-3-YLAMINO)IMIDAZO[12-C]PYRIMIDINE-5-CARBOXAMIDE BOUND TO HUMAN CHK1 KINASE DOMAIN
2235, d4ivcA1, 0.7437, 3.44, 0.205, 290, 258, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
2236, d3r71A_, 0.7437, 3.18, 0.166, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-162
2237, d2wmrA_, 0.7437, 2.80, 0.216, 254, 245, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2238, d2qohA2, 0.7437, 3.29, 0.211, 270, 256, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
2239, d5w5oN_, 0.7436, 3.05, 0.171, 272, 252, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2240, d5gmpA_, 0.7436, 3.32, 0.189, 305, 254, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH XTF-262
2241, d5dosA_, 0.7436, 2.75, 0.195, 259, 246, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
2242, d5ar2A_, 0.7436, 3.04, 0.171, 277, 252, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
2243, d4gsbA_, 0.7436, 2.80, 0.220, 343, 246, MONOCLINIC CRYSTAL FORM OF THE APO-ERK2
2244, p3vukA_, 0.7436, 2.78, 0.221, 355, 244, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M5 IN MAP KINASE JNK1
2245, d5lmbA_, 0.7435, 3.21, 0.185, 264, 254, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
2246, d4pv0A1, 0.7435, 3.18, 0.196, 266, 255, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH AN IMIDAZOPYRAZINE INHIBITOR
2247, p2no3A_, 0.7435, 2.97, 0.212, 357, 250, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
2248, d2fo0A3, 0.7435, 3.40, 0.201, 291, 259, ORGANIZATION OF THE SH3-SH2 UNIT IN ACTIVE AND INACTIVE FORMS OF THE C-ABL TYROSINE KINASE
2249, d1jktB_, 0.7435, 3.29, 0.189, 276, 254, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2250, d5ttsA_, 0.7434, 3.36, 0.227, 274, 256, JAK3 WITH COVALENT INHIBITOR 4
2251, d4ftlA_, 0.7434, 3.01, 0.202, 263, 247, CRYSTAL STRUCTURE OF THE CHK1
2252, d2z7rA_, 0.7434, 2.84, 0.181, 265, 243, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO STAUROSPORINE
2253, d4ftmA_, 0.7433, 3.01, 0.202, 263, 247, CRYSTAL STRUCTURE OF THE CHK1
2254, d2bfxB_, 0.7433, 2.86, 0.169, 275, 249, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
2255, d1mruA_, 0.7433, 2.61, 0.216, 269, 241, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
2256, d5dt4A_, 0.7432, 2.75, 0.195, 259, 246, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
2257, d5cs6B_, 0.7432, 2.70, 0.177, 316, 243, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
2258, d4zy4B_, 0.7432, 3.27, 0.226, 292, 252, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
2259, d4jboA_, 0.7432, 3.12, 0.198, 266, 252, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
2260, d5b2lA_, 0.7431, 3.13, 0.198, 288, 252, A CRUCIAL ROLE OF CYS218 IN THE STABILIZATION OF AN UNPRECEDENTED AUTO-INHIBITION FORM OF MAP2K7
2261, d4ivdA1, 0.7431, 3.41, 0.202, 289, 257, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
2262, d4ehzA_, 0.7431, 3.52, 0.200, 290, 260, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
2263, d4c2wB_, 0.7431, 3.14, 0.179, 277, 252, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
2264, d3ql8A_, 0.7431, 3.28, 0.185, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-260
2265, d3pxfA1, 0.7431, 3.14, 0.197, 298, 249, CDK2 IN COMPLEX WITH TWO MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
2266, d3kxzA_, 0.7431, 3.09, 0.202, 263, 253, THE COMPLEX CRYSTAL STRUCTURE OF LCK WITH A PROBE MOLECULE W259
2267, d3kmmA_, 0.7431, 3.12, 0.202, 270, 253, STRUCTURE OF HUMAN LCK KINASE WITH A SMALL MOLECULE INHIBITOR
2268, d3bu6A_, 0.7431, 3.17, 0.202, 294, 253, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PHOSPHOPEPTIDE
2269, d2pzrB_, 0.7431, 3.10, 0.171, 282, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
2270, d2pzpB_, 0.7431, 3.11, 0.171, 282, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
2271, d2pz5B_, 0.7431, 3.16, 0.174, 280, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
2272, d5drdA_, 0.7430, 2.77, 0.195, 259, 246, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
2273, d4fsqA_, 0.7430, 2.96, 0.211, 263, 246, CRYSTAL STRUCTURE OF THE CHK1
2274, d3zepD_, 0.7430, 3.14, 0.227, 272, 251, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
2275, d3srvB_, 0.7430, 3.18, 0.201, 263, 254, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
2276, d3qzfA_, 0.7430, 3.22, 0.174, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-52
2277, d3qtqA_, 0.7430, 3.15, 0.178, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR RC-1-137
2278, d2pvyD_, 0.7430, 3.02, 0.163, 283, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
2279, d2b52A_, 0.7430, 2.87, 0.177, 283, 248, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH- 042562
2280, d4j99A_, 0.7429, 3.09, 0.178, 280, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
2281, d3vw6A_, 0.7429, 2.69, 0.223, 255, 242, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
2282, d3qtuA_, 0.7429, 3.28, 0.185, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-2-132
2283, d1o6yA_, 0.7429, 2.43, 0.210, 260, 238, CATALYTIC DOMAIN OF PKNB KINASE FROM MYCOBACTERIUM TUBERCULOSIS
2284, d3r8uA_, 0.7428, 3.43, 0.160, 294, 256, CDK2 IN COMPLEX WITH INHIBITOR RC-1-132
2285, d3qxpA_, 0.7428, 3.08, 0.187, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
2286, d2q0bA_, 0.7428, 3.10, 0.171, 280, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
2287, d1pxjA_, 0.7428, 3.23, 0.157, 294, 254, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINE
2288, d5objA_, 0.7427, 2.89, 0.194, 260, 248, AURORA A KINASE IN COMPLEX WITH 2-(3-FLUOROPHENYL)QUINOLINE-4- CARBOXYLIC ACID AND ATP
2289, d5mjbA_, 0.7427, 3.18, 0.150, 276, 254, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
2290, d4ei4B_, 0.7427, 3.45, 0.202, 280, 258, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
2291, d3dk7B_, 0.7427, 3.54, 0.205, 268, 259, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
2292, d2pvyA_, 0.7427, 3.04, 0.163, 288, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
2293, d4dhfA_, 0.7426, 2.78, 0.195, 258, 246, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
2294, d3fqsA1, 0.7426, 3.15, 0.202, 264, 253, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R406
2295, d2x6dA_, 0.7426, 2.79, 0.195, 255, 246, AURORA-A BOUND TO AN INHIBITOR
2296, d2r2pA1, 0.7426, 3.14, 0.157, 276, 255, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 5 (EPHA5)
2297, d1pxpA_, 0.7426, 3.16, 0.166, 294, 253, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- N N -DIMETHYL-BENZENE-14-DIAMINE
2298, d3fqeA1, 0.7425, 3.12, 0.201, 265, 254, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH YM193306
2299, d3dk3B_, 0.7425, 3.57, 0.204, 269, 260, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
2300, d2vgpB_, 0.7425, 3.04, 0.175, 277, 251, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
2301, d4zxtA_, 0.7424, 2.88, 0.222, 348, 248, COMPLEX OF ERK2 WITH CATECHOL
2302, d4px6A1, 0.7424, 3.09, 0.202, 261, 253, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT PYRIDOPYRIMIDINONE INHIBITOR
2303, d4k6zA_, 0.7424, 3.42, 0.205, 279, 258, THE JAK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 37
2304, d4j97D_, 0.7424, 3.14, 0.170, 285, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
2305, d3ti1A_, 0.7424, 3.21, 0.173, 294, 254, CDK2 IN COMPLEX WITH SUNITINIB
2306, d3rk5A_, 0.7424, 3.22, 0.177, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-2-72
2307, d5j7bA_, 0.7423, 3.11, 0.158, 277, 253, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
2308, d4rj3A_, 0.7423, 3.09, 0.169, 287, 248, CDK2 WITH EGFR INHIBITOR COMPOUND 8
2309, d4ftkA_, 0.7423, 3.01, 0.202, 263, 247, CRYSTAL STRUCTURE OF THE CHK1
2310, d4bhnA_, 0.7423, 2.77, 0.222, 256, 243, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2311, d4au8B_, 0.7423, 2.67, 0.202, 277, 242, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
2312, d3sqqA_, 0.7423, 3.02, 0.175, 288, 251, CDK2 IN COMPLEX WITH INHIBITOR RC-3-96
2313, d3socA1, 0.7423, 3.15, 0.202, 296, 252, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
2314, p3o17B_, 0.7423, 3.02, 0.212, 357, 250, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
2315, d3amyA_, 0.7423, 2.87, 0.176, 318, 245, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH APIGENIN
2316, d2zm3B2, 0.7423, 3.10, 0.194, 295, 252, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
2317, d1y8yA_, 0.7423, 3.15, 0.175, 292, 252, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
2318, d1oirA_, 0.7423, 3.02, 0.170, 286, 247, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
2319, d1h0uA_, 0.7423, 3.26, 0.174, 291, 253,  
2320, d2zybA_, 0.7422, 3.13, 0.202, 270, 253, CRYSTAL STRUCTURE OF PHENYLIMIDAZO PYRAZIN 2 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2321, d2r3hA_, 0.7422, 3.17, 0.173, 289, 249, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2322, d5jzjA_, 0.7421, 2.80, 0.204, 271, 245, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
2323, d4mygB_, 0.7421, 2.75, 0.214, 335, 243, MAPK13 ACTIVE FORM
2324, d4e4lD_, 0.7421, 3.57, 0.196, 281, 260, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
2325, d3lcdA_, 0.7421, 3.09, 0.203, 290, 251, INHIBITOR BOUND TO A DFG-IN STRUCTURE OF THE KINASE DOMAIN OF CSF-1R
2326, d1mruB_, 0.7421, 2.61, 0.216, 271, 241, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
2327, d4fk6B_, 0.7420, 3.53, 0.192, 284, 261, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
2328, d4ek5A_, 0.7420, 3.15, 0.173, 289, 249, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
2329, d3uliA_, 0.7420, 3.00, 0.172, 286, 250, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) BOUND TO AZABENZIMIDAZOLE DERIVATIVE
2330, d3r9hA_, 0.7420, 3.17, 0.178, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR RC-2-142
2331, d2vtoA_, 0.7420, 3.16, 0.175, 283, 251, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
2332, d2dq7X_, 0.7420, 2.97, 0.217, 262, 249, CRYSTAL STRUCTURE OF FYN KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
2333, d3r8zA_, 0.7419, 3.09, 0.187, 290, 252, CDK2 IN COMPLEX WITH INHIBITOR RC-1-136
2334, d3q4tA1, 0.7419, 3.08, 0.204, 294, 250, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
2335, d3pxqA1, 0.7419, 3.12, 0.198, 294, 248, CDK2 IN COMPLEX WITH 3 MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
2336, d2x2mB1, 0.7419, 2.96, 0.161, 274, 248, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
2337, d2of4A_, 0.7419, 3.17, 0.201, 271, 254, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 1 BOUND TO LCK
2338, d2of2A_, 0.7419, 3.17, 0.201, 271, 254, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 8 BOUND TO LCK
2339, d1mq4A_, 0.7419, 2.85, 0.198, 261, 248, CRYSTAL STRUCTURE OF AURORA-A PROTEIN KINASE
2340, d1fvtA_, 0.7419, 3.16, 0.175, 282, 251, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH AN OXINDOLE INHIBITOR
2341, d4xg9B_, 0.7418, 3.11, 0.187, 265, 252, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2342, d3lxkA_, 0.7418, 3.51, 0.233, 279, 258, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
2343, d3fz1A_, 0.7418, 2.98, 0.177, 284, 249, CRYSTAL STRUCTURE OF A BENZTHIOPHENE INHIBITOR BOUND TO HUMAN CYCLIN-DEPENDENT KINASE-2 (CDK-2)
2344, d2ym6A_, 0.7418, 2.86, 0.212, 253, 245, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2345, d1xbbA1, 0.7418, 3.18, 0.201, 266, 254, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH GLEEVEC
2346, d4puzB_, 0.7417, 3.14, 0.186, 265, 253, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
2347, d4dhfB_, 0.7417, 2.85, 0.194, 258, 247, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
2348, d3ad4A_, 0.7417, 3.14, 0.202, 270, 253, CRYSTAL STRUCTURE OF METHOXY BENZOFURAN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2349, d3ac5A_, 0.7417, 3.14, 0.202, 270, 253, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2350, d2xeyA_, 0.7417, 2.82, 0.209, 252, 244, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2351, d2ittA_, 0.7417, 3.41, 0.180, 302, 255, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AEE788
2352, d5vt1A1, 0.7416, 2.84, 0.207, 264, 246, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO A BENZAMIDE INHIBITOR
2353, d4zs0A_, 0.7416, 2.73, 0.192, 257, 245, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO SB-6-OH
2354, d4zjiB_, 0.7416, 3.35, 0.202, 276, 257, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
2355, d4fkvA_, 0.7416, 3.01, 0.188, 282, 250, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
2356, d4fkuA_, 0.7416, 3.33, 0.189, 293, 254, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
2357, d2pzpA_, 0.7416, 3.06, 0.179, 280, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
2358, d1h0vA_, 0.7416, 3.26, 0.170, 288, 253, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R)-PYRROLIDINO-5 -YL]METHOXYPURINE
2359, d6b16B_, 0.7415, 3.19, 0.229, 281, 249, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
2360, d5jq5A_, 0.7415, 3.04, 0.174, 287, 247, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0942
2361, d4dflA1, 0.7415, 3.17, 0.189, 262, 254, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A SULFONAMIDOPYRAZINE PIPERIDINE INHIBITOR
2362, d3tiyA_, 0.7415, 3.23, 0.182, 293, 253, CDK2 IN COMPLEX WITH NSC 35676
2363, d3srvA_, 0.7415, 3.18, 0.174, 262, 253, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
2364, d3s00A_, 0.7415, 3.34, 0.161, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR L4-14
2365, d3gxlA_, 0.7415, 3.18, 0.206, 285, 252, ALK-5 KINASE COMPLEX WITH GW857175
2366, d3ac3A_, 0.7415, 3.15, 0.202, 270, 253, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2367, d3ac1A_, 0.7415, 3.15, 0.202, 270, 253, CRYSTAL STRUCTURE OF PYRAZIN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2368, d4qp8B_, 0.7414, 2.77, 0.222, 337, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
2369, d2xnbA_, 0.7414, 3.01, 0.181, 296, 249, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
2370, d2j5fA_, 0.7414, 3.47, 0.167, 308, 258, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 34-JAB
2371, d1b38A_, 0.7414, 3.24, 0.175, 290, 252, HUMAN CYCLIN-DEPENDENT KINASE 2
2372, d5deyB_, 0.7413, 3.17, 0.229, 281, 249, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
2373, d5byzA_, 0.7413, 3.11, 0.210, 348, 252, ERK5 IN COMPLEX WITH SMALL MOLECULE
2374, d4i5cA_, 0.7413, 3.42, 0.202, 279, 257, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
2375, d4fk6A_, 0.7413, 3.51, 0.192, 285, 260, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
2376, d3wf7A_, 0.7413, 3.34, 0.186, 288, 253, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PURINE DERIVATIVE 1-(9H-PURIN-6-YL)-N-[3-(TRIFLUOROMETHYL)PHENYL]PIPERIDINE- 4-CARBOXAMIDE
2377, p3o17A_, 0.7413, 2.95, 0.209, 357, 249, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
2378, d3acjA_, 0.7413, 3.14, 0.202, 270, 253, CRYSTAL STRUCTURE OF IMIDAZO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2379, d2x4fB_, 0.7413, 3.38, 0.179, 288, 257, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
2380, d3vw6B_, 0.7412, 2.56, 0.221, 253, 240, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
2381, d3jvsA_, 0.7412, 2.85, 0.218, 256, 243, CHARACTERIZATION OF THE CHK1 ALLOSTERIC INHIBITOR BINDING SITE
2382, d3ackA_, 0.7412, 3.15, 0.202, 270, 253, CRYSTAL STRUCTURE OF PYRROLO PYRAZINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2383, d3ac4A_, 0.7412, 3.16, 0.202, 270, 253, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2384, d4xg3B_, 0.7411, 3.03, 0.199, 267, 251, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2385, d3iggA_, 0.7411, 3.26, 0.175, 290, 252, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFQ WITH CDK-2
2386, d2pz5A_, 0.7411, 3.12, 0.179, 280, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
2387, d2c5yA_, 0.7411, 3.12, 0.179, 290, 251, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2388, d1wccA_, 0.7411, 3.01, 0.172, 283, 250, SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY
2389, d1tkiB_, 0.7411, 3.39, 0.167, 321, 257, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
2390, d1tkiA_, 0.7411, 3.39, 0.167, 321, 257, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
2391, d4fynA1, 0.7410, 3.08, 0.198, 263, 252, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 3-(8-{4- [ETHYL-(2-HYDROXY-ETHYL)-AMINO]-PHENYLAMINO}-IMIDAZO[12-A]PYRAZIN-5- YL)-PHENOL
2392, d3bymA_, 0.7410, 3.14, 0.202, 271, 253, X-RAY CO-CRYSTAL STRUCTURE AMINOBENZIMIDAZOLE TRIAZINE 1 BOUND TO LCK
2393, d1qpcA_, 0.7410, 3.15, 0.202, 270, 253, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
2394, d1h01A_, 0.7410, 3.04, 0.170, 286, 247, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
2395, p6cpwA_, 0.7409, 2.87, 0.203, 328, 246, DISCOVERY OF 3(S)-THIOMETHYL PYRROLIDINE ERK INHIBITORS FOR ONCOLOGY 
2396, d4qnyB_, 0.7409, 2.92, 0.202, 339, 247, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
2397, p3v3vA_, 0.7409, 2.75, 0.222, 351, 243, STRUCTURAL AND FUNCTIONAL ANALYSIS OF QUERCETAGETIN A NATURAL JNK1 INHIBITOR
2398, d3ad5A_, 0.7409, 3.15, 0.202, 270, 253, CRYSTAL STRUCTURE OF TRIAZOLONE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2399, d2x8iA_, 0.7409, 3.07, 0.204, 261, 250, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
2400, d2wmvA_, 0.7409, 2.77, 0.206, 251, 243, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2401, d1pxoA_, 0.7409, 3.25, 0.162, 294, 253, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2-AMINO-4-METHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YL]-(3-NITRO-PHENYL)-AMINE
2402, d3zepC_, 0.7408, 3.14, 0.215, 276, 251, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
2403, d2zv2A_, 0.7408, 2.82, 0.196, 256, 245, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2 BETA CAMKK2 KINASE DOMAIN IN COMPLEX WITH STO-609
2404, d2g2hA_, 0.7408, 3.50, 0.204, 272, 260, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
2405, d6eixA_, 0.7407, 3.50, 0.181, 312, 259, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE Q207E MUTANT OF ACVR1 (ALK2) IN COMPLEX WITH A 2-AMINOPYRIDINE INHIBITOR K02288
2406, d3bu3A_, 0.7407, 3.20, 0.202, 294, 253, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE
2407, d2r3pA_, 0.7407, 3.27, 0.175, 289, 252, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2408, d1pf8A_, 0.7407, 2.99, 0.188, 298, 250, CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH A NUCLEOSIDE INHIBITOR
2409, d1ckpA_, 0.7407, 3.12, 0.176, 279, 250, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B
2410, d4z16A_, 0.7406, 3.22, 0.226, 271, 252, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
2411, d4r5sA_, 0.7406, 3.41, 0.180, 299, 255, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH FIIN-3
2412, d3byoA_, 0.7406, 3.16, 0.202, 270, 253, X-RAY CO-CRYSTAL STRUCTURE OF 2-AMINO-6-PHENYLPYRIMIDO[5  4 :56]PYRIMIDO[12-A]BENZIMIDAZOL-5(6H)-ONE 25 BOUND TO LCK
2413, d3a62A_, 0.7406, 2.90, 0.201, 263, 244, CRYSTAL STRUCTURE OF PHOSPHORYLATED P70S6K1
2414, d2pzrA_, 0.7406, 3.08, 0.171, 280, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
2415, d2jiuB_, 0.7406, 3.70, 0.147, 309, 266, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
2416, d1buhA_, 0.7406, 3.07, 0.190, 287, 248, CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITH CELL CYCLE-REGULATORY PROTEIN CKSHS1
2417, d4j95A_, 0.7405, 3.15, 0.178, 279, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
2418, d2zm1A_, 0.7405, 3.15, 0.202, 270, 253, CRYSTAL STRUCTURE OF IMIDAZO PYRAZIN 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2419, d2uzoA_, 0.7405, 3.30, 0.174, 290, 253, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2420, d2qg5A1, 0.7405, 3.13, 0.179, 268, 251, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
2421, d2itnA_, 0.7405, 3.48, 0.180, 304, 256, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AMP-PNP
2422, d1qpeA_, 0.7405, 3.16, 0.202, 270, 253, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
2423, d1pkgA_, 0.7405, 3.24, 0.209, 290, 254, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
2424, d1gz8A_, 0.7405, 3.29, 0.174, 290, 253, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-AMINO-6-(3 -METHYL-2 -OXO)BUTOXYPURINE
2425, d5khxA_, 0.7404, 3.47, 0.191, 276, 257, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH PF-4950736
2426, d5j7bB_, 0.7404, 3.25, 0.157, 281, 255, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
2427, d4lg4A_, 0.7404, 3.27, 0.170, 289, 253, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2428, d3rkbA_, 0.7404, 3.09, 0.179, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR RC-2-73
2429, d3pxzA1, 0.7404, 3.00, 0.198, 298, 247, CDK2 TERNARY COMPLEX WITH JWS648 AND ANS
2430, d3ac8A_, 0.7404, 3.16, 0.202, 270, 253, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2431, d3ac2A_, 0.7404, 3.15, 0.202, 270, 253, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2432, d2vrxB_, 0.7404, 2.86, 0.169, 274, 248, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
2433, d2pmiC_, 0.7404, 2.69, 0.187, 285, 241, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
2434, p2no3B_, 0.7404, 3.04, 0.216, 357, 250, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
2435, d1qpdA_, 0.7404, 3.15, 0.198, 270, 253, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
2436, d5tq7B_, 0.7403, 3.39, 0.203, 269, 256, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
2437, d4zauA_, 0.7403, 3.23, 0.187, 283, 252, AZD9291 COMPLEX WITH WILD TYPE EGFR
2438, d4xliA_, 0.7403, 3.29, 0.208, 264, 255, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
2439, d4qp7A_, 0.7403, 2.77, 0.222, 337, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
2440, d3r8lA_, 0.7403, 3.24, 0.170, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR L3-4
2441, d3ppzB_, 0.7403, 2.78, 0.200, 264, 245, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2442, d2a4lA_, 0.7403, 2.92, 0.176, 286, 245, HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE
2443, d1u54A_, 0.7403, 3.03, 0.204, 262, 250, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
2444, d5l8lA_, 0.7402, 2.91, 0.185, 263, 249, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 1)
2445, d4twpA_, 0.7402, 3.46, 0.210, 266, 257, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
2446, d4mneB_, 0.7402, 3.13, 0.203, 270, 251, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
2447, d2vtrA_, 0.7402, 3.25, 0.171, 290, 252, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
2448, d2vtmA_, 0.7402, 3.28, 0.175, 290, 252, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
2449, d5lmaA_, 0.7401, 3.06, 0.195, 267, 251, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
2450, d5fedA_, 0.7401, 3.45, 0.173, 288, 255, EGFR KINASE DOMAIN IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
2451, d5anjA_, 0.7401, 3.17, 0.171, 291, 251, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH N-(9H-PURIN-6-YL) THIOPHENE-2-CARBOXAMIDE  PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
2452, d2zm4A_, 0.7401, 3.18, 0.202, 270, 253, CRYSTAL STRUCTURE OF IMIDAZO QUINOXALINE 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK ACTIVATED FORM (AUTO- PHOSPHORYLATED ON TYR394)
2453, p2g01B_, 0.7401, 3.12, 0.215, 356, 251, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
2454, d1w8cA_, 0.7401, 3.30, 0.174, 290, 253, CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL-9H- PURIN-2-YLAMINE AND MONOMERIC CDK2
2455, d4xg7A1, 0.7400, 3.18, 0.181, 265, 254, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2456, d4fkiA_, 0.7400, 3.04, 0.173, 287, 249, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
2457, d4e5wB_, 0.7400, 3.42, 0.207, 278, 256, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
2458, d3sxsA1, 0.7400, 3.08, 0.151, 261, 252, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEXED WITH PP2
2459, d2c6iA_, 0.7400, 3.21, 0.175, 292, 252, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2460, d5e8vA_, 0.7399, 3.25, 0.161, 296, 254, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A)
2461, d2r3rA_, 0.7399, 3.26, 0.175, 290, 252, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2462, d2c6lA_, 0.7399, 3.32, 0.174, 291, 253, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2463, d2c6kA_, 0.7399, 3.19, 0.175, 292, 252, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2464, d1aq1A_, 0.7399, 2.94, 0.192, 277, 245, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE
2465, d5t68B_, 0.7398, 3.08, 0.194, 264, 252, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
2466, d4zsjA_, 0.7398, 3.03, 0.225, 344, 249, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
2467, d4zjjA_, 0.7398, 3.25, 0.204, 280, 255, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
2468, d3r8vA_, 0.7398, 3.26, 0.170, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR RC-1-135
2469, d3lckA_, 0.7398, 3.17, 0.202, 270, 253, THE KINASE DOMAIN OF HUMAN LYMPHOCYTE KINASE (LCK) ACTIVATED FORM (AUTO-PHOSPHORYLATED ON TYR394)
2470, d2vtlA_, 0.7398, 3.27, 0.175, 290, 252, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
2471, p2h96A_, 0.7398, 3.04, 0.212, 358, 250, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
2472, d2c6oA_, 0.7398, 3.15, 0.175, 290, 251, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2473, d2c69A_, 0.7398, 3.19, 0.175, 292, 252, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2474, d4zy6B_, 0.7397, 3.18, 0.229, 280, 249, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
2475, d4qp4A_, 0.7397, 2.78, 0.222, 337, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
2476, d4fkqA_, 0.7397, 3.11, 0.175, 283, 251, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
2477, d4ei4A1, 0.7397, 3.47, 0.195, 288, 257, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
2478, d1pxlA_, 0.7397, 3.25, 0.175, 290, 252, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- (4-TRIFLUOROMETHYL-PHENYL)-AMINE
2479, d5l8kA_, 0.7396, 3.01, 0.192, 266, 250, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 2)
2480, d2v0dA_, 0.7396, 3.20, 0.175, 292, 252, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2481, d2itzA_, 0.7396, 3.30, 0.177, 302, 254, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH IRESSA
2482, d5ievA_, 0.7395, 3.06, 0.176, 284, 250, CRYSTAL STRUCTURE OF BAY 1000394 (RONICICLIB) BOUND TO CDK2
2483, d2zm3D2, 0.7395, 3.11, 0.195, 292, 251, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
2484, d2ityA1, 0.7395, 3.36, 0.185, 299, 254, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH IRESSA
2485, d4rx9A1, 0.7394, 3.16, 0.193, 264, 254, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT PYRIMIDINE INHIBITOR
2486, d4fklA_, 0.7394, 3.24, 0.171, 290, 252, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
2487, d2ofuA_, 0.7394, 3.17, 0.202, 272, 253, X-RAY CRYSTAL STRUCTURE OF 2-AMINOPYRIMIDINE CARBAMATE 43 BOUND TO LCK
2488, d2gqgB1, 0.7394, 3.22, 0.206, 270, 253, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
2489, d1fvrB_, 0.7394, 3.39, 0.175, 300, 257, TIE2 KINASE DOMAIN
2490, d4gcjA1, 0.7393, 3.23, 0.178, 298, 253, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
2491, d3r7iA_, 0.7393, 3.22, 0.171, 282, 251, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-74
2492, d3qqgA_, 0.7393, 3.42, 0.180, 294, 256, CDK2 IN COMPLEX WITH INHIBITOR L2-5
2493, d4zjiA_, 0.7392, 3.35, 0.203, 278, 256, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
2494, d3ztxB_, 0.7392, 2.84, 0.166, 272, 247, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
2495, d2qg5B1, 0.7392, 3.17, 0.179, 275, 251, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
2496, d1u4dA_, 0.7392, 3.05, 0.218, 258, 248, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
2497, d6bqlA1, 0.7391, 2.95, 0.202, 276, 247, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH TAE-226
2498, d5t68A1, 0.7391, 3.14, 0.198, 264, 253, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
2499, d4z16C_, 0.7391, 3.16, 0.227, 271, 251, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
2500, d4at3A1, 0.7391, 3.23, 0.229, 286, 253, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH CPD5N
2501, d2r3oA_, 0.7391, 3.18, 0.175, 289, 251, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2502, d4xg3A_, 0.7390, 3.15, 0.190, 262, 252, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2503, d4trlA_, 0.7390, 3.05, 0.163, 268, 251, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
2504, d4id7A_, 0.7390, 3.18, 0.220, 268, 254, ACK1 KINASE IN COMPLEX WITH THE INHIBITOR CIS-3-[8-AMINO-1-(4- PHENOXYPHENYL)IMIDAZO[15-A]PYRAZIN-3-YL]CYCLOBUTANOL
2505, d3zduA_, 0.7390, 3.25, 0.190, 297, 252, CRYSTAL STRUCTURE OF THE HUMAN CDKL3 KINASE DOMAIN
2506, d2r3fA_, 0.7390, 3.16, 0.171, 290, 251, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2507, d2bdwA_, 0.7390, 3.46, 0.186, 309, 258, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
2508, d3s0oA_, 0.7389, 3.37, 0.165, 293, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-1-138
2509, d5mjaB_, 0.7388, 3.13, 0.150, 274, 253, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
2510, d5ieyA_, 0.7388, 3.13, 0.176, 286, 250, CRYSTAL STRUCTURE OF A CDK INHIBITOR BOUND TO CDK2
2511, d4o0rB_, 0.7388, 3.20, 0.229, 282, 249, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2512, d4fkrA_, 0.7388, 3.11, 0.172, 282, 250, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
2513, d4ehzB_, 0.7388, 3.47, 0.194, 280, 258, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
2514, d4e4lE_, 0.7388, 3.45, 0.195, 280, 257, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
2515, d3zhpD_, 0.7388, 3.12, 0.183, 264, 251, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
2516, d3r7uA_, 0.7388, 3.29, 0.167, 282, 252, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-75
2517, d3dk3A_, 0.7388, 3.41, 0.206, 266, 257, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
2518, d2r64A_, 0.7388, 3.06, 0.177, 279, 249, CRYSTAL STRUCTURE OF A 3-AMINOINDAZOLE COMPOUND WITH CDK2
2519, d4wrgA1, 0.7387, 3.28, 0.175, 287, 252, 1.9 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN
2520, d4ehzC_, 0.7387, 3.46, 0.195, 278, 257, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
2521, d2w06A_, 0.7387, 3.20, 0.175, 282, 251, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5C
2522, d1ke7A_, 0.7387, 3.12, 0.176, 281, 250, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(22- DIOXIDO-13-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5- (13-OXAZOL-5-YL)-13-DIHYDRO-2H-INDOL-2-ONE
2523, d1di8A_, 0.7387, 3.11, 0.176, 283, 250, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3-HYDROXYANILINO]-67-DIMETHOXYQUINAZOLINE
2524, d4u5jB_, 0.7386, 3.01, 0.209, 267, 249, C-SRC IN COMPLEX WITH RUXOLITINIB
2525, d4e26A_, 0.7386, 3.04, 0.217, 270, 249, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
2526, d3tizA_, 0.7386, 3.42, 0.165, 293, 255, CDK2 IN COMPLEX WITH NSC 111848
2527, d1ke8A_, 0.7386, 3.23, 0.175, 282, 251, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO- 12-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(13- THIAZOL-2-YL)BENZENESULFONAMIDE
2528, d5w86D_, 0.7385, 3.18, 0.231, 272, 251, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
2529, d4z16D_, 0.7385, 3.24, 0.226, 271, 252, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
2530, d3wblA_, 0.7385, 2.93, 0.173, 283, 248, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR
2531, p2h96B_, 0.7385, 2.96, 0.214, 357, 248, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
2532, d1jowB_, 0.7385, 2.58, 0.179, 277, 240, CRYSTAL STRUCTURE OF A COMPLEX OF HUMAN CDK6 AND A VIRAL CYCLIN
2533, d5k4jA1, 0.7384, 3.12, 0.176, 281, 250, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH COMPOUND 22
2534, d5dt0A_, 0.7384, 2.87, 0.195, 259, 246, AURORA A KINASE IN COMPLEX WITH JNJ-7706621 IN SPACE GROUP P6122
2535, d4i0tA1, 0.7384, 3.15, 0.206, 262, 252, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(5678- TETRAHYDRO-IMIDAZO[15-A]PYRIDIN-1-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID TERT-BUTYLAMIDE
2536, d3qzgA_, 0.7384, 3.30, 0.165, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-76
2537, d1v0oA_, 0.7384, 2.76, 0.207, 276, 241, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
2538, d1h0wA_, 0.7384, 3.14, 0.175, 283, 251, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[CYCLOHEX-3-ENYL]METHOXYPURINE
2539, d5hcyA_, 0.7383, 3.37, 0.169, 302, 254, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-CARBOXAMIDE AZAINDOLE COMPOUND 13
2540, d5casA_, 0.7383, 3.34, 0.182, 299, 253, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41A
2541, d4yznA_, 0.7383, 3.15, 0.199, 269, 251, HUMANIZED ROCO4 BOUND TO COMPOUND 19
2542, d4puzA_, 0.7383, 3.12, 0.187, 263, 251, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
2543, d4e4lB_, 0.7383, 3.49, 0.195, 279, 257, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
2544, d3zhpC1, 0.7383, 3.09, 0.183, 267, 251, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
2545, d2itvA_, 0.7383, 3.45, 0.180, 303, 255, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AMP-PNP
2546, d1b39A_, 0.7383, 3.19, 0.175, 290, 251, HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160
2547, d5canA_, 0.7382, 3.28, 0.183, 301, 252, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 27
2548, d3s2pA_, 0.7382, 3.07, 0.177, 279, 249, CRYSTAL STRUCTURE OF CDK2 WITH A 2-AMINOPYRIMIDINE COMPOUND
2549, d1ke5A_, 0.7382, 3.14, 0.176, 281, 250, CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO-12-DIHYDRO-3H- INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
2550, d1fvrA_, 0.7382, 3.34, 0.176, 299, 256, TIE2 KINASE DOMAIN
2551, d5dr9A_, 0.7381, 2.79, 0.197, 257, 244, AURORA A KINASE IN COMPLEX WITH AA29 AND JNJ-7706621 IN SPACE GROUP P6122
2552, d4v0gB_, 0.7381, 3.22, 0.231, 272, 251, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
2553, d2dwbA_, 0.7381, 2.82, 0.195, 259, 246, AURORA-A KINASE COMPLEXED WITH AMPPNP
2554, d1ke9A_, 0.7381, 3.13, 0.176, 281, 250, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4- ({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2- OXO-23-DIHYDRO-1H-INDOLE
2555, d5iexA_, 0.7380, 3.19, 0.171, 285, 252, CRYSTAL STRUCTURE OF (RS)-S-{4-[(5-BROMO-4-{[(2R3R)-2-HYDROXY-1- METHYLPROPYL]OXY}- PYRIMIDIN-2-YL)AMINO]PHENYL}-S- CYCLOPROPYLSULFOXIMIDE BOUND TO CDK2
2556, d4lg4C_, 0.7380, 3.27, 0.181, 288, 254, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2557, d3ns9A_, 0.7380, 3.16, 0.176, 289, 250, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR BS-194
2558, d2w1hA_, 0.7380, 3.12, 0.187, 283, 251, FRAGMENT-BASED DISCOVERY OF THE PYRAZOL-4-YL UREA (AT9283) A MULTI-TARGETED KINASE INHIBITOR WITH POTENT AURORA KINASE ACTIVITY
2559, d2vtsA_, 0.7380, 2.98, 0.173, 282, 248, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
2560, d2r3iA_, 0.7380, 3.29, 0.175, 289, 252, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2561, d1u54B_, 0.7380, 3.18, 0.207, 261, 251, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
2562, d1ke6A_, 0.7380, 3.14, 0.176, 280, 250, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4- [2-(7-OXO-67-DIHYDRO-8H-[13]THIAZOLO[54-E]INDOL-8- YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE
2563, d4xoyA_, 0.7379, 3.04, 0.224, 326, 246, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
2564, d3lm0A1, 0.7379, 3.25, 0.159, 271, 251, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B)
2565, d2x4fA_, 0.7379, 3.38, 0.180, 289, 255, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
2566, d5tq6B_, 0.7378, 3.26, 0.206, 271, 253, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
2567, d5hcxA_, 0.7378, 3.34, 0.170, 298, 253, EGFR KINASE DOMAIN MUTANT TMLR WITH AZABENZIMIDAZOLE COMPOUND 7
2568, d4xeyA_, 0.7378, 3.31, 0.193, 269, 254, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
2569, d4fkwA_, 0.7378, 3.03, 0.189, 280, 249, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
2570, d3ig7A_, 0.7378, 3.04, 0.177, 278, 248, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFP WITH CDK-2
2571, d5uoxB_, 0.7377, 2.62, 0.217, 252, 240, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
2572, d5dpvA_, 0.7377, 2.76, 0.197, 257, 244, AURORA A KINASE IN COMPLEX WITH AA35 AND JNJ-7706621 IN SPACE GROUP P6122
2573, d5imeB_, 0.7376, 3.23, 0.230, 280, 248, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
2574, d2qluA1, 0.7376, 3.15, 0.173, 295, 249, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE II KINASE DOMAIN FROM HUMAN
2575, d5ar4A_, 0.7375, 3.05, 0.156, 274, 250, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
2576, d4zjjB_, 0.7375, 3.26, 0.205, 277, 254, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
2577, p4h3pA_, 0.7375, 2.89, 0.224, 342, 245, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
2578, d4ehzD_, 0.7375, 3.53, 0.194, 280, 258, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
2579, d4c8bB_, 0.7375, 2.96, 0.146, 281, 247, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
2580, d3qqjA_, 0.7375, 3.41, 0.180, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR L2
2581, d3o2mB_, 0.7375, 2.99, 0.210, 358, 248, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
2582, d4fkgA_, 0.7374, 3.03, 0.173, 286, 248, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
2583, d3kf4B_, 0.7374, 3.38, 0.211, 270, 256, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
2584, d2c68A_, 0.7374, 3.16, 0.175, 290, 251, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2585, d5tiuA1, 0.7373, 3.17, 0.186, 262, 253, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH INHIBITOR
2586, d5dr6A_, 0.7373, 2.80, 0.197, 257, 244, AURORA A KINASE IN COMPLEX WITH AA30 AND JNJ-7706621 IN SPACE GROUP P6122
2587, d3py0A_, 0.7373, 3.36, 0.180, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR SU9516
2588, d2ituA_, 0.7373, 3.44, 0.164, 304, 256, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AFN941
2589, d2hziB_, 0.7372, 3.39, 0.204, 264, 255, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
2590, d4qnyA_, 0.7371, 2.95, 0.207, 333, 246, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
2591, d4ek3A_, 0.7371, 3.11, 0.173, 287, 249, CRYSTAL STRUCTURE OF APO CDK2
2592, d3f9nA_, 0.7371, 2.91, 0.212, 253, 245, CRYSTAL STRUCTURE OF CHK1 KINASE IN COMPLEX WITH INHIBITOR 38
2593, d2bvaA_, 0.7371, 3.01, 0.173, 272, 249, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
2594, d1oplB2, 0.7371, 3.36, 0.200, 267, 255, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
2595, d4w9wA_, 0.7370, 2.97, 0.182, 306, 247, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH SMALL MOLECULE AZD-7762
2596, d4u5jA_, 0.7370, 3.08, 0.209, 267, 249, C-SRC IN COMPLEX WITH RUXOLITINIB
2597, d4at5A1, 0.7370, 3.25, 0.221, 291, 253, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH GW2580
2598, d3r9oA_, 0.7370, 3.15, 0.192, 282, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-143
2599, d3dk7A_, 0.7370, 3.36, 0.204, 265, 255, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
2600, d2hziA_, 0.7370, 3.38, 0.200, 268, 255, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
2601, d5c8mA_, 0.7369, 3.27, 0.183, 302, 251, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 17
2602, d5ar7B_, 0.7369, 3.18, 0.162, 278, 253, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
2603, d3fqhA_, 0.7369, 3.14, 0.167, 262, 251, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
2604, d2xf0A_, 0.7369, 2.81, 0.202, 251, 242, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2605, d2vtpA_, 0.7369, 3.00, 0.177, 281, 248, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
2606, d2r3gA_, 0.7369, 3.14, 0.173, 287, 249, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2607, d1pxmA_, 0.7369, 3.47, 0.173, 290, 254, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 3-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL
2608, d5ttuA_, 0.7368, 3.29, 0.222, 271, 252, JAK3 WITH COVALENT INHIBITOR 7
2609, d5te0A_, 0.7368, 3.04, 0.177, 316, 248, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH BIBF 1120
2610, d3gxjA_, 0.7368, 3.18, 0.203, 288, 251,  
2611, d3eqfA_, 0.7368, 3.26, 0.193, 314, 254, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH K252A AND MG2P
2612, d2c6mA_, 0.7368, 3.19, 0.175, 290, 251, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2613, d1h07A_, 0.7368, 2.99, 0.194, 285, 248, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
2614, d4gfoA1, 0.7367, 3.25, 0.237, 270, 253, TYK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
2615, d4ek6A_, 0.7367, 2.98, 0.174, 278, 247, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
2616, d2vthA_, 0.7367, 3.03, 0.173, 278, 248, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN
2617, d1giiA_, 0.7366, 3.13, 0.173, 279, 249, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
2618, d5hczA_, 0.7365, 3.43, 0.169, 300, 254, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-AZETIDINYL AZAINDAZOLE COMPOUND 21
2619, d5buiA_, 0.7365, 2.75, 0.223, 338, 242, ERK2 COMPLEXED WITH 2-PYRIDIYL TETRAHYDROAZAINDAZOLE
2620, d4zsgA_, 0.7365, 3.08, 0.221, 347, 249, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
2621, d4qpsC_, 0.7365, 3.43, 0.215, 276, 256, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
2622, d3ckwA_, 0.7365, 2.64, 0.191, 255, 241, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24)
2623, d1jsvA_, 0.7365, 3.15, 0.173, 287, 249, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[(6-AMINO-4-PYRIMIDINYL) AMINO]BENZENESULFONAMIDE
2624, d5caqA_, 0.7364, 3.31, 0.183, 301, 252, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 33
2625, d4qp3A_, 0.7364, 2.80, 0.226, 339, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
2626, d4fkjA_, 0.7364, 3.05, 0.173, 278, 248, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
2627, d1e1xA_, 0.7364, 3.32, 0.175, 290, 252, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027
2628, d4tthB_, 0.7363, 2.63, 0.172, 256, 239, CRYSTAL STRUCTURE OF A CDK6/VCYCLIN COMPLEX WITH INHIBITOR BOUND
2629, d4bf2B_, 0.7363, 2.64, 0.222, 252, 239, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2630, d4yjoA_, 0.7362, 3.09, 0.195, 267, 251, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000222
2631, d4ek4A_, 0.7362, 3.12, 0.173, 287, 249, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
2632, d3nsvA_, 0.7362, 3.32, 0.205, 264, 254,  
2633, d1g5sA_, 0.7362, 2.87, 0.184, 275, 245, CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH THE INHIBITOR H717
2634, d2r3mA_, 0.7361, 2.99, 0.194, 278, 248, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2635, d4e4lA_, 0.7360, 3.51, 0.195, 277, 257, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
2636, d4zogA_, 0.7359, 3.44, 0.206, 269, 257, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
2637, d2xynA_, 0.7359, 3.33, 0.205, 264, 254, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
2638, d2gqgA1, 0.7359, 3.28, 0.209, 271, 254, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
2639, d5ng0A_, 0.7358, 2.86, 0.156, 274, 244, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
2640, d5mhqA1, 0.7358, 3.14, 0.169, 288, 248, CCT068127 IN COMPLEX WITH CDK2
2641, d4w9xA_, 0.7358, 2.97, 0.174, 300, 247, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH BARICITINIB
2642, d4mkcA_, 0.7358, 3.59, 0.175, 303, 257, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE COMPLEXED WITH LDK378
2643, d4c02A_, 0.7358, 3.43, 0.173, 313, 255, CRYSTAL STRUCTURE OF HUMAN ACVR1 (ALK2) IN COMPLEX WITH FKBP12.6 AND DORSOMORPHIN
2644, d5aniA_, 0.7357, 3.02, 0.173, 280, 248, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-CHLORO-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
2645, d5a14A_, 0.7357, 3.07, 0.191, 284, 246, HUMAN CDK2 WITH TYPE II INHIBITOR
2646, d3lm5A1, 0.7357, 3.28, 0.159, 267, 251, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B) IN COMPLEX WITH QUERCETIN
2647, d3ggfA_, 0.7357, 3.09, 0.199, 275, 251, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
2648, d2zm3A2, 0.7357, 3.27, 0.197, 299, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
2649, d2r3qA_, 0.7357, 3.16, 0.173, 286, 249, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2650, d2jfmA_, 0.7357, 3.27, 0.175, 287, 251, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE (UNLIGANDED FORM)
2651, d2hz4A_, 0.7357, 3.19, 0.203, 262, 251, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
2652, d1rqqB_, 0.7357, 3.28, 0.185, 294, 254, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
2653, d1jsuA_, 0.7357, 2.99, 0.180, 285, 244, P27(KIP1)/CYCLIN A/CDK2 COMPLEX
2654, d5capA_, 0.7356, 3.28, 0.183, 303, 251, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 30
2655, d4xliB_, 0.7356, 3.15, 0.207, 264, 251, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
2656, d3py3A1, 0.7356, 2.94, 0.204, 352, 245, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38ALPHA MAP KINASE
2657, d2vtaA_, 0.7356, 3.04, 0.173, 278, 248, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
2658, d2jitB_, 0.7356, 3.81, 0.148, 312, 264, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
2659, p5oo0A_, 0.7355, 3.19, 0.176, 288, 250, CDK2(WT) COVALENT ADDUCT WITH D28 AT C177
2660, d4wsqA_, 0.7355, 2.98, 0.173, 317, 248, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2661, d4p41B_, 0.7355, 2.64, 0.172, 256, 239,  
2662, d1pxkA_, 0.7355, 3.16, 0.172, 290, 250, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)PYRIMIDIN-2-YL]- N -HYDROXYIMINOFORMAMIDE
2663, p5o7iA_, 0.7354, 2.97, 0.220, 340, 246, ERK5 IN COMPLEX WITH A PYRROLE INHIBITOR 
2664, d5c8nA_, 0.7354, 3.33, 0.183, 300, 252, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 23
2665, d2vv9A_, 0.7354, 2.98, 0.194, 279, 248, CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE
2666, d1v0oB_, 0.7354, 2.68, 0.209, 274, 239, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
2667, d5hicA_, 0.7353, 3.36, 0.170, 302, 253, EGFR KINASE DOMAIN MUTANT TMLR WITH A IMIDAZOPYRIDINYL- AMINOPYRIMIDINE INHIBITOR
2668, d4fz6A1, 0.7353, 3.11, 0.199, 262, 251, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH [6-((S)-2- METHYL-PYRROLIDIN-1-YL)-PYRIDIN-2-YL]-(6-PHENYL-IMIDAZO[12- B]PYRIDAZIN-8-YL)-AMINE
2669, d3unkA_, 0.7353, 3.37, 0.180, 295, 255, CDK2 IN COMPLEX WITH INHIBITOR YL5-083
2670, d1w0xC_, 0.7353, 3.15, 0.192, 280, 250, CRYSTAL STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR OLOMOUCINE.
2671, d1e1vA_, 0.7353, 3.27, 0.175, 290, 251, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058
2672, d4ftqA_, 0.7352, 2.87, 0.231, 254, 242, CRYSTAL STRUCTURE OF THE CHK1
2673, d4bidA_, 0.7352, 2.82, 0.216, 254, 241, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2674, d4au8A1, 0.7352, 2.77, 0.195, 274, 241, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
2675, d3py1A1, 0.7351, 3.32, 0.179, 298, 252, CDK2 TERNARY COMPLEX WITH SU9516 AND ANS
2676, d3pxyA_, 0.7351, 3.38, 0.176, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR JWS648
2677, d3f69A_, 0.7351, 2.69, 0.220, 270, 241, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
2678, d2xynB_, 0.7351, 3.30, 0.205, 264, 254, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
2679, d1p4fA_, 0.7351, 2.99, 0.199, 269, 246, DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH BOUND INHIBITOR FRAGMENT
2680, d4rj4A_, 0.7350, 3.37, 0.187, 299, 252, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 6
2681, d4fkpA_, 0.7350, 3.06, 0.173, 279, 248, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
2682, d3eqhA_, 0.7350, 3.43, 0.187, 314, 257, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH U0126 ADP AND MG2P
2683, d2vtiA_, 0.7350, 3.12, 0.177, 280, 249, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
2684, d4u40B_, 0.7349, 3.39, 0.185, 299, 259, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
2685, d4ek8A_, 0.7349, 2.98, 0.174, 280, 247, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
2686, d3qtrA_, 0.7349, 3.20, 0.192, 282, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-1-148
2687, d3nsvB_, 0.7349, 3.30, 0.205, 264, 254,  
2688, d5i3oB_, 0.7348, 2.93, 0.179, 302, 246, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2689, d4rj8A_, 0.7347, 3.35, 0.183, 298, 252, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 8
2690, d4fkoA_, 0.7347, 3.17, 0.180, 291, 250, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
2691, d3rahA_, 0.7347, 3.19, 0.172, 282, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-22
2692, d3o2mA_, 0.7347, 3.03, 0.210, 358, 248, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
2693, d3my0M1, 0.7347, 3.47, 0.184, 297, 256, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2694, d5eykA_, 0.7346, 2.81, 0.155, 263, 245, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
2695, d5em7A_, 0.7346, 3.34, 0.183, 300, 252, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 13: 4-[(2- METHOXYPHENYL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
2696, d5bx0A_, 0.7346, 3.37, 0.187, 315, 256, AN AUTOMATED MICROSCALE THERMOPHORESIS SCREENING APPROACH FOR FRAGMENT-BASED LEAD DISCOVERY
2697, d4lg4F_, 0.7346, 2.96, 0.186, 276, 247, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2698, d3r9nA_, 0.7346, 3.27, 0.171, 282, 251, CDK2 IN COMPLEX WITH INHIBITOR RC-2-21
2699, d3qqhA_, 0.7345, 3.41, 0.180, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR L2-2
2700, d5ar8B_, 0.7344, 3.28, 0.158, 274, 253, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIPHENYLSULFONAMIDE
2701, d3sw7A_, 0.7344, 3.02, 0.181, 278, 248, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
2702, d5ih9A_, 0.7343, 2.64, 0.239, 308, 238, MELK IN COMPLEX WITH NVS-MELK8A
2703, d4qp9A_, 0.7343, 2.87, 0.222, 335, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-PROPYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
2704, d4byiA_, 0.7343, 2.59, 0.201, 254, 239, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
2705, d2uznA_, 0.7343, 2.97, 0.174, 279, 247, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2706, d1h08A_, 0.7343, 3.04, 0.177, 283, 248, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
2707, d5ugxB_, 0.7342, 2.99, 0.178, 282, 247, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
2708, d5cauA_, 0.7342, 3.40, 0.170, 297, 253, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41B
2709, d4fz7A1, 0.7342, 3.18, 0.198, 261, 252, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 6-((1R2S)- 2-AMINO-CYCLOHEXYLAMINO)-4-(6-ETHYL-PYRIDIN-2-YLAMINO)-PYRIDAZINE-3- CARBOXYLIC ACID AMIDE
2710, d3qtsA_, 0.7342, 3.25, 0.187, 282, 251, CDK2 IN COMPLEX WITH INHIBITOR RC-2-12
2711, d2w17A_, 0.7342, 2.90, 0.175, 278, 246, CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE COMPOUND (S)-8B
2712, d2qg5D1, 0.7342, 3.10, 0.181, 267, 249, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
2713, d2btsA_, 0.7342, 2.97, 0.183, 274, 246, STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032
2714, d4nj3A_, 0.7341, 3.04, 0.190, 277, 247, MODULATING THE INTERACTION BETWEEN CDK2 AND CYCLIN A WITH A QUINOLINE- BASED INHIBITOR
2715, d4fktA_, 0.7341, 2.93, 0.175, 278, 246, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
2716, d3rprA_, 0.7341, 3.25, 0.187, 282, 251, CDK2 IN COMPLEX WITH INHIBITOR RC-2-49
2717, d5calA_, 0.7340, 3.29, 0.183, 300, 251, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 24
2718, d4xg2A1, 0.7340, 3.00, 0.185, 258, 248, CRYSTAL STRUCTURE OF LIGAND-FREE SYK
2719, d2r3kA_, 0.7340, 3.04, 0.194, 277, 248, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2720, d2np8A_, 0.7340, 2.65, 0.198, 256, 242, STRUCTURAL BASIS FOR THE INHIBITION OF AURORA A KINASE BY A NOVEL CLASS OF HIGH AFFINITY DISUBSTITUTED PYRIMIDINE INHIBITORS
2721, d2ivsB1, 0.7340, 3.01, 0.175, 272, 246, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
2722, d1pxnA_, 0.7340, 3.47, 0.156, 294, 256, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-[4-(4-METHYL-2-METHYLAMINO-THIAZOL-5-YL)- PYRIMIDIN-2-YLAMINO]-PHENOL
2723, d3ezvA_, 0.7339, 3.02, 0.190, 277, 247, CDK-2 WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
2724, d3dj7A_, 0.7339, 2.73, 0.189, 257, 243, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 130.
2725, d2b9iA_, 0.7339, 2.96, 0.217, 338, 244, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM MSG5
2726, d1v1kA_, 0.7339, 2.95, 0.190, 277, 247, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
2727, d3rmfA_, 0.7338, 3.05, 0.181, 278, 248, CDK2 IN COMPLEX WITH INHIBITOR RC-2-33
2728, d3le6A_, 0.7338, 3.07, 0.176, 283, 244, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A PYRAZOLOBENZODIAZEPINE INHIBITOR
2729, d5em6A_, 0.7337, 3.45, 0.186, 301, 253, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 19: 4-[(2- AZANYLPYRIMIDIN-4-YL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]- 2-OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
2730, d4cnhB_, 0.7337, 3.52, 0.180, 293, 255, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
2731, d3d14A1, 0.7337, 2.74, 0.189, 257, 243, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-{5-[2-(THIENO[32-D]PYRIMIDIN-4-YLAMINO)- ETHYL]- THIAZOL-2-YL}-3-(3-TRIFLUOROMETHYL-PHENYL)-UREA
2732, d2zm3C2, 0.7337, 3.20, 0.194, 295, 252, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
2733, p2g01A_, 0.7337, 3.06, 0.213, 355, 249, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
2734, d5v19A_, 0.7336, 2.52, 0.224, 250, 237, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
2735, d4v0gA_, 0.7336, 3.21, 0.233, 267, 249, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
2736, d2xynC_, 0.7336, 3.29, 0.206, 262, 253, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
2737, d1h06A_, 0.7336, 2.96, 0.190, 277, 247,  
2738, d1dm2A_, 0.7336, 2.91, 0.180, 274, 245, HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE
2739, d5ar7A_, 0.7335, 3.15, 0.164, 278, 250, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
2740, d4bf2A_, 0.7335, 2.71, 0.222, 253, 239, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2741, d3ppkB_, 0.7335, 2.83, 0.221, 264, 244, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
2742, d3lvpC_, 0.7335, 3.32, 0.200, 293, 255, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
2743, d2r3jA_, 0.7335, 3.14, 0.193, 278, 249, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2744, d2jflA_, 0.7335, 3.26, 0.172, 286, 250, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE ( DIPHOSPHORYLATED FORM) BOUND TO 5- AMINO-3-((4-( AMINOSULFONYL)PHENYL)AMINO)-N-(26- DIFLUOROPHENYL)-1H-12 4-TRIAZOLE-1-CARBOTHIOAMIDE
2745, d5c8kA_, 0.7334, 3.32, 0.183, 300, 251, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 1
2746, d4i0rA1, 0.7334, 3.11, 0.200, 260, 250, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(345- TRIMETHOXY-PHENYL)-5H-PYRROLO[23-B]PYRAZINE-7-CARBOXYLIC ACID ISOPROPYLAMIDE
2747, d4bibA_, 0.7334, 2.81, 0.220, 254, 241, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2748, d2j51A_, 0.7334, 3.30, 0.171, 288, 251, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE BOUND TO 5- AMINO-3-((4-(AMINOSULFONYL)PHENYL)AMINO)-N-(26- DIFLUOROPHENYL)-1H-124-TRIAZOLE-1-CARBOTHIOAMIDE
2749, d5feeA_, 0.7333, 3.47, 0.174, 287, 253, EGFR KINASE DOMAIN T790M MUTANT IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
2750, d5dewB_, 0.7333, 3.11, 0.231, 281, 247, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
2751, d1rqqA_, 0.7333, 3.31, 0.185, 294, 254, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
2752, d5wfjA_, 0.7332, 3.35, 0.222, 265, 252, THE JAK3 KINASE DOMAIN IN COMPLEX WITH A COVALENT INHIBITOR
2753, d5w86C_, 0.7332, 3.23, 0.233, 273, 249, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
2754, d5anoA_, 0.7331, 2.94, 0.175, 277, 246, CRYSTAL STRUCTURE OF CDK2 PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
2755, d4yc8B_, 0.7331, 3.20, 0.199, 264, 251, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
2756, d4hzrA_, 0.7331, 3.10, 0.225, 261, 249, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
2757, d3nsvC_, 0.7331, 3.31, 0.206, 262, 253,  
2758, d3f6xD_, 0.7331, 3.01, 0.206, 267, 247, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2759, d2vtjA_, 0.7331, 2.98, 0.190, 276, 247, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
2760, d4qp6A_, 0.7330, 2.85, 0.226, 339, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
2761, d4yc6C_, 0.7329, 2.82, 0.179, 285, 240, CDK1/CKS1
2762, d4rj7A_, 0.7329, 3.38, 0.183, 295, 252, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 1
2763, d2j9mA_, 0.7329, 2.92, 0.183, 275, 246, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC AMINOPYRIMIDINE
2764, d1u46B_, 0.7329, 3.01, 0.211, 257, 246, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
2765, d5ng2B_, 0.7328, 3.01, 0.150, 278, 246, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
2766, d4fksA_, 0.7328, 2.96, 0.191, 275, 246, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
2767, d3q4uB1, 0.7328, 3.37, 0.181, 298, 254, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
2768, d3kulA_, 0.7328, 3.18, 0.167, 267, 251, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
2769, d2ja0A_, 0.7328, 3.11, 0.174, 285, 247,  
2770, d2fvdA_, 0.7328, 2.87, 0.180, 284, 244, CYCLIN DEPENDENT KINASE 2 (CDK2) WITH DIAMINOPYRIMIDINE INHIBITOR
2771, d5k00A_, 0.7327, 2.59, 0.233, 311, 236, MELK IN COMPLEX WITH NVS-MELK5
2772, d5ew8A_, 0.7327, 3.24, 0.196, 291, 250, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
2773, d4yc6E_, 0.7327, 2.86, 0.183, 285, 240, CDK1/CKS1
2774, d1vyzA_, 0.7327, 3.08, 0.174, 279, 247, STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227
2775, d5vndB_, 0.7326, 3.34, 0.210, 295, 252, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
2776, d3zbfA_, 0.7326, 3.23, 0.169, 281, 249, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH CRIZOTINIB
2777, d3pa5A_, 0.7326, 2.86, 0.223, 255, 242, X-RAY CRYSTAL STRUCTURE OF COMPOUND 1 BOUND TO HUMAN CHK1 KINASE DOMAIN
2778, d2uv2A1, 0.7326, 3.11, 0.170, 286, 247, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE BOUND TO 4-(4-( 5-CYCLOPROPYL-1H-PYRAZOL-3-YLAMINO)-QUINAZOLIN-2-YLAMINO)- PHENYL)-ACETONITRILE
2779, d5v24A_, 0.7325, 2.54, 0.224, 249, 237, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
2780, d4fstA_, 0.7325, 2.83, 0.212, 253, 241, CRYSTAL STRUCTURE OF THE CHK1
2781, p3nieA_, 0.7325, 3.07, 0.215, 369, 247, CRYSTAL STRUCTURE OF PF11_0147
2782, p3n9xB_, 0.7325, 3.17, 0.189, 362, 249, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
2783, d3g6hA_, 0.7325, 3.00, 0.206, 266, 247, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
2784, d2vu3A_, 0.7325, 2.96, 0.184, 285, 245, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
2785, d4rj6A_, 0.7324, 3.33, 0.183, 297, 251, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 4
2786, d4ftnA_, 0.7324, 3.00, 0.206, 253, 243, CRYSTAL STRUCTURE OF THE CHK1
2787, d4acmA_, 0.7324, 3.12, 0.194, 277, 248, CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL] SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2-CARBOXAMIDE
2788, d3zepB_, 0.7324, 2.97, 0.224, 268, 245, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
2789, d5vndA_, 0.7323, 3.24, 0.212, 302, 250, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
2790, d4zslA_, 0.7323, 3.06, 0.219, 341, 247, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
2791, d3zm4A_, 0.7323, 3.30, 0.190, 309, 253, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 1
2792, d3dk6A_, 0.7323, 3.37, 0.213, 262, 254, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
2793, d4qp2A_, 0.7322, 2.86, 0.226, 336, 243, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
2794, d4p90A_, 0.7322, 3.08, 0.202, 272, 247, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN PAK1 IN COMPLEX WITH COMPOUND 15
2795, d4f1oA1, 0.7321, 3.18, 0.187, 274, 251, CRYSTAL STRUCTURE OF THE L1180T MUTANT ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO APPCP
2796, d5i3rB_, 0.7320, 3.04, 0.178, 302, 247, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2797, d3ot8A_, 0.7320, 2.99, 0.202, 251, 243, X-RAY CRYSTAL STRUCTURE OF COMPOUND 17R BOUND TO HUMAN CHK1 KINASE DOMAIN
2798, d2xezA_, 0.7320, 2.75, 0.208, 249, 240, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2799, d2b9hA_, 0.7320, 2.96, 0.218, 337, 243, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM STE7
2800, d5jzjB_, 0.7319, 2.91, 0.210, 261, 243, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
2801, d5j7hA_, 0.7319, 3.42, 0.178, 291, 253, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) BOUND BY BRIGATINIB
2802, d4z55A_, 0.7319, 3.53, 0.176, 294, 255, ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE DERIVATIVE OF LDK378
2803, d3s1hA_, 0.7319, 3.02, 0.182, 277, 247, CDK2 IN COMPLEX WITH INHIBITOR RC-2-39
2804, d2b4sB_, 0.7319, 3.26, 0.203, 294, 251, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
2805, d5ng2A_, 0.7318, 2.92, 0.152, 274, 244, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
2806, d4qpsA_, 0.7318, 3.27, 0.219, 270, 251, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
2807, d4lmnA1, 0.7318, 3.49, 0.174, 291, 258, CRYSTAL STRUCTURE OF MEK1 KINASE BOUND TO GDC0973
2808, d4arkA1, 0.7318, 3.50, 0.174, 290, 258, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN MAP KINASE KINASE 1 (MEK1) IN COMPLEX WITH  A SMALL MOLECULE INHIBITOR AND ADP
2809, d3zlsA_, 0.7318, 3.60, 0.190, 315, 258, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 6
2810, d2w05A_, 0.7318, 2.90, 0.184, 276, 245, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5B
2811, d4wsqB_, 0.7317, 3.02, 0.177, 310, 248, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2812, d3emgA_, 0.7317, 3.07, 0.206, 255, 248, DISCOVERY AND SAR OF NOVEL 4-THIAZOLYL-2- PHENYLAMINOPYRIMIDINES AS POTENT INHIBITORS OF SPLEEN TYROSINE KINASE (SYK)
2813, d2bheA_, 0.7317, 2.92, 0.184, 274, 245, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO-INDIRUBINE
2814, d1s9iA_, 0.7317, 3.41, 0.169, 303, 255, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
2815, d4yc6A_, 0.7316, 2.84, 0.179, 285, 240, CDK1/CKS1
2816, d4u44B_, 0.7316, 3.44, 0.198, 296, 257, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
2817, p3teiA_, 0.7316, 2.87, 0.230, 339, 243, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
2818, d3js2A_, 0.7316, 3.34, 0.210, 295, 252, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
2819, d2w1gA1, 0.7316, 2.65, 0.200, 254, 240, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
2820, d2b9jA_, 0.7316, 2.95, 0.218, 337, 243, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM FAR1
2821, d4f4pA1, 0.7315, 3.30, 0.198, 260, 252, SYK IN COMPLEX WITH LIGAND LASW836
2822, d4cd0A_, 0.7314, 3.51, 0.181, 295, 254, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPANE-12-DIOL
2823, d3eqgA_, 0.7313, 3.41, 0.187, 314, 256, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH PD ADP AND MG2P
2824, d3d15A_, 0.7313, 2.82, 0.189, 256, 243, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-(3-CHLORO-PHENYL)-3-{5-[2-(THIENO[32- D]PYRIMIDIN-4-YLAMINO)- ETHYL]-THIAZOL-2-YL}-UREA [SNS-314]
2825, d4e26B_, 0.7312, 3.05, 0.223, 264, 247, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
2826, d2r3lA_, 0.7312, 3.03, 0.194, 275, 247, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2827, d1yi6B_, 0.7312, 3.39, 0.213, 274, 254, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
2828, d4iz7C_, 0.7311, 2.88, 0.226, 340, 243, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
2829, d3q4uC_, 0.7311, 3.45, 0.184, 296, 255, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
2830, d3bqrA1, 0.7311, 3.33, 0.183, 273, 246, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH AN IMIDAZO-PYRIDAZINE LIGAND
2831, d5ikwA_, 0.7310, 3.02, 0.174, 297, 247, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2832, d4uwbB_, 0.7310, 3.23, 0.212, 299, 250, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
2833, d3rzbA_, 0.7310, 3.27, 0.188, 282, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-23
2834, d3ralA_, 0.7310, 3.08, 0.182, 277, 247, CDK2 IN COMPLEX WITH INHIBITOR RC-2-34
2835, d3pp1A1, 0.7310, 3.58, 0.185, 290, 259, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGATP
2836, d3lctA_, 0.7310, 3.78, 0.174, 308, 259, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
2837, d3lcsA_, 0.7310, 3.74, 0.178, 304, 259, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
2838, d1yi6A_, 0.7310, 3.62, 0.202, 274, 257, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
2839, d5lmbB_, 0.7309, 2.91, 0.204, 261, 245, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
2840, d5caoA_, 0.7309, 3.31, 0.180, 300, 250, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 29
2841, d4zsaA_, 0.7309, 3.36, 0.210, 289, 252, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
2842, d3my0L1, 0.7309, 3.48, 0.184, 295, 255, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2843, d2ym5A_, 0.7309, 2.79, 0.204, 248, 240, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2844, d2b55A_, 0.7309, 2.95, 0.184, 276, 245, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH INDENOPYRAXOLE DIN-101312
2845, d1h00A_, 0.7309, 3.00, 0.175, 278, 246, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
2846, d4xlvA_, 0.7308, 3.33, 0.185, 307, 254, CRYSTAL STRUCTURE OF THE ACTIVATED INSULIN RECEPTOR TYROSINE KINASE DIMER
2847, d3oomA_, 0.7308, 3.57, 0.191, 297, 257, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00507
2848, d2ydjA_, 0.7308, 2.91, 0.222, 252, 243, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
2849, d2hk5A2, 0.7308, 3.07, 0.193, 268, 249, HCK KINASE IN COMPLEX WITH LCK TARGETTED INHIBITOR PG-1009247
2850, d2eb3A_, 0.7308, 3.20, 0.181, 294, 249, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (L858R) IN COMPLEX WITH AMPPNP
2851, d5ajqB_, 0.7307, 3.27, 0.188, 267, 250, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
2852, d4at4A1, 0.7307, 3.32, 0.222, 289, 252, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH EX429
2853, d3f6xC_, 0.7307, 3.08, 0.206, 265, 247, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2854, d2vtqA_, 0.7307, 2.98, 0.184, 274, 245, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
2855, d1gihA_, 0.7307, 3.06, 0.190, 276, 247, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
2856, d5jq8A_, 0.7306, 3.04, 0.175, 278, 246, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0943
2857, d4xg8A_, 0.7306, 3.26, 0.194, 258, 252, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2858, d4fodA_, 0.7306, 3.64, 0.176, 308, 256, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 36
2859, d4bzdA_, 0.7306, 2.97, 0.187, 277, 246, STRUCTURE OF CDK2 IN COMPLEX WITH A BENZIMIDAZOPYRIMIDINE
2860, d3w55A_, 0.7306, 2.77, 0.225, 335, 240, THE STRUCTURE OF ERK2 IN COMPLEX WITH FR148083
2861, d3sw4A_, 0.7306, 3.22, 0.173, 279, 249, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
2862, d3e8nA1, 0.7306, 3.57, 0.185, 290, 259, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) COMPLEXED WITH A POTENT INHIBITOR RDEA119 AND MGATP
2863, d3d2iA_, 0.7306, 2.69, 0.191, 255, 241, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH 1-{5-[2-(1-METHYL-1H- PYRAZOLO[43-D]PYRIMIDIN-7-YLAMINO)-ETHYL]-THIAZOL-2-YL}-3- (3-TRIFLUOROMETHYL-PHENYL)-UREA
2864, d2e14A_, 0.7306, 2.77, 0.225, 335, 240,  
2865, d2duvA_, 0.7306, 2.81, 0.193, 272, 243, STRUCTURE OF CDK2 WITH A 3-HYDROXYCHROMONES
2866, d4mxxA_, 0.7305, 3.01, 0.207, 266, 246, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
2867, d4f1mA1, 0.7305, 3.21, 0.187, 274, 251, CRYSTAL STRUCTURE OF THE G1179S ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM.
2868, d3dqxB_, 0.7305, 3.23, 0.212, 268, 250, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
2869, d3d4qB_, 0.7305, 2.85, 0.218, 264, 243, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
2870, d2xngA_, 0.7305, 2.67, 0.196, 253, 240, STRUCTURE OF AURORA-A BOUND TO A SELECTIVE IMIDAZOPYRAZINE INHIBITOR
2871, d5a46B_, 0.7304, 3.35, 0.211, 297, 251, FGFR1 IN COMPLEX WITH DOVITINIB
2872, d4yjtA_, 0.7304, 3.13, 0.189, 268, 249, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000233
2873, d3rpyA_, 0.7304, 3.04, 0.186, 277, 247, CDK2 IN COMPLEX WITH INHIBITOR RC-2-40
2874, d3bu5A_, 0.7304, 3.22, 0.192, 291, 250, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE AND ATP
2875, d5ew8B_, 0.7303, 3.30, 0.211, 290, 251, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
2876, d4fobA_, 0.7302, 3.54, 0.176, 295, 255, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 1
2877, d3unjA_, 0.7302, 3.34, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR YL1-038-31
2878, d3eqcA_, 0.7302, 3.49, 0.187, 312, 257, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH COMPOUND 1 ATP-GS AND MG2P
2879, d1r78A_, 0.7302, 2.91, 0.180, 273, 244, CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR
2880, d4yc6G_, 0.7301, 2.85, 0.179, 285, 240, CDK1/CKS1
2881, p4ux9A_, 0.7301, 2.83, 0.228, 343, 241, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
2882, d4focA_, 0.7301, 3.48, 0.177, 296, 254, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 2
2883, d4bbmA1, 0.7301, 3.41, 0.190, 306, 247, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
2884, d3rakA_, 0.7301, 3.06, 0.182, 277, 247, CDK2 IN COMPLEX WITH INHIBITOR RC-2-32
2885, d3o71A_, 0.7301, 3.10, 0.223, 340, 247, CRYSTAL STRUCTURE OF ERK2/DCC PEPTIDE COMPLEX
2886, p3n9xA_, 0.7301, 3.21, 0.194, 374, 248, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
2887, d3eqiA_, 0.7301, 3.34, 0.193, 315, 254, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ADP AND MG2P
2888, d2wmtA_, 0.7301, 2.80, 0.204, 248, 240, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2889, d1k3aA_, 0.7301, 3.35, 0.197, 288, 254, STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR KINASE
2890, d4uwbA_, 0.7300, 3.27, 0.212, 299, 250, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
2891, d4n4sA_, 0.7300, 2.95, 0.220, 342, 245, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
2892, d3zlwA_, 0.7300, 3.33, 0.189, 312, 254, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 3
2893, d3r8mA_, 0.7300, 3.28, 0.187, 286, 252, CDK2 IN COMPLEX WITH INHIBITOR L3-3
2894, p3nieB_, 0.7300, 3.16, 0.219, 367, 247, CRYSTAL STRUCTURE OF PF11_0147
2895, d3my0A1, 0.7300, 3.50, 0.184, 295, 255, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2896, d3eqdA_, 0.7300, 3.31, 0.193, 315, 254, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ATP-GS AND MG2P
2897, d4uwcA_, 0.7299, 3.26, 0.212, 300, 250, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
2898, d4useA_, 0.7299, 3.63, 0.183, 286, 252, HUMAN STK10 (LOK) WITH SB-633825
2899, d3fqhB_, 0.7299, 3.05, 0.194, 258, 247, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
2900, d3c9wA2, 0.7299, 2.74, 0.230, 335, 239, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
2901, d2r3nA_, 0.7299, 3.08, 0.186, 275, 247, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2902, d5hznE_, 0.7298, 3.31, 0.193, 296, 249, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2903, d5hznA_, 0.7298, 3.30, 0.193, 296, 249, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2904, d5ftoA1, 0.7298, 3.56, 0.176, 297, 256, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH ENTRECTINIB
2905, d4jbqA_, 0.7298, 2.88, 0.193, 257, 243, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
2906, d3my0B_, 0.7298, 3.49, 0.188, 295, 255, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2907, d3mblA_, 0.7298, 3.60, 0.185, 290, 259, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGADP
2908, d2wmxA_, 0.7298, 2.74, 0.213, 248, 239, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2909, d2f49A_, 0.7298, 2.91, 0.218, 335, 243, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
2910, d4xg9A_, 0.7297, 3.09, 0.210, 259, 248, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2911, d4u7zA1, 0.7297, 3.59, 0.189, 290, 259, MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK1) BOUND TO G805
2912, d4h58B_, 0.7297, 3.02, 0.224, 262, 245, BRAF IN COMPLEX WITH COMPOUND 3
2913, d3mtfB_, 0.7297, 3.59, 0.191, 298, 257, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
2914, d3gc0A_, 0.7297, 3.12, 0.180, 278, 245, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA IN COMPLEX WITH AMP
2915, d2bhhA_, 0.7297, 2.95, 0.188, 274, 245, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 4-HYDROXYPIPERINDINESULFONYL-INDIRUBINE
2916, d5xp7B_, 0.7296, 3.03, 0.207, 267, 246, C-SRC IN COMPLEX WITH ATP-CHCL
2917, d5es1A_, 0.7296, 2.73, 0.239, 304, 238, CRYSTAL STRUCTURE OF MICROTUBULE AFFINITY-REGULATING KINASE 4 CATALYTIC DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
2918, d4hzrB_, 0.7296, 3.22, 0.209, 258, 249, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
2919, d3i60A_, 0.7296, 2.64, 0.228, 335, 237, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-4-(2-(2-CHLOROPHENYLAMINO)-5- METHYLPYRIMIDIN-4-YL)-N-(2-HYDROXY-1-PHENYLETHYL)-1H-PYRROLE-2- CARBOXAMIDE
2920, p5w5qB_, 0.7295, 3.43, 0.195, 297, 257, MAP4K4 IN COMPLEX WITH INHIBITOR COMPOUND 12 (N3-METHYL-10-(3-METHYL- 3-(5-METHYLOXAZOL-2-YL)BUT-1-YN-1-YL)-6;7-DIHYDRO-5H-5;7- METHANOBENZO[C]IMIDAZO[1;2-A]AZEPINE-2;3-DICARBOXAMIDE) 
2921, d4uwcB_, 0.7295, 3.26, 0.212, 301, 250, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
2922, d4o0tB_, 0.7295, 3.35, 0.230, 280, 248, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2923, d4f1tA1, 0.7295, 3.28, 0.187, 267, 251, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO THE ROCK INHIBITOR H1152
2924, d3my0N1, 0.7295, 3.47, 0.189, 299, 254, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2925, d2btrA_, 0.7295, 2.98, 0.192, 275, 245, STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873
2926, d2b4sD_, 0.7295, 3.31, 0.195, 294, 251, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
2927, d4o0wA_, 0.7294, 2.77, 0.199, 259, 241, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
2928, d3prfB_, 0.7294, 2.81, 0.211, 262, 242, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
2929, d3c4fB_, 0.7294, 3.46, 0.209, 290, 253, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
2930, d1gijA_, 0.7294, 2.97, 0.188, 273, 245, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
2931, d5hznH_, 0.7293, 3.31, 0.176, 303, 250, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2932, d4un0D_, 0.7293, 2.73, 0.242, 276, 240, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
2933, d4bggB_, 0.7293, 3.44, 0.185, 293, 254, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
2934, d3dqxA_, 0.7293, 3.19, 0.213, 267, 249, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
2935, d5hznD_, 0.7292, 3.32, 0.176, 304, 250, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2936, d3c9wB2, 0.7292, 2.77, 0.230, 335, 239, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
2937, d3c4fA_, 0.7292, 3.40, 0.210, 290, 252, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
2938, d2fysB_, 0.7292, 2.92, 0.225, 338, 244, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
2939, d5hznG_, 0.7291, 3.35, 0.192, 296, 250, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2940, d5hznC_, 0.7291, 3.35, 0.192, 296, 250, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2941, d4uy9A_, 0.7291, 3.40, 0.211, 313, 251, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
2942, d4mxoA_, 0.7291, 3.03, 0.207, 266, 246, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
2943, d3f6xA_, 0.7291, 3.01, 0.215, 264, 246, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2944, d2ym4A_, 0.7291, 2.92, 0.207, 251, 241, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2945, d5mjaA_, 0.7290, 3.06, 0.153, 271, 248, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
2946, d5aafA_, 0.7290, 2.66, 0.197, 254, 239, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14A)
2947, d4yjpA_, 0.7290, 3.18, 0.195, 263, 251, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000223
2948, d4p2wB_, 0.7290, 2.83, 0.165, 253, 243,  
2949, d4f0fA1, 0.7290, 3.22, 0.191, 274, 251, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM
2950, d4xeyB2, 0.7289, 3.49, 0.193, 264, 254, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
2951, d4mxzA_, 0.7289, 3.01, 0.215, 266, 246, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
2952, d4mxyA_, 0.7289, 3.01, 0.215, 266, 246, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
2953, d3zlxA_, 0.7289, 3.34, 0.193, 312, 254, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 18
2954, d3r22A_, 0.7289, 2.76, 0.195, 255, 241, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
2955, d3hmiA_, 0.7289, 3.45, 0.200, 268, 255, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
2956, d2vttA_, 0.7289, 2.97, 0.180, 272, 244, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
2957, d5hznF_, 0.7288, 3.32, 0.193, 296, 249, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2958, d4bggA_, 0.7288, 3.45, 0.185, 296, 254, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
2959, d3l8vA_, 0.7288, 3.39, 0.168, 293, 250, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A BIARYLAMINE BASED INHIBITOR
2960, d3f6xB_, 0.7288, 2.97, 0.204, 267, 245, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2961, d3ezrA_, 0.7288, 2.92, 0.184, 273, 244, CDK-2 WITH INDAZOLE INHIBITOR 17 BOUND AT ITS ACTIVE SITE
2962, d2z7sA_, 0.7288, 2.74, 0.181, 256, 237, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO PURVALNOL A
2963, d2ym7A_, 0.7288, 2.83, 0.204, 248, 240, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2964, d5aagA_, 0.7287, 2.69, 0.200, 253, 240, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14B)
2965, d2w1fA1, 0.7287, 2.66, 0.201, 253, 239, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
2966, d2p55A2, 0.7287, 3.48, 0.187, 288, 257, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
2967, d3rhxA_, 0.7286, 3.32, 0.211, 289, 251, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
2968, d3r21A_, 0.7286, 2.73, 0.200, 254, 240, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
2969, d2ym3A_, 0.7286, 2.79, 0.209, 247, 239, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2970, d1k2pA_, 0.7286, 3.16, 0.164, 258, 250, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
2971, d5hznB_, 0.7285, 3.31, 0.193, 296, 249, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2972, d3m11A_, 0.7285, 2.85, 0.198, 256, 242, CRYSTAL STRUCTURE OF AURORA A KINASE COMPLEXED WITH INHIBITOR
2973, d3d4qA_, 0.7285, 2.89, 0.218, 264, 243, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
2974, d2i6lA_, 0.7285, 2.72, 0.211, 292, 237, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
2975, d4b99A_, 0.7284, 3.10, 0.233, 335, 245, CRYSTAL STRUCTURE OF MAPK7 (ERK5) WITH INHIBITOR
2976, d2fa2A_, 0.7284, 2.90, 0.214, 333, 243, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
2977, d5ajqA_, 0.7283, 3.41, 0.190, 280, 252, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
2978, d4u81A1, 0.7283, 3.47, 0.187, 288, 257, MEK1 KINASE BOUND TO SMALL MOLECULE INHIBITOR G659
2979, d3mtfA_, 0.7283, 3.47, 0.189, 296, 254, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
2980, d2vtnA_, 0.7283, 2.98, 0.180, 274, 245, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
2981, d2pvyC_, 0.7283, 3.07, 0.166, 285, 247, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
2982, d2b9fA_, 0.7283, 2.97, 0.218, 337, 243, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED FUS3
2983, d1cm8B_, 0.7283, 2.83, 0.183, 327, 240, PHOSPHORYLATED MAP KINASE P38-GAMMA
2984, d1cm8A_, 0.7283, 2.83, 0.183, 327, 240, PHOSPHORYLATED MAP KINASE P38-GAMMA
2985, d5fm3A_, 0.7282, 3.29, 0.173, 276, 249, CRYSTAL STRUCTURE OF HYPER-PHOSPHORYLATED RET KINASE DOMAIN WITH (PROXIMAL) JUXTAMEMBRANE SEGMENT
2986, d5oxgB_, 0.7281, 3.45, 0.185, 296, 254, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
2987, p5nzzE_, 0.7281, 2.81, 0.192, 343, 240, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
2988, d4h58A_, 0.7281, 2.94, 0.224, 263, 245, BRAF IN COMPLEX WITH COMPOUND 3
2989, d3l9pA_, 0.7281, 3.76, 0.174, 303, 259, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
2990, d5aadA_, 0.7280, 2.67, 0.197, 252, 239, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (7A)
2991, d4rvtB_, 0.7280, 3.56, 0.186, 297, 258, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
2992, d3eqbA1, 0.7280, 3.46, 0.187, 288, 257, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
2993, d4yjuA_, 0.7279, 2.99, 0.191, 262, 246, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000249
2994, d3dv3A_, 0.7279, 3.51, 0.187, 288, 257, MEK1 WITH PF-04622664 BOUND
2995, d5obrA_, 0.7278, 2.78, 0.199, 255, 241, AURORA A KINASE IN COMPLEX WITH 2-(3-CHLORO-5-FLUOROPHENYL)QUINOLINE- 4-CARBOXYLIC ACID AND JNJ-7706621
2996, d5i3oA_, 0.7278, 2.95, 0.180, 302, 245, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2997, p4h3pD_, 0.7278, 2.84, 0.228, 338, 241, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
2998, d3v04A1, 0.7278, 3.48, 0.187, 288, 257, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
2999, d3od6X_, 0.7278, 2.95, 0.177, 344, 243, CRYSTAL STRUCTURE OF P38ALPHA Y323T ACTIVE MUTANT
3000, d3js2B_, 0.7278, 3.27, 0.197, 291, 249, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
3001, d5andA_, 0.7277, 3.00, 0.176, 273, 244, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 2-IMIDAZOL-1-YL-1H- BENZIMIDAZOLE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
3002, d4nifD_, 0.7277, 3.69, 0.197, 313, 254, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
3003, d3my0C1, 0.7276, 3.47, 0.190, 298, 253, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3004, d5xdlA_, 0.7275, 3.23, 0.190, 292, 248, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH CO-1686
3005, d5edrA_, 0.7275, 3.33, 0.181, 299, 249, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 27: ~{N}-(1~{H}- INDAZOL-3-YL)-77-DIMETHYL-2-(2-METHYLPYRAZOL-3-YL)-5~{H}-FURO[34- D]PYRIMIDIN-4-AMINE
3006, d4u80A_, 0.7275, 3.49, 0.187, 286, 257, MEK 1 KINASE BOUND TO G799
3007, d4lg4B_, 0.7275, 3.22, 0.177, 284, 249, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3008, d3f5pT1, 0.7275, 3.34, 0.197, 294, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3009, d5oxgD_, 0.7274, 3.50, 0.184, 293, 255, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
3010, d5oxgA_, 0.7274, 3.46, 0.185, 293, 254, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
3011, d4p2wA_, 0.7274, 2.79, 0.165, 250, 242,  
3012, d4c8bA_, 0.7274, 3.08, 0.158, 279, 247, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
3013, d3tt0A_, 0.7274, 3.31, 0.211, 305, 251, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
3014, d3oz6A_, 0.7274, 3.14, 0.195, 343, 246, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
3015, d2oiqB_, 0.7274, 3.04, 0.211, 265, 246, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
3016, d5oxgC1, 0.7273, 3.50, 0.188, 299, 255, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
3017, d4d9tA_, 0.7273, 3.45, 0.190, 299, 252, RSK2 C-TERMINAL KINASE DOMAIN WITH INHIBITOR (E)-METHYL 3-(4-AMINO-7- (3-HYDROXYPROPYL)-5-P-TOLYL-7H-PYRROLO[23-D]PYRIMIDIN-6-YL)-2- CYANOACRYLATE
3018, d3sxrA1, 0.7273, 3.09, 0.137, 257, 248, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
3019, d3l8pA_, 0.7273, 3.29, 0.176, 292, 250, CRYSTAL STRUCTURE OF CYTOPLASMIC KINASE DOMAIN OF TIE2 COMPLEXED WITH INHIBITOR CEP11207
3020, d1gagA_, 0.7273, 3.32, 0.202, 300, 253, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH A BISUBSTRATE INHIBITOR
3021, d5fp6A_, 0.7271, 2.89, 0.185, 278, 243, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 3-(47-DICHLORO-1H-INDOL-3-YL)PROP-2-YN-1-OL (AT17833) IN AN ALTERNATE BINDING SITE.
3022, d3q4uD_, 0.7271, 3.60, 0.187, 299, 257, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
3023, d3ggfB_, 0.7271, 3.16, 0.204, 270, 250, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
3024, d2pvyB_, 0.7271, 3.07, 0.163, 286, 246, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
3025, d1k9aE3, 0.7271, 3.18, 0.202, 268, 248, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
3026, d4fv6A_, 0.7270, 2.65, 0.229, 332, 236, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E57
3027, d4ftoA_, 0.7270, 2.97, 0.203, 252, 241, CRYSTAL STRUCTURE OF THE CHK1
3028, d4d55A_, 0.7270, 2.89, 0.210, 260, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN
3029, d3gqlA_, 0.7269, 3.50, 0.215, 287, 251, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
3030, d5vo6A_, 0.7268, 3.34, 0.228, 271, 250, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE INHIBITOR
3031, d5uhnB_, 0.7268, 2.99, 0.176, 269, 245, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
3032, d4bc6A_, 0.7268, 3.55, 0.184, 285, 250, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO NOVEL BOSUTINIB ISOFORM 1 PREVIOUSLY THOUGHT TO BE BOSUTINIB
3033, d3zzeA_, 0.7268, 3.16, 0.182, 286, 247, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH N - ((3Z)-4-CHLORO-7-METHYL-2-OXO-12-DIHYDRO-3H-INDOL-3- YLIDENE)-2-(4-HYDROXYPHENYL)PROPANOHYDRAZIDE
3034, d3zlyA_, 0.7268, 3.43, 0.193, 310, 254, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 8
3035, d3zfxA_, 0.7268, 3.14, 0.146, 267, 247, CRYSTAL STRUCTURE OF EPHB1
3036, d1ungB_, 0.7268, 2.44, 0.159, 268, 233, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
3037, d5ih8A_, 0.7267, 2.61, 0.234, 306, 235, MELK IN COMPLEX WITH NVS-MELK1
3038, d4yc8A_, 0.7267, 3.31, 0.199, 259, 251, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
3039, d4rwiA_, 0.7267, 3.27, 0.216, 305, 250, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
3040, d3zfxD_, 0.7267, 3.11, 0.146, 265, 246, CRYSTAL STRUCTURE OF EPHB1
3041, d3my0E1, 0.7267, 3.46, 0.186, 293, 253, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3042, d3dk6B_, 0.7267, 3.42, 0.203, 259, 251, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3043, d5am7A_, 0.7266, 3.25, 0.210, 294, 248, FGFR1 MUTANT WITH AN INHIBITOR
3044, p4ux9C_, 0.7266, 2.77, 0.230, 333, 239, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
3045, d4rwkA1, 0.7266, 3.36, 0.215, 307, 251, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
3046, d4mxcA_, 0.7266, 3.02, 0.180, 290, 244, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
3047, d4jg8A_, 0.7266, 3.51, 0.194, 300, 253, STRUCTURE OF RSK2 T493M CTD MUTANT BOUND TO 2-CYANO-N-(1-HYDROXY-2- METHYLPROPAN-2-YL)-3-(3-(345-TRIMETHOXYPHENYL)-1H-INDAZOL-5-YL) ACRYLAMIDE
3048, d2c6eA_, 0.7266, 2.64, 0.207, 251, 237, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
3049, p5nzzF_, 0.7265, 2.74, 0.193, 341, 238, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
3050, d4uy9B_, 0.7265, 3.43, 0.211, 315, 251, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
3051, d2f49B_, 0.7265, 2.94, 0.214, 337, 243, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
3052, d5am6A1, 0.7264, 3.23, 0.198, 294, 248, NATIVE FGFR1 WITH AN INHIBITOR
3053, d3en4B_, 0.7264, 3.06, 0.207, 266, 246, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
3054, d2j7tA_, 0.7264, 3.68, 0.187, 285, 252, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO SU11274
3055, d3my0U1, 0.7263, 3.47, 0.186, 284, 253, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3056, d2wmwA_, 0.7263, 2.75, 0.214, 247, 238, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3057, d1s9jA1, 0.7263, 3.48, 0.187, 288, 257, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
3058, d1ir3A_, 0.7263, 3.38, 0.185, 300, 254, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH PEPTIDE SUBSTRATE AND ATP ANALOG
3059, d5ankA_, 0.7262, 2.97, 0.177, 273, 243, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 246-TRIOXO-1- PHENYL-HEXAHYDROPYRIMIDINE-5-CARBOXAMIDE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
3060, d4zk5B_, 0.7262, 3.37, 0.189, 294, 254, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
3061, d4aszA1, 0.7262, 3.31, 0.224, 286, 250, CRYSTAL STRUCTURE OF APO TRKB KINASE DOMAIN
3062, d3v01A1, 0.7262, 3.50, 0.187, 288, 257, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
3063, d2wtkF1, 0.7262, 2.70, 0.202, 250, 238, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
3064, p5nzzG_, 0.7260, 2.77, 0.197, 342, 239, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
3065, d5j95B_, 0.7260, 3.43, 0.192, 300, 255, MAP4K4 IN COMPLEX WITH INHIBITOR
3066, d3uqgA_, 0.7260, 3.00, 0.213, 263, 244, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
3067, d3prfA_, 0.7260, 2.93, 0.217, 262, 244, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
3068, d4mxzB_, 0.7258, 3.06, 0.212, 264, 245, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
3069, d4mxyB_, 0.7258, 3.06, 0.212, 264, 245, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
3070, d3a4pA_, 0.7258, 3.46, 0.168, 285, 250, HUMAN C-MET KINASE DOMAIN COMPLEXED WITH 6-BENZYLOXYQUINOLINE INHIBITOR
3071, d2ydjB_, 0.7258, 2.87, 0.232, 251, 241, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
3072, d5t0pB_, 0.7257, 3.01, 0.205, 263, 244, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
3073, d4cmoA_, 0.7257, 3.54, 0.178, 295, 253, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 2-((1R)-1-((3-AMINO-6-(2- METHOXYPYRIDIN- -YL)PYRAZIN-2-YL)OXY)ETHYL)-4-FLUORO-N-METHYLBENZAMIDE
3074, d5ihaA_, 0.7256, 2.59, 0.235, 303, 234, MELK IN COMPLEX WITH NVS-MELK8F
3075, d5i3rA_, 0.7256, 3.00, 0.171, 302, 245, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3076, d5di1B_, 0.7256, 3.43, 0.188, 300, 255, MAP4K4 IN COMPLEX WITH AN INHIBITOR
3077, d5aaaA_, 0.7256, 3.68, 0.173, 294, 255, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
3078, d4qrcA_, 0.7256, 3.12, 0.199, 297, 246, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 4 IN COMPLEX WITH PONATINIB
3079, d4nk9B_, 0.7256, 3.26, 0.202, 282, 247, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
3080, d3k5uA_, 0.7256, 2.87, 0.194, 260, 242, IDENTIFICATION SAR STUDIES AND X-RAY COCRYSTAL ANALYSIS OF A NOVEL FURANO-PYRIMIDINE AURORA KINASE A INHIBITOR
3081, d2w1eA1, 0.7256, 2.65, 0.202, 252, 238, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3082, d1k9aA3, 0.7256, 3.18, 0.202, 267, 247, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
3083, d5edqA_, 0.7255, 3.42, 0.167, 298, 251, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 15: ~{N}-(7- CHLORANYL-1~{H}-INDAZOL-3-YL)-77-DIMETHYL-2-(1~{H}-PYRAZOL-4-YL)- 5~{H}-FURO[34-D]PYRIMIDIN-4-AMINE
3084, d5edpA_, 0.7255, 3.43, 0.179, 295, 251, EGFR KINASE (T790M/L858R) APO
3085, d5a46A_, 0.7255, 3.31, 0.213, 289, 249, FGFR1 IN COMPLEX WITH DOVITINIB
3086, d3vvhC1, 0.7255, 3.67, 0.173, 282, 260, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
3087, d3ppkA_, 0.7255, 2.93, 0.225, 262, 244, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
3088, d3f5pD1, 0.7255, 3.27, 0.194, 296, 252, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3089, d5i9vA_, 0.7254, 3.11, 0.166, 279, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH AGS
3090, d5htiA_, 0.7254, 3.01, 0.184, 290, 244, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH LXM108
3091, d4bggD_, 0.7254, 3.43, 0.187, 286, 252, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
3092, d3my0G1, 0.7254, 3.49, 0.190, 293, 253, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3093, d3f5pA1, 0.7254, 3.36, 0.197, 298, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3094, d2z7qA_, 0.7254, 2.73, 0.182, 255, 236, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK-1 BOUND TO AMP-PCP
3095, d2pmiA_, 0.7254, 2.80, 0.186, 284, 237, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
3096, d5uorA_, 0.7253, 2.48, 0.223, 249, 233, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3097, d5iuiA_, 0.7253, 3.72, 0.167, 303, 257, CRYSTAL STRUCTURE OF ANAPLASTIC LYPHOMA KINASE (ALK) IN COMPLEX WITH 4
3098, d4o6eA_, 0.7253, 2.82, 0.234, 328, 239, DISCOVERY OF 5678-TETRAHYDROPYRIDO[34-D]PYRIMIDINE INHIBITORS OF ERK2
3099, d3zclA_, 0.7253, 3.23, 0.182, 289, 247, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-3-(1-(1H-PYRROLO(23-B)PYRIDIN-3-YL)ETHYL)-N-ISOPROPYL-( 124)TRIAZOLO(43-B)PYRIDAZIN-6-AMINE
3100, d3my0D1, 0.7253, 3.45, 0.190, 297, 252, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3101, d2wmuA_, 0.7253, 2.79, 0.206, 246, 238, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3102, d2fumD_, 0.7253, 2.44, 0.215, 258, 233, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
3103, d5w86A_, 0.7252, 3.16, 0.228, 269, 246, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
3104, d4d9uA_, 0.7252, 3.45, 0.190, 307, 252, RSK2 C-TERMINAL KINASE DOMAIN (E)-TERT-BUTYL 3-(4-AMINO-7-(3- HYDROXYPROPYL)-5-P-TOLYL-7H-PYRROLO[23-D]PYRIMIDIN-6-YL)-2- CYANOACRYLATE
3105, d3zfxI_, 0.7252, 3.12, 0.146, 263, 246, CRYSTAL STRUCTURE OF EPHB1
3106, d3my0F1, 0.7252, 3.50, 0.186, 293, 253, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3107, d2xruA_, 0.7252, 2.71, 0.205, 253, 239, AURORA-A T288E COMPLEXED WITH PHA-828300
3108, d2etmB_, 0.7252, 3.05, 0.208, 263, 245, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
3109, d2bdfB_, 0.7252, 3.07, 0.211, 265, 247, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
3110, d1urwA_, 0.7252, 3.02, 0.172, 274, 244, CDK2 IN COMPLEX WITH AN IMIDAZO[12-B]PYRIDAZINE
3111, d5a4cB1, 0.7251, 3.31, 0.213, 284, 249, FGFR1 LIGAND COMPLEX
3112, d4qqjA_, 0.7251, 3.17, 0.175, 282, 246, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN HARBORING THE V550L GATE-KEEPER MUTATION
3113, d4j95D_, 0.7251, 3.04, 0.180, 271, 245, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
3114, d4bghA_, 0.7251, 3.08, 0.191, 275, 246, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PAN-CDK INHIBITOR
3115, d3q4zB_, 0.7251, 3.30, 0.222, 279, 248, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
3116, d5j9zA_, 0.7250, 3.22, 0.198, 291, 247, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1A
3117, d4zp5B_, 0.7250, 3.44, 0.188, 300, 255, MAP4K4 IN COMPLEX WITH INHIBITOR
3118, d3f5pC1, 0.7250, 3.37, 0.197, 300, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3119, d2ym8A_, 0.7250, 2.80, 0.206, 246, 238, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3120, d4rwlB_, 0.7249, 3.20, 0.211, 285, 247, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
3121, d3f5pB1, 0.7249, 3.37, 0.197, 297, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3122, d1u46A_, 0.7249, 3.12, 0.208, 255, 245, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
3123, d5hezD_, 0.7248, 3.46, 0.215, 289, 251, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
3124, d4qtaA_, 0.7248, 2.75, 0.231, 335, 238, STRUCTURE OF HUMAN ERK2 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
3125, d4cljA_, 0.7248, 3.65, 0.180, 295, 255, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
3126, d3q4uA_, 0.7248, 3.52, 0.188, 298, 255, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
3127, d3my0Q1, 0.7248, 3.49, 0.190, 293, 253, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3128, d3f5pI1, 0.7248, 3.37, 0.197, 293, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3129, d2xb7A_, 0.7248, 3.37, 0.181, 286, 249, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH NVP- TAE684
3130, d2j0mB_, 0.7248, 2.84, 0.207, 257, 241, CRYSTAL STRUCTURE A TWO-CHAIN COMPLEX BETWEEN THE FERM AND KINASE DOMAINS OF FOCAL ADHESION KINASE.
3131, d5nkeA_, 0.7247, 3.68, 0.160, 292, 256, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3A
3132, d4rj5A_, 0.7247, 3.49, 0.183, 296, 251, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 5
3133, d4lg4E_, 0.7247, 3.25, 0.165, 275, 249, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3134, d3my0R1, 0.7247, 3.48, 0.186, 293, 253, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3135, d3f5pS1, 0.7247, 3.37, 0.197, 294, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3136, d1mqbB_, 0.7247, 2.93, 0.168, 265, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
3137, d5k4iA_, 0.7246, 2.77, 0.231, 336, 238, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH COMPOUND 22
3138, d4aotA1, 0.7246, 3.10, 0.195, 276, 246, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
3139, d3zfxH_, 0.7246, 3.21, 0.146, 266, 247, CRYSTAL STRUCTURE OF EPHB1
3140, d1k9aB3, 0.7246, 3.20, 0.206, 267, 247, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
3141, d1k2pB_, 0.7246, 3.22, 0.164, 258, 250, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
3142, d5larA_, 0.7245, 3.26, 0.198, 350, 247, CRYSTAL STRUCTURE OF P38 ALPHA MAPK14 IN COMPLEX WITH VPC00628
3143, d4u0iA_, 0.7245, 3.21, 0.215, 297, 247, CRYSTAL STRUCTURE OF KIT IN COMPLEX WITH PONATINIB
3144, d4gu6A_, 0.7245, 3.15, 0.204, 271, 245, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
3145, d4ccbA_, 0.7245, 3.42, 0.180, 287, 250, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 3-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(5-METHYL-1H-PYRAZOL-4-YL)PYRIDIN-2-AMINE
3146, d2zvaA1, 0.7245, 3.00, 0.193, 260, 244, LYN TYROSINE KINASE DOMAIN-DASATINIB COMPLEX
3147, d5w86B_, 0.7244, 3.23, 0.220, 267, 245, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
3148, d4maoA_, 0.7244, 3.54, 0.194, 298, 253, RSK2 T493M C-TERMINAL KINASE DOMAIN IN COMPLEX WITH RMM58
3149, d4fg7A_, 0.7244, 2.92, 0.200, 250, 240, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-293 IN COMPLEX WITH ATP
3150, d4bggC_, 0.7244, 3.34, 0.184, 279, 250, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
3151, d3plsA_, 0.7244, 3.51, 0.142, 298, 254, RON IN COMPLEX WITH LIGAND AMP-PNP
3152, d3f5pG1, 0.7244, 3.38, 0.197, 298, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3153, d2wgjA_, 0.7244, 3.24, 0.182, 289, 247, X-RAY STRUCTURE OF PF-02341066 BOUND TO THE KINASE DOMAIN OF C-MET
3154, d1p2aA_, 0.7244, 2.86, 0.182, 271, 242, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A TRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR
3155, d6eimB_, 0.7243, 3.43, 0.184, 295, 250, HUMAN STK10 BOUND TO GW683134A
3156, d4nifA_, 0.7243, 3.56, 0.198, 313, 252, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
3157, d4jbpA_, 0.7243, 2.87, 0.199, 255, 241, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
3158, d3my0S1, 0.7243, 3.47, 0.187, 293, 252, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3159, d3geqB1, 0.7243, 3.00, 0.213, 270, 244, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
3160, d2fb8A_, 0.7243, 2.86, 0.227, 259, 242, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
3161, d1fgiA_, 0.7243, 3.35, 0.212, 283, 250, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
3162, d3vvhA1, 0.7242, 3.50, 0.184, 286, 256, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
3163, p2y4iC_, 0.7242, 3.53, 0.174, 313, 253, KSR2-MEK1 HETERODIMER
3164, d4kipB_, 0.7241, 2.83, 0.211, 338, 237, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
3165, d3f5pH1, 0.7241, 3.37, 0.197, 298, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3166, d3dbdA_, 0.7241, 2.67, 0.220, 261, 236, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 094
3167, d4v05A_, 0.7240, 3.33, 0.212, 287, 250, FGFR1 IN COMPLEX WITH AZD4547.
3168, d4u3yB_, 0.7240, 3.61, 0.190, 300, 258, APO MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4)
3169, p4ux9B_, 0.7239, 2.74, 0.224, 327, 237, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
3170, d3zxzA_, 0.7238, 3.25, 0.182, 289, 247, X-RAY STRUCTURE OF PF-04217903 BOUND TO THE KINASE DOMAIN OF C-MET
3171, d3gbzA_, 0.7238, 2.88, 0.183, 274, 241, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA
3172, d1oitA_, 0.7238, 2.89, 0.178, 273, 242, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
3173, d5t0pA_, 0.7237, 3.02, 0.205, 264, 244, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
3174, d4nk9A_, 0.7237, 3.24, 0.202, 281, 247, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
3175, d4mxoB_, 0.7237, 3.08, 0.212, 264, 245, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
3176, d4ap7A_, 0.7237, 3.24, 0.182, 289, 247, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( (6-(4- FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN-3-YL)METHYL) PHENOL
3177, d4qp8A_, 0.7236, 2.90, 0.224, 335, 241, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
3178, d3fdnA_, 0.7236, 2.99, 0.193, 261, 244, STRUCTURE-BASED DRUG DESIGN OF NOVEL AURORA KINASE A INHIBITORS: STRUCTURE BASIS FOR POTENCY AND SPECIFICITY
3179, d2x9fA_, 0.7236, 3.13, 0.150, 265, 247, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3180, d2hz4C_, 0.7236, 3.25, 0.201, 259, 249, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
3181, d4o2pB_, 0.7235, 2.99, 0.209, 265, 244, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
3182, d4m8tA_, 0.7235, 3.52, 0.194, 303, 253, RSK2 T493M C-TERMINAL KINASE DOMAIN IN COMPLEX WITH 3-(3-(1H-PYRAZOL- 4-YL)PHENYL)-2-CYANOACRYLAMIDE
3183, d4cliA_, 0.7235, 3.71, 0.176, 294, 255, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-21016-TRIMETHYL-15 -OXO-10151617-TETRAHYDRO-2H-84-(METHENO)PYRAZOLO(43-H) (2511)BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
3184, d4v05B_, 0.7234, 3.27, 0.210, 286, 248, FGFR1 IN COMPLEX WITH AZD4547.
3185, d4rwjA1, 0.7234, 3.35, 0.203, 306, 251, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
3186, d4nkaB_, 0.7234, 3.21, 0.203, 287, 246, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
3187, d3zbxA_, 0.7234, 3.17, 0.183, 282, 246, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR 6- ((6-(4-FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN- 3-YL)METHYL)QUINOLINE.
3188, d5nkhA_, 0.7233, 3.57, 0.161, 295, 254, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3E
3189, d5kz0A_, 0.7233, 3.48, 0.179, 293, 252, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-[(1R)- 1-{[2-AMINO-5-(13-DIMETHYL-1H-PYRAZOL-4-YL)PYRIDIN-3-YL]OXY}ETHYL]- 4-FLUORO-NN-DIMETHYLBENZAMIDE
3190, d4yhtB_, 0.7233, 2.93, 0.226, 258, 243, BRAF COMPLEXED WITH AN INHIBITOR
3191, d4mneC_, 0.7233, 2.98, 0.206, 260, 243, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3192, d4aoiA_, 0.7233, 3.18, 0.183, 289, 246, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( 3-((1H- PYRROLO(23-B)PYRIDIN-3-YL)METHYL)-(124)TRIAZOLO( 43-B)(124) TRIAZIN-6-YL)BENZONITRILE
3193, d3txoA_, 0.7233, 3.37, 0.193, 317, 244, PKC ETA KINASE IN COMPLEX WITH A NAPHTHYRIDINE
3194, d3d7uC1, 0.7233, 3.09, 0.204, 255, 245, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
3195, d3d7uA1, 0.7233, 3.09, 0.204, 255, 245, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
3196, d2j4zB_, 0.7233, 2.97, 0.207, 269, 242, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
3197, d5imxA_, 0.7232, 3.35, 0.181, 266, 249, ANAPLASTIC LYMPHOMA KINASE (ALK) CATALYTIC DOMAIN COMPLEXED WITH NOVEL INHIBITOR 3-SULFONYLPYRAZOL-4-AMINO PYRIMIDINE
3198, d3oriB_, 0.7232, 2.85, 0.213, 267, 239, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
3199, d3my0I1, 0.7232, 3.47, 0.190, 292, 252, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3200, d3my0H1, 0.7232, 3.48, 0.187, 293, 252, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3201, d4u45B_, 0.7231, 3.52, 0.196, 295, 255, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
3202, d4o0uA_, 0.7231, 2.93, 0.198, 259, 242, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
3203, d4j8mA_, 0.7231, 3.04, 0.204, 265, 240, AURORA A IN COMPLEX WITH CD532
3204, d4cjyD_, 0.7231, 2.61, 0.241, 272, 237,  
3205, d2j4zA_, 0.7231, 2.76, 0.209, 263, 239, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
3206, d5oy6D_, 0.7230, 3.41, 0.179, 292, 251, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
3207, d5ftqA1, 0.7230, 3.51, 0.179, 292, 252, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH CMPD 17
3208, d3mygA_, 0.7230, 2.70, 0.197, 252, 238, AURORA A KINASE COMPLEXED WITH SCH 1473759
3209, d3f5pE1, 0.7230, 3.39, 0.197, 298, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3210, d5kbqB_, 0.7229, 3.15, 0.223, 273, 242, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
3211, d4equB_, 0.7229, 3.44, 0.185, 282, 248, HUMAN STK-10 (LOK) KINASE DOMAIN IN DFG-OUT CONFORMATION WITH INHIBITOR DSA-7
3212, d3ky2A1, 0.7229, 3.28, 0.197, 305, 249, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
3213, d3f5pK1, 0.7229, 3.36, 0.198, 292, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3214, d5aaeA_, 0.7228, 2.64, 0.203, 252, 237, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14D)
3215, d4zloB_, 0.7228, 3.03, 0.210, 263, 243, SERINE/THREONINE-PROTEIN KINASE PAK1 COMPLEXED WITH A DIBENZODIAZEPINE: IDENTIFICATION OF AN ALLOSTERIC SITE ON PAK1
3216, d4yjqA_, 0.7228, 3.09, 0.179, 264, 246, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000224
3217, d4u41B_, 0.7228, 3.55, 0.187, 297, 256, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
3218, d4dymA_, 0.7228, 3.48, 0.187, 293, 252, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00135
3219, d4cmuA_, 0.7228, 3.56, 0.178, 294, 253, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (10R)-7-AMINO-12-FLUORO-1310 16-TETRAMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(43- H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
3220, d3fzrA_, 0.7228, 3.01, 0.173, 261, 243, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-431396
3221, d5oneA_, 0.7227, 2.83, 0.202, 257, 238, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH FMF-03-145-1 (COMPOUND 2)
3222, d4u3zB_, 0.7227, 3.37, 0.177, 294, 254, APO MAP4K4 T181E PHOSPHOMIMETIC MUTANT
3223, d3vvhB1, 0.7227, 3.65, 0.178, 289, 259, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
3224, d3et7A_, 0.7227, 3.01, 0.173, 261, 243, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-2318841
3225, d5aa9A_, 0.7226, 3.65, 0.173, 295, 254, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
3226, d3oriA_, 0.7226, 2.86, 0.213, 267, 239, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
3227, d4oboB_, 0.7225, 3.56, 0.191, 297, 256, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
3228, d3my0P_, 0.7225, 3.49, 0.190, 290, 252, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3229, d4usdA_, 0.7224, 3.16, 0.194, 268, 248, HUMAN STK10 (LOK) WITH SB-633825
3230, d4mneG_, 0.7224, 2.92, 0.207, 259, 242, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3231, d4mcvB_, 0.7224, 3.08, 0.207, 265, 246, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
3232, d4fv8A_, 0.7224, 2.72, 0.229, 333, 236, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E63
3233, d3zc5A_, 0.7224, 3.26, 0.182, 289, 247, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-6-(1-(6-(1-METHYL-1H-PYRAZOL-4-YL)-(124)TRIAZOLO(43- B)PYRIDAZIN-3-YL)ETHYL)QUINOLINE.
3234, d3lvpD_, 0.7224, 3.19, 0.205, 282, 249, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
3235, d3db8A_, 0.7224, 2.74, 0.219, 261, 237, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 041
3236, d2iwiB_, 0.7224, 2.56, 0.201, 249, 234, CRYSTAL STRUCTURE OF THE HUMAN PIM2 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
3237, d5aabA_, 0.7223, 3.62, 0.171, 293, 252, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
3238, d4obqB_, 0.7223, 3.38, 0.190, 293, 253, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
3239, d3zz2A_, 0.7223, 3.60, 0.184, 281, 250,  
3240, d3my0O1, 0.7223, 3.45, 0.191, 296, 251, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3241, d5k9iB_, 0.7222, 2.99, 0.209, 262, 244, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
3242, d4xcuA1, 0.7222, 3.19, 0.179, 287, 246, CRYSTAL STRUCTURE OF FGFR4 WITH AN IRREVERSIBLE INHIBITOR
3243, d3f5pL1, 0.7222, 3.37, 0.198, 292, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3244, d3f5pF1, 0.7222, 3.40, 0.197, 298, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3245, d2wkmA_, 0.7222, 3.32, 0.177, 286, 248, X-RAY STRUCTURE OF PHA-00665752 BOUND TO THE KINASE DOMAIN OF C-MET
3246, d2qr8A_, 0.7222, 3.59, 0.190, 298, 253, 2.0A X-RAY STRUCTURE OF C-TERMINAL KINASE DOMAIN OF P90 RIBOSOMAL S6 KINASE 2 (RSK2)
3247, d3an0A_, 0.7221, 3.66, 0.166, 291, 259,  
3248, d2xneA_, 0.7221, 2.63, 0.194, 246, 237, STRUCTURE OF AURORA-A BOUND TO AN IMIDAZOPYRAZINE INHIBITOR
3249, d2qkrA1, 0.7221, 2.96, 0.173, 269, 237, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH INDIRUBIN 3 -MONOXIME BOUND
3250, d5xp7A_, 0.7220, 3.09, 0.208, 265, 245, C-SRC IN COMPLEX WITH ATP-CHCL
3251, d5dg5B_, 0.7220, 3.03, 0.181, 297, 243, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
3252, d5d12A_, 0.7220, 3.05, 0.209, 260, 244, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL40
3253, d4tt7A_, 0.7220, 3.63, 0.171, 291, 252, CRYSTAL STRUCTURE OF HUMAN ALK WITH A COVALENT MODIFICATION
3254, d3vn9A_, 0.7220, 3.66, 0.166, 291, 259, RIFINED CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED MAP2K6 IN A PUTATIVE AUTO-INHIBITION STATE
3255, p5oktD2, 0.7219, 0.73, 1.000, 210, 210, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH IWP-2 
3256, d4ztrA_, 0.7218, 2.54, 0.196, 249, 235, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1141
3257, d3sxrB1, 0.7218, 3.08, 0.130, 255, 246, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
3258, d3h0zA_, 0.7218, 2.56, 0.200, 248, 235, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
3259, d1vzoA_, 0.7218, 3.47, 0.153, 319, 248, THE STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF MSK1 REVEALS A NOVEL AUTOINHIBITORY CONFORMATION FOR A DUAL KINASE PROTEIN
3260, d3o0gB_, 0.7217, 2.50, 0.164, 264, 232, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
3261, d3f5pM1, 0.7217, 3.40, 0.197, 294, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3262, d5up3B_, 0.7216, 2.52, 0.223, 243, 233, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3263, d5eakA_, 0.7216, 3.03, 0.233, 305, 240, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
3264, d5am6B_, 0.7216, 2.99, 0.219, 280, 242, NATIVE FGFR1 WITH AN INHIBITOR
3265, d1ua2C_, 0.7216, 3.11, 0.164, 286, 244, CRYSTAL STRUCTURE OF HUMAN CDK7
3266, p5oktC2, 0.7215, 0.74, 1.000, 210, 210, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH IWP-2 
3267, d3zosB1, 0.7215, 3.31, 0.200, 301, 245, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
3268, d3geqA1, 0.7214, 3.01, 0.218, 269, 243, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
3269, d3f5pR1, 0.7214, 3.41, 0.197, 293, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3270, d4qp7B_, 0.7213, 2.92, 0.224, 335, 241, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
3271, d4k8aB_, 0.7213, 2.93, 0.211, 258, 242, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
3272, d4ccuA_, 0.7213, 3.49, 0.172, 292, 250, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPAN-2-OL
3273, d3slsB1, 0.7213, 3.67, 0.178, 291, 258, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
3274, d3my0T1, 0.7213, 3.48, 0.187, 291, 251, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3275, d3mvlB_, 0.7213, 2.77, 0.211, 339, 237, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
3276, d3beaA_, 0.7213, 3.40, 0.209, 310, 249, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH A PYRIMIDINOPYRIDONE INHIBITOR
3277, d1t46A_, 0.7213, 3.24, 0.215, 297, 247, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C-KIT TYROSINE KINASE
3278, d4mcvA_, 0.7212, 3.12, 0.203, 267, 246, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
3279, d3ma6B_, 0.7212, 3.31, 0.233, 266, 245, CRYSTAL STRUCTURE OF KINASE DOMAIN OF TGCDPK1 IN PRESENCE OF 3BRB-PP1
3280, d1ol6A_, 0.7212, 2.62, 0.186, 245, 236, STRUCTURE OF UNPHOSPHORYLATED D274N MUTANT OF AURORA-A
3281, d5hezB_, 0.7211, 3.86, 0.189, 289, 259, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
3282, d3zfxE_, 0.7211, 3.14, 0.143, 262, 245, CRYSTAL STRUCTURE OF EPHB1
3283, d2dylA_, 0.7211, 2.91, 0.183, 272, 240, CRYSTAL STRUCTURE OF HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 7 ACTIVATED MUTANT (S287D T291D)
3284, d5grnA_, 0.7210, 3.24, 0.232, 285, 246, CRYSTAL STRUCTURE OF PDGFRA IN COMPLEX WITH WQ-C-159
3285, d4d1xA_, 0.7210, 3.04, 0.193, 274, 244, CDK2 IN COMPLEX WITH LUCIFERIN
3286, d5nk5A_, 0.7209, 3.49, 0.159, 287, 252, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1M
3287, d3f5pJ1, 0.7209, 3.39, 0.198, 292, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3288, d3cthA_, 0.7209, 3.46, 0.172, 295, 250, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A AMINOPYRIDINE BASED INHIBITOR
3289, d1s9iB_, 0.7209, 3.62, 0.173, 291, 255, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
3290, d5am7B_, 0.7208, 3.12, 0.213, 287, 244, FGFR1 MUTANT WITH AN INHIBITOR
3291, d4dfyE_, 0.7208, 3.31, 0.206, 312, 247, CRYSTAL STRUCTURE OF R194A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED ACTIVATION LOOP
3292, d4deiA_, 0.7208, 3.34, 0.173, 287, 248, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 24
3293, d3d7tB_, 0.7208, 3.11, 0.191, 265, 246, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
3294, d2f9gA_, 0.7208, 2.79, 0.223, 332, 238, CRYSTAL STRUCTURE OF FUS3 PHOSPHORYLATED ON TYR182
3295, d2bdfA_, 0.7208, 2.99, 0.205, 261, 244, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
3296, d5em5A_, 0.7207, 3.55, 0.183, 298, 251, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 2: 4-[2-(4- CHLOROPHENYL)ETHYLAMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
3297, d1ua2B_, 0.7207, 3.10, 0.160, 286, 244, CRYSTAL STRUCTURE OF HUMAN CDK7
3298, p5lw1H_, 0.7206, 2.99, 0.217, 355, 240, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
3299, d4u42B_, 0.7206, 3.11, 0.193, 265, 244, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
3300, d2w1dA1, 0.7206, 2.68, 0.203, 251, 237, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3301, d2jkmA_, 0.7206, 3.10, 0.210, 260, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
3302, d1t45A_, 0.7206, 3.43, 0.208, 331, 250, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C- KIT TYROSINE KINASE
3303, d5uglB_, 0.7205, 3.13, 0.179, 271, 246, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
3304, d4u43B_, 0.7205, 3.45, 0.188, 302, 255, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
3305, d4c3rA_, 0.7205, 2.69, 0.197, 252, 238, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP
3306, p3hdmA_, 0.7205, 3.48, 0.206, 285, 247, CRYSTAL STRUCTURE OF SERUM AND GLUCOCORTICOID-REGULATED KINASE 1 IN COMPLEX WITH COMPOUND 1
3307, d4mnfB_, 0.7204, 2.77, 0.222, 257, 239, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
3308, d3oz6B_, 0.7204, 3.04, 0.222, 341, 243, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
3309, d2qocA_, 0.7204, 3.04, 0.163, 283, 246, HUMAN EPHA3 KINASE DOMAIN PHOSPHORYLATED AMP-PNP BOUND STRUCTURE
3310, p4looA_, 0.7203, 3.01, 0.203, 349, 241, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (MONOCLINIC CRYSTAL FORM)
3311, d4gk4A_, 0.7203, 3.05, 0.167, 275, 245, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 90
3312, d2wd1A_, 0.7203, 3.20, 0.183, 289, 246, HUMAN C-MET KINASE IN COMPLEX WITH AZAINDOLE INHIBITOR
3313, d2bdjA_, 0.7203, 2.88, 0.216, 254, 241, SRC KINASE IN COMPLEX WITH INHIBITOR AP23464
3314, d5i9uA_, 0.7202, 3.30, 0.165, 281, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
3315, d4yjvA_, 0.7202, 3.09, 0.180, 263, 245, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000250
3316, d4gk3A_, 0.7202, 2.95, 0.165, 275, 243, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 87
3317, d3f66B_, 0.7202, 3.28, 0.183, 269, 246, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
3318, d3d5vA_, 0.7202, 2.71, 0.220, 260, 236, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN.
3319, d4ztsA_, 0.7201, 2.61, 0.199, 249, 236, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1142
3320, d4qp4B_, 0.7201, 2.94, 0.224, 335, 241, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
3321, d4ansA_, 0.7201, 3.68, 0.178, 293, 253, STRUCTURE OF L1196MG1269A DOUBLE MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
3322, d4anqA_, 0.7201, 3.68, 0.174, 293, 253, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
3323, d3zosA_, 0.7201, 3.21, 0.210, 301, 243, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
3324, d3qlgB_, 0.7201, 3.03, 0.218, 260, 243, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
3325, d2fb8B_, 0.7201, 2.93, 0.227, 259, 242, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
3326, d2fa2B_, 0.7201, 3.06, 0.218, 332, 243, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
3327, d5xy1A1, 0.7200, 2.85, 0.196, 252, 240, CRYSTAL STRUCTURE OF LYN KINASE DOMAIN IN COMPLEX WITH N-(1H-INDAZOL- 6-YL)-8-(PIPERIDIN-4-YLOXY)-6-PROPYLQUINAZOLIN-2-AMINE
3328, d5xgnB_, 0.7200, 3.93, 0.142, 308, 261, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
3329, d5hezC_, 0.7200, 3.54, 0.219, 289, 251, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
3330, d5dg5A_, 0.7200, 3.06, 0.177, 297, 243, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
3331, d5a4cA_, 0.7200, 3.20, 0.208, 294, 245, FGFR1 LIGAND COMPLEX
3332, d4rwlA_, 0.7200, 3.18, 0.204, 282, 245, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
3333, d3uo6B_, 0.7200, 2.71, 0.203, 264, 236, AURORA A IN COMPLEX WITH YL5-083
3334, d3u6iA_, 0.7200, 3.08, 0.164, 281, 244, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 58A
3335, p5lw1E_, 0.7199, 2.99, 0.217, 355, 240, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
3336, p5ax3A_, 0.7199, 2.96, 0.221, 329, 240, CRYSTAL STRUCTURE OF ERK2 COMPLEXED WITH ALLOSTERIC AND ATP- COMPETITIVE INHIBITORS.
3337, d4prjA_, 0.7199, 2.68, 0.198, 251, 237, AURORA A KINASE DOMAIN WITH COMPOUND 2 (N-[1-(3-CYANOBENZYL)-1H- PYRAZOL-4-YL]-6-(1H-PYRAZOL-4-YL)-1H-INDAZOLE-3-CARBOXAMIDE)
3338, d4kiqA_, 0.7199, 2.75, 0.212, 338, 236, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
3339, d3uo6A_, 0.7199, 2.71, 0.203, 264, 236, AURORA A IN COMPLEX WITH YL5-083
3340, d3slsA1, 0.7199, 3.50, 0.188, 289, 255, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
3341, d3el8B_, 0.7199, 2.97, 0.219, 259, 242, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
3342, d2yjrA_, 0.7199, 3.32, 0.178, 278, 247, STRUCTURE OF F1174L MUTANT ANAPLASTIC LYMPHOMA KINASE
3343, p5lw1B_, 0.7198, 2.99, 0.217, 355, 240, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
3344, d4yhtA_, 0.7198, 2.89, 0.228, 256, 241, BRAF COMPLEXED WITH AN INHIBITOR
3345, d4f0iB_, 0.7198, 3.17, 0.209, 294, 244, CRYSTAL STRUCTURE OF APO TRKA
3346, d3h3cA_, 0.7198, 3.07, 0.169, 263, 243, CRYSTAL STRUCTURE OF PYK2 IN COMPLEX WITH SULFOXIMINE- SUBSTITUTED TRIFLUOROMETHYLPYRIMIDINE ANALOG
3347, d2fumC_, 0.7198, 2.39, 0.212, 254, 231, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
3348, d5nkgA_, 0.7197, 3.33, 0.165, 292, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3D
3349, d4usdB_, 0.7196, 3.17, 0.190, 267, 247, HUMAN STK10 (LOK) WITH SB-633825
3350, d4mnfA_, 0.7196, 2.87, 0.225, 257, 240, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
3351, d3uohB_, 0.7196, 2.84, 0.202, 264, 238, AURORA A IN COMPLEX WITH RPM1722
3352, d3uohA_, 0.7196, 2.84, 0.202, 264, 238, AURORA A IN COMPLEX WITH RPM1722
3353, d3lvpB_, 0.7196, 3.50, 0.178, 295, 253, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
3354, d5nkfA_, 0.7195, 3.34, 0.165, 291, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3B
3355, d4mneE_, 0.7195, 3.57, 0.184, 286, 256, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3356, d3gqlB_, 0.7195, 3.12, 0.216, 276, 245, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
3357, d2i1mA_, 0.7195, 3.38, 0.209, 311, 249, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
3358, p5nzzH_, 0.7194, 2.88, 0.180, 335, 239, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
3359, d3uojB_, 0.7194, 2.82, 0.202, 263, 238, AURORA A IN COMPLEX WITH RPM1715
3360, d1ua2D_, 0.7194, 3.11, 0.160, 286, 244, CRYSTAL STRUCTURE OF HUMAN CDK7
3361, d3uojA_, 0.7193, 2.82, 0.202, 263, 238, AURORA A IN COMPLEX WITH RPM1715
3362, d3ikaB_, 0.7193, 3.90, 0.142, 310, 261, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
3363, d3ce3A_, 0.7193, 3.42, 0.169, 293, 249, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOPYRIDINEPYRIDONE BASED INHIBITOR
3364, d2wmqA_, 0.7193, 2.82, 0.215, 246, 237, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3365, d1x8bA_, 0.7193, 2.94, 0.175, 259, 240, STRUCTURE OF HUMAN WEE1A KINASE: KINASE DOMAIN COMPLEXED WITH INHIBITOR PD0407824
3366, d4xg8C_, 0.7192, 3.02, 0.206, 254, 243, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3367, d3ormA_, 0.7192, 2.91, 0.209, 266, 239, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN D76A MUTANT
3368, d5eydA_, 0.7191, 3.29, 0.170, 289, 247, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH AMG 337
3369, d4v04B_, 0.7191, 3.29, 0.199, 287, 246, FGFR1 IN COMPLEX WITH PONATINIB.
3370, d4izaC_, 0.7191, 2.84, 0.234, 335, 239, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
3371, d5vdkA_, 0.7190, 3.13, 0.173, 260, 243, CRYSTAL STRUCTURE OF HUMAN WEE2 KINASE DOMAIN IN COMPLEX WITH MK1775
3372, d4o2pA_, 0.7190, 3.21, 0.196, 265, 245, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
3373, d3el8A_, 0.7190, 3.09, 0.217, 263, 244, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
3374, d5kmoA1, 0.7189, 3.32, 0.207, 290, 246, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(2- PYRIDYL)UREA
3375, d4yjrA_, 0.7189, 3.10, 0.171, 263, 245, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000225
3376, d4g5pB_, 0.7189, 3.74, 0.136, 303, 257, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
3377, d2ijmB_, 0.7189, 3.06, 0.213, 261, 244, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
3378, d4yjsA_, 0.7188, 3.29, 0.189, 257, 249, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000226
3379, d4xyfA_, 0.7188, 3.27, 0.174, 290, 247, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (S)-5-(8-FLUORO-3-(1-(3-(2- METHOXYETHOXY)QUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43-A]PYRIDIN-6- YL)-3-METHYLISOXAZOLE
3380, d4mneF_, 0.7188, 2.91, 0.207, 258, 241, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3381, d4fnwA_, 0.7188, 3.66, 0.171, 304, 252, CRYSTAL STRUCTURE OF THE APO F1174L ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
3382, d3unzB_, 0.7188, 2.84, 0.206, 263, 238, AURORA A IN COMPLEX WITH RPM1679
3383, d3unzA_, 0.7188, 2.84, 0.206, 263, 238, AURORA A IN COMPLEX WITH RPM1679
3384, d5jfsA_, 0.7187, 2.91, 0.212, 277, 240, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-00593174
3385, d5b7vA_, 0.7187, 3.14, 0.205, 282, 244, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
3386, d2xvdA_, 0.7187, 3.36, 0.149, 270, 249, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3387, d2vx0A_, 0.7187, 3.28, 0.153, 273, 249, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3388, d4wa9B1, 0.7186, 3.47, 0.196, 263, 250, THE CRYSTAL STRUCTURE OF HUMAN ABL1 WILD TYPE KINASE DOMAIN IN COMPLEX WITH AXITINIB
3389, d3uolB_, 0.7186, 2.83, 0.202, 263, 238, AURORA A IN COMPLEX WITH SO2-162
3390, d3uolA_, 0.7186, 2.83, 0.202, 263, 238, AURORA A IN COMPLEX WITH SO2-162
3391, d3pxkB_, 0.7186, 2.98, 0.211, 258, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
3392, d3kfaB1, 0.7186, 3.57, 0.211, 283, 251, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
3393, d3kfaA1, 0.7186, 3.57, 0.211, 283, 251, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
3394, d2z2wA_, 0.7186, 3.09, 0.178, 260, 242, HUMAND WEE1 KINASE COMPLEXED WITH INHIBITOR PF0335770
3395, d2jboA_, 0.7186, 3.55, 0.169, 295, 248, PROTEIN KINASE MK2 IN COMPLEX WITH AN INHIBITOR (CRYSTAL FORM-1 SOAKING)
3396, d3wj6A_, 0.7185, 3.24, 0.204, 282, 245,  
3397, d3rhxB_, 0.7185, 3.19, 0.217, 275, 244, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
3398, d4ctbA_, 0.7184, 3.63, 0.175, 292, 251, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (5R)-8-AMINO-3-FLUORO-519-DIMETHYL-20-OXO-5181920- TETRAHYDRO-711-(AZENO)PYRIDO(2 1 :23)IMIDAZO(45-H)(2511) BENZOXADIAZACYCLOTETRADECINE-14-CARBONITRILE
3399, d5ia2A_, 0.7183, 3.33, 0.165, 287, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 66
3400, d5eobA_, 0.7183, 3.23, 0.183, 288, 246, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
3401, d3ik3A1, 0.7183, 3.50, 0.208, 279, 250, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
3402, d1zz2A_, 0.7183, 2.79, 0.212, 337, 236, TWO CLASSES OF P38ALPHA MAP KINASE INHIBITORS HAVING A COMMON DIPHENYLETHER CORE BUT EXHIBITING DIVERGENT BINDING MODES
3403, d4fv4A_, 0.7181, 2.64, 0.227, 329, 233, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK7
3404, d2oiqA_, 0.7181, 3.16, 0.205, 265, 244, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
3405, d5nk6A_, 0.7180, 3.37, 0.166, 284, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2D
3406, d5kbrA_, 0.7180, 2.92, 0.213, 259, 239, PAK1 IN COMPLEX WITH 7-AZAINDOLE INHIBITOR
3407, d4qqtA_, 0.7180, 3.10, 0.193, 283, 243, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 TYROSINE KINASE DOMAIN
3408, d4kipA_, 0.7180, 2.81, 0.212, 337, 236, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
3409, d3kc3F_, 0.7180, 3.33, 0.176, 293, 245, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
3410, d2vwyA_, 0.7180, 3.30, 0.149, 274, 249, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3411, d5eycA_, 0.7179, 3.25, 0.175, 288, 246, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH NAPHTHYRIDINONE INHIBITOR 5
3412, d3mvlA_, 0.7179, 2.83, 0.211, 339, 237, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
3413, d5kmjA_, 0.7178, 3.25, 0.204, 300, 245, TRKA JM-KINASE WITH {N}-(2-PYRIDYLMETHYL)-2-[2-(2-THIENYL)INDOL-1- YL]ACETAMIDE
3414, d3ugcA_, 0.7178, 3.25, 0.204, 274, 245, STRUCTURAL BASIS OF JAK2 INHIBITION BY THE TYPE II INHIBTOR NVP-BBT594
3415, d3cc6A_, 0.7178, 3.34, 0.178, 269, 247, CRYSTAL STRUCTURE OF KINASE DOMAIN OF PROTEIN TYROSINE KINASE 2 BETA (PTK2B)
3416, d2in6A_, 0.7178, 2.96, 0.175, 256, 240, WEE1 KINASE COMPLEX WITH INHIBITOR PD311839
3417, d5kmnA1, 0.7177, 3.32, 0.207, 290, 246, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
3418, d5hzeA_, 0.7177, 3.48, 0.190, 305, 253, MEK1 ADOPTS DFG-OUT CONFORMATION WHEN BOUND TO AN ANALOG OF E6201.
3419, d4zseB_, 0.7177, 3.36, 0.172, 313, 250, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
3420, d4yneA1, 0.7177, 3.10, 0.209, 276, 244, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
3421, d3aoxA_, 0.7177, 3.58, 0.164, 298, 250, X-RAY CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CH5424802
3422, d1v0bA_, 0.7177, 3.04, 0.205, 286, 239, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
3423, d5v5yA_, 0.7176, 3.07, 0.178, 259, 242, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH MK1775
3424, d4fv9A_, 0.7176, 2.71, 0.231, 331, 234, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E71
3425, d2yfxA_, 0.7175, 3.56, 0.179, 292, 251, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
3426, d2vx1A_, 0.7175, 3.31, 0.149, 274, 249, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3427, d5a9uA_, 0.7174, 3.69, 0.171, 292, 252, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
3428, d4mneA_, 0.7174, 3.64, 0.183, 286, 257, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3429, d4aa4A_, 0.7174, 3.15, 0.203, 347, 241, P38ALPHA MAP KINASE BOUND TO CMPD 22
3430, d3uokB_, 0.7174, 2.86, 0.202, 265, 238, AURORA A IN COMPLEX WITH YL5-81-1
3431, d3uokA_, 0.7174, 2.86, 0.202, 265, 238, AURORA A IN COMPLEX WITH YL5-81-1
3432, d3ik3B1, 0.7174, 3.60, 0.211, 285, 251, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
3433, d5oy6B_, 0.7173, 3.42, 0.184, 292, 250, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
3434, d5jfxA_, 0.7173, 2.91, 0.212, 277, 240, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-06273340
3435, d4obpB_, 0.7173, 3.37, 0.187, 290, 251, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
3436, d3is5F1, 0.7173, 3.30, 0.233, 259, 245, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
3437, d2xp2A_, 0.7173, 3.55, 0.177, 285, 249, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB (PF-02341066)
3438, p4xh0A2, 0.7172, 0.89, 0.681, 273, 210, STRUCTURE OF C. GLABRATA HRR25 BOUND TO ADP (SO4 CONDITION)
3439, d4eqmF_, 0.7172, 3.04, 0.228, 268, 241, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
3440, d6eimA_, 0.7171, 3.31, 0.180, 286, 244, HUMAN STK10 BOUND TO GW683134A
3441, d5jfwA_, 0.7171, 2.93, 0.212, 277, 240, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05247452
3442, d2zv8A1, 0.7171, 2.97, 0.199, 256, 241, LYN TYROSINE KINASE DOMAIN-AMP-PNP COMPLEX
3443, d2vwzA_, 0.7171, 3.31, 0.149, 274, 249, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3444, d3u6hA_, 0.7170, 3.07, 0.165, 280, 243, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 26
3445, d2auhA1, 0.7170, 3.38, 0.200, 294, 250, CRYSTAL STRUCTURE OF THE GRB14 BPS REGION IN COMPLEX WITH THE INSULIN RECEPTOR TYROSINE KINASE
3446, d5owrA_, 0.7169, 3.62, 0.181, 282, 248, HUMAN STK10 BOUND TO DASATINIB
3447, d4x7qB_, 0.7169, 2.54, 0.193, 243, 233, PIM2 KINASE IN COMPLEX WITH COMPOUND 1S
3448, d4gt5A_, 0.7169, 3.21, 0.209, 290, 244, CRYSTAL STRUCTURE OF THE INACTIVE TRKA KINASE DOMAIN
3449, d4f64B_, 0.7169, 3.16, 0.218, 272, 243, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
3450, d4eqmE_, 0.7169, 3.05, 0.228, 268, 241, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
3451, d2fgiB_, 0.7169, 3.18, 0.218, 272, 243, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
3452, d1ua2A_, 0.7169, 3.24, 0.154, 286, 247, CRYSTAL STRUCTURE OF HUMAN CDK7
3453, p5oatF_, 0.7168, 3.98, 0.146, 359, 260, PINK1 STRUCTURE
3454, d5aacA_, 0.7168, 3.69, 0.171, 292, 252, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
3455, d4rwkB_, 0.7168, 3.20, 0.220, 282, 245, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
3456, d4fv5A_, 0.7168, 2.72, 0.235, 330, 234, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK9
3457, d3u6jA1, 0.7168, 3.54, 0.203, 305, 251, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
3458, d3oy3B1, 0.7168, 3.58, 0.211, 283, 251, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
3459, d2r4bA_, 0.7168, 3.52, 0.155, 292, 252, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
3460, d1opjB1, 0.7168, 3.51, 0.217, 284, 249, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
3461, d5cenA_, 0.7167, 3.14, 0.184, 281, 244, CRYSTAL STRUCTURE OF DLK (KINASE DOMAIN)
3462, d5bvdA_, 0.7167, 2.66, 0.232, 330, 233, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
3463, d5aa8A_, 0.7167, 3.62, 0.171, 292, 251, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12- FLUORO-21016-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H- 84-(METHENO)PYRAZOLO(43-H)(2511) BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
3464, d4r1vA_, 0.7167, 3.24, 0.183, 289, 246, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITORS
3465, d4nksB_, 0.7167, 3.16, 0.214, 271, 243, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
3466, d4eqmD_, 0.7167, 3.07, 0.224, 268, 241, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
3467, d5jfvA_, 0.7166, 2.93, 0.212, 277, 240, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05206283
3468, d5ci6B_, 0.7166, 2.90, 0.205, 350, 239, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
3469, d4zloA_, 0.7166, 3.41, 0.219, 277, 247, SERINE/THREONINE-PROTEIN KINASE PAK1 COMPLEXED WITH A DIBENZODIAZEPINE: IDENTIFICATION OF AN ALLOSTERIC SITE ON PAK1
3470, d5vc4A_, 0.7165, 3.25, 0.167, 261, 245, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB-ISOMER
3471, d4kabB_, 0.7165, 3.07, 0.210, 258, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
3472, d3oy3A1, 0.7165, 3.60, 0.211, 283, 251, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
3473, d3i5zA_, 0.7165, 2.71, 0.235, 331, 234, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-N-(2-HYDROXY-1-PHENYLETHYL)-4- (5-METHYL-2-(PHENYLAMINO)PYRIMIDIN-4-YL)-1H-PYRROLE-2-CARBOXAMIDE
3474, d3h9rA_, 0.7165, 3.24, 0.184, 312, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TYPE I ACTIVIN RECEPTOR (ACVR1) IN COMPLEX WITH FKBP12 AND DORSOMORPHIN
3475, d3f82A_, 0.7165, 3.13, 0.178, 278, 242, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH N- (4-(2-AMINO-3-CHLOROPYRIDIN-4-YLOXY)-3-FLUOROPHENYL)-4- ETHOXY-1-(4-FLUOROPHENYL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
3476, d2zv9A1, 0.7165, 2.96, 0.199, 255, 241, LYN TYROSINE KINASE DOMAIN-PP2 COMPLEX
3477, d1pkgB_, 0.7165, 3.10, 0.210, 277, 243, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
3478, d5nk9A_, 0.7164, 3.40, 0.166, 285, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2E
3479, d4g2fA_, 0.7164, 3.03, 0.169, 275, 243, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 7
3480, d4aaaA1, 0.7164, 3.42, 0.189, 290, 244, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN
3481, d3q6uA1, 0.7164, 3.04, 0.178, 281, 242, STRUCTURE OF THE APO MET RECEPTOR KINASE IN THE DUALLY-PHOSPHORYLATED ACTIVATED STATE
3482, d3eknA_, 0.7164, 3.35, 0.202, 297, 248, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
3483, d2vwxA_, 0.7164, 3.30, 0.153, 274, 249, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3484, d1v0pA_, 0.7164, 2.93, 0.218, 277, 238, STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX
3485, d4fnyA_, 0.7163, 3.36, 0.163, 273, 245, CRYSTAL STRUCTURE OF THE R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
3486, d4cmtA_, 0.7163, 3.57, 0.173, 284, 249, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(3-(METHYLSULFONYL)PHENYL)PYRIDIN-2-AMINE
3487, d4bb4A_, 0.7163, 3.17, 0.150, 265, 246, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3488, d3vntA_, 0.7163, 3.36, 0.206, 301, 247, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
3489, d3f3tB_, 0.7163, 2.97, 0.207, 259, 241, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL38 (TYPE III)
3490, d3cqeA_, 0.7163, 3.11, 0.178, 258, 242, WEE1 KINASE COMPLEX WITH INHIBITOR PD074291
3491, d2qr7A_, 0.7163, 3.43, 0.193, 292, 249, 2.0A X-RAY STRUCTURE OF C-TERMINAL KINASE DOMAIN OF P90 RIBOSOMAL S6 KINASE 2: SE-MET DERIVATIVE
3492, d1agwB_, 0.7163, 3.18, 0.218, 272, 243, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
3493, d4zsaB_, 0.7162, 3.18, 0.213, 282, 244, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
3494, d1fgkB_, 0.7162, 3.18, 0.218, 272, 243, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
3495, d5nkbA_, 0.7161, 3.40, 0.166, 285, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4A
3496, d4anlA_, 0.7161, 3.56, 0.175, 292, 251, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE
3497, d2hz0A_, 0.7161, 3.19, 0.208, 265, 245, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AEG082
3498, d4aojA_, 0.7160, 2.87, 0.204, 260, 240, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
3499, d3svvA_, 0.7160, 2.99, 0.199, 261, 241, CRYSTAL STRUCTURE OF T338C C-SRC COVALENTLY BOUND TO VINYLSULFONAMIDE- PYRAZOLOPYRIMIDINE 9
3500, d3kc3E_, 0.7160, 3.30, 0.172, 287, 244, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
3501, d3hl7A_, 0.7160, 2.82, 0.212, 336, 236, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH SD-0006
3502, d3fzpA_, 0.7160, 3.08, 0.169, 259, 242, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH ATPGS
3503, d5ihcA_, 0.7159, 2.59, 0.221, 305, 231, MELK IN COMPLEX WITH NVS-MELK12B
3504, d3g5dB_, 0.7159, 2.99, 0.207, 257, 241, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
3505, d3g5dA_, 0.7159, 2.96, 0.200, 256, 240, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
3506, d2weiA1, 0.7159, 3.25, 0.199, 269, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE IN COMPLEX WITH 3- MB-PP1
3507, d2etmA_, 0.7159, 3.26, 0.207, 262, 246, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
3508, d4c7tA_, 0.7158, 3.14, 0.206, 259, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
3509, d4aotB1, 0.7158, 3.40, 0.198, 277, 248, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
3510, d5nk1A_, 0.7157, 3.31, 0.163, 284, 245, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1K
3511, p4xhgA2, 0.7157, 0.97, 0.681, 274, 210, STRUCTURE OF C. GLABRATA HRR25 BOUND TO ADP (FORMATE CONDITION)
3512, p4ux9D_, 0.7157, 3.06, 0.198, 344, 242, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
3513, d4jg7A_, 0.7156, 3.59, 0.187, 307, 251, STRUCTURE OF RSK2 CTD BOUND TO 3-(3-(1H-PYRROLO[23-B]PYRIDINE-3- CARBONYL)PHENYL)-2-CYANOACRYLAMIDE
3514, d3nwwA_, 0.7156, 2.85, 0.211, 339, 237, P38 ALPHA KINASE COMPLEXED WITH A 2-AMINOTHIAZOL-5-YL-PYRIMIDINE BASED INHIBITOR
3515, d3g51A_, 0.7156, 3.10, 0.166, 280, 241, STRUCTURAL DIVERSITY OF THE ACTIVE CONFORMATION OF THE N- TERMINAL KINASE DOMAIN OF P90 RIBOSOMAL S6 KINASE 2
3516, d3bi6A_, 0.7156, 3.03, 0.174, 258, 241, WEE1 KINASE COMPLEX WITH INHIBITOR PD352396
3517, d2r4bB_, 0.7156, 3.66, 0.158, 291, 253, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
3518, d5xgmA_, 0.7155, 3.27, 0.188, 288, 245, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH GO6976
3519, d4uynA_, 0.7155, 2.68, 0.201, 249, 234, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
3520, d4v01B_, 0.7154, 3.10, 0.195, 275, 241, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
3521, d4h1jA_, 0.7154, 3.16, 0.171, 263, 245, CRYSTAL STRUCTURE OF PYK2 WITH THE PYRAZOLE 13A
3522, d3wj6B_, 0.7154, 3.18, 0.210, 277, 243,  
3523, d3g6gB_, 0.7154, 3.06, 0.194, 263, 242, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
3524, d3fklA_, 0.7154, 2.98, 0.210, 344, 238, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO9552
3525, d2qo9A_, 0.7154, 3.04, 0.164, 277, 244, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION PHOSPHORYLATED AMP-PNP BOUND
3526, d2balA_, 0.7154, 2.78, 0.209, 337, 235, P38ALPHA MAP KINASE BOUND TO PYRAZOLOAMINE
3527, d5wr7A_, 0.7153, 3.23, 0.209, 301, 244, CRYSTAL STRUCTURE OF TRK-A COMPLEXED WITH A SELECTIVE INHIBITOR CH7057288
3528, d5vc5A_, 0.7153, 3.20, 0.172, 261, 244, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PD- 166285
3529, d5oy6C_, 0.7153, 3.46, 0.184, 291, 250, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
3530, d5kmlA1, 0.7153, 3.27, 0.208, 290, 245, TRKA JM-KINASE WITH 1-(5-METHYL-3-PHENYL-12-OXAZOL-4-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
3531, d3dkcA1, 0.7153, 3.65, 0.146, 310, 254, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH ATP
3532, d5vc6A_, 0.7152, 3.21, 0.173, 259, 243, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PHA- 848125
3533, d4dfyA_, 0.7152, 3.31, 0.204, 310, 245, CRYSTAL STRUCTURE OF R194A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED ACTIVATION LOOP
3534, d2yhvA_, 0.7152, 3.62, 0.175, 291, 251, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE
3535, d5nk7A_, 0.7151, 3.32, 0.163, 284, 245, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2A
3536, d5nk3A_, 0.7151, 3.41, 0.169, 281, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1L
3537, d2a19B1, 0.7151, 3.04, 0.224, 261, 241, PKR KINASE DOMAIN- EIF2ALPHA- AMP-PNP COMPLEX.
3538, d5kmiA_, 0.7150, 3.29, 0.204, 300, 245, TRKA JM-KINASE WITH 1-(9{H}-FLUOREN-9-YL)-3-(2-METHYL-4-PHENYL- PYRIMIDIN-5-YL)UREA
3539, d5b7vB_, 0.7150, 3.20, 0.210, 277, 243, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
3540, d4aojC_, 0.7150, 2.93, 0.207, 261, 241, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
3541, d3w2rA_, 0.7150, 3.28, 0.179, 297, 246, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 4
3542, d3fmeA1, 0.7150, 3.48, 0.174, 267, 247, CRYSTAL STRUCTURE OF HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (MEK6) ACTIVATED MUTANT (S207D T211D)
3543, d3e7oA_, 0.7150, 3.30, 0.221, 342, 244, CRYSTAL STRUCTURE OF JNK2
3544, d1fgkA_, 0.7150, 3.09, 0.207, 278, 242, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
3545, d5dbxB_, 0.7149, 3.72, 0.198, 282, 253, CRYSTAL STRUCTURE OF MURINE SPAK(T243D) IN COMPLEX WITH AMPPNP
3546, d4f0iA_, 0.7149, 3.26, 0.204, 284, 245, CRYSTAL STRUCTURE OF APO TRKA
3547, d3g6gA_, 0.7149, 3.10, 0.207, 264, 242, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
3548, d3fmhA_, 0.7149, 3.05, 0.210, 347, 238, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((R)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
3549, d5kmkA1, 0.7148, 3.29, 0.208, 302, 245, TRKA JM-KINASE WITH 2-FLUORO-{N}-[2-(4-FLUOROPHENYL)-6-METHYL-3- PYRIDYL]-4-(TRIFLUOROMETHYL)BENZAMIDE
3550, d4ctcA_, 0.7148, 3.47, 0.173, 288, 248, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 7-AMINO-3-CYCLOPROPYL-12-FLUORO- 11016-TRIMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(4 3-H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
3551, d3oriD_, 0.7148, 2.92, 0.209, 267, 239, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
3552, d2jkqA_, 0.7148, 3.06, 0.211, 258, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
3553, d4f63B_, 0.7147, 3.14, 0.215, 271, 242, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
3554, d4asdA_, 0.7147, 3.38, 0.206, 305, 247, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SORAFENIB (BAY 43-9006)
3555, d3uqgB_, 0.7147, 2.91, 0.205, 257, 239, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
3556, d2c6dA_, 0.7147, 2.93, 0.202, 254, 238, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH ADPNP
3557, d5i9xA_, 0.7146, 3.35, 0.167, 284, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH BOSUTINIB (SKI-606)
3558, d5nk2A_, 0.7145, 3.36, 0.167, 290, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2B
3559, d5i9zA_, 0.7145, 3.22, 0.164, 273, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DANUSERTIB (PHA739358)
3560, d4mxxB_, 0.7145, 3.07, 0.203, 260, 241, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
3561, d4f64A_, 0.7145, 3.18, 0.206, 278, 243, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
3562, d3oriC_, 0.7145, 2.87, 0.218, 267, 238, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
3563, d2ijmA_, 0.7145, 3.17, 0.209, 260, 244, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
3564, d1agwA_, 0.7145, 3.22, 0.205, 278, 244, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
3565, d5ur1A_, 0.7144, 3.17, 0.206, 278, 243, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
3566, d4dehA_, 0.7144, 3.29, 0.171, 286, 245, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 3
3567, d2wmsA_, 0.7144, 2.82, 0.209, 243, 235, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3568, d5oy6A_, 0.7143, 3.46, 0.184, 291, 250, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
3569, d4aseA_, 0.7143, 3.46, 0.206, 305, 248, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH TIVOZANIB (AV-951)
3570, d3w2sA_, 0.7143, 3.59, 0.185, 307, 254, EGFR KINASE DOMAIN WITH COMPOUND4
3571, d3rocA_, 0.7143, 2.81, 0.209, 337, 235, CRYSTAL STRUCTURE OF HUMAN P38 ALPHA COMPLEXED WITH A PYRIMIDINONE COMPOUND
3572, d3flyA_, 0.7143, 3.06, 0.202, 347, 238, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-ISOPROPYLAMINO-8-METHYL-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
3573, d4gg7A_, 0.7142, 3.34, 0.183, 278, 246, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
3574, d4y95A1, 0.7141, 3.11, 0.159, 265, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
3575, d4f63A_, 0.7141, 3.11, 0.207, 278, 242, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
3576, d3kc3B_, 0.7141, 3.31, 0.177, 290, 243, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
3577, d4y95D_, 0.7140, 3.11, 0.159, 265, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
3578, d4otrA_, 0.7140, 3.09, 0.160, 263, 244, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6-CYCLOPROPYL-2- [3-[5-[[5-(4-ETHYLPIPERAZIN-1-YL)-2-PYRIDYL]AMINO]-1-METHYL-6-OXO-3- PYRIDYL]-2-(HYDROXYMETHYL)PHENYL]-8-FLUORO-ISOQUINOLIN-1-ONE
3579, d4f65A_, 0.7140, 3.18, 0.198, 279, 243, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
3580, d3g0fB_, 0.7140, 3.36, 0.207, 293, 246, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
3581, d4y95C1, 0.7139, 3.11, 0.159, 265, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
3582, d3kc3A_, 0.7139, 3.28, 0.173, 288, 243, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
3583, d2iwiA_, 0.7139, 2.58, 0.203, 244, 232, CRYSTAL STRUCTURE OF THE HUMAN PIM2 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
3584, d2fgiA_, 0.7139, 3.11, 0.207, 274, 242, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
3585, d5nk4A_, 0.7138, 3.34, 0.167, 290, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2C
3586, d4p90B_, 0.7138, 3.15, 0.227, 262, 238, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN PAK1 IN COMPLEX WITH COMPOUND 15
3587, d3kc3I_, 0.7138, 3.34, 0.172, 295, 244, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
3588, d3f66A_, 0.7138, 3.41, 0.186, 288, 247, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
3589, d3c1xA_, 0.7138, 3.32, 0.168, 290, 244, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOTRIAZINE BASED INHIBITOR
3590, d1ob3A_, 0.7138, 3.10, 0.212, 277, 240, STRUCTURE OF P. FALCIPARUM PFPK5
3591, d5ia0B_, 0.7137, 3.03, 0.169, 266, 243, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
3592, d4rfyA_, 0.7137, 3.19, 0.159, 263, 246, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(MORPHOLINE-4- CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-34- DIHYDROISOQUINOLIN-1-ONE
3593, d4f65B_, 0.7137, 3.24, 0.204, 279, 245, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
3594, d4ag8A_, 0.7137, 3.39, 0.206, 296, 247, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-(3-((E)-2-PYRIDIN-2-YL-VINYL)-1H- INDAZOL-6- YLSULFANYL)-BENZAMIDE)
3595, d3a60A_, 0.7137, 3.14, 0.193, 263, 238, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED P70S6K1 (FORM I)
3596, d2qu5A_, 0.7137, 3.27, 0.215, 292, 246, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR
3597, d1fgiB_, 0.7137, 3.19, 0.218, 272, 243, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
3598, d4y95B1, 0.7136, 3.11, 0.159, 265, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
3599, d4otqA_, 0.7136, 3.09, 0.160, 263, 244, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 1-[5-[3-(7-TERT- BUTYL-4-OXO-QUINAZOLIN-3-YL)-2-METHYL-PHENYL]-1-METHYL-2-OXO-3- PYRIDYL]-3-METHYL-UREA
3600, d4dceA_, 0.7136, 3.40, 0.166, 288, 247, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
3601, d3h10A_, 0.7136, 3.09, 0.202, 268, 242, AURORA A INHIBITOR COMPLEX
3602, d3efkA_, 0.7136, 3.17, 0.173, 276, 243, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
3603, d2helA_, 0.7136, 3.07, 0.156, 256, 244, CRYSTAL STRUCTURE OF A MUTANT EPHA4 KINASE DOMAIN (Y742A)
3604, d5kmmA1, 0.7135, 3.33, 0.204, 300, 245, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(1- NAPHTHYL)UREA
3605, d5gtyH_, 0.7135, 3.62, 0.155, 300, 252, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
3606, d4rg0A_, 0.7135, 3.13, 0.156, 263, 244, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[8-FLUORO-2- [2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(4-METHYLPIPERAZIN-1-YL)-2- PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-1-OXO-34-DIHYDROISOQUINOLIN- 6-YL]-2-METHYL-PROPANENITRILE
3607, d4gu9B_, 0.7135, 3.07, 0.211, 255, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
3608, d4agcA_, 0.7135, 3.40, 0.206, 304, 247, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-( 3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDAZOL-6-YLSULFANYL)- BENZAMIDE)
3609, d3k5vB1, 0.7135, 3.50, 0.230, 279, 248, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
3610, d3dkfA1, 0.7135, 3.44, 0.183, 293, 246, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
3611, d4gu6B_, 0.7134, 3.11, 0.206, 258, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
3612, d4d4vA_, 0.7134, 2.97, 0.207, 256, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN
3613, d4bkjB1, 0.7134, 3.32, 0.201, 296, 244, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
3614, d3vw8A_, 0.7134, 3.28, 0.181, 303, 243, CRYSTAL STRUCTURE OF HUMAN C-MET KINASE DOMAIN WITH ITS INHIBITOR
3615, d3uqfA_, 0.7134, 3.04, 0.212, 260, 241, C-SRC KINASE DOMAIN IN COMPLEX WITH BKI RM-1-89
3616, d3flzA_, 0.7134, 3.06, 0.202, 347, 238, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 8-METHYL-6-PHENOXY-2- (TETRAHYDRO-PYRAN-4-YLAMINO)-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
3617, d3b2wA_, 0.7134, 3.32, 0.203, 261, 246, CRYSTAL STRUCTURE OF PYRIMIDINE AMIDE 11 BOUND TO LCK
3618, d5hezA_, 0.7133, 3.83, 0.188, 287, 255, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
3619, d4zseC_, 0.7133, 3.50, 0.168, 301, 250, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
3620, d4rfzA_, 0.7133, 3.09, 0.160, 263, 244, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-8-FLUORO-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5- (MORPHOLINE-4-CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3- PYRIDYL]PHENYL]ISOQUINOLIN-1-ONE
3621, d3lvpA_, 0.7133, 3.44, 0.180, 289, 250, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
3622, d1oukA_, 0.7133, 3.20, 0.204, 348, 240, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR
3623, d5p9fA_, 0.7132, 3.13, 0.159, 266, 245, BTK IN COMPLEX WITH GDC-0834
3624, d5eakB_, 0.7132, 2.91, 0.237, 300, 236, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
3625, d3d94A_, 0.7132, 3.15, 0.198, 288, 242, CRYSTAL STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE IN COMPLEX WITH PQIP
3626, d1uwjA_, 0.7132, 3.20, 0.213, 264, 244, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
3627, d5vamB_, 0.7131, 3.12, 0.212, 260, 241, BRAF IN COMPLEX WITH RAF709
3628, d4ymjB1, 0.7131, 3.19, 0.214, 272, 243, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
3629, d4kinD_, 0.7131, 2.84, 0.200, 339, 235, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
3630, d3zewB_, 0.7131, 2.84, 0.152, 252, 237, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
3631, d3h0yA_, 0.7131, 2.72, 0.195, 250, 236, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
3632, d3cr0A_, 0.7131, 3.05, 0.162, 257, 240, WEE1 KINASE COMPLEX WITH INHIBITOR PD259_809
3633, d5ia0C_, 0.7130, 3.09, 0.169, 269, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
3634, d3tz8B_, 0.7130, 3.14, 0.202, 263, 242, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
3635, d3gqlC_, 0.7130, 3.29, 0.215, 275, 246, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
3636, d2zv7A1, 0.7130, 3.11, 0.194, 256, 242, LYN TYROSINE KINASE DOMAIN APO FORM
3637, d2jkkA_, 0.7130, 3.04, 0.207, 258, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
3638, d5fp5A_, 0.7129, 2.79, 0.195, 264, 236, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 4-FLUOROBENZOIC ACID (AT222) IN AN ALTERNATE BINDING SITE.
3639, d3ctqA_, 0.7129, 2.83, 0.209, 336, 234, STRUCTURE OF MAP KINASE P38 IN COMPLEX WITH A 1-O-TOLYL-12 3-TRIAZOLE-4-CARBOXAMIDE
3640, d5vamA_, 0.7128, 3.38, 0.211, 269, 247, BRAF IN COMPLEX WITH RAF709
3641, d5ia3A_, 0.7128, 3.25, 0.165, 275, 243, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH PD173955
3642, d4zseA_, 0.7128, 3.52, 0.175, 297, 251, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
3643, d4xmoA_, 0.7128, 3.27, 0.176, 289, 245, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (R)-5-(8-FLUORO-3-(1- FLUORO-1-(3-METHOXYQUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43- A]PYRIDIN-6-YL)-3-METHYLISOXAZOLE
3644, d4usfB1, 0.7128, 3.37, 0.170, 283, 247, HUMAN SLK WITH SB-440719
3645, d4nkaA_, 0.7128, 3.18, 0.194, 279, 242, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
3646, d4fnzA_, 0.7128, 3.34, 0.167, 287, 246, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PIPERIDINE-CARBOXAMIDE INHIBITOR 2
3647, d5cnnB_, 0.7127, 3.59, 0.167, 304, 252, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT I682Q
3648, d4pmmA1, 0.7127, 3.21, 0.207, 281, 242, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N-(3-CYCLOPROPYL- 1-PHENYL-1H-PYRAZOL-5-YL)-2-{4-[3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1- YL)PHENYL]-1H-123-TRIAZOL-1-YL}ACETAMIDE
3649, d3zfxB_, 0.7127, 2.95, 0.146, 254, 239, CRYSTAL STRUCTURE OF EPHB1
3650, d3vo3A_, 0.7127, 3.40, 0.206, 303, 247, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH IMIDAZO[1 2-B]PYRIDAZINE DERIVATIVE
3651, d3ocgA_, 0.7127, 2.78, 0.209, 336, 234, P38 ALPHA KINASE COMPLEXED WITH A 5-AMINO-PYRAZOLE BASED INHIBITOR
3652, d5iugA_, 0.7126, 3.59, 0.173, 285, 248, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5A
3653, d5d1jA_, 0.7126, 2.89, 0.177, 265, 237, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH N-[5-[[[5-(11-DIMETHYLETHYL)-2-OXAZOLYL] METHYL]THIO]-2-THIAZOLYL]- 4-PIPERIDINECARBOXAMIDE (BMS-387032)
3654, d5angA_, 0.7126, 2.90, 0.189, 268, 238, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 7-HYDROXY-4-( MORPHOLINOMETHYL)CHROMEN-2-ONE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
3655, d5dbxA_, 0.7125, 3.43, 0.198, 284, 247, CRYSTAL STRUCTURE OF MURINE SPAK(T243D) IN COMPLEX WITH AMPPNP
3656, d4v04A_, 0.7125, 3.19, 0.194, 290, 242, FGFR1 IN COMPLEX WITH PONATINIB.
3657, d4pmsA1, 0.7125, 3.06, 0.212, 279, 241, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 4-NAPHTHALEN-1-YL- 1-[(5-PHENYL-124-OXADIAZOL-3-YL)METHYL]-1H-PYRROLO[32-C]PYRIDINE- 2-CARBOXYLIC ACID
3658, d4dceB_, 0.7125, 3.39, 0.163, 284, 245, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
3659, d4d58B_, 0.7125, 3.11, 0.207, 261, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
3660, d3lauA1, 0.7125, 2.69, 0.197, 250, 233, CRYSTAL STRUCTURE OF AURORA2 KINASE IN COMPLEX WITH A GSK3BETA INHIBITOR
3661, d3kc3L_, 0.7125, 3.31, 0.177, 291, 243, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
3662, d4rwiB_, 0.7124, 3.30, 0.212, 280, 245, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
3663, d3wzeA_, 0.7124, 3.30, 0.212, 298, 245, KDR IN COMPLEX WITH LIGAND SORAFENIB
3664, p4xhlA2, 0.7122, 1.04, 0.671, 255, 210, STRUCTURE OF S. CEREVISIAE HRR25 1-394 (K38R MUTANT)
3665, d4eevA_, 0.7122, 3.08, 0.178, 283, 241, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH LY2801653
3666, d3zfxF_, 0.7122, 2.81, 0.148, 254, 236, CRYSTAL STRUCTURE OF EPHB1
3667, d1di9A_, 0.7122, 3.22, 0.204, 348, 240, THE STRUCTURE OF P38 MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH 4-[3-METHYLSULFANYLANILINO]-67- DIMETHOXYQUINAZOLINE
3668, d4zseD_, 0.7121, 3.64, 0.171, 297, 252, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
3669, d4uxqA_, 0.7121, 3.20, 0.197, 286, 244, FGFR4 IN COMPLEX WITH PONATINIB
3670, d4kaoB_, 0.7121, 2.95, 0.204, 254, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-TERT- BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-(4-PYRIDIN-3- YL-PHENYL)-UREA
3671, d4eqmB_, 0.7121, 3.18, 0.202, 269, 243, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
3672, d4d4sB_, 0.7121, 3.11, 0.207, 260, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN
3673, d3hllA_, 0.7121, 2.83, 0.209, 337, 235, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH PH-797804
3674, d2wtvD_, 0.7121, 2.86, 0.207, 262, 237, AURORA-A INHIBITOR STRUCTURE
3675, d2wtvA_, 0.7121, 2.86, 0.207, 262, 237, AURORA-A INHIBITOR STRUCTURE
3676, d1blxA_, 0.7121, 3.29, 0.168, 305, 244, P19INK4D/CDK6 COMPLEX
3677, d5j87A_, 0.7120, 3.10, 0.160, 263, 244, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
3678, d5iuhA_, 0.7120, 3.54, 0.170, 285, 247, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5D
3679, d5a6nA1, 0.7120, 3.16, 0.183, 270, 240, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH COMPOUND 2
3680, d4wunA_, 0.7120, 3.15, 0.214, 282, 243, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
3681, d4bkjA1, 0.7120, 3.33, 0.201, 294, 244, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
3682, d3h10B_, 0.7120, 3.07, 0.203, 267, 241, AURORA A INHIBITOR COMPLEX
3683, d5nkcA_, 0.7119, 3.38, 0.167, 286, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2H
3684, d5i4nA1, 0.7119, 3.41, 0.170, 273, 247, CRYSTAL STRUCTURE OF THE E596A V617F MUTANT JAK2 PSEUDOKINASE DOMAIN BOUND TO MG-ATP
3685, d5bveA_, 0.7119, 2.89, 0.228, 330, 237, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
3686, d3ky2B_, 0.7119, 3.28, 0.209, 280, 244, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
3687, d3cohB_, 0.7119, 2.75, 0.201, 247, 234, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
3688, d2x7fE_, 0.7119, 2.63, 0.189, 251, 233, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
3689, d1uwhA_, 0.7119, 3.20, 0.231, 264, 242, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
3690, d4kinB_, 0.7118, 3.00, 0.210, 341, 238, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
3691, d4b0gA_, 0.7118, 2.73, 0.191, 247, 235, COMPLEX OF AURORA-A BOUND TO AN IMIDAZOPYRIDINE-BASED INHIBITOR
3692, d3h10D_, 0.7118, 2.69, 0.205, 255, 234, AURORA A INHIBITOR COMPLEX
3693, d3efkB_, 0.7118, 3.24, 0.160, 272, 243, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
3694, d1lewA_, 0.7118, 2.97, 0.203, 341, 237, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS NUCLEAR SUBSTRATE MEF2A
3695, d5hieC_, 0.7117, 3.00, 0.228, 253, 241, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
3696, d4ot6A_, 0.7117, 3.11, 0.160, 265, 244, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4- METHANESULFONYL-N-(3-{8-[4-(MORPHOLINE-4-CARBONYL)-PHENYLAMINO]- IMIDAZO[12-A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
3697, d3mptA_, 0.7117, 3.15, 0.201, 347, 239, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A PYRROLE-2- CARBOXAMIDE INHIBITOR
3698, d3k5vA1, 0.7117, 3.45, 0.223, 281, 247, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
3699, d3dt1A2, 0.7117, 3.19, 0.204, 352, 240, P38 COMPLEXED WITH A QUINAZOLINE INHIBITOR
3700, d5hesA_, 0.7116, 3.32, 0.205, 287, 244, HUMAN LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK MLT HCCS-4 MRK AZK MLTK) IN COMPLEX WITH VEMURAFENIB
3701, d5bpyA1, 0.7116, 3.07, 0.160, 262, 243, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
3702, p4e3cF1, 0.7116, 3.14, 0.194, 290, 242, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
3703, d3my0V1, 0.7116, 3.43, 0.194, 281, 247, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3704, p4lopD_, 0.7115, 3.17, 0.191, 351, 241, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
3705, d3kc3H_, 0.7115, 3.29, 0.178, 290, 242, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
3706, d3cohA_, 0.7115, 2.75, 0.201, 247, 234, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
3707, d3bz3A_, 0.7115, 3.24, 0.204, 259, 245, CRYSTAL STRUCTURE ANALYSIS OF FOCAL ADHESION KINASE WITH A METHANESULFONAMIDE DIAMINOPYRIMIDINE INHIBITOR
3708, d2c6eB_, 0.7115, 2.59, 0.198, 246, 232, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
3709, d4l7sA1, 0.7114, 2.96, 0.197, 248, 239, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
3710, p4e3cC1, 0.7114, 3.26, 0.193, 290, 243, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
3711, d3og7B_, 0.7114, 3.09, 0.232, 254, 241, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
3712, d3en4A_, 0.7114, 3.03, 0.212, 257, 240, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
3713, d5njzA_, 0.7113, 3.17, 0.165, 273, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1G
3714, d5hieB_, 0.7113, 3.25, 0.230, 259, 244, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
3715, d4hvsA1, 0.7113, 3.33, 0.212, 323, 245, CRYSTAL STRUCTURE OF KIT KINASE DOMAIN WITH A SMALL MOLECULE INHIBITOR PLX647
3716, d4aacA_, 0.7113, 3.18, 0.204, 350, 240, P38ALPHA MAP KINASE BOUND TO CMPD 29
3717, d3qlgA_, 0.7113, 3.03, 0.204, 259, 240, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
3718, d3f3vB_, 0.7113, 3.10, 0.203, 262, 241, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
3719, d2pzyB_, 0.7113, 3.24, 0.175, 283, 240, STRUCTURE OF MK2 COMPLEXED WITH COMPOUND 76
3720, d2okrA_, 0.7113, 2.99, 0.203, 339, 237, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
3721, d5bujA_, 0.7112, 2.84, 0.228, 331, 237, ERK2 COMPLEXED WITH A N-H TETRAHYDROAZAINDAZOLE
3722, d4v01A_, 0.7112, 3.19, 0.195, 273, 241, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
3723, d4knbA_, 0.7112, 3.32, 0.184, 273, 244, C-MET IN COMPLEX WITH OSI LIGAND
3724, d4eqmC_, 0.7112, 3.20, 0.202, 269, 243, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
3725, d4eqmA_, 0.7112, 3.19, 0.202, 269, 243, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
3726, d4d4yB_, 0.7112, 3.13, 0.207, 260, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN
3727, d3oezA_, 0.7112, 3.12, 0.207, 261, 241, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
3728, d3kc3J_, 0.7112, 3.28, 0.178, 288, 242, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
3729, d2pzyA_, 0.7112, 3.32, 0.174, 291, 242, STRUCTURE OF MK2 COMPLEXED WITH COMPOUND 76
3730, d5p9gA_, 0.7111, 3.12, 0.160, 265, 244, STRUCTURE OF BTK WITH RN486
3731, d4kioC1, 0.7111, 3.02, 0.196, 249, 240, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
3732, d3fzoA_, 0.7111, 3.26, 0.180, 262, 244, CRYSTAL STRUCTURE OF PYK2-APO PROLINE-RICH TYROSINE KINASE
3733, d4n4sB_, 0.7110, 2.97, 0.217, 337, 240, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
3734, d4mneH_, 0.7110, 3.61, 0.189, 275, 254, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3735, d4fnxA_, 0.7110, 3.71, 0.163, 292, 251, CRYSTAL STRUCTURE OF THE APO R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
3736, d3v6rA_, 0.7110, 3.18, 0.202, 349, 242, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
3737, d2yjsA_, 0.7110, 3.59, 0.169, 286, 248, STRUCTURE OF C1156Y MUTANT ANAPLASTIC LYMPHOMA KINASE
3738, p5xyyA_, 0.7109, 3.25, 0.204, 350, 240, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A TRIAZOL INHIBITOR
3739, d5hieA_, 0.7109, 3.21, 0.230, 258, 243, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
3740, d4uwyA_, 0.7109, 3.24, 0.197, 296, 244, FGFR1 APO STRUCTURE
3741, d4ot5A_, 0.7109, 3.12, 0.160, 263, 244, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4-TERT-BUTYL-N- (3-{8-[4-(4-METHYL-PIPERAZINE-1-CARBONYL)-PHENYLAMINO]-IMIDAZO[12- A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
3742, p4lopC_, 0.7109, 3.02, 0.188, 341, 239, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
3743, d3g0fA_, 0.7109, 3.27, 0.213, 291, 244, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
3744, d3bx5A_, 0.7109, 3.01, 0.211, 338, 237, P38 ALPHA MAP KINASE COMPLEXED WITH BMS-640994
3745, d2wtvC_, 0.7109, 2.81, 0.211, 261, 237, AURORA-A INHIBITOR STRUCTURE
3746, d2wtvB_, 0.7109, 2.81, 0.211, 261, 237, AURORA-A INHIBITOR STRUCTURE
3747, d2onlB1, 0.7109, 3.00, 0.203, 339, 237, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
3748, d4yhfB_, 0.7108, 3.14, 0.160, 269, 244, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
3749, d4pmpA1, 0.7108, 3.17, 0.207, 276, 242, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 1-CYCLOPROPYL-1- [3-(13-THIAZOL-2-YL)BENZYL]-3-[4-(TRIFLUOROMETHOXY)PHENYL]UREA
3750, d4l7sB1, 0.7108, 2.98, 0.197, 248, 239, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
3751, d4ckrA1, 0.7108, 3.34, 0.201, 294, 244, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH DDR1-IN-1
3752, d4bkiA1, 0.7108, 3.34, 0.201, 294, 244,  
3753, d4agdA_, 0.7108, 3.51, 0.206, 303, 248, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SUNITINIB (SU11248) (N-2- DIETHYLAMINOETHYL)-5-((Z)-(5-FLUORO-2-OXO-1H-INDOL-3- YLIDENE)METHYL)-24-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE)
3754, d3w32A_, 0.7108, 4.03, 0.165, 317, 260, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 20A
3755, d3oroA_, 0.7108, 3.31, 0.209, 272, 244, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 4)
3756, d5tehA_, 0.7107, 3.04, 0.200, 261, 240, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
3757, d5nkdA_, 0.7107, 3.37, 0.167, 287, 245, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2I
3758, d4ewqA_, 0.7107, 3.12, 0.197, 346, 239, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A PYRIDAZINE BASED INHIBITOR
3759, d5t3qA1, 0.7106, 2.98, 0.162, 277, 240, CRYSTAL STRUCTURE OF THE C-MET KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
3760, d4uwyB_, 0.7106, 3.03, 0.212, 273, 240, FGFR1 APO STRUCTURE
3761, d4i5hA_, 0.7106, 2.92, 0.226, 335, 235, CRYSTAL STRUCTURE OF A DOUBLE MUTANT RAT ERK2 COMPLEXED WITH A TYPE II QUINAZOLINE INHIBITOR
3762, d4d5hB_, 0.7106, 3.13, 0.207, 260, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN
3763, d3flwA_, 0.7106, 2.97, 0.195, 345, 236, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH PAMAPIMOD
3764, d3f3wA_, 0.7106, 3.10, 0.207, 261, 241, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
3765, d5i9yA_, 0.7105, 3.39, 0.167, 287, 245, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DASATINIB
3766, d3is5B1, 0.7105, 3.20, 0.228, 255, 241, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
3767, d2g15A_, 0.7105, 3.62, 0.152, 301, 250, STRUCTURAL CHARACTERIZATION OF AUTOINHIBITED C-MET KINASE
3768, d5d41B_, 0.7104, 3.55, 0.171, 302, 251, EGFR KINASE DOMAIN IN COMPLEX WITH MUTANT SELECTIVE ALLOSTERIC INHIBITOR
3769, d4equA_, 0.7104, 3.36, 0.183, 274, 241, HUMAN STK-10 (LOK) KINASE DOMAIN IN DFG-OUT CONFORMATION WITH INHIBITOR DSA-7
3770, d4aojB_, 0.7104, 2.96, 0.205, 258, 239, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
3771, d3oxzA1, 0.7104, 3.44, 0.215, 267, 246, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN BOUND WITH A DFG-OUT INHIBITOR AP24534
3772, d2r0iB_, 0.7104, 2.87, 0.238, 300, 235, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
3773, d1r3cA_, 0.7104, 3.24, 0.204, 349, 240, THE STRUCTURE OF P38ALPHA C162S MUTANT
3774, d1lezA_, 0.7104, 3.04, 0.202, 343, 238, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS ACTIVATOR MKK3B
3775, d4ymjA1, 0.7103, 3.12, 0.216, 267, 241, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
3776, d4twoA_, 0.7103, 3.03, 0.165, 278, 242, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 164
3777, d4kiqB_, 0.7103, 2.91, 0.212, 338, 236, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
3778, d2pzyD_, 0.7103, 3.48, 0.177, 288, 243, STRUCTURE OF MK2 COMPLEXED WITH COMPOUND 76
3779, d2pzyC_, 0.7103, 3.43, 0.172, 307, 244, STRUCTURE OF MK2 COMPLEXED WITH COMPOUND 76
3780, d5uq0A_, 0.7102, 3.12, 0.207, 266, 241, FGFR1 KINASE DOMAIN COMPLEX WITH FRAGMENT 22-DIMETHYL-23- DIHYDROBENZOFURAN-7-CARBOXAMIDE
3781, d5lohA_, 0.7102, 3.06, 0.196, 248, 235, KINASE DOMAIN OF HUMAN GREATWALL
3782, d3zfxG_, 0.7102, 2.95, 0.147, 253, 238, CRYSTAL STRUCTURE OF EPHB1
3783, d3kf7A_, 0.7102, 2.85, 0.200, 337, 235, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A TRIAZOLOPYRIMIDINE COMPOUND
3784, d2rgpA_, 0.7102, 3.64, 0.171, 284, 251, STRUCTURE OF EGFR IN COMPLEX WITH HYDRAZONE A POTENT DUAL INHIBITOR
3785, d2p2iA2, 0.7102, 3.29, 0.220, 283, 245, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
3786, d1opjA1, 0.7102, 3.42, 0.227, 282, 247, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
3787, d5gtyG_, 0.7101, 3.59, 0.172, 299, 250, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
3788, d4uzhA1, 0.7101, 2.72, 0.193, 250, 233, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
3789, p5o90A_, 0.7100, 3.07, 0.202, 330, 238, CRYSTAL STRUCTURE OF A P38ALPHA T185G MUTANT IN COMPLEX WITH TAB1 PEPTIDE.
3790, d5l4qB_, 0.7100, 2.92, 0.177, 287, 237, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE 1 (AAK1) IN COMPLEX WITH LKB1 (AAK1 DUAL INHIBITOR)
3791, d4rwjB_, 0.7100, 3.29, 0.213, 282, 244, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
3792, d4i24B_, 0.7100, 3.71, 0.171, 304, 252, STRUCTURE OF T790M EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH DACOMITINIB
3793, d3vapA_, 0.7100, 2.73, 0.204, 249, 235, SYNTHESIS AND SAR STUDIES OF IMIDAZO-[12-A]-PYRAZINE AURORA KINASE INHIBITORS WITH IMPROVED OFF TARGET KINASE SELECTIVITY
3794, d1wbwA_, 0.7100, 3.26, 0.212, 351, 240, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
3795, d1lufA_, 0.7100, 3.13, 0.207, 275, 241, CRYSTAL STRUCTURE OF THE MUSK TYROSINE KINASE: INSIGHTS INTO RECEPTOR AUTOREGULATION
3796, d1bl6A_, 0.7100, 3.23, 0.204, 351, 240, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB216995
3797, d5p9kA_, 0.7099, 3.25, 0.154, 271, 247, CRYSTAL STRUCTURE OF BTK WITH CNX 774
3798, d4tyjA1, 0.7099, 3.17, 0.191, 275, 241, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
3799, d4p5qA_, 0.7099, 3.10, 0.165, 275, 243, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
3800, d4degA_, 0.7099, 3.31, 0.172, 286, 244, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDAZINE INHIBITOR 2
3801, d3tt0B_, 0.7099, 3.05, 0.220, 272, 241, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
3802, d3lq8A_, 0.7099, 3.11, 0.183, 278, 240, STRUCTURE OF THE KINASE DOMAIN OF C-MET BOUND TO XL880 (GSK1363089)
3803, d4brxA_, 0.7098, 3.20, 0.189, 259, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
3804, d3pxkA_, 0.7098, 3.05, 0.212, 256, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
3805, d4zegA_, 0.7097, 2.85, 0.204, 260, 235, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
3806, d3w33A_, 0.7097, 3.53, 0.163, 297, 251, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 19B
3807, d3g0eA1, 0.7097, 3.35, 0.216, 330, 245, KIT KINASE DOMAIN IN COMPLEX WITH SUNITINIB
3808, d1m7qA_, 0.7097, 3.25, 0.204, 348, 240, CRYSTAL STRUCTURE OF P38 MAP KINASE IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
3809, d5nttA1, 0.7096, 3.08, 0.197, 268, 239, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) C604Y MUTANT IN COMPLEX WITH NMS-P715
3810, d5hieD_, 0.7096, 2.98, 0.217, 253, 240, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
3811, d5ew3A_, 0.7096, 3.15, 0.207, 274, 242, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
3812, d3lw0A_, 0.7096, 3.26, 0.198, 292, 243, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3813, d3fztA_, 0.7096, 3.10, 0.178, 259, 242, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-4618433
3814, d2zb0A_, 0.7096, 3.25, 0.204, 349, 240, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
3815, d1xkkA_, 0.7096, 3.74, 0.167, 289, 252, EGFR KINASE DOMAIN COMPLEXED WITH A QUINAZOLINE INHIBITOR- GW572016
3816, d1ouyA_, 0.7096, 3.27, 0.204, 350, 240, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROPYRIDO- PYRIMIDINE INHIBITOR
3817, d5jkgA_, 0.7095, 3.05, 0.183, 266, 240, THE CRYSTAL STRUCTURE OF FGFR4 KINASE DOMAIN IN COMPLEX WITH LY2874455
3818, d4gg5A_, 0.7095, 3.33, 0.184, 274, 244, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
3819, d3oezB_, 0.7095, 3.08, 0.204, 261, 240, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
3820, d3lw0D_, 0.7095, 3.27, 0.198, 292, 243, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3821, d3lw0C_, 0.7095, 3.27, 0.198, 292, 243, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3822, d3f3uB_, 0.7095, 3.12, 0.203, 259, 241, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL37 (TYPE III)
3823, d3f3tA_, 0.7095, 3.12, 0.203, 261, 241, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL38 (TYPE III)
3824, d4mneD_, 0.7094, 3.60, 0.185, 285, 254, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3825, p4lopB_, 0.7094, 3.02, 0.192, 350, 239, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
3826, d3f3vA_, 0.7094, 3.13, 0.199, 261, 241, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
3827, d3cjgA_, 0.7094, 3.11, 0.212, 280, 241, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 345-TRIMETHOXY ANILINE CONTAINING PYRIMIDINE
3828, d1uwjB_, 0.7094, 3.14, 0.217, 263, 240, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
3829, d1muoA_, 0.7094, 2.93, 0.203, 251, 237, CRYSTAL STRUCTURE OF AURORA-2 AN ONCOGENIC SERINE- THREONINE KINASE
3830, d4kiqC_, 0.7093, 2.92, 0.212, 338, 236, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
3831, d4ka3A_, 0.7093, 2.97, 0.191, 340, 236, STRUCTURE OF MAP KINASE IN COMPLEX WITH A DOCKING PEPTIDE
3832, d4d4vB_, 0.7093, 3.02, 0.204, 255, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN
3833, d1f3mC_, 0.7093, 3.44, 0.227, 287, 247, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE PAK1
3834, d5p9hA_, 0.7092, 3.13, 0.160, 264, 244, BTK1 COCRYSTALLIZED WITH RN983
3835, d5fd2A_, 0.7092, 3.31, 0.238, 264, 244, B-RAF WILD-TYPE KINASE DOMAIN IN COMPLEX WITH A PURINYLPYRIDINYLAMINO- BASED INHIBITOR
3836, d4kabA_, 0.7092, 2.94, 0.209, 255, 239, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
3837, d3pozA_, 0.7092, 3.75, 0.161, 293, 254, EGFR KINASE DOMAIN COMPLEXED WITH TAK-285
3838, d3b8qA1, 0.7092, 3.23, 0.198, 285, 243, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
3839, d2onlA1, 0.7092, 2.95, 0.203, 338, 236, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
3840, d4f9yA_, 0.7091, 2.88, 0.213, 339, 235, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
3841, d3lw0B_, 0.7091, 3.27, 0.198, 292, 243, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3842, d3g6hB_, 0.7091, 3.07, 0.204, 259, 240, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
3843, d3f3uA_, 0.7091, 3.12, 0.199, 261, 241, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL37 (TYPE III)
3844, d1pyeA_, 0.7091, 2.84, 0.182, 266, 236, CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR
3845, d5l8jA_, 0.7090, 2.82, 0.157, 253, 235, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 S93R
3846, d5j5sA_, 0.7090, 2.96, 0.201, 258, 239, SRC KINASE IN COMPLEX WITH A SULFONAMIDE INHIBITOR
3847, d5ia1A_, 0.7090, 2.95, 0.172, 261, 238, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH MLN8054
3848, d5gtyD_, 0.7090, 3.63, 0.171, 297, 251, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
3849, d5ek7B_, 0.7090, 3.08, 0.165, 286, 242, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
3850, d4d5kA_, 0.7090, 2.99, 0.204, 255, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN
3851, d3of0A_, 0.7090, 3.05, 0.200, 260, 240, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN
3852, d3is5A1, 0.7090, 3.16, 0.242, 254, 240, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
3853, d2r0iA_, 0.7090, 2.89, 0.234, 300, 235, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
3854, d1g3nE_, 0.7090, 3.03, 0.190, 293, 237, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
3855, d5p9iA_, 0.7089, 3.30, 0.153, 271, 248, BTK1 SOAKED WITH IBRUTINIB-REV
3856, d2wzjF_, 0.7089, 2.97, 0.226, 310, 234, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3857, d4ynzB1, 0.7088, 3.23, 0.198, 316, 242, STRUCTURE OF THE N-TERMINAL DOMAIN OF SAD
3858, d4fvrA_, 0.7088, 3.46, 0.170, 274, 247, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN MUTANT V617F (MG- ATP-BOUND FORM)
3859, d4d5kB_, 0.7088, 3.03, 0.208, 256, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN
3860, d4d4sA_, 0.7088, 2.98, 0.204, 255, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN
3861, d3ii5A_, 0.7088, 3.41, 0.217, 262, 244, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
3862, d2io6A_, 0.7088, 2.90, 0.165, 252, 236, WEE1 KINASE COMPLEXED WITH INHIBITOR PD330961
3863, d1k9aF3, 0.7088, 3.18, 0.198, 264, 243, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
3864, d5lohB_, 0.7087, 3.11, 0.199, 250, 236, KINASE DOMAIN OF HUMAN GREATWALL
3865, d4jg6A_, 0.7087, 3.54, 0.181, 302, 248, RSK2 CTD BOUND TO 2-CYANO-3-(1H-INDAZOL-5-YL)ACRYLAMIDE
3866, d4fg8B_, 0.7087, 3.51, 0.176, 268, 245, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-315 IN COMPLEX WITH ATP
3867, d4d4yA_, 0.7087, 3.00, 0.204, 255, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN
3868, d3my0W1, 0.7087, 3.37, 0.192, 280, 245, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3869, p4xhhA2, 0.7086, 0.84, 0.676, 207, 207, STRUCTURE OF C. GLABRATA HRR25 APO STATE
3870, d4d5hA_, 0.7086, 3.00, 0.204, 255, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN
3871, d4c3pA_, 0.7086, 3.22, 0.182, 264, 242, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO TPX2 AND AMPPCP
3872, d2qobA_, 0.7086, 3.25, 0.163, 279, 245, HUMAN EPHA3 KINASE DOMAIN BASE STRUCTURE
3873, d4ztqA_, 0.7085, 2.66, 0.202, 247, 233, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK932
3874, d4cnhA_, 0.7085, 3.60, 0.170, 285, 247, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
3875, d3v6sA_, 0.7085, 3.07, 0.212, 349, 241, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
3876, d3tz9A_, 0.7085, 3.13, 0.199, 261, 241, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL130
3877, d4ypsA1, 0.7084, 3.06, 0.197, 275, 239, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
3878, d4eh2A_, 0.7084, 2.76, 0.198, 337, 232, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F1 AND RL87
3879, d3s3iA_, 0.7084, 3.26, 0.204, 349, 240, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3880, d3qlfB_, 0.7084, 3.09, 0.212, 258, 241, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE 5
3881, d3fe3B_, 0.7084, 3.20, 0.226, 317, 239, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
3882, d2qnjB1, 0.7084, 3.17, 0.230, 321, 239, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
3883, d2i0yA_, 0.7084, 3.22, 0.207, 289, 242, CFMS TYROSINE KINASE (FGF KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
3884, d1wboA_, 0.7084, 3.26, 0.204, 351, 240, FRAGMENT BASED P38 INHIBITORS
3885, d5i9wA_, 0.7083, 3.04, 0.163, 267, 239, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ANP
3886, d5h3qA_, 0.7083, 3.33, 0.205, 302, 244, CRYSTAL STRUCTURE OF TRKA KINASE WITH LIGAND
3887, d3gfeA_, 0.7083, 3.18, 0.201, 352, 239, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR
3888, d3bv3A_, 0.7083, 2.91, 0.205, 338, 234, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 2
3889, d2ozaB_, 0.7083, 3.11, 0.209, 340, 239, STRUCTURE OF P38ALPHA COMPLEX
3890, d4yhfA_, 0.7082, 3.18, 0.159, 268, 245, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
3891, d4rlpA_, 0.7082, 3.06, 0.204, 261, 235, HUMAN P70S6K1 WITH RUTHENIUM-BASED INHIBITOR FL772
3892, d4apcB1, 0.7082, 3.42, 0.175, 291, 246, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
3893, d4aa5A_, 0.7082, 2.97, 0.208, 340, 236, P38ALPHA MAP KINASE BOUND TO CMPD 33
3894, d1gzoA_, 0.7082, 3.25, 0.198, 271, 242, STRUCTURE OF PROTEIN KINASE B UNPHOSPHORYLATED
3895, p4lopA_, 0.7081, 3.11, 0.204, 351, 240, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
3896, d3iphA_, 0.7081, 3.13, 0.203, 345, 237, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH A BIPHENYLAMIDE INHIBITOR
3897, d2wzjC_, 0.7081, 3.00, 0.226, 310, 235, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3898, d2wzjB_, 0.7081, 2.94, 0.218, 310, 234, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3899, d1g3nA_, 0.7081, 3.04, 0.190, 293, 237, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
3900, d4k8aA_, 0.7080, 2.86, 0.215, 251, 237, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
3901, d3u8wA_, 0.7080, 3.22, 0.204, 349, 240, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A TRIAZOLOPYRIDAZINONE INHIBITOR
3902, d2yn8B_, 0.7080, 2.93, 0.143, 260, 237, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3903, d2e2bA1, 0.7080, 3.38, 0.224, 266, 245, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
3904, d5gtyE_, 0.7079, 3.58, 0.172, 297, 250, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
3905, d3kc3G_, 0.7079, 3.29, 0.179, 276, 240, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
3906, d2rfsA_, 0.7079, 3.28, 0.174, 264, 242, X-RAY STRUCTURE OF SU11274 BOUND TO C-MET
3907, d3wi6C_, 0.7078, 3.28, 0.174, 283, 241, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
3908, d3byuA_, 0.7078, 3.02, 0.209, 256, 239, CO-CRYSTAL STRUCTURE OF LCK AND AMINOPYRIMIDINE REVERSE AMIDE 23
3909, d1uwhB_, 0.7078, 3.33, 0.226, 264, 243, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
3910, d4z3vA_, 0.7077, 3.31, 0.158, 271, 247, FRAGMENT-BASED DISCOVERY OF A SMALL MOLECULE REVERSIBLE INHIBITOR OF BRUTON S TYROSINE KINASE
3911, p4loqD_, 0.7077, 3.06, 0.184, 351, 239, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
3912, d4hctA_, 0.7077, 3.20, 0.184, 265, 245, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 52
3913, d5gtyB_, 0.7076, 3.65, 0.175, 299, 251, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
3914, d4zjiD_, 0.7076, 3.51, 0.219, 280, 247, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
3915, d3wi6B_, 0.7076, 3.28, 0.174, 283, 241, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
3916, p3vumA_, 0.7076, 2.90, 0.220, 347, 236, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M7 IN MAP KINASE JNK1
3917, d5d11B_, 0.7075, 3.02, 0.226, 255, 239, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL235
3918, d3gc8B_, 0.7075, 3.15, 0.211, 346, 237, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
3919, d3d2kA_, 0.7075, 2.68, 0.189, 245, 233, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH [7-(2-{2-[3-(3-CHLORO- PHENYL)-UREIDO]-THIAZOL-5-YL}-ETHYLAMINO)-PYRAZOLO[43- D]PYRIMIDIN-1-YL]-ACETIC ACID
3920, d5bvkA_, 0.7074, 3.26, 0.216, 278, 241, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
3921, d4ybjB_, 0.7074, 3.06, 0.205, 253, 239, TYPE II DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
3922, d4useB_, 0.7074, 3.62, 0.188, 278, 245, HUMAN STK10 (LOK) WITH SB-633825
3923, d4kspA_, 0.7074, 3.18, 0.217, 257, 240, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
3924, d3fmkA_, 0.7074, 3.05, 0.203, 346, 237, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((S)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
3925, d3belA_, 0.7074, 3.65, 0.164, 280, 250, X-RAY STRUCTURE OF EGFR IN COMPLEX WITH OXIME INHIBITOR
3926, d1ywrA_, 0.7074, 2.96, 0.216, 338, 236, CRYSTAL STRUCTURE ANALYSIS OF INACTIVE P38 KINASE DOMAIN IN COMPLEX WITH A MONOCYCLIC PYRAZOLONE INHIBITOR
3927, d5swhA_, 0.7073, 3.06, 0.209, 258, 239, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
3928, d5j87B_, 0.7073, 3.20, 0.159, 274, 245, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
3929, d5bueA_, 0.7073, 2.99, 0.227, 329, 238, ERK2 COMPLEXED WITH N-BENZYLPYRIDONE TETRAHYDROAZAINDAZOLE
3930, d4d58A_, 0.7073, 2.97, 0.205, 255, 239, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
3931, d3tz8A_, 0.7073, 3.15, 0.203, 261, 241, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
3932, d3f3wB_, 0.7073, 3.16, 0.203, 260, 241, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
3933, d2qokA_, 0.7073, 3.18, 0.168, 281, 244, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:S768A TRIPLE MUTANT
3934, d2j50B_, 0.7073, 2.97, 0.197, 249, 238, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
3935, d2j50A_, 0.7073, 2.97, 0.197, 249, 238, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
3936, d4tygA1, 0.7072, 3.33, 0.192, 290, 245, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
3937, d4o2zA1, 0.7072, 3.06, 0.169, 357, 237, CRYSTAL STRUCTURE OF MPK3 FROM LEISHMANIA DONOVANI LDBPK_100540 IN THE PRESENCE OF NVP-BBT594
3938, d4b9dB1, 0.7072, 3.40, 0.171, 291, 245, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
3939, d3wi6F_, 0.7072, 3.31, 0.174, 283, 241, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
3940, d3wi6E_, 0.7072, 3.31, 0.174, 283, 241, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
3941, d3gc9B_, 0.7072, 3.12, 0.211, 339, 237, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
3942, d1bl7A_, 0.7072, 3.21, 0.192, 351, 239, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB220025
3943, d4ehvA_, 0.7071, 2.89, 0.205, 337, 234, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F10 AND RL87
3944, d4dggA_, 0.7071, 3.07, 0.200, 261, 240, C-SRC KINASE DOMAIN IN COMPLEX WITH RM-1-176
3945, d3vquA_, 0.7071, 3.04, 0.208, 258, 236, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4- [(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2- YL)AMINO]BENZAMIDE
3946, d3bizA_, 0.7071, 2.92, 0.165, 250, 236, WEE1 KINASE COMPLEX WITH INHIBITOR PD331618
3947, d5cnoA_, 0.7070, 3.71, 0.159, 300, 252, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT V924R
3948, d5bvfA_, 0.7070, 2.67, 0.226, 327, 230, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
3949, d4y46A_, 0.7070, 3.08, 0.203, 340, 237, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
3950, p4loqC_, 0.7070, 3.07, 0.188, 337, 239, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
3951, d4gu9A_, 0.7070, 2.91, 0.210, 252, 238, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
3952, d3qtiA_, 0.7070, 3.50, 0.180, 292, 244, C-MET KINASE IN COMPLEX WITH NVP-BVU972
3953, d1oiqA_, 0.7070, 2.94, 0.191, 264, 236, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
3954, p5x02A_, 0.7069, 3.29, 0.190, 305, 242, CRYSTAL STRUCTURE OF THE FLT3 KINASE DOMAIN BOUND TO THE INHIBITOR FF- 10101
3955, d5ng3A_, 0.7069, 3.30, 0.171, 283, 246, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
3956, d4fc0A_, 0.7069, 3.03, 0.218, 254, 238, CRYSTAL STRUCTURE OF HUMAN KINASE DOMAIN OF B-RAF WITH A DFG-OUT INHIBITOR
3957, d3gc8A_, 0.7069, 3.13, 0.211, 347, 237, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
3958, d3dtwA1, 0.7069, 3.18, 0.191, 281, 241, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
3959, d2qi8A_, 0.7069, 3.02, 0.213, 255, 239, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN
3960, d2okrD_, 0.7069, 2.95, 0.200, 339, 235, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
3961, d5j87D_, 0.7068, 3.19, 0.160, 263, 244, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
3962, p3vulA_, 0.7068, 2.91, 0.220, 344, 236, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
3963, d3tz9B_, 0.7068, 3.05, 0.192, 259, 239, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL130
3964, d3rhkA_, 0.7068, 3.55, 0.169, 298, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
3965, d2reiA1, 0.7068, 3.06, 0.154, 274, 240, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 7 (EPHA7)
3966, d2i0vA_, 0.7068, 3.32, 0.206, 303, 243, C-FMS TYROSINE KINASE IN COMPLEX WITH A QUINOLONE INHIBITOR
3967, d1yomA_, 0.7068, 3.01, 0.193, 260, 238, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH PURVALANOL A
3968, d5u9dA_, 0.7067, 3.26, 0.159, 271, 246, DISCOVERY OF A POTENT BTK INHIBITOR WITH A NOVEL BINDING MODE USING PARALLEL SELECTIONS WITH A DNA-ENCODED CHEMICAL LIBRARY
3969, d5swhB_, 0.7067, 3.07, 0.209, 261, 239, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
3970, d3mvmA_, 0.7067, 2.94, 0.203, 335, 236, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
3971, d1gznA_, 0.7067, 3.25, 0.198, 271, 242, STRUCTURE OF PKB KINASE DOMAIN
3972, d5p9jA_, 0.7066, 3.28, 0.154, 263, 246, BTK1 COCRYSTALLIZED WITH IBRUTINIB
3973, d5n87A1, 0.7066, 3.03, 0.199, 252, 236, TTK KINASE DOMAIN IN COMPLEX WITH NTRC 0066-0
3974, d5hlwA_, 0.7066, 3.53, 0.184, 284, 245, CRYSTAL STRUCTURE OF C-MET MUTANT Y1230H IN COMPLEX WITH COMPOUND 14
3975, d5ct7A_, 0.7066, 3.16, 0.222, 257, 239, BRAF IN COMPLEX WITH RAF265
3976, d3krjA_, 0.7066, 3.24, 0.207, 304, 241, CFMS TYROSINE KINASE IN COMPLEX WITH 4-CYANO-1H-IMIDAZOLE-2-CARBOXYLIC ACID (2-CYCLOHEX-1-ENYL-4-PIPERIDIN-4-YL-PHENYL)-AMIDE
3977, d3efjB_, 0.7066, 3.29, 0.165, 275, 243, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
3978, d3ctjA_, 0.7066, 3.43, 0.168, 289, 244, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A AMINOPYRIDINE BASED INHIBITOR
3979, d3bv2A_, 0.7066, 2.95, 0.205, 337, 234, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 30
3980, d1w84A_, 0.7066, 3.29, 0.204, 351, 240, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3981, d5vd2A_, 0.7065, 3.17, 0.162, 258, 241, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PF- 03814735
3982, d5mz3A_, 0.7065, 3.27, 0.210, 350, 238, P38 ALPHA MUTANT C162S IN COMPLEX WITH CMPD2 [N-(4-METHYL-3-(4455- TETRAMETHYL-132-DIOXABOROLAN-2-YL)PHENYL)-3-(TRIFLUOROMETHYL) BENZAMIDE]
3983, d5l4qA_, 0.7065, 3.01, 0.176, 293, 238, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE 1 (AAK1) IN COMPLEX WITH LKB1 (AAK1 DUAL INHIBITOR)
3984, d5gtyA_, 0.7065, 3.74, 0.175, 300, 252, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
3985, d5cnnA_, 0.7065, 3.63, 0.163, 300, 251, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT I682Q
3986, d4u3zA_, 0.7065, 3.65, 0.166, 282, 253, APO MAP4K4 T181E PHOSPHOMIMETIC MUTANT
3987, d4f9wA_, 0.7065, 2.91, 0.209, 336, 235, HUMAN P38ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
3988, d3d7zA_, 0.7065, 3.24, 0.205, 348, 239, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
3989, d2hznA2, 0.7065, 3.19, 0.228, 268, 241, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AFG210
3990, d1bmkA_, 0.7065, 3.28, 0.204, 351, 240, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB218655
3991, d5m57A1, 0.7064, 2.64, 0.183, 253, 230, NEK2 BOUND TO ARYLAMINOPURINE 6
3992, d4b8lA_, 0.7064, 2.77, 0.145, 249, 234, AURORA B KINASE P353G MUTANT
3993, d3efjA_, 0.7064, 3.31, 0.173, 276, 243, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
3994, d2wqbA_, 0.7064, 3.47, 0.177, 289, 248, STRUCTURE OF THE TIE2 KINASE DOMAIN IN COMPLEX WITH A THIAZOLOPYRIMIDINE INHIBITOR
3995, d5vgoA1, 0.7063, 3.17, 0.156, 264, 243, BRUTON S TYROSINE KINASE (BTK) WITH COMPOUND G-744
3996, d5gnkA_, 0.7063, 3.51, 0.170, 277, 247, CRYSTAL STRUCTURE OF EGFR 696-988 T790M IN COMPLEX WITH LXX-6-34
3997, d5ceoA_, 0.7063, 3.19, 0.195, 269, 241, DLK IN COMPLEX WITH INHIBITOR 2-((6-(33-DIFLUOROPYRROLIDIN-1-YL)-4- (1-(OXETAN-3-YL)PIPERIDIN-4-YL)PYRIDIN-2-YL)AMINO)ISONICOTINONITRILE
3998, d4pp9B1, 0.7063, 2.94, 0.198, 246, 237, ITK KINASE DOMAIN WITH COMPOUND 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4- YL]-2H-INDAZOLE-3-CARBOXAMIDE)
3999, p4loqB_, 0.7063, 3.08, 0.188, 351, 239, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
4000, d4kinA_, 0.7063, 3.01, 0.212, 338, 236, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
4001, d4hcuA_, 0.7063, 3.22, 0.184, 263, 245, CRYSTAL STRUCTURE OF ITK IN COMPLEXT WITH COMPOUND 40
4002, d3wi6D_, 0.7063, 3.26, 0.175, 282, 240, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4003, d2hakF_, 0.7063, 3.11, 0.235, 318, 238, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4004, d4dbnA_, 0.7061, 3.22, 0.221, 257, 240, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
4005, d3mj2A_, 0.7061, 3.10, 0.187, 259, 241, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH INHIBITOR BMS-509744
4006, d3gt8B_, 0.7061, 3.57, 0.168, 292, 250, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
4007, d5u6bC_, 0.7060, 3.18, 0.172, 270, 244, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
4008, d5sysB_, 0.7060, 3.04, 0.210, 258, 238, C-SRC V281C BOUND TO N-[3-({6-[(1E)-2-CYANO-3-(METHYLAMINO)-3-OXOPROP- 1-EN-1-YL]-7-(2-METHOXYETHYL)-7H-PYRROLO[23-D]PYRIMIDIN-5- YL}ETHYNYL)-4-METHYLPHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE INHIBITOR
4009, d5hhwA_, 0.7060, 3.33, 0.205, 306, 244, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH CIS-(R)-7-(3-(AZETIDIN-1-YLMETHYL)CYCLOBUTYL)-5-(3-((TETRAHYDRO-2H- PYRAN-2-YL)METHOXY)PHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE.
4010, d3u51A_, 0.7060, 3.05, 0.208, 256, 240, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
4011, d3gc9A_, 0.7060, 3.04, 0.212, 335, 236, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
4012, d3b8rA1, 0.7060, 3.15, 0.200, 282, 240, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
4013, d1w82A_, 0.7060, 3.22, 0.210, 351, 238, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4014, d5ur1B_, 0.7059, 3.06, 0.217, 265, 240, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
4015, d5ia0A_, 0.7059, 3.01, 0.167, 263, 239, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
4016, d5bvwA_, 0.7059, 3.25, 0.216, 274, 241, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
4017, d4rloA_, 0.7059, 3.02, 0.193, 259, 233, HUMAN P70S6K1 WITH RUTHENIUM-BASED INHIBITOR EM5
4018, d2ghmA_, 0.7059, 2.97, 0.213, 336, 235, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-895449
4019, d5vc3A_, 0.7058, 3.34, 0.164, 260, 244, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB
4020, d5etcA_, 0.7058, 3.30, 0.204, 355, 240, STRUCTURE OF INACTIVE MAPK14 WITH ORDERED ACTIVATION LOOP
4021, d4fa2A_, 0.7058, 2.97, 0.209, 339, 235, HUMAN P38 ALPHA MITOGEN-ACTIVATED KINASE IN COMPLEX WITH SB239063
4022, d4aw5A_, 0.7058, 3.11, 0.149, 261, 241, COMPLEX OF THE EPHB4 KINASE DOMAIN WITH AN OXINDOLE INHIBITOR
4023, d1snuA_, 0.7058, 2.88, 0.195, 245, 236, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4024, p6groA2, 0.7057, 1.24, 0.632, 211, 209, HUMAN CSNK1G3 BOUND TO SB-223133 
4025, d5ehlA1, 0.7057, 3.05, 0.207, 254, 237, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4026, d4p2kA_, 0.7057, 3.03, 0.170, 259, 241, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
4027, d3wi6A_, 0.7057, 3.27, 0.175, 282, 240, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4028, d3ewhA1, 0.7057, 3.65, 0.213, 295, 249, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDYL-PYRIMIDINE BENZIMIDAZOLE INHIBITOR
4029, d2jkoA_, 0.7057, 3.08, 0.212, 256, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4030, d5nadA1, 0.7056, 3.04, 0.200, 253, 235, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1217389
4031, d4kiqD_, 0.7056, 2.99, 0.199, 338, 236, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
4032, d2zb1A_, 0.7056, 3.17, 0.194, 345, 237, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
4033, d1k9aD3, 0.7056, 3.33, 0.204, 268, 245, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
4034, d5ek7A_, 0.7055, 3.19, 0.169, 286, 243, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
4035, d4wunB_, 0.7055, 3.04, 0.209, 268, 239, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
4036, d4rx5A1, 0.7055, 3.14, 0.161, 264, 242, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 23
4037, d4otfA1, 0.7055, 3.16, 0.160, 261, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH GDC0834
4038, d3nnvA_, 0.7055, 3.23, 0.210, 348, 238, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP437
4039, d4i24A_, 0.7054, 3.60, 0.173, 295, 249, STRUCTURE OF T790M EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH DACOMITINIB
4040, d3w10A_, 0.7054, 2.90, 0.174, 263, 236, AURORA KINASE A COMPLEXED TO PYRAZOLE AMINOQUINOLINE I
4041, d3nnwA_, 0.7054, 3.25, 0.210, 349, 238, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP802
4042, d3hmpA_, 0.7054, 3.00, 0.209, 258, 235, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH A QUINAZOLIN LIGAND COMPOUND 4
4043, d5kupA1, 0.7053, 3.17, 0.156, 264, 243, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 9
4044, d2rioA_, 0.7053, 3.21, 0.199, 396, 241, STRUCTURE OF THE DUAL ENZYME IRE1 REVEALS THE BASIS FOR CATALYSIS AND REGULATION OF NON-CONVENTIONAL SPLICING
4045, d1sm2A_, 0.7053, 2.89, 0.195, 245, 236, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4046, d5ng3D_, 0.7052, 3.31, 0.163, 278, 246, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
4047, p4loqA_, 0.7052, 3.10, 0.188, 352, 239, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
4048, d3h0zC_, 0.7052, 2.66, 0.195, 246, 231, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
4049, d1yomB_, 0.7052, 3.06, 0.201, 261, 239, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH PURVALANOL A
4050, d4y5hA_, 0.7051, 3.32, 0.208, 349, 240, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
4051, d4r1yA_, 0.7051, 3.21, 0.187, 265, 240, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITOR
4052, d3p9jA_, 0.7051, 2.86, 0.199, 249, 236, AURORA A KINASE DOMAIN WITH PHTHALAZINONE PYRAZOLE INHIBITOR
4053, d4yomB1, 0.7050, 3.27, 0.198, 320, 242, STRUCTURE OF SAD KINASE
4054, d4nwmB_, 0.7050, 3.15, 0.156, 261, 243, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
4055, d3p7aA_, 0.7050, 2.78, 0.203, 332, 231, P38 INHIBITOR-BOUND
4056, d3dbqA_, 0.7050, 3.17, 0.207, 259, 237, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN
4057, d2xbaA_, 0.7050, 3.65, 0.166, 283, 247, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PHA-E429
4058, d2pk9C_, 0.7050, 2.68, 0.188, 266, 229, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
4059, d5m51A1, 0.7049, 2.66, 0.183, 253, 230, NEK2 BOUND TO ARYLAMINOPURINE COMPOUND 8
4060, d3hp2A_, 0.7049, 2.93, 0.205, 341, 234, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A PYRIDINONE COMPOUND
4061, d5ia5A_, 0.7048, 3.43, 0.167, 273, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH GOLVATINIB (E7050)
4062, d3ma6A_, 0.7048, 3.38, 0.215, 267, 246, CRYSTAL STRUCTURE OF KINASE DOMAIN OF TGCDPK1 IN PRESENCE OF 3BRB-PP1
4063, d3kq7A_, 0.7048, 3.28, 0.210, 348, 238, STRUCTURE OF HUMAN P38ALPHA WITH N-[4-METHYL-3-(6-{[2-(1- METHYLPYRROLIDIN-2-YL)ETHYL]AMINO}PYRIDINE-3-AMIDO)PHENYL]- 2-(MORPHOLIN-4-YL)PYRIDINE-4-CARBOXAMIDE
4064, d5sysA_, 0.7047, 3.10, 0.209, 258, 239, C-SRC V281C BOUND TO N-[3-({6-[(1E)-2-CYANO-3-(METHYLAMINO)-3-OXOPROP- 1-EN-1-YL]-7-(2-METHOXYETHYL)-7H-PYRROLO[23-D]PYRIMIDIN-5- YL}ETHYNYL)-4-METHYLPHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE INHIBITOR
4065, d3w16A_, 0.7047, 2.83, 0.200, 249, 235, STRUCTURE OF AURORA KINASE A COMPLEXED TO PYRAZOLE-AMINOQUINOLINE INHIBITOR III
4066, d3p4kA_, 0.7047, 2.96, 0.200, 338, 235, THE THIRD CONFORMATION OF P38A MAP KINASE OBSERVED IN PHOSPHORYLATED P38A AND IN SOLUTION
4067, d3nnuA_, 0.7047, 3.27, 0.210, 348, 238, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP1376
4068, d3gvuA1, 0.7047, 3.35, 0.226, 261, 243, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH GLEEVEC
4069, d3flsA_, 0.7047, 3.04, 0.205, 343, 234, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((R)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
4070, d5n84A1, 0.7046, 3.08, 0.208, 253, 236, TTK KINASE DOMAIN IN COMPLEX WITH MPS-BAY2B
4071, d4kinC_, 0.7046, 3.02, 0.190, 338, 237, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
4072, d3ptgA_, 0.7046, 2.93, 0.231, 340, 234, DESIGN AND SYNTHESIS OF A NOVEL ORALLY EFFICACIOUS TRI-SUBSTITUTED THIOPHENE BASED JNK INHIBITOR
4073, d4zlzA_, 0.7045, 3.26, 0.159, 270, 245, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH A SUBSTITUTED CINNOLINE
4074, d3kc3K_, 0.7045, 3.32, 0.175, 280, 240, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4075, d4i22A_, 0.7044, 3.67, 0.172, 297, 250, STRUCTURE OF THE MONOMERIC (V948R)GEFITINIB/ERLOTINIB RESISTANT DOUBLE MUTANT (L858R+T790M) EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH GEFITINIB
4076, d3gt8C_, 0.7044, 3.71, 0.167, 296, 252, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
4077, d3eflA1, 0.7044, 3.29, 0.185, 279, 243, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
4078, d2o0uA_, 0.7044, 2.95, 0.204, 331, 235, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-{3-CYANO-6-[3-(1- PIPERIDINYL)PROPANOYL]-4567-TETRAHYDROTHIENO[23-C]PYRIDIN-2-YL}- 1-NAPHTHALENECARBOXAMIDE
4079, d4zjiC_, 0.7043, 3.48, 0.224, 281, 246, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
4080, d4l00B_, 0.7043, 3.56, 0.181, 278, 249, CRYSTAL STRUCTURE OF THE APO JAK1 PSEUDOKINASE DOMAIN
4081, d3qgwA_, 0.7043, 2.92, 0.199, 244, 236, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
4082, d3e92A_, 0.7043, 3.22, 0.206, 348, 238, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
4083, d1w7hA_, 0.7043, 3.28, 0.197, 351, 239, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4084, d1p38A_, 0.7043, 3.32, 0.197, 351, 239, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTOMS RESOLUTION
4085, d5uafA_, 0.7042, 3.61, 0.184, 291, 244, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
4086, d5uadA_, 0.7042, 3.61, 0.184, 291, 244, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
4087, d4zthA_, 0.7042, 3.01, 0.209, 339, 235, STRUCTURE OF HUMAN P38AMAPK-ARYLPYRIDAZINYLPYRIDINE FRAGMENT COMPLEX USED IN INHIBITOR DISCOVERY
4088, d4byjA_, 0.7042, 2.62, 0.195, 246, 231, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
4089, d3newA_, 0.7042, 2.86, 0.202, 334, 233, P38-ALPHA COMPLEXED WITH COMPOUND 10
4090, d1f3mD_, 0.7042, 3.48, 0.215, 285, 247, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE PAK1
4091, d5a6oA_, 0.7041, 3.03, 0.195, 265, 236, CRYSTAL STRUCTURE OF THE APO FORM OF THE UNPHOSPHORYLATED HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3)
4092, d4tyeA_, 0.7041, 3.35, 0.193, 292, 244, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
4093, d4bi0A1, 0.7041, 2.96, 0.209, 251, 234, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4094, d3rhkB_, 0.7041, 3.49, 0.175, 299, 246, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
4095, d1wbsA_, 0.7041, 3.28, 0.210, 351, 238, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
4096, d5k9iA_, 0.7040, 3.02, 0.209, 258, 239, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
4097, d5ap0A1, 0.7040, 2.92, 0.201, 250, 234, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4098, d3wyxA_, 0.7040, 2.92, 0.209, 258, 234, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 6- ((3-(CYANOMETHOXY)-4-(1-METHYL-1H-PYRAZOL-4-YL)PHENYL)AMINO)-2- (CYCLOHEXYLAMINO)NICOTINONITRILE
4099, d3ocsA1, 0.7040, 3.16, 0.157, 262, 242, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI1746
4100, d3hv4A_, 0.7040, 3.08, 0.209, 339, 235, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
4101, d2qnjA1, 0.7040, 3.30, 0.233, 317, 240, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
4102, d1snxA_, 0.7040, 2.86, 0.191, 245, 235, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4103, d5mrbA1, 0.7039, 2.90, 0.209, 259, 234, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH CPD-5
4104, d4othA_, 0.7039, 2.81, 0.212, 305, 231, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH RO-31-8220
4105, d4nksA_, 0.7039, 3.15, 0.205, 265, 239, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
4106, d3u51B_, 0.7039, 3.04, 0.209, 255, 239, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
4107, d2wzjD_, 0.7039, 3.07, 0.226, 313, 235, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4108, d5nkaA_, 0.7038, 3.16, 0.166, 271, 241, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2G
4109, d3cs9A_, 0.7038, 3.36, 0.210, 264, 243, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
4110, d2gs7A_, 0.7038, 3.70, 0.163, 281, 251, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
4111, d1gzkA_, 0.7038, 3.12, 0.200, 271, 240, MOLECULAR MECHANISM FOR THE REGULATION OF PROTEIN KINASE B/ AKT BY HYDROPHOBIC MOTIF PHOSPHORYLATION
4112, d4zlyA_, 0.7037, 3.29, 0.154, 270, 246, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE BOUND TO A CINNOLINE FRAGMENT
4113, d4ybjA_, 0.7037, 3.00, 0.207, 255, 237, TYPE II DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
4114, d3qgyB1, 0.7037, 2.90, 0.200, 244, 235, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
4115, d3gt8D_, 0.7037, 3.63, 0.169, 295, 249, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
4116, d3fskA_, 0.7037, 3.02, 0.191, 342, 235, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6257
4117, d2rg5A_, 0.7037, 2.80, 0.203, 333, 232, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11B
4118, d2gsfA_, 0.7037, 3.24, 0.164, 281, 244, THE HUMAN EPHA3 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
4119, d1yw2A_, 0.7037, 2.93, 0.205, 341, 234, MUTATED MUS MUSCULUS P38 KINASE (MP38)
4120, d1wbtA_, 0.7037, 3.28, 0.210, 351, 238, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
4121, d5u6bA_, 0.7036, 3.15, 0.177, 270, 243, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
4122, d5ei6A1, 0.7036, 2.89, 0.209, 261, 234, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4123, d5awmA_, 0.7036, 3.26, 0.204, 345, 240, THE CRYSTAL STRUCTURE OF JNK FROM DROSOPHILA MELANOGASTER REVEALS AN EVOLUTIONARILY CONSERVED TOPOLOGY WITH THAT OF MAMMALIAN JNK PROTEINS.
4124, d4h58C_, 0.7036, 3.24, 0.223, 272, 242, BRAF IN COMPLEX WITH COMPOUND 3
4125, d3e93A_, 0.7036, 3.24, 0.211, 346, 237, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
4126, d3bysA_, 0.7036, 3.00, 0.207, 255, 237, CO-CRYSTAL STRUCTURE OF LCK AND AMINOPYRIMIDINE AMIDE 10B
4127, d5valB_, 0.7035, 3.10, 0.222, 254, 239, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
4128, d5n93A1, 0.7035, 2.94, 0.201, 256, 234, TTK KINASE DOMAIN IN COMPLEX WITH TC-MPS1-12
4129, d3wyyA_, 0.7035, 3.01, 0.209, 258, 235, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH (E)- 3-(4-((6-(((3S5S7S)-ADAMANTAN-1-YL)AMINO)-4-AMINO-5-CYANOPYRIDIN-2- YL)AMINO)-2-(CYANOMETHOXY)PHENYL)-N-(2-METHOXYETHYL)ACRYLAMIDE
4130, d2wzjA_, 0.7035, 3.07, 0.226, 310, 235, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4131, d2rioB_, 0.7035, 3.19, 0.200, 395, 240, STRUCTURE OF THE DUAL ENZYME IRE1 REVEALS THE BASIS FOR CATALYSIS AND REGULATION OF NON-CONVENTIONAL SPLICING
4132, d2hz4B1, 0.7035, 3.18, 0.208, 248, 240, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
4133, d5tehB_, 0.7034, 3.18, 0.212, 262, 241, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
4134, d3zfxC_, 0.7034, 2.85, 0.150, 248, 234, CRYSTAL STRUCTURE OF EPHB1
4135, p3lhjA_, 0.7034, 3.02, 0.199, 341, 236, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR.
4136, d1a9uA_, 0.7034, 3.29, 0.187, 351, 240, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB203580
4137, d3qudA_, 0.7033, 2.96, 0.205, 345, 234, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO-BENZOPHENONE
4138, d2zazA_, 0.7033, 3.17, 0.199, 345, 236, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH 4-ANILINO QUINOLINE INHIBITOR
4139, d2ogvA_, 0.7033, 3.50, 0.203, 317, 246, CRYSTAL STRUCTURE OF THE AUTOINHIBITED HUMAN C-FMS KINASE DOMAIN
4140, d5tobA_, 0.7032, 3.13, 0.181, 245, 238, SELECTIVITY SWITCH BETWEEN FAK AND PYK2: MACROCYCLIZATION OF FAK INHIBITORS IMPROVES PYK2 POTENCY
4141, d5gtyF_, 0.7032, 3.64, 0.176, 297, 250, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
4142, d4r7hA_, 0.7032, 3.41, 0.205, 308, 244, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX3397
4143, d3rinA_, 0.7032, 3.34, 0.204, 349, 240, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4144, d5cnoB_, 0.7031, 3.63, 0.164, 302, 250, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT V924R
4145, d4r7iA_, 0.7031, 3.38, 0.206, 290, 243, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR GLEEVEC
4146, d4nwmA_, 0.7031, 3.12, 0.161, 261, 242, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
4147, d4i4fA_, 0.7031, 3.21, 0.204, 255, 240, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH AN ALLOSTERIC BINDING PYRAZOLOBENZOTHIAZINE COMPOUND.
4148, p4d28C_, 0.7031, 3.22, 0.202, 279, 238, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
4149, d2rfnB_, 0.7031, 3.06, 0.155, 269, 238, X-RAY STRUCTURE OF C-MET WITH INHIBITOR.
4150, d1snxB_, 0.7031, 2.81, 0.192, 245, 234, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4151, d5nk0A_, 0.7030, 3.16, 0.172, 273, 239, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1J
4152, d4eh7A_, 0.7030, 2.86, 0.207, 337, 232, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F6 AND RL87
4153, d3o8uA_, 0.7030, 2.82, 0.199, 332, 231, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
4154, d3i5nA_, 0.7030, 3.38, 0.186, 280, 242, CRYSTAL STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR 13
4155, d2gs7B_, 0.7030, 3.83, 0.154, 288, 253, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
4156, d1p4oA_, 0.7030, 3.44, 0.200, 308, 245, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
4157, d5ap1A1, 0.7029, 2.93, 0.201, 264, 234, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4158, d4fvqA_, 0.7029, 3.61, 0.161, 274, 248, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN (MG-ATP-BOUND FORM)
4159, d3cekA1, 0.7029, 3.06, 0.208, 252, 236, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK)
4160, d2rg6A_, 0.7029, 2.87, 0.206, 335, 233, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11J
4161, d2hiwA1, 0.7029, 3.42, 0.214, 270, 243, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
4162, d5o26A_, 0.7028, 3.74, 0.182, 271, 253, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A DIPHOSPHORYLATED STATE AND IN COMPLEX WITH AMP-PNP/MG2+
4163, d5mtxA_, 0.7028, 2.83, 0.198, 331, 232, DIBENZOOXEPINONE INHIBITOR 12B IN COMPLEX WITH P38 MAPK
4164, d5kbrB_, 0.7028, 3.11, 0.226, 260, 234, PAK1 IN COMPLEX WITH 7-AZAINDOLE INHIBITOR
4165, d4ibmA_, 0.7028, 3.33, 0.188, 301, 245, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH AN INHIBITOR IRFIN-1
4166, d4ebvA1, 0.7028, 3.22, 0.204, 261, 240, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH NOVEL ALLOSTERIC INHIBITOR
4167, d3zxtA_, 0.7028, 3.02, 0.188, 249, 234, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN IN COMPLEX WITH AMPPCP-MG
4168, d3fmjA_, 0.7028, 3.09, 0.191, 344, 235, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 4-(5-METHYL-3-PHENYL- ISOXAZOL-4-YL)-PYRIMIDIN-2-YLAMINE
4169, d3etaB_, 0.7028, 3.37, 0.210, 292, 243, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
4170, d1p4oB_, 0.7028, 3.45, 0.200, 314, 245, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
4171, d1fpuA1, 0.7028, 3.41, 0.230, 271, 243, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
4172, d5n7vA1, 0.7027, 2.91, 0.201, 257, 234, TTK KINASE DOMAIN IN COMPLEX WITH MPI-0479605
4173, d2rfnA_, 0.7027, 3.07, 0.155, 268, 238, X-RAY STRUCTURE OF C-MET WITH INHIBITOR.
4174, d4eh3A_, 0.7026, 2.87, 0.203, 339, 232, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F2 AND RL87
4175, d4b9dA1, 0.7026, 3.43, 0.172, 286, 244, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
4176, d4apcA1, 0.7026, 3.43, 0.176, 289, 244, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
4177, d5ia4A_, 0.7025, 3.39, 0.168, 269, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH FORETINIB (XL880)
4178, d5ew9A_, 0.7025, 3.22, 0.166, 257, 241, CRYSTAL STRUCTURE OF AURORA A KINASE DOMAIN BOUND TO MK-5108
4179, d5d41A_, 0.7025, 3.53, 0.177, 300, 248, EGFR KINASE DOMAIN IN COMPLEX WITH MUTANT SELECTIVE ALLOSTERIC INHIBITOR
4180, d5ct7B_, 0.7025, 3.05, 0.218, 254, 238, BRAF IN COMPLEX WITH RAF265
4181, d4hcvA_, 0.7025, 3.30, 0.184, 263, 245, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 53
4182, d2rl5A1, 0.7025, 3.33, 0.202, 290, 242, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A 23-DIHYDRO-14-BENZOXAZINE INHIBITOR
4183, d1w83A_, 0.7025, 3.23, 0.211, 351, 237, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4184, d5hesB_, 0.7024, 3.28, 0.226, 278, 239, HUMAN LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK MLT HCCS-4 MRK AZK MLTK) IN COMPLEX WITH VEMURAFENIB
4185, d4awiA_, 0.7024, 3.05, 0.221, 352, 235, HUMAN JNK1ALPHA KINASE WITH 4-PHENYL-7-AZAINDOLE IKK2 INHIBITOR.
4186, d3ii5B_, 0.7024, 3.33, 0.220, 257, 241, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
4187, d3a2cF_, 0.7024, 3.77, 0.166, 287, 247, CRYSTAL STRUCTURE OF A PYRAZOLOPYRIMIDINE INHIBITOR COMPLEX BOUND TO MAPKAP KINASE-2 (MK2)
4188, d5p9mA_, 0.7023, 3.22, 0.156, 271, 244, BTK1 BINDS COVALENTLY TO HY-15771 ONO-4059
4189, d5j5sB_, 0.7023, 3.00, 0.203, 258, 237, SRC KINASE IN COMPLEX WITH A SULFONAMIDE INHIBITOR
4190, d4dggB_, 0.7023, 3.21, 0.220, 259, 241, C-SRC KINASE DOMAIN IN COMPLEX WITH RM-1-176
4191, d4c4fA1, 0.7023, 3.01, 0.201, 250, 234, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4192, d4bi2A1, 0.7023, 2.97, 0.209, 250, 234, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4193, d3qriA1, 0.7023, 3.36, 0.211, 270, 242, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
4194, d3hv4B_, 0.7023, 3.10, 0.209, 338, 235, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
4195, d3flqA_, 0.7023, 3.11, 0.209, 345, 235, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((S)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN
4196, d2oh4A1, 0.7023, 3.52, 0.208, 296, 245, CRYSTAL STRUCTURE OF VEGFR2 WITH A BENZIMIDAZOLE-UREA INHIBITOR
4197, d1mqbA_, 0.7023, 3.15, 0.170, 263, 241, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
4198, d5tbeA_, 0.7022, 2.78, 0.185, 332, 232, HUMAN P38ALPHA MAP KINASE IN COMPLEX WITH DIBENZOSUBERONE COMPOUND 2
4199, d5ehyA1, 0.7022, 3.07, 0.209, 251, 235, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4200, d3c4cA1, 0.7022, 2.99, 0.224, 257, 237, B-RAF KINASE IN COMPLEX WITH PLX4720
4201, d2yn8A_, 0.7022, 2.94, 0.140, 253, 235, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4202, d4usfA1, 0.7021, 3.36, 0.168, 275, 244, HUMAN SLK WITH SB-440719
4203, d4pp9A1, 0.7021, 2.95, 0.195, 245, 236, ITK KINASE DOMAIN WITH COMPOUND 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4- YL]-2H-INDAZOLE-3-CARBOXAMIDE)
4204, d3gcuA_, 0.7021, 3.11, 0.200, 339, 235, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
4205, d3cgoA_, 0.7021, 2.96, 0.205, 332, 234, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
4206, d2vwvA_, 0.7021, 3.01, 0.147, 255, 238, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4207, d5fbnC_, 0.7020, 3.28, 0.156, 256, 243, BTK KINASE DOMAIN WITH INHIBITOR 1
4208, d5csxA_, 0.7020, 3.29, 0.219, 261, 242, CRYSTAL STRUCTURE OF B-RAF IN COMPLEX WITH BI 882370
4209, d4eh6A_, 0.7020, 2.82, 0.195, 335, 231, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F5 AND RL87
4210, d3kc3C_, 0.7020, 3.17, 0.178, 281, 236, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4211, d2hyyA_, 0.7020, 3.23, 0.221, 263, 240, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
4212, d5d11A_, 0.7019, 3.10, 0.213, 254, 239, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL235
4213, d5ceqA_, 0.7019, 3.25, 0.195, 269, 241, DLK IN COMPLEX WITH INHIBITOR 2-((1-CYCLOPENTYL-5-(1-(OXETAN-3-YL) PIPERIDIN-4-YL)-1H-PYRAZOL-3-YL)AMINO)ISONICOTINONITRILE
4214, d3gt8A_, 0.7019, 3.59, 0.164, 300, 250, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
4215, d3b8rB_, 0.7019, 3.05, 0.207, 267, 237, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
4216, d2pkjA_, 0.7019, 2.71, 0.204, 332, 230,  
4217, d1zmwB_, 0.7019, 3.18, 0.225, 302, 236, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
4218, d1zmwA_, 0.7019, 3.18, 0.225, 302, 236, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
4219, d1fpuB1, 0.7019, 3.43, 0.230, 266, 243, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
4220, d4hw7A_, 0.7018, 3.40, 0.206, 289, 243, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX647-OME
4221, d4hjoA_, 0.7018, 3.89, 0.161, 278, 254, CRYSTAL STRUCTURE OF THE INACTIVE EGFR TYROSINE KINASE DOMAIN WITH ERLOTINIB
4222, d4eh8A_, 0.7018, 2.82, 0.195, 336, 231, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F7 AND RL87
4223, d3qgyA1, 0.7018, 2.91, 0.196, 244, 235, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
4224, d2w99B_, 0.7018, 3.16, 0.176, 291, 238, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
4225, d1wbnA_, 0.7018, 3.33, 0.202, 351, 238, FRAGMENT BASED P38 INHIBITORS
4226, d1ukiA_, 0.7018, 2.93, 0.231, 328, 234, STRUCTURAL BASIS FOR THE SELECTIVE INHIBITION OF JNK1 BY THE SCAFFOLDING PROTEIN JIP1 AND SP600125
4227, d5w5jB_, 0.7017, 3.12, 0.150, 257, 240, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
4228, d5to8A_, 0.7017, 2.97, 0.165, 250, 236, SELECTIVITY SWITCH BETWEEN FAK AND PYK2: MACROCYCLIZATION OF FAK INHIBITORS IMPROVES PYK2 POTENCY
4229, d5ap4A1, 0.7017, 2.94, 0.202, 253, 233, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4230, d4qtdA_, 0.7017, 3.25, 0.218, 355, 239, STRUCTURE OF HUMAN JNK1 IN COMPLEX WITH SCH772984 AND THE AMPPNP- HYDROLYSED TRIPHOSPHATE REVEALING THE SECOND TYPE-I BINDING MODE
4231, d3tudA1, 0.7017, 3.06, 0.189, 255, 238, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH N-(4-METHYL-3-(8-METHYL-7- OXO-2-(PHENYLAMINO)-78-DIHYDROPYRIDO[23-D]PYRIMIDIN-6-YL)PHENYL)-3- (TRIFLUOROMETHYL)BENZAMIDE
4232, d3hv5A_, 0.7017, 3.13, 0.209, 339, 235, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
4233, d2gtnA_, 0.7017, 2.97, 0.209, 337, 234, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-951717
4234, d5ng3B_, 0.7016, 3.22, 0.173, 275, 243, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
4235, d5ehoA1, 0.7016, 2.89, 0.210, 255, 233, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4236, d4u3yA_, 0.7016, 3.99, 0.169, 295, 260, APO MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4)
4237, d4bi1A1, 0.7016, 2.95, 0.210, 249, 233, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4238, d3t9tA_, 0.7016, 3.28, 0.184, 263, 245, CRYSTAL STRUCTURE OF BTK MUTANT (F435TK596R) COMPLEXED WITH IMIDAZO[15-A]QUINOXALINE
4239, d3o50B_, 0.7016, 2.88, 0.199, 249, 236, CRYSTAL STRUCTURE OF BENZAMIDE 9 BOUND TO AURORAA
4240, d3mvmB_, 0.7016, 2.77, 0.203, 332, 231, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
4241, d3dxnA_, 0.7016, 3.59, 0.228, 258, 246, CRYSTAL STRUCTURE OF THE CALCIUM-DEPENDENT KINASE FROM TOXOPLASMA GONDII 541.M00134 KINASE DOMAIN.
4242, d2wzjE_, 0.7016, 3.05, 0.226, 310, 234, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4243, d5cepA_, 0.7015, 3.28, 0.195, 269, 241, DLK IN COMPLEX WITH INHIBITOR N-(1-ISOPROPYL-5-(PIPERIDIN-4-YL)-1H- PYRAZOL-3-YL)-4-(TRIFLUOROMETHYL)PYRIDIN-2-AMINE
4244, d4fg9B_, 0.7015, 3.55, 0.171, 279, 245, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-320 IN COMPLEX WITH ATP
4245, d3uc3A_, 0.7015, 3.05, 0.182, 272, 236, THE CRYSTAL STRUCTURE OF SNF1-RELATED KINASE 2.3
4246, d3q96A_, 0.7015, 3.25, 0.221, 253, 240, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
4247, d2qonA_, 0.7015, 3.21, 0.165, 281, 243, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:Y742A TRIPLE MUTANT
4248, d5i8aA1, 0.7014, 2.89, 0.205, 265, 234, TRKA WITH (6~{R})-3-METHYLSULFANYL-6-PHENYL-1-(1~{H}-PYRAZOL-3-YL)-6 7-DIHYDRO-5~{H}-THIENO[34-C]PYRIDIN-4-ONE
4249, d1wbvA_, 0.7014, 3.29, 0.202, 351, 238, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
4250, d5jrsA1, 0.7013, 3.05, 0.163, 257, 239, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -34-DIHYDROQUINAZOLIN-3-YL) PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
4251, d5fbnD_, 0.7013, 3.18, 0.158, 255, 241, BTK KINASE DOMAIN WITH INHIBITOR 1
4252, d4c4eA1, 0.7013, 2.97, 0.202, 253, 233, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4253, d3o23A_, 0.7013, 3.44, 0.201, 293, 244, HUMAN UNPHOSPHORYLATED IGF1-R KINASE DOMAIN IN COMPLEX WITH AN HYDANTOIN INHIBITOR
4254, d1iepB1, 0.7013, 3.27, 0.228, 270, 241, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
4255, d5ljjA1, 0.7012, 2.99, 0.209, 260, 234, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH REVERSINE
4256, d3svvB_, 0.7012, 2.95, 0.216, 257, 236, CRYSTAL STRUCTURE OF T338C C-SRC COVALENTLY BOUND TO VINYLSULFONAMIDE- PYRAZOLOPYRIMIDINE 9
4257, d3queA_, 0.7012, 2.92, 0.206, 343, 233, HUMAN P38 MAP KINASE IN COMPLEX WITH SKEPINONE-L
4258, d3c4dA1, 0.7012, 3.01, 0.224, 257, 237,  
4259, d2zduA_, 0.7012, 3.01, 0.207, 330, 237, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
4260, d2yixA_, 0.7012, 3.37, 0.204, 351, 240, TRIAZOLOPYRIDINE INHIBITORS OF P38
4261, d1zyjA_, 0.7012, 2.75, 0.204, 331, 230, HUMAN P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1A
4262, d4dbnB_, 0.7011, 3.13, 0.218, 263, 238, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
4263, d4c4gA1, 0.7011, 2.87, 0.194, 247, 232, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4264, d3is5C1, 0.7011, 3.33, 0.229, 254, 240, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4265, d3idpA_, 0.7011, 3.27, 0.229, 255, 240, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
4266, d3dajA_, 0.7011, 2.69, 0.190, 245, 232, CRYSTAL STRUCTURE OF AURORA A COMPLEXED WITH AN INHIBITOR DISCOVERED THROUGH SITE-DIRECTED DYNAMIC TETHERING
4267, d3uvqA_, 0.7010, 2.80, 0.199, 333, 231, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOSUBERONE DERIVATIVE
4268, d3p78A_, 0.7010, 2.85, 0.203, 332, 231, P38 INHIBITOR-BOUND
4269, d3p5kA_, 0.7010, 2.84, 0.203, 332, 231, P38 INHIBITOR-BOUND
4270, d3mh0A_, 0.7010, 2.80, 0.203, 332, 231, MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
4271, d3flnC_, 0.7010, 2.97, 0.202, 343, 233, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH R1487
4272, d2j90A1, 0.7010, 3.07, 0.183, 259, 235, CRYSTAL STRUCTURE OF HUMAN ZIP KINASE IN COMPLEX WITH A TETRACYCLIC PYRIDONE INHIBITOR (PYRIDONE 6)
4273, d1r0pA_, 0.7010, 3.46, 0.185, 301, 243, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH THE MICROBIAL ALKALOID K-252A
4274, d1m7nB_, 0.7010, 3.46, 0.200, 299, 245, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
4275, d5etiA1, 0.7009, 3.29, 0.197, 352, 239, STRUCTURE OF DEAD KINASE MAPK14
4276, d5ei2A_, 0.7009, 2.95, 0.209, 256, 234, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4277, d4mf1B1, 0.7009, 3.06, 0.193, 244, 238, ITK KINASE DOMAIN IN COMPLEX WITH BENZOTHIAZOLE INHIBITOR 12B (1S2S)- 2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-13- BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
4278, d3w1fA_, 0.7009, 3.12, 0.208, 259, 236, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 5-(5- ETHOXY-6-(1-METHYL-1H-PYRAZOL-4-YL)-1H-INDAZOL-3-YL)-2- METHYLBENZENESULFONAMIDE
4279, d3fe3A_, 0.7009, 3.19, 0.231, 317, 238, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
4280, d3c4cB1, 0.7009, 3.16, 0.218, 256, 239, B-RAF KINASE IN COMPLEX WITH PLX4720
4281, d1qcfA3, 0.7009, 3.48, 0.166, 281, 247, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH A SRC FAMILY- SELECTIVE TYROSINE KINASE INHIBITOR
4282, d6b8uA_, 0.7008, 3.29, 0.225, 253, 240, CRYSTALS STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINYL BENZAMIDE INHIBITOR
4283, d5ap6A1, 0.7008, 2.95, 0.209, 259, 234, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4284, d4w4xA_, 0.7008, 3.33, 0.192, 342, 240, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-FLUOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
4285, d3fknA_, 0.7008, 3.24, 0.194, 346, 237, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO7125
4286, d5ap7A1, 0.7007, 3.00, 0.209, 253, 234, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4287, d4kkeA_, 0.7006, 3.21, 0.202, 354, 238, THE CRYSTAL STRUCTURE OF AMP-BOUND JNK3
4288, d4c3pD_, 0.7006, 3.24, 0.188, 260, 239, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO TPX2 AND AMPPCP
4289, d3p7bA_, 0.7006, 2.85, 0.203, 332, 231, P38 INHIBITOR-BOUND
4290, d3gcuB_, 0.7006, 3.12, 0.209, 337, 235, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
4291, d3cd8A_, 0.7006, 3.40, 0.174, 278, 242, X-RAY STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR.
4292, d2a1aB1, 0.7006, 3.38, 0.226, 266, 243, PKR KINASE DOMAIN-EIF2ALPHA COMPLEX
4293, d5vo1A_, 0.7005, 3.28, 0.195, 269, 241, DLK IN COMPLEX WITH COMPOUND 10 (5-(1-ISOPROPYL-5-(3-(OXETAN-3-YL)-3- AZABICYCLO[3.1.0]HEXAN-6-YL)-1H-PYRAZOL-3-YL)-3-(TRIFLUOROMETHYL) PYRIDIN-2-AMINE)
4294, d5l6pA_, 0.7005, 3.08, 0.155, 274, 239, EPHB3 KINASE DOMAIN COVALENTLY BOUND TO AN IRREVERSIBLE INHIBITOR (COMPOUND 6)
4295, d4w4yA_, 0.7005, 3.57, 0.198, 350, 242, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-METHYLPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
4296, d4i4eA_, 0.7005, 3.06, 0.209, 254, 239, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH HINGE BINDING PYRAZOLOBENZOTHIAZINE COMPOUND.
4297, d3g33C_, 0.7005, 3.01, 0.196, 291, 235, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
4298, d5uojA_, 0.7004, 3.07, 0.183, 343, 235, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTROMS RESOLUTION
4299, d5uabA_, 0.7004, 3.59, 0.189, 288, 243, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
4300, d5d12B_, 0.7004, 3.11, 0.210, 253, 238, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL40
4301, d3en5B_, 0.7004, 3.09, 0.218, 261, 239, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP494 A MULTITARGETED KINASE INHIBITOR
4302, d3uvpA_, 0.7003, 2.89, 0.185, 334, 232, HUMAN P38 MAP KINASE IN COMPLEX WITH A BENZAMIDE SUBSTITUTED BENZOSUBERONE
4303, d3p7cA_, 0.7003, 2.86, 0.203, 332, 231, P38 INHIBITOR-BOUND
4304, d3p79A_, 0.7003, 2.86, 0.203, 332, 231, P38 INHIBITOR-BOUND
4305, d2oibD_, 0.7003, 3.47, 0.207, 288, 246, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
4306, p5oktA2, 0.7002, 0.77, 0.995, 204, 204, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH IWP-2 
4307, d5l6oA_, 0.7002, 3.22, 0.146, 267, 240, EPHB3 KINASE DOMAIN COVALENTLY BOUND TO AN IRREVERSIBLE INHIBITOR (COMPOUND 3)
4308, d5e1sA_, 0.7002, 3.21, 0.208, 284, 240, THE CRYSTAL STRUCTURE OF INSR TYROSINE KINASE IN COMPLEX WITH THE INHIBITOR BI 885578
4309, d4w4vA_, 0.7002, 3.39, 0.199, 342, 241, JNK2/3 IN COMPLEX WITH 3-(4-{[(2-CHLOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
4310, d4qq5A1, 0.7002, 3.19, 0.204, 272, 240, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE HARBORING THE V550L GATE-KEEPER MUTATION IN COMPLEX WITH FIIN-2 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
4311, d4c4jA1, 0.7002, 3.03, 0.205, 258, 234, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4312, d1yqjA2, 0.7002, 3.32, 0.197, 351, 239, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH A SELECTIVE PYRIDAZINE INHIBITOR
4313, d1iepA1, 0.7002, 3.31, 0.228, 270, 241, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
4314, d4knbC_, 0.7001, 3.41, 0.183, 271, 241, C-MET IN COMPLEX WITH OSI LIGAND
4315, d3wzdA_, 0.7001, 3.11, 0.206, 278, 238, KDR IN COMPLEX WITH LIGAND LENVATINIB
4316, d3v5qB1, 0.7001, 3.08, 0.198, 262, 237, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
4317, d3o8tA_, 0.7001, 2.87, 0.199, 332, 231, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG-MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
4318, d3itzA1, 0.7001, 3.29, 0.201, 353, 239, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDAZINE INHIBITOR
4319, d3cjfA_, 0.7001, 3.27, 0.212, 276, 241, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 345-TRIMETHOXY ANILINE CONTAINING PYRIMIDINE
4320, d3cgfA_, 0.7001, 3.06, 0.213, 346, 235, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
4321, d2y6oA_, 0.7001, 3.15, 0.151, 263, 239, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH DASATINIB.
4322, d1r39A_, 0.7001, 3.27, 0.193, 345, 238, THE STRUCTURE OF P38ALPHA
4323, d1m7nA_, 0.7001, 3.41, 0.201, 299, 244, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
4324, d5n9sA1, 0.7000, 3.02, 0.201, 256, 234, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1161909
4325, d5fboA_, 0.7000, 3.19, 0.169, 255, 242, BTK-INHIBITOR CO-STRUCTURE
4326, d4c4iA1, 0.7000, 2.98, 0.205, 250, 234, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4327, d5vo2A_, 0.6999, 3.29, 0.195, 269, 241, DLK IN COMPLEX WITH INHIBITOR 5-(1-ISOPROPYL-5-(1-(OXETAN-3-YL) PIPERIDIN-4-YL)-1H-PYRAZOL-3-YL)-3-(TRIFLUOROMETHYL)PYRIDIN-2-AMINE (COMPOUND 7)
4328, d5nkiA_, 0.6999, 3.14, 0.169, 268, 237, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4B
4329, d4cv9A1, 0.6999, 3.14, 0.191, 250, 235, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
4330, d3vrzB3, 0.6999, 3.27, 0.170, 269, 241, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
4331, d1zzlA_, 0.6999, 3.39, 0.204, 351, 240, CRYSTAL STRUCTURE OF P38 WITH TRIAZOLOPYRIDINE
4332, d5c9cA_, 0.6998, 3.24, 0.215, 254, 237, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
4333, d3hv5B_, 0.6998, 3.14, 0.213, 339, 235, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
4334, d3dkgA_, 0.6998, 3.39, 0.170, 281, 241, STRUCTURE OF MUTANT(Y1248L) MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
4335, d3c4dB1, 0.6998, 3.23, 0.218, 256, 239,  
4336, d2zdtA_, 0.6998, 3.07, 0.213, 342, 235, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
4337, d2w5aA1, 0.6998, 3.09, 0.174, 259, 235, HUMAN NEK2 KINASE ADP-BOUND
4338, d2p33A_, 0.6998, 3.01, 0.213, 332, 235, SYNTHESIS AND SAR OF AMINOPYRIMIDINES AS NOVEL C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
4339, d2hakD_, 0.6998, 3.04, 0.234, 309, 235, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4340, d1jvpP_, 0.6998, 3.32, 0.178, 268, 241, CRYSTAL STRUCTURE OF HUMAN CDK2 (UNPHOSPHORYLATED) IN COMPLEX WITH PKF049-365
4341, d5ap3A1, 0.6997, 2.96, 0.202, 250, 233, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4342, d4cvaA1, 0.6997, 3.02, 0.192, 250, 234, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
4343, d4cv8A1, 0.6997, 3.12, 0.213, 252, 235, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
4344, d3fv8A_, 0.6997, 3.07, 0.208, 331, 236, JNK3 BOUND TO PIPERAZINE AMIDE INHIBITOR SR2774.
4345, d2x9eA_, 0.6997, 3.04, 0.200, 253, 235, HUMAN MPS1 IN COMPLEX WITH NMS-P715
4346, d2qq7A_, 0.6997, 2.97, 0.226, 251, 235, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN WITH IRREVERSIBLE INHIBITOR
4347, d2oicD_, 0.6997, 3.31, 0.220, 284, 241, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
4348, d3p86A_, 0.6996, 2.85, 0.209, 250, 234, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN MUTANT D676N IN COMPLEX WITH STAUROSPORINE
4349, d3mh1A_, 0.6996, 2.94, 0.189, 337, 233, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
4350, d3gcvA_, 0.6996, 2.95, 0.203, 338, 232, HUMAN P38 MAP KINASE IN COMPLEX WITH RL62
4351, d3ds6D_, 0.6996, 3.29, 0.205, 349, 239, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
4352, d2vwwA_, 0.6996, 2.98, 0.148, 253, 237, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4353, d1zmuB_, 0.6996, 2.82, 0.229, 296, 231, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: WILD TYPE
4354, d5bvnA_, 0.6995, 3.28, 0.216, 278, 241, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
4355, d5ar8A_, 0.6995, 3.08, 0.164, 255, 238, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIPHENYLSULFONAMIDE
4356, d4r3cA_, 0.6995, 2.89, 0.203, 335, 232, CRYSTAL STRUCTURE OF P38 ALPHA MAP KINASE IN COMPLEX WITH A NOVEL ISOFORM SELECTIVE DRUG CANDIDATE
4357, d3g33A_, 0.6995, 3.03, 0.196, 291, 235, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
4358, d2pl0A_, 0.6995, 3.27, 0.217, 268, 240, LCK BOUND TO IMATINIB
4359, d5l2sA_, 0.6994, 2.95, 0.194, 263, 232, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND ABEMACICLIB.
4360, d4w4wA_, 0.6994, 3.22, 0.210, 349, 238, JNK2/3 IN COMPLEX WITH N-(2-METHYLPYRIDIN-4-YL)-3-{4- [(PHENYLCARBAMOYL)AMINO]-1H-PYRAZOL-1-YL}BENZAMIDE
4361, d4gk2A_, 0.6994, 3.02, 0.169, 265, 237, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 66
4362, d4ebwA_, 0.6994, 3.29, 0.204, 259, 240, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH NOVEL ALLOSTERIC INHIBITOR
4363, d2pv8A_, 0.6994, 2.95, 0.185, 337, 233,  
4364, d4l7fA1, 0.6993, 3.15, 0.219, 343, 237, CO-CRYSTAL STRUCTURE OF JNK1 AND AX13587
4365, d2nruA_, 0.6993, 3.47, 0.203, 293, 246, CRYSTAL STRUCTURE OF IRAK-4
4366, d5valA_, 0.6992, 3.13, 0.215, 254, 237, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
4367, d4o6lB_, 0.6992, 2.99, 0.209, 256, 234, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
4368, d4h1mA_, 0.6992, 3.18, 0.154, 256, 240, CRYSTAL STRUCTURE OF PYK2 WITH THE INDOLE 10C
4369, d2x81A_, 0.6992, 2.58, 0.193, 242, 228, STRUCTURE OF AURORA A IN COMPLEX WITH MLN8054
4370, d2ghlA_, 0.6992, 2.97, 0.197, 334, 233, MUTANT MUS MUSCULUS P38 KINASE DOMAIN IN COMPLEX WITH INHIBITOR PG-874743
4371, d1yolB_, 0.6992, 2.97, 0.191, 253, 235, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH CGP77675
4372, d1jqhB_, 0.6992, 3.45, 0.203, 287, 246, IGF-1 RECEPTOR KINASE DOMAIN
4373, d5ut4A_, 0.6991, 3.65, 0.157, 273, 248, JAK2 JH2 IN COMPLEX WITH NVP-BSK805
4374, d5j87C_, 0.6991, 3.20, 0.161, 261, 242, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
4375, d5hu9A1, 0.6991, 3.50, 0.215, 262, 242, CRYSTAL STRUCTURE OF ABL1 IN COMPLEX WITH CHMFL-074
4376, d4x21A_, 0.6991, 2.93, 0.219, 336, 233, THE MAP KINASE JNK3 AS TARGET FOR HALOGEN BONDING
4377, d3ccnA_, 0.6991, 3.33, 0.187, 275, 240, X-RAY STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR.
4378, d2hiwB1, 0.6991, 3.39, 0.223, 270, 242, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
4379, d1rjbA_, 0.6991, 3.44, 0.190, 298, 242, CRYSTAL STRUCTURE OF FLT3
4380, p5etaB_, 0.6990, 2.89, 0.198, 335, 232, STRUCTURE OF MAPK14 WITH BOUND THE KIM DOMAIN OF THE TOXOPLASMA PROTEIN GRA24
4381, d4kkhA_, 0.6990, 3.24, 0.210, 351, 238, THE CRYSTAL STRUCTURE OF INHIBITOR-BOUND JNK3
4382, d4agwB_, 0.6990, 3.11, 0.197, 257, 238, DISCOVERY OF A SMALL MOLECULE TYPE II INHIBITOR OF WILD- TYPE AND GATEKEEPER MUTANTS OF BCR-ABL PDGFRALPHA KIT AND SRC KINASES
4383, d3wzkA_, 0.6990, 3.05, 0.209, 258, 234, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH N- CYCLOPROPYL-4-(8-((THIOPHEN-2-YLMETHYL)AMINO)IMIDAZO[12-A]PYRAZIN-3- YL)BENZAMIDE
4384, d3v5lD1, 0.6990, 3.05, 0.194, 244, 237, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
4385, d3mpmA_, 0.6990, 3.20, 0.192, 257, 239, LCK COMPLEXED WITH A PYRAZOLOPYRIMIDINE
4386, d3gfwA1, 0.6990, 3.04, 0.205, 249, 234, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYROLO-PYRIDIN LIGAND
4387, d2zmcA_, 0.6990, 3.05, 0.213, 260, 235, CRYSTAL STRUCTURE OF HUMAN MITOTIC CHECKPOINT KINASE MPS1 CATALYTIC DOMAIN APO FORM
4388, d1wfcA_, 0.6990, 3.30, 0.194, 340, 237, STRUCTURE OF APO UNPHOSPHORYLATED P38 MITOGEN ACTIVATED PROTEIN KINASE P38 (P38 MAP KINASE) THE MAMMALIAN HOMOLOGUE OF THE YEAST HOG1 PROTEIN
4389, d1jqhA_, 0.6990, 3.44, 0.203, 291, 246, IGF-1 RECEPTOR KINASE DOMAIN
4390, d5jsmA1, 0.6989, 3.38, 0.242, 262, 244, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
4391, d4l01B_, 0.6989, 3.48, 0.183, 274, 246, CRYSTAL STRUCTURE OF THE V658F APO JAK1 PSEUDOKINASE DOMAIN
4392, d3wzjA_, 0.6989, 3.20, 0.208, 257, 236, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(6- (CYCLOHEXYLAMINO)-8-(((TETRAHYDRO-2H-PYRAN-4-YL)METHYL)AMINO) IMIDAZO[12-B]PYRIDAZIN-3-YL)-N-CYCLOPROPYLBENZAMIDE
4393, d3v8tB1, 0.6989, 3.05, 0.195, 242, 236, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 477
4394, d2nryD_, 0.6989, 3.58, 0.212, 282, 245, CRYSTAL STRUCTURE OF IRAK-4
4395, d3nuxA_, 0.6988, 2.92, 0.173, 261, 231, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
4396, d2xyuA_, 0.6988, 3.17, 0.151, 260, 239, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH VUF 12058
4397, d4ic8B_, 0.6987, 3.30, 0.229, 336, 240, CRYSTAL STRUCTURE OF THE APO ERK5 KINASE DOMAIN
4398, d4fvpA_, 0.6987, 3.59, 0.170, 274, 247, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN (APO FORM)
4399, d3oefX_, 0.6987, 2.97, 0.197, 334, 233, CRYSTAL STRUCTURE OF Y323F INACTIVE MUTANT OF P38ALPHA MAP KINASE
4400, d3o50A_, 0.6987, 2.77, 0.193, 246, 233, CRYSTAL STRUCTURE OF BENZAMIDE 9 BOUND TO AURORAA
4401, d5ap5A1, 0.6986, 2.96, 0.202, 248, 233, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4402, d4q9sA_, 0.6986, 2.98, 0.203, 252, 236, CRYSTAL STRUCTURE OF HUMAN FOCAL ADHESION KINASE (FAK) BOUND TO COMPOUND1 (35-DIHYDRO[124]TRIAZINO[34-C][14]BENZOXAZIN-2(1H)- ONE)
4403, d3o8pA_, 0.6986, 3.00, 0.201, 336, 234, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
4404, d2p2hA1, 0.6986, 3.47, 0.201, 289, 244, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDINYL-TRIAZINE INHIBITOR
4405, d5o26B_, 0.6985, 3.67, 0.189, 265, 249, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A DIPHOSPHORYLATED STATE AND IN COMPLEX WITH AMP-PNP/MG2+
4406, d4m0yA_, 0.6985, 3.33, 0.188, 263, 245, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 1 [4- (CARBAMOYLAMINO)-1-(NAPHTHALEN-1-YL)-1H-PYRAZOLE-3-CARBOXAMIDE]
4407, d3be2A1, 0.6985, 3.41, 0.210, 285, 243, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZAMIDE INHIBITOR
4408, d1zmvB_, 0.6985, 2.83, 0.216, 296, 231, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: K82R MUTANT
4409, d5l2iA_, 0.6984, 2.90, 0.183, 260, 230, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND PALBOCICLIB.
4410, d4ynoA_, 0.6984, 3.19, 0.218, 342, 238, CRYSTAL STRUCTURE OF MAPK13 AT INACTIVE FORM
4411, d3idpB_, 0.6984, 3.32, 0.221, 256, 240, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
4412, d3genA_, 0.6984, 3.23, 0.152, 264, 243, THE 1.6 A CRYSTAL STRUCTURE OF HUMAN BRUTON S TYROSINE KINASE BOUND TO A PYRROLOPYRIMIDINE-CONTAINING COMPOUND
4413, d3bbtB_, 0.6984, 3.43, 0.172, 274, 244, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN COMPLEX WITH LAPATINIB
4414, d2nruB_, 0.6984, 3.50, 0.203, 294, 246, CRYSTAL STRUCTURE OF IRAK-4
4415, d1k9aC3, 0.6984, 3.36, 0.206, 266, 243, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
4416, d1jqhC_, 0.6984, 3.46, 0.203, 291, 246, IGF-1 RECEPTOR KINASE DOMAIN
4417, d4qqcA1, 0.6983, 3.26, 0.175, 271, 240, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN IN COMPLEX WITH FIIN-2 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
4418, d3uvrA_, 0.6983, 3.12, 0.196, 331, 235, HUMAN P38 MAP KINASE IN COMPLEX WITH KM064
4419, d3mpaA_, 0.6983, 2.79, 0.196, 331, 230, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
4420, d3hmoA_, 0.6983, 3.02, 0.209, 257, 234, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH THE INHIBITOR STAUROSPORINE
4421, d3hecA_, 0.6983, 2.74, 0.189, 329, 228, P38 IN COMPLEX WITH IMATINIB
4422, d3etaA_, 0.6983, 3.49, 0.205, 293, 244, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
4423, d2w5bA1, 0.6983, 3.11, 0.183, 263, 235, HUMAN NEK2 KINASE ATPGAMMAS-BOUND
4424, d5n66A_, 0.6982, 2.82, 0.196, 332, 230, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9J
4425, d3piyA_, 0.6982, 3.29, 0.171, 262, 240, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH R406
4426, d3lmgA_, 0.6982, 3.56, 0.146, 268, 247, CRYSTAL STRUCTURE OF THE ERBB3 KINASE DOMAIN IN COMPLEX WITH AMP-PNP
4427, d3ds6A_, 0.6982, 3.33, 0.187, 343, 240, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
4428, d3vs3B3, 0.6981, 3.15, 0.167, 271, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
4429, d3gcqA_, 0.6981, 2.88, 0.203, 337, 231, HUMAN P38 MAP KINASE IN COMPLEX WITH RL45
4430, d3dfaA1, 0.6981, 3.25, 0.194, 262, 242, CRYSTAL STRUCTURE OF KINASE DOMAIN OF CALCIUM-DEPENDENT PROTEIN KINASE CGD3_920 FROM CRYPTOSPORIDIUM PARVUM
4431, d3w18B_, 0.6980, 2.79, 0.197, 236, 229, STRUCTURE OF AURORA KINASE A COMPLEXED TO BENZOIMIDAZOLE-INDAZOLE INHIBITOR XIII
4432, d3fmmA_, 0.6980, 3.23, 0.203, 346, 237, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6226
4433, d1snuB_, 0.6980, 2.88, 0.197, 241, 233, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4434, d5gtyC_, 0.6979, 3.64, 0.190, 295, 248, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
4435, d2c0tA3, 0.6979, 3.20, 0.167, 268, 240, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
4436, d4ynzA1, 0.6978, 3.03, 0.220, 306, 236, STRUCTURE OF THE N-TERMINAL DOMAIN OF SAD
4437, p4whzA_, 0.6978, 3.11, 0.209, 342, 235, DESIGN AND SYNTHESIS OF HIGHLY POTENT AND ISOFORM SELECTIVE JNK3 INHIBITORS: SAR STUDIES ON AMINOPYRAZOLE DERIVATIVES
4438, d4dljA_, 0.6978, 2.90, 0.199, 336, 231, HUMAN P38 MAP KINASE IN COMPLEX WITH RL163
4439, d2w9zB_, 0.6978, 3.23, 0.176, 287, 239, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
4440, d2gfsA_, 0.6978, 3.22, 0.194, 344, 237, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3201195
4441, d1ny3A_, 0.6978, 3.15, 0.179, 277, 235, CRYSTAL STRUCTURE OF ADP BOUND TO MAP KAP KINASE 2
4442, d1jnkA_, 0.6978, 3.10, 0.204, 346, 235, THE C-JUN N-TERMINAL KINASE (JNK3S) COMPLEXED WITH MGAMP-PNP
4443, d1i44A_, 0.6978, 3.17, 0.218, 282, 239, CRYSTALLOGRAPHIC STUDIES OF AN ACTIVATION LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
4444, d4agwA_, 0.6977, 3.09, 0.197, 258, 238, DISCOVERY OF A SMALL MOLECULE TYPE II INHIBITOR OF WILD- TYPE AND GATEKEEPER MUTANTS OF BCR-ABL PDGFRALPHA KIT AND SRC KINASES
4445, d3v5qA1, 0.6977, 3.13, 0.203, 260, 237, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
4446, d3u4wA_, 0.6977, 3.48, 0.186, 275, 247, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC4B
4447, d3hv3A_, 0.6977, 2.88, 0.199, 335, 231, HUMAN P38 MAP KINASE IN COMPLEX WITH RL49
4448, d2henD1, 0.6977, 3.10, 0.146, 258, 239, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
4449, d1irkA_, 0.6977, 3.34, 0.207, 303, 241, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HUMAN INSULIN RECEPTOR
4450, d5tcoA_, 0.6976, 2.74, 0.197, 327, 229, HUMAN P38 MAP KINASE IN COMPLEX WITH DIBENZOSUBERONE COMPOUND 1
4451, d5c9cB_, 0.6976, 3.26, 0.218, 251, 238, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
4452, d2c0tB3, 0.6976, 3.21, 0.167, 268, 240, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
4453, d5jsmB1, 0.6975, 3.47, 0.238, 259, 244, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
4454, d5cswB_, 0.6975, 3.10, 0.224, 252, 237, B-RAF IN COMPLEX WITH DABRAFENIB
4455, d4kkgA_, 0.6975, 3.17, 0.215, 353, 237, CRYSTAL STRUCTURE OF APO AND AMP-BOUND JNK3
4456, d3b8qB_, 0.6975, 3.12, 0.203, 271, 237, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
4457, d2henB1, 0.6975, 3.10, 0.146, 258, 239, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
4458, d2c0iA3, 0.6975, 3.17, 0.167, 268, 239, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
4459, d4pmtA1, 0.6974, 3.13, 0.206, 269, 238, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N~4~-(4-MORPHOLIN- 4-YLPHENYL)-N~6~-(PYRIDIN-3-YLMETHYL)PYRIDO[32-D]PYRIMIDINE-46- DIAMINE
4460, d3vs7A3, 0.6974, 3.20, 0.183, 267, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
4461, d3vs6B3, 0.6974, 3.17, 0.171, 269, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
4462, d2og8A_, 0.6974, 2.96, 0.205, 246, 234, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 36 BOUND TO LCK
4463, d1yolA_, 0.6974, 3.01, 0.196, 256, 235, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH CGP77675
4464, d4bbmB1, 0.6973, 3.40, 0.196, 288, 235, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
4465, d3kc3D_, 0.6973, 3.25, 0.174, 269, 236, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4466, d1oveA_, 0.6973, 3.44, 0.204, 349, 240, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROQUINOLINONE
4467, d5jrqA1, 0.6972, 3.33, 0.244, 257, 242, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-6-VEM
4468, d5bvoA_, 0.6972, 3.23, 0.213, 276, 239, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
4469, d5a6nB1, 0.6972, 3.15, 0.191, 265, 236, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH COMPOUND 2
4470, d3vs1A3, 0.6972, 3.27, 0.187, 268, 241, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
4471, d3gi3A_, 0.6972, 2.75, 0.193, 330, 228, CRYSTAL STRUCTURE OF A N-PHENYL-N -NAPHTHYLUREA ANALOG IN COMPLEX WITH P38 MAP KINASE
4472, d4otiA_, 0.6971, 2.72, 0.211, 303, 228, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH TOFACITINIB
4473, d3ms9B1, 0.6971, 3.39, 0.216, 267, 241, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
4474, d3kexA_, 0.6971, 3.52, 0.146, 292, 247, CRYSTAL STRUCTURE OF THE CATALYTICALLY INACTIVE KINASE DOMAIN OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
4475, d4yr8A_, 0.6970, 2.83, 0.213, 320, 230, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
4476, d3ds6B_, 0.6970, 3.37, 0.199, 343, 241, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
4477, d5cswA_, 0.6969, 3.16, 0.227, 254, 238, B-RAF IN COMPLEX WITH DABRAFENIB
4478, d4oa2A_, 0.6969, 3.40, 0.213, 280, 244,  
4479, d4js8A_, 0.6969, 3.02, 0.202, 259, 233, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401348
4480, d4c3fA_, 0.6969, 3.14, 0.197, 257, 238, STRUCTURE OF LCK IN COMPLEX WITH A COMPOUND DISCOVERED BY VIRTUAL FRAGMENT LINKING
4481, d4bhzA1, 0.6969, 2.91, 0.203, 248, 231, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4482, d3kexB_, 0.6969, 3.53, 0.146, 283, 247, CRYSTAL STRUCTURE OF THE CATALYTICALLY INACTIVE KINASE DOMAIN OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
4483, d3fkoA_, 0.6969, 3.24, 0.203, 343, 236, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3668
4484, d3cp9B_, 0.6969, 3.21, 0.206, 269, 238, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
4485, d1sm2B_, 0.6969, 2.88, 0.197, 241, 233, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4486, d5h0eA3, 0.6968, 3.35, 0.169, 281, 243, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANAMIDE
4487, d3nnxA_, 0.6968, 2.96, 0.208, 336, 231, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38 ALPHA IN COMPLEX WITH DP802
4488, d2rfeD_, 0.6968, 3.50, 0.167, 278, 245, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
4489, d4kspB_, 0.6967, 3.24, 0.218, 256, 238, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
4490, d3eflB_, 0.6967, 3.09, 0.203, 263, 236, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
4491, d2jc6A_, 0.6967, 3.36, 0.159, 278, 239, CRYSTAL STRUCTURE OF HUMAN CALMODULIN-DEPENDENT PROTEIN KINASE 1D
4492, d1v0bB_, 0.6967, 2.81, 0.230, 261, 230, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
4493, d4xi2A2, 0.6966, 3.36, 0.155, 274, 245, CRYSTAL STRUCTURE OF AN AUTO-INHIBITED FORM OF BRUTON S TRYROSINE KINASE
4494, d3vs3A3, 0.6966, 3.17, 0.171, 269, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
4495, d3v8wB1, 0.6966, 2.98, 0.192, 240, 234, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 469
4496, d3dtwB_, 0.6966, 3.23, 0.206, 269, 238, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
4497, d2y4pC_, 0.6966, 3.13, 0.191, 264, 235, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN
4498, d4kioD1, 0.6965, 2.98, 0.200, 240, 235, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
4499, d4dliA_, 0.6965, 2.83, 0.205, 334, 229, HUMAN P38 MAP KINASE IN COMPLEX WITH RL87
4500, d3vs0B3, 0.6965, 3.15, 0.172, 268, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
4501, d3nw6A_, 0.6965, 3.45, 0.200, 301, 245, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (11A)
4502, d5h09A3, 0.6964, 3.34, 0.169, 281, 243, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-ETHYL2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOATE
4503, d4yfiB_, 0.6964, 3.53, 0.198, 262, 243, TNNI3K COMPLEXED WITH INHIBITOR 1
4504, d2c0oB3, 0.6964, 3.11, 0.168, 268, 238, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
4505, d1jpaA_, 0.6964, 3.09, 0.147, 273, 238, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED EPHB2 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
4506, d3vs6A3, 0.6963, 3.18, 0.171, 269, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
4507, d3pzeA_, 0.6963, 3.06, 0.218, 347, 234, JNK1 IN COMPLEX WITH INHIBITOR
4508, d2y4pA_, 0.6963, 3.04, 0.193, 251, 233, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN
4509, d2lgcA1, 0.6963, 3.22, 0.211, 353, 237, JOINT NMR AND X-RAY REFINEMENT REVEALS THE STRUCTURE OF A NOVEL DIBENZO[AD]CYCLOHEPTENONE INHIBITOR/P38 MAP KINASE COMPLEX IN SOLUTION
4510, d2c0oA3, 0.6963, 3.12, 0.172, 268, 238, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
4511, d1mp8A_, 0.6963, 3.09, 0.206, 252, 238, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE (FAK)
4512, d4mf1A1, 0.6962, 2.99, 0.192, 241, 234, ITK KINASE DOMAIN IN COMPLEX WITH BENZOTHIAZOLE INHIBITOR 12B (1S2S)- 2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-13- BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
4513, d4jt3A_, 0.6962, 3.13, 0.218, 254, 234, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 400740
4514, d3vs2A3, 0.6962, 3.18, 0.167, 268, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
4515, d3lffA_, 0.6962, 2.99, 0.197, 335, 233, HUMAN P38 MAP KINASE IN COMPLEX WITH RL166
4516, d3hegA_, 0.6962, 2.87, 0.187, 333, 230, P38 IN COMPLEX WITH SORAFENIB
4517, d3fzsA_, 0.6962, 3.13, 0.155, 254, 238, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH BIRB796
4518, d2vwuA_, 0.6962, 3.03, 0.148, 253, 237, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4519, d2nryB_, 0.6962, 3.50, 0.205, 286, 244, CRYSTAL STRUCTURE OF IRAK-4
4520, d5h0gA3, 0.6961, 3.35, 0.169, 281, 243, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-N4-DIMETHYLPENTANAMIDE
4521, d4m13A_, 0.6961, 3.34, 0.188, 264, 245, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 8 [4- (CARBAMOYLAMINO)-1-(7-PROPOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
4522, d1mryA_, 0.6961, 3.32, 0.188, 270, 239, CRYSTAL STRUCTURE OF AN INACTIVE AKT2 KINASE DOMAIN
4523, d3vs4A3, 0.6960, 3.15, 0.167, 270, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
4524, d3obgA_, 0.6960, 2.85, 0.203, 332, 231, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MUTANTS IN RESPONSE TO INHIBITOR BINDING
4525, d3mgyA_, 0.6960, 2.75, 0.197, 329, 228, MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
4526, d3h9fA1, 0.6960, 3.18, 0.208, 256, 236, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYRIMIDO-DIAZEPIN LIGAND
4527, d3tl8D_, 0.6959, 3.60, 0.186, 306, 247, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
4528, d2x7fD_, 0.6959, 2.86, 0.182, 236, 231, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
4529, d2pv5A_, 0.6959, 2.75, 0.193, 329, 228,  
4530, d4rfmA1, 0.6958, 3.09, 0.176, 248, 238, ITK KINASE DOMAIN IN COMPLEX WITH COMPOUND 1 N-{1-[(11-DIOXO-1-THIAN- 2-YL)(PHENYL)METHYL]-1H- PYRAZOL-4-YL}-55-DIFLUORO-5A-METHYL-1H4H 4AH5H5AH6H-CYCLOPROPA[F]INDAZOLE-3-CARBOXAMIDE
4531, d2jc6C_, 0.6958, 3.40, 0.159, 277, 239, CRYSTAL STRUCTURE OF HUMAN CALMODULIN-DEPENDENT PROTEIN KINASE 1D
4532, d5ut1A_, 0.6957, 3.60, 0.167, 272, 246, JAK2 JH2 IN COMPLEX WITH BI-D1870
4533, d5ut0A_, 0.6957, 3.60, 0.167, 272, 246, JAK2 JH2 IN COMPLEX WITH AT9283
4534, d5ng3C_, 0.6957, 3.19, 0.167, 272, 240, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
4535, d5ci6A_, 0.6957, 2.84, 0.195, 335, 231, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
4536, d3hmnA_, 0.6957, 3.11, 0.209, 255, 234, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH ATP
4537, d3d83A_, 0.6957, 3.32, 0.203, 347, 236, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
4538, d2zmdA_, 0.6957, 3.12, 0.209, 259, 235, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN T686A MUTANT IN COMPLEX WITH SP600125 INHIBITOR
4539, d2ptjA_, 0.6957, 2.97, 0.194, 334, 232,  
4540, d5na0A1, 0.6956, 3.01, 0.201, 250, 234, TTK KINASE DOMAIN IN COMPLEX WITH A PEG-LINKED PYRIMIDO-INDOLIZINE
4541, d4r6vA1, 0.6956, 3.30, 0.175, 271, 240, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE HARBORING THE V550L GATE-KEEPER MUTATION IN COMPLEX WITH FIIN-3 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
4542, d3orpA_, 0.6956, 3.25, 0.212, 274, 240, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 5)
4543, d2c0iB3, 0.6956, 3.14, 0.168, 268, 238, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
4544, d5l2tA_, 0.6955, 2.84, 0.191, 261, 230, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND RIBOCICLIB.
4545, d4m0zA_, 0.6955, 3.32, 0.168, 264, 244, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 5 {4- (CARBAMOYLAMINO)-1-(7-METHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE}
4546, d3qriB_, 0.6955, 3.35, 0.217, 262, 240, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
4547, d3cp9A1, 0.6955, 3.30, 0.183, 281, 240, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
4548, d3bbtD_, 0.6955, 3.43, 0.177, 259, 243, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN COMPLEX WITH LAPATINIB
4549, d2qu6A1, 0.6955, 3.23, 0.188, 276, 239, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
4550, d2qoqA_, 0.6955, 3.26, 0.161, 284, 242, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION BASE AMP-PNP BOUND STRUCTURE
4551, d2og8B2, 0.6955, 3.08, 0.217, 247, 235, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 36 BOUND TO LCK
4552, d4o6lA_, 0.6954, 3.01, 0.207, 257, 232, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
4553, d4eh4A_, 0.6954, 2.89, 0.204, 337, 230, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F3 AND RL87
4554, d3vs4B3, 0.6954, 3.22, 0.171, 269, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
4555, d3mh3A_, 0.6954, 2.97, 0.194, 334, 232, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
4556, d3lmgB_, 0.6954, 3.59, 0.146, 268, 247, CRYSTAL STRUCTURE OF THE ERBB3 KINASE DOMAIN IN COMPLEX WITH AMP-PNP
4557, d2nruD_, 0.6954, 3.57, 0.200, 293, 245, CRYSTAL STRUCTURE OF IRAK-4
4558, d5t18A1, 0.6953, 3.20, 0.158, 259, 241, CRYSTAL STRUCTURE OF BRUTON AGAMMABULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-986142 AKA (2S)-6-FLUORO-5-[3-(8-FLUORO-1-METHYL-24-DIOXO- 1234-TETRAHYDROQUINAZOLIN-3-YL)-2-METHYLPHENYL]-2-(2- HYDROXYPROPAN-2-YL)-2349-TETRAHYDRO-1H-CARBAZOLE-8-CARBOXAMIDE
4559, d5itaA_, 0.6953, 2.93, 0.235, 250, 234, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
4560, d5eymA_, 0.6953, 3.32, 0.169, 292, 242, MEK1 IN COMPLEX WITH BI 847325
4561, d3vs1B3, 0.6953, 3.21, 0.184, 268, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
4562, d3vs0A3, 0.6953, 3.17, 0.172, 268, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
4563, d3qtiB_, 0.6953, 3.46, 0.184, 280, 239, C-MET KINASE IN COMPLEX WITH NVP-BVU972
4564, d3pg1A_, 0.6953, 3.08, 0.175, 341, 234, MAP KINASE LMAMPK10 FROM LEISHMANIA MAJOR (1.95 ANGS RESOLUTION)
4565, d3krlA_, 0.6953, 3.28, 0.210, 281, 238, CFMS TYROSINE KINASE IN COMPLEX WITH 5-CYANO-FURAN-2-CARBOXYLIC ACID [4-(4-METHYL-PIPERAZIN-1-YL)-2-PIPERIDIN-1-YL-PHENYL]-AMIDE
4566, d3fmnA_, 0.6953, 3.02, 0.190, 341, 232, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO2530
4567, d4ztmA_, 0.6952, 3.44, 0.197, 287, 244, IRAK4-INHIBITOR CO-STRUCTURE
4568, d4twnA1, 0.6952, 3.38, 0.165, 275, 242, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH BIRB796
4569, d4m15A_, 0.6952, 3.32, 0.189, 263, 244, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE] AND ADP
4570, d4fg8A_, 0.6952, 3.34, 0.180, 263, 239, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-315 IN COMPLEX WITH ATP
4571, d3vs2B3, 0.6952, 3.22, 0.167, 268, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
4572, d3hp5A_, 0.6952, 2.82, 0.192, 330, 229, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A PYRIMIDOPYRIDAZINONE COMPOUND
4573, d1oz1A_, 0.6952, 3.33, 0.203, 344, 236, P38 MITOGEN-ACTIVATED KINASE IN COMPLEX WITH 4-AZAINDOLE INHIBITOR
4574, d3vryA3, 0.6951, 3.26, 0.171, 269, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
4575, d3q96B_, 0.6951, 3.21, 0.223, 262, 238, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
4576, d3oxiA_, 0.6951, 2.96, 0.220, 322, 232, DESIGN AND SYNTHESIS OF DISUBSTITUTED THIOPHENE AND THIAZOLE BASED INHIBITORS OF JNK FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
4577, d2e2bB1, 0.6951, 3.30, 0.230, 258, 239, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
4578, d5ut3A_, 0.6950, 3.61, 0.167, 272, 246, JAK2 JH2 IN COMPLEX WITH IKK-2 INHIBITOR VI
4579, d5lpvA_, 0.6950, 3.53, 0.215, 282, 246, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH AMPPNP AND MN FROM ARABIDOPSIS THALIANA
4580, d5h0hA3, 0.6950, 3.38, 0.169, 281, 243, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-NN4-TRIMETHYLPENTANAMIDE
4581, d5ekoA_, 0.6950, 3.19, 0.211, 341, 237, CRYSTAL STRUCTURE OF MAPK13 COMPLEX WITH INHIBITOR
4582, d4ztlD_, 0.6950, 3.56, 0.195, 285, 246, IRAK4-INHIBITOR CO-STRUCTURE
4583, d4itjB_, 0.6950, 3.59, 0.188, 276, 245, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-4
4584, d3vrzA3, 0.6950, 3.23, 0.171, 268, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
4585, d3octA_, 0.6950, 3.01, 0.166, 244, 235, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE MUTANT V555R IN COMPLEX WITH DASATINIB
4586, d4yffA_, 0.6949, 3.43, 0.196, 264, 240, TNNI3K COMPLEXED WITH INHIBITOR 2
4587, d5o21B_, 0.6948, 3.58, 0.178, 273, 242, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
4588, d4lg4D_, 0.6948, 2.93, 0.185, 250, 232, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4589, d2hckA3, 0.6948, 3.41, 0.185, 271, 243, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
4590, d1vr2A_, 0.6948, 3.33, 0.204, 275, 240, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN
4591, d5ut5A_, 0.6947, 3.67, 0.158, 272, 247, JAK2 JH2 IN COMPLEX WITH GLPG0634
4592, d5o21A_, 0.6947, 3.56, 0.182, 272, 242, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
4593, d5lpzA_, 0.6947, 3.44, 0.214, 283, 243, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1196) IN COMPLEX WITH ADP FROM ARABIDOPSIS THALIANA
4594, d5h0bA3, 0.6947, 3.39, 0.169, 281, 243, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOIC ACID
4595, d5ap2A1, 0.6947, 2.96, 0.216, 253, 232, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4596, d4fc0B_, 0.6947, 3.11, 0.217, 263, 235, CRYSTAL STRUCTURE OF HUMAN KINASE DOMAIN OF B-RAF WITH A DFG-OUT INHIBITOR
4597, d4d1zA_, 0.6947, 2.73, 0.174, 258, 230, CDK2 IN COMPLEX WITH A LUCIFERIN DERIVATE
4598, d3zyaA1, 0.6947, 3.10, 0.200, 341, 235, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO- DIBENZOSUBERONE
4599, d3vs7B3, 0.6947, 3.27, 0.187, 266, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
4600, d3vryB3, 0.6947, 3.24, 0.171, 269, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
4601, d3v5lB1, 0.6947, 2.98, 0.188, 239, 234, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
4602, d3r2bK_, 0.6947, 3.50, 0.181, 272, 237, MK2 KINASE BOUND TO COMPOUND 5B
4603, d3gp0A1, 0.6947, 2.75, 0.197, 332, 228, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 11 (P38 BETA) IN COMPLEX WITH NILOTINIB
4604, d2ptoA_, 0.6947, 2.79, 0.188, 330, 229,  
4605, d1ad5A3, 0.6947, 3.42, 0.185, 271, 243, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
4606, d5uszA_, 0.6946, 3.61, 0.167, 272, 246, JAK2 JH2 IN COMPLEX WITH JNJ-7706621
4607, d5mo4A3, 0.6946, 3.41, 0.207, 271, 241, ABL1 KINASE (T334I_D382N) IN COMPLEX WITH ASCIMINIB AND NILOTINIB
4608, d5eymB_, 0.6946, 3.41, 0.169, 292, 243, MEK1 IN COMPLEX WITH BI 847325
4609, d4pdoA_, 0.6946, 2.78, 0.165, 261, 231, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
4610, d4m12A_, 0.6946, 3.36, 0.188, 264, 245, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 7 [4- (CARBAMOYLAMINO)-1-(7-ETHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
4611, d4kioA1, 0.6946, 2.92, 0.193, 238, 233, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
4612, d3w8qA_, 0.6946, 3.81, 0.160, 318, 250, STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1)
4613, d3r2bJ_, 0.6946, 3.39, 0.182, 272, 236, MK2 KINASE BOUND TO COMPOUND 5B
4614, d3mh2A_, 0.6945, 2.80, 0.188, 330, 229, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
4615, d3fmlA_, 0.6945, 3.15, 0.180, 342, 233, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6224
4616, d3efwB_, 0.6945, 2.67, 0.192, 242, 229, STRUCTURE OF AURORAA WITH PYRIDYL-PYRIMIDINE UREA INHIBITOR
4617, d3d7tA_, 0.6945, 3.00, 0.200, 249, 235, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
4618, d3c5uA_, 0.6945, 3.11, 0.196, 338, 235, P38 ALPHA MAP KINASE COMPLEXED WITH A BENZOTHIAZOLE BASED INHIBITOR
4619, d2wajA_, 0.6945, 3.32, 0.203, 348, 237, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH A 1-ARYL-34- DIHYDROISOQUINOLINE INHIBITOR
4620, d5jsmC1, 0.6944, 3.26, 0.241, 259, 241, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
4621, d4xs2A_, 0.6944, 3.42, 0.207, 283, 241, IRAK4-INHIBITOR CO-STRUCTURE
4622, d3r2bH_, 0.6944, 3.40, 0.182, 272, 236, MK2 KINASE BOUND TO COMPOUND 5B
4623, d5ut6A_, 0.6943, 3.61, 0.167, 272, 246, JAK2 JH2 IN COMPLEX WITH A DIAMINOPYRIMIDINE
4624, d5uq0B_, 0.6943, 2.99, 0.214, 256, 234, FGFR1 KINASE DOMAIN COMPLEX WITH FRAGMENT 22-DIMETHYL-23- DIHYDROBENZOFURAN-7-CARBOXAMIDE
4625, d4oa6A_, 0.6943, 3.37, 0.212, 279, 241,  
4626, d2y6mA_, 0.6943, 3.15, 0.155, 262, 238, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN
4627, d4x21B_, 0.6942, 3.06, 0.214, 336, 234, THE MAP KINASE JNK3 AS TARGET FOR HALOGEN BONDING
4628, d2qd9A_, 0.6942, 2.81, 0.201, 330, 229, P38 ALPHA MAP KINASE INHIBITOR BASED ON HETEROBICYCLIC SCAFFOLDS
4629, d5ut2A_, 0.6941, 3.62, 0.167, 273, 246, JAK2 JH2 IN COMPLEX WITH PRT062607
4630, d4pdoB_, 0.6941, 2.91, 0.163, 261, 233, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
4631, d4l8mA_, 0.6941, 2.99, 0.207, 339, 232, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOXEPINONE
4632, d3r2bD_, 0.6941, 3.39, 0.182, 272, 236, MK2 KINASE BOUND TO COMPOUND 5B
4633, d3el7A_, 0.6941, 3.05, 0.213, 254, 235, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 3
4634, d3cpcA1, 0.6941, 3.28, 0.176, 277, 239, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
4635, d5a6oB1, 0.6940, 3.15, 0.191, 264, 235, CRYSTAL STRUCTURE OF THE APO FORM OF THE UNPHOSPHORYLATED HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3)
4636, p4h3bA_, 0.6940, 3.22, 0.221, 351, 235, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH SAB PEPTIDE
4637, d3v5lC1, 0.6940, 2.95, 0.193, 242, 233, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
4638, d3mssB1, 0.6940, 3.41, 0.233, 260, 240, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
4639, d2hakE_, 0.6940, 3.26, 0.232, 318, 237, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4640, d2cn5A1, 0.6940, 4.00, 0.208, 281, 245, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH ADP
4641, d1ad5B3, 0.6940, 3.31, 0.187, 271, 241, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
4642, d6b4wA_, 0.6939, 3.00, 0.210, 259, 233, TTK IN COMPLEX WITH INHIBITOR
4643, d4p5zA_, 0.6939, 3.02, 0.157, 267, 236, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
4644, d4h36A_, 0.6939, 3.11, 0.222, 353, 234, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH ATF2 PEPTIDE
4645, d4eh9A_, 0.6939, 2.89, 0.205, 334, 229, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F11 AND RL87
4646, d3wzuA_, 0.6939, 3.54, 0.191, 270, 246, THE STRUCTURE OF MAP2K7 IN COMPLEX WITH 5Z-7-OXOZEAENOL
4647, d1pmuA_, 0.6939, 3.24, 0.197, 342, 238, THE CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PHENANTROLINE INHIBITOR
4648, d4eymA_, 0.6938, 3.23, 0.215, 340, 237, MAPK13 COMPLEX WITH INHIBITOR
4649, d3r2bF_, 0.6938, 3.41, 0.182, 272, 236, MK2 KINASE BOUND TO COMPOUND 5B
4650, d3r2bA_, 0.6938, 3.43, 0.182, 272, 236, MK2 KINASE BOUND TO COMPOUND 5B
4651, d3qlfA_, 0.6938, 2.99, 0.214, 249, 234, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE 5
4652, d5t1tC_, 0.6937, 3.44, 0.206, 286, 243, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4653, d5n65A_, 0.6937, 2.98, 0.190, 333, 231, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9H
4654, d3r2bL_, 0.6937, 3.44, 0.182, 272, 236, MK2 KINASE BOUND TO COMPOUND 5B
4655, d3r2bG_, 0.6937, 3.44, 0.182, 272, 236, MK2 KINASE BOUND TO COMPOUND 5B
4656, d1jpaB_, 0.6937, 3.02, 0.149, 269, 235, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED EPHB2 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
4657, d5nk8A_, 0.6936, 3.12, 0.161, 266, 236, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2F
4658, d4l00A_, 0.6936, 3.67, 0.181, 277, 249, CRYSTAL STRUCTURE OF THE APO JAK1 PSEUDOKINASE DOMAIN
4659, d4eyjA_, 0.6936, 3.08, 0.217, 338, 235, MAPK13 COMPLEX WITH INHIBITOR
4660, d3v6rB_, 0.6936, 3.36, 0.207, 346, 237, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
4661, d3r2bI_, 0.6936, 3.40, 0.182, 272, 236, MK2 KINASE BOUND TO COMPOUND 5B
4662, d2xrwA1, 0.6936, 3.01, 0.209, 346, 234, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
4663, d2nryC_, 0.6936, 3.52, 0.210, 280, 243, CRYSTAL STRUCTURE OF IRAK-4
4664, d1zmuA_, 0.6936, 2.82, 0.236, 293, 229, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: WILD TYPE
4665, p5yj9D_, 0.6935, 3.66, 0.121, 333, 247, CRYSTAL STRUCTURE OF TRIBOLIUM CASTANEUM PINK1 KINASE DOMAIN IN COMPLEX WITH AMP-PNP 
4666, p4d28B_, 0.6935, 3.28, 0.210, 277, 238, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
4667, d3v5jB1, 0.6935, 3.07, 0.192, 239, 234, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 090
4668, d3r2bB_, 0.6935, 3.44, 0.182, 272, 236, MK2 KINASE BOUND TO COMPOUND 5B
4669, d2qi8B_, 0.6935, 3.01, 0.205, 249, 234, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN
4670, d2nruC_, 0.6935, 3.54, 0.194, 293, 247, CRYSTAL STRUCTURE OF IRAK-4
4671, d1pmnA_, 0.6935, 3.14, 0.213, 344, 235, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE- PYRIMIDINE INHIBITOR
4672, d5itaB_, 0.6934, 3.12, 0.212, 252, 236, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
4673, d4tyhB_, 0.6934, 3.17, 0.200, 335, 235, TERNARY COMPLEX OF P38 AND MK2 WITH A P38 INHIBITOR
4674, d4ludB3, 0.6934, 3.18, 0.172, 264, 239, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
4675, d3pg3A_, 0.6934, 3.01, 0.194, 337, 232, HUMAN P38 MAP KINASE IN COMPLEX WITH RL182
4676, d3mssA1, 0.6934, 3.37, 0.222, 260, 239, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
4677, d3kvxA_, 0.6934, 3.19, 0.198, 327, 237, JNK3 BOUND TO AMINOPYRIMIDINE INHIBITOR SR-3562
4678, d1r1wA_, 0.6934, 3.51, 0.183, 287, 240, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET
4679, d5t1sA_, 0.6933, 3.46, 0.210, 280, 243, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4680, d4pqnA_, 0.6933, 2.87, 0.199, 240, 231, ITK KINASE DOMAIN WITH COMPOUND GNE-9822
4681, d4m14A_, 0.6933, 3.31, 0.173, 263, 243, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE]
4682, d4kioB1, 0.6933, 2.87, 0.194, 237, 232, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
4683, d3vs5A3, 0.6933, 3.16, 0.168, 268, 238, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
4684, d4c4hA1, 0.6932, 2.88, 0.196, 245, 230, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4685, d3orkA1, 0.6932, 3.24, 0.208, 272, 240, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 2)
4686, d3miyA1, 0.6932, 2.80, 0.191, 237, 230, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH SUNITINIB
4687, d4otwA_, 0.6931, 3.62, 0.146, 272, 247, HER3 PSEUDOKINASE DOMAIN BOUND TO BOSUTINIB
4688, p4h3bC_, 0.6931, 3.13, 0.222, 351, 234, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH SAB PEPTIDE
4689, d4gt4B_, 0.6931, 3.21, 0.155, 273, 239, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
4690, d3r2bC_, 0.6931, 3.41, 0.182, 272, 236, MK2 KINASE BOUND TO COMPOUND 5B
4691, d3ms9A1, 0.6931, 3.31, 0.231, 261, 238, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
4692, d3a2cJ_, 0.6931, 3.67, 0.170, 275, 241, CRYSTAL STRUCTURE OF A PYRAZOLOPYRIMIDINE INHIBITOR COMPLEX BOUND TO MAPKAP KINASE-2 (MK2)
4693, d2o2uA_, 0.6931, 2.95, 0.207, 319, 232, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-CYANO-4567- TETRAHYDRO-1-BENZOTHIEN-2-YL)-2-FLUOROBENZAMIDE
4694, d1mrvA_, 0.6931, 3.09, 0.183, 261, 235, CRYSTAL STRUCTURE OF AN INACTIVE AKT2 KINASE DOMAIN
4695, d1bygA_, 0.6930, 3.07, 0.216, 246, 236, KINASE DOMAIN OF HUMAN C-TERMINAL SRC KINASE (CSK) IN COMPLEX WITH INHIBITOR STAUROSPORINE
4696, d4k11A3, 0.6929, 3.54, 0.194, 282, 247, THE STRUCTURE OF 1NA IN COMPLEX WITH SRC T338G
4697, d4a9yA_, 0.6929, 3.01, 0.208, 334, 231, P38ALPHA MAP KINASE BOUND TO CMPD 8
4698, d3oc1A_, 0.6929, 2.86, 0.192, 330, 229, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
4699, d3mssD1, 0.6929, 3.34, 0.234, 260, 239, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
4700, d3k3iA_, 0.6929, 2.93, 0.209, 332, 230, P38ALPHA BOUND TO NOVEL DGF-OUT COMPOUND PF-00215955
4701, d3dy7A_, 0.6929, 3.41, 0.194, 260, 242, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
4702, d3dpkA_, 0.6929, 3.19, 0.203, 279, 236, CFMS TYROSINE KINASE IN COMPLEX WITH A PYRIDOPYRIMIDINONE INHIBITOR
4703, d2bakA_, 0.6929, 3.01, 0.208, 334, 231, P38ALPHA MAP KINASE BOUND TO MPAQ
4704, d3v8wA1, 0.6928, 3.02, 0.185, 241, 233, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 469
4705, d2h8hA3, 0.6928, 3.55, 0.194, 280, 247, SRC KINASE IN COMPLEX WITH A QUINAZOLINE INHIBITOR
4706, d6b8uB_, 0.6927, 3.11, 0.221, 248, 235, CRYSTALS STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINYL BENZAMIDE INHIBITOR
4707, d4yfiD_, 0.6927, 3.51, 0.198, 261, 242, TNNI3K COMPLEXED WITH INHIBITOR 1
4708, d4p4cA_, 0.6927, 3.04, 0.161, 266, 236, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
4709, d3objA_, 0.6927, 2.97, 0.199, 332, 231, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MUTANTS IN RESPONSE TO INHIBITOR BINDING
4710, d3lzbB_, 0.6927, 3.55, 0.184, 265, 245, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
4711, d3gc7A_, 0.6927, 3.49, 0.208, 349, 240, THE STRUCTURE OF P38ALPHA IN COMPLEX WITH A DIHYDROQUINAZOLINONE
4712, d3ekkA_, 0.6927, 3.17, 0.211, 285, 237, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
4713, d2p2iB_, 0.6927, 3.13, 0.191, 263, 236, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
4714, d3r2bE_, 0.6926, 3.44, 0.182, 272, 236, MK2 KINASE BOUND TO COMPOUND 5B
4715, d3qgwB_, 0.6926, 2.93, 0.198, 240, 232, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
4716, d3mssC1, 0.6926, 3.37, 0.222, 260, 239, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
4717, d3ds6C_, 0.6926, 3.37, 0.201, 349, 239, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
4718, d1kswA3, 0.6926, 3.65, 0.194, 284, 248, STRUCTURE OF HUMAN C-SRC TYROSINE KINASE (THR338GLY MUTANT) IN COMPLEX WITH N6-BENZYL ADP
4719, d3tg1A_, 0.6925, 2.99, 0.194, 334, 232, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH A MAPK DOCKING PARTNER
4720, d3lzbC_, 0.6925, 3.51, 0.180, 259, 244, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
4721, d3iw7A_, 0.6925, 2.97, 0.199, 335, 231, HUMAN P38 MAP KINASE IN COMPLEX WITH AN IMIDAZO-PYRIDINE
4722, d4fg9A_, 0.6924, 3.49, 0.170, 278, 241, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-320 IN COMPLEX WITH ATP
4723, d2hw7A1, 0.6924, 3.32, 0.184, 269, 234, CRYSTAL STRUCTURE OF MNK2-D228G IN COMPLEX WITH STAUROSPORINE
4724, d2ac3A1, 0.6924, 3.35, 0.186, 275, 236, STRUCTURE OF HUMAN MNK2 KINASE DOMAIN
4725, d5ew3B_, 0.6923, 3.11, 0.200, 266, 235, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
4726, d3iw6A_, 0.6923, 3.03, 0.198, 337, 232, HUMAN P38 MAP KINASE IN COMPLEX WITH A BENZYLPIPERAZIN- PYRROL
4727, d1zmvA_, 0.6923, 2.83, 0.218, 293, 229, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: K82R MUTANT
4728, d5w84A_, 0.6922, 3.47, 0.202, 279, 242, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 4)
4729, d4yr8E_, 0.6922, 2.89, 0.209, 317, 230, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
4730, d4oa9A_, 0.6922, 3.51, 0.216, 280, 245,  
4731, d3pixA_, 0.6922, 3.36, 0.169, 268, 242, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-ISOPROPYL-7- (4-METHYL-PIPERAZIN-1-YL)-4-(5-METHYL-2H-PYRAZOL-3-YLAMINO)-2H- PHTHALAZIN-1-ONE
4732, d3p86B_, 0.6922, 2.81, 0.213, 239, 230, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN MUTANT D676N IN COMPLEX WITH STAUROSPORINE
4733, d4oacA_, 0.6921, 3.49, 0.216, 280, 245,  
4734, d3miyB1, 0.6921, 2.95, 0.193, 238, 233, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH SUNITINIB
4735, d4ez5A_, 0.6920, 2.84, 0.171, 258, 228, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
4736, d3cpbA1, 0.6920, 3.30, 0.176, 278, 239, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BISAMIDE INHIBITOR
4737, d4x7jA_, 0.6919, 3.29, 0.191, 257, 236, CO-CRYSTAL STRUCTURE OF PERK WITH 2-AMINO-N-[4-METHOXY-3- (TRIFLUOROMETHYL)PHENYL]-4-METHYL-3-[2-(METHYLAMINO)QUINAZOLIN-6- YL]BENZAMIDE INHIBITOR
4738, d4x7hA_, 0.6919, 3.21, 0.191, 256, 236, CO-CRYSTAL STRUCTURE OF PERK BOUND TO N-{5-[(67-DIMETHOXYQUINOLIN-4- YL)OXY]PYRIDIN-2-YL}-1-METHYL-3-OXO-2-PHENYL-5-(PYRIDIN-4-YL)-23- DIHYDRO-1H-PYRAZOLE-4-CARBOXAMIDE INHIBITOR
4739, d3ttjA_, 0.6919, 3.24, 0.212, 333, 236, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-359 A JNK INHIBITOR FOR THE PREVENTION OF ISCHEMIA-REPERFUSION INJURY
4740, d3lzbA_, 0.6919, 3.53, 0.180, 265, 245, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
4741, d3g90X_, 0.6919, 3.11, 0.202, 345, 233, JNK-3 BOUND TO (Z)-5-FLUORO-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL) METHYL)-3-(HYDROXYIMINO)INDOLIN-2-ONE
4742, d3dzqA_, 0.6919, 3.11, 0.152, 268, 237, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH INHIBITOR AWL-II- 38.3
4743, d3a2cH_, 0.6919, 3.78, 0.169, 275, 242, CRYSTAL STRUCTURE OF A PYRAZOLOPYRIMIDINE INHIBITOR COMPLEX BOUND TO MAPKAP KINASE-2 (MK2)
4744, d3qquA_, 0.6918, 3.48, 0.198, 285, 243, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
4745, d3pizA_, 0.6918, 3.06, 0.166, 245, 235, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH (5-AMINO-1-O- TOLYL-1H-PYRAZOL-4-YL)-[3-(1-METHANESULFONYL-PIPERIDIN-4-YL)-PHENYL]- METHANONE
4746, p3c4wB3, 0.6918, 3.01, 0.196, 287, 230, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.7A
4747, d1p14A_, 0.6918, 3.24, 0.206, 287, 238, CRYSTAL STRUCTURE OF A CATALYTIC-LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
4748, d5we8B_, 0.6917, 3.62, 0.198, 272, 243, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH N-{(3R)-1-[(4-CHLOROPHENYL) METHYL]PYRROLIDIN-3-YL}-2-(3-METHOXYPHENYL)-N-METHYLQUINOLINE-4- CARBOXAMIDE (COMPOUND 8)
4749, d4k9yA_, 0.6917, 3.67, 0.198, 271, 248, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-[4-(6-AMINO- PURIN-9-YL)-PHENYL]-3-(5-TERT-BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-UREA
4750, d3npcA_, 0.6917, 3.17, 0.223, 357, 233, CRYSTAL STRUCTURE OF JNK2 COMPLEXED WITH BIRB796
4751, d3lfbA_, 0.6917, 2.94, 0.191, 333, 230, HUMAN P38 MAP KINASE IN COMPLEX WITH RL98
4752, d3da6A_, 0.6917, 3.10, 0.205, 328, 234, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-METHYL- 4-(3-(2-(METHYLAMINO)PYRIMIDIN-4-YL)PYRIDIN-2-YLOXY) NAPHTHALEN-1-YL)-1H-BENZO[D]IMIDAZOL-2-AMINE
4753, d2wqnA_, 0.6917, 2.96, 0.209, 259, 235, STRUCTURE OF ADP-BOUND HUMAN NEK7
4754, d1kv1A_, 0.6917, 2.93, 0.204, 331, 230, P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1
4755, d3vs5B3, 0.6916, 3.20, 0.172, 268, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
4756, d2henA1, 0.6916, 3.17, 0.146, 258, 239, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
4757, d2hckB3, 0.6916, 3.46, 0.181, 271, 243, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
4758, d4yffB_, 0.6915, 3.26, 0.198, 264, 237, TNNI3K COMPLEXED WITH INHIBITOR 2
4759, d5n68A_, 0.6914, 2.76, 0.203, 328, 227, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9M
4760, d4yo6A_, 0.6914, 3.49, 0.197, 286, 244, IRAK4-INHIBITOR CO-STRUCTURE
4761, d4yfiC_, 0.6914, 3.39, 0.203, 269, 237, TNNI3K COMPLEXED WITH INHIBITOR 1
4762, d4x7kA_, 0.6914, 3.22, 0.195, 260, 236, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-{2-AMINO-3-[5-FLUORO-2- (METHYLAMINO)QUINAZOLIN-6-YL]-4-METHYLBENZOYL}-1-METHYL-25-DIPHENYL- 12-DIHYDRO-3H-PYRAZOL-3-ONE INHIBITOR
4763, d2j90B_, 0.6914, 3.42, 0.179, 262, 235, CRYSTAL STRUCTURE OF HUMAN ZIP KINASE IN COMPLEX WITH A TETRACYCLIC PYRIDONE INHIBITOR (PYRIDONE 6)
4764, d1v0pB_, 0.6914, 2.93, 0.224, 258, 228, STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX
4765, d4x7lA_, 0.6913, 3.19, 0.195, 260, 236, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-{2-AMINO-4-METHYL-3-[2- (METHYLAMINO)-13-BENZOTHIAZOL-6-YL]BENZOYL}-1-METHYL-25-DIPHENYL-1 2-DIHYDRO-3H-PYRAZOL-3-ONE INHIBITOR
4766, d1ukhA_, 0.6913, 2.93, 0.217, 321, 230, STRUCTURAL BASIS FOR THE SELECTIVE INHIBITION OF JNK1 BY THE SCAFFOLDING PROTEIN JIP1 AND SP600125
4767, d5owqA_, 0.6912, 3.38, 0.194, 255, 237, HUMAN STK10 BOUND TO DOVITINIB
4768, d4ybkA_, 0.6912, 3.46, 0.184, 266, 245, C-HELIX-OUT DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
4769, d4x7nA_, 0.6912, 3.23, 0.195, 259, 236, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-[2-AMINO-4-METHYL-3-(2- METHYLQUINOLIN-6-YL)BENZOYL]-1-METHYL-25-DIPHENYL-12-DIHYDRO-3H- PYRAZOL-3-ONE INHIBITOR
4770, d4knbB_, 0.6912, 3.30, 0.191, 256, 236, C-MET IN COMPLEX WITH OSI LIGAND
4771, d3uqfB_, 0.6912, 3.13, 0.216, 253, 236, C-SRC KINASE DOMAIN IN COMPLEX WITH BKI RM-1-89
4772, d3repA_, 0.6912, 3.45, 0.099, 268, 243, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MNATP)
4773, d2gtmA_, 0.6912, 2.98, 0.203, 341, 231, MUTATED MOUSE P38 MAP KINASE DOMAIN IN COMPLEX WITH INHIBITOR PG-892579
4774, d5b2kA_, 0.6911, 3.51, 0.189, 264, 244, A CRUCIAL ROLE OF CYS218 IN THE STABILIZATION OF AN UNPRECEDENTED AUTO-INHIBITION FORM OF MAP2K7
4775, d4ficA_, 0.6911, 2.92, 0.211, 251, 232, KINASE DOMAIN OF CSRC IN COMPLEX WITH A HINGE REGION-BINDING FRAGMENT
4776, d3zxtC_, 0.6911, 3.10, 0.180, 259, 233, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN IN COMPLEX WITH AMPPCP-MG
4777, d3v6sB_, 0.6911, 3.05, 0.215, 340, 233, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
4778, d3dkoA1, 0.6911, 3.20, 0.139, 272, 238, COMPLEX BETWEEN THE KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 7 (EPHA7) AND INHIBITOR ALW-II-49-7
4779, d2ok1A_, 0.6911, 3.09, 0.191, 333, 235, CRYSTAL STRUCTURE OF JNK3 BOUND TO N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
4780, d2henC1, 0.6911, 3.25, 0.146, 258, 240, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
4781, d1ywnA_, 0.6911, 3.50, 0.198, 279, 242, VEGFR2 IN COMPLEX WITH A NOVEL 4-AMINO-FURO[23-D]PYRIMIDINE
4782, d3v5lA1, 0.6910, 3.01, 0.197, 238, 233, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
4783, d5fdpA_, 0.6909, 3.54, 0.214, 285, 243, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2099 INHIBITOR AT 2.25 ANGSTROMS RESOLUTION.
4784, d3nw7A_, 0.6909, 3.50, 0.201, 297, 244, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (34)
4785, d3fi4A_, 0.6909, 2.98, 0.213, 339, 230, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO4499
4786, d2qo7A_, 0.6909, 3.10, 0.165, 278, 237, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION DEPHOSPHORYLATED AMP-PNP BOUND
4787, d4u79A_, 0.6908, 3.14, 0.205, 337, 234, CRYSTAL STRUCTURE OF HUMAN JNK3 IN COMPLEX WITH A BENZENESULFONAMIDE INHIBITOR.
4788, d3tubA_, 0.6908, 3.07, 0.197, 253, 234, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-3-((1R2S)-2- PHENYLCYCLOPROPYL)UREA
4789, d2puuA_, 0.6908, 2.83, 0.189, 330, 228, CRYSTAL STRUCTURE OF P38 COMPLEX WITH 1-(5-TERT-BUTYL-2-P- TOLYL-2H-PYRAZOL-3-YL)-3-[4-(6-MORPHOLIN-4-YLMETHYL- PYRIDIN-3-YL)NAPHTHALEN-1-YL]UREA
4790, d3qrkA1, 0.6907, 3.37, 0.213, 268, 239, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DP- 987
4791, d2oibC_, 0.6907, 3.41, 0.200, 278, 240, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
4792, d5t1sC_, 0.6906, 3.45, 0.211, 284, 242, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4793, d5t1sB_, 0.6905, 3.47, 0.216, 282, 241, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4794, d5d10A_, 0.6905, 3.04, 0.189, 248, 233, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL236
4795, d3hrbA_, 0.6905, 3.22, 0.196, 344, 235, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4796, d2srcA3, 0.6905, 3.45, 0.196, 284, 245, CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC IN COMPLEX WITH AMP-PNP
4797, d5p9lA_, 0.6904, 3.12, 0.148, 252, 237, BTK1 IN COMPLEX WITH CC 292
4798, d4yo6C_, 0.6904, 3.41, 0.207, 286, 242, IRAK4-INHIBITOR CO-STRUCTURE
4799, d4d4rA_, 0.6904, 3.03, 0.208, 251, 236, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4800, d2i0hA_, 0.6904, 3.46, 0.197, 349, 239, THE STRUCTURE OF P38ALPHA IN COMPLEX WITH AN ARYLPYRIDAZINONE
4801, d5c03B_, 0.6903, 3.40, 0.145, 260, 241, CRYSTAL STRUCTURE OF KINASE
4802, d3of0B_, 0.6903, 3.12, 0.213, 251, 235, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN
4803, d3kmwA_, 0.6903, 3.44, 0.103, 268, 243, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MGATP)
4804, d3hvcA_, 0.6903, 2.74, 0.199, 327, 226, CRYSTAL STRUCTURE OF HUMAN P38ALPHA MAP KINASE
4805, d3fsfA_, 0.6903, 3.20, 0.189, 340, 233, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 3-(26- DICHLORO-PHENYL)-7-[4-(2-DIETHYLAMINO-ETHOXY)-PHENYLAMINO]- 1-METHYL-34-DIHYDRO-1H-PYRIMIDO[45-D]PYRIMIDIN-2-ONE
4806, d2qo2A_, 0.6903, 3.27, 0.162, 282, 240, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION DEPHOSPHORYLATED APO STRUCTURE
4807, d2p5aA_, 0.6903, 2.74, 0.199, 327, 226,  
4808, d5jsmD1, 0.6902, 3.49, 0.244, 255, 242, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
4809, d1pmvA_, 0.6902, 3.19, 0.204, 347, 235, THE STRUCTURE OF JNK3 IN COMPLEX WITH A DIHYDROANTHRAPYRAZOLE INHIBITOR
4810, d5o8uA_, 0.6901, 2.85, 0.184, 331, 228, COVALENT INHIBITOR 4B BOUND TO THE LIPID POCKET OF P38ALPHA MUTANT S252C
4811, d3i81A_, 0.6901, 3.47, 0.202, 296, 243, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH BMS-754807 [1-(4-((5-CYCLOPROPYL- 1H-PYRAZOL-3-YL)AMINO)PYRROLO[21-F][124]TRIAZIN-2-YL)-N- (6-FLUORO-3-PYRIDINYL)-2-METHYL-L-PROLINAMIDE]
4812, d5lpwA_, 0.6900, 3.52, 0.218, 280, 243, CRYSTAL STRUCTURE OF THE APO-BRI1 KINASE DOMAIN (865-1160)
4813, d5kx8C_, 0.6900, 3.50, 0.197, 287, 244, IRAK4-INHIBITOR CO-STRUCTURE
4814, d4mwiA_, 0.6900, 3.14, 0.169, 266, 237, CRYSTAL STRUCTURE OF THE HUMAN MLKL PSEUDOKINASE DOMAIN
4815, d3eljA_, 0.6900, 3.22, 0.211, 347, 237, JNK1 COMPLEXED WITH A BIS-ANILINO-PYRROLOPYRIMIDINE INHIBITOR.
4816, d3a2cE_, 0.6900, 3.58, 0.172, 276, 239, CRYSTAL STRUCTURE OF A PYRAZOLOPYRIMIDINE INHIBITOR COMPLEX BOUND TO MAPKAP KINASE-2 (MK2)
4817, p2xs0A_, 0.6900, 3.12, 0.216, 346, 236, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
4818, d5w5jA_, 0.6899, 3.04, 0.158, 251, 234, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
4819, d4y73C_, 0.6899, 3.57, 0.196, 290, 245, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
4820, d3lzbD_, 0.6898, 3.53, 0.180, 261, 244, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
4821, d3cs9B_, 0.6898, 3.21, 0.212, 247, 236, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
4822, d3pj2A_, 0.6897, 3.05, 0.158, 248, 234, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[4-(2- DIETHYLAMINO-ETHOXY)-PHENYLAMINO]-6-(4-FLUORO-PHENOXY)-8-METHYL-8H- PYRIDO[23-D]PYRIMIDIN-7-ONE
4823, d3hucA_, 0.6897, 3.24, 0.197, 337, 234, HUMAN P38 MAP KINASE IN COMPLEX WITH RL40
4824, d3lokA_, 0.6896, 2.96, 0.220, 248, 232, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR PD168393
4825, d3lfeA_, 0.6896, 3.02, 0.199, 334, 231, HUMAN P38 MAP KINASE IN COMPLEX WITH RL116
4826, d3cg2A_, 0.6895, 2.77, 0.203, 327, 227,  
4827, d5ml5A_, 0.6894, 3.03, 0.195, 326, 231, HUMAN P38ALPHA MAPK IN COMPLEX WITH IMIDAZOLYL PYRIDINE INHIBITOR 11B
4828, d4ztnB_, 0.6894, 3.43, 0.212, 282, 241, IRAK4-INHIBITOR CO-STRUCTURE
4829, d3e7oB_, 0.6894, 2.88, 0.228, 326, 228, CRYSTAL STRUCTURE OF JNK2
4830, d5mtyA_, 0.6893, 2.80, 0.189, 328, 227, DIBENZOSUBERONE INHIBITOR 8E IN COMPLEX WITH P38 MAPK
4831, d5fdxA_, 0.6893, 3.42, 0.213, 280, 239, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2164 INHIBITOR AT 2.65 ANGSTROMS RESOLUTION.
4832, d4lghB_, 0.6893, 3.11, 0.214, 247, 234, CRYSTAL STRUCTURE OF 1NM-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
4833, d4f0gA1, 0.6893, 3.23, 0.181, 260, 237, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM
4834, d3nw5A_, 0.6893, 3.63, 0.199, 302, 246, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (11B)
4835, d5t1sD_, 0.6892, 3.46, 0.212, 281, 241, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4836, d5lpbA_, 0.6892, 3.54, 0.217, 280, 244, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH ADP FROM ARABIDOPSIS THALIANA
4837, d5d7vB1, 0.6892, 3.33, 0.212, 262, 241, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
4838, d4cqeA_, 0.6892, 2.96, 0.211, 250, 232, B-RAF KINASE V600E MUTANT IN COMPLEX WITH  A DIARYLTHIAZOLE B-RAF INHIBITOR
4839, d2hakC_, 0.6892, 3.24, 0.234, 310, 235, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4840, d1ob3B_, 0.6892, 2.91, 0.207, 258, 227, STRUCTURE OF P. FALCIPARUM PFPK5
4841, d5we8A_, 0.6891, 3.61, 0.194, 270, 242, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH N-{(3R)-1-[(4-CHLOROPHENYL) METHYL]PYRROLIDIN-3-YL}-2-(3-METHOXYPHENYL)-N-METHYLQUINOLINE-4- CARBOXAMIDE (COMPOUND 8)
4842, d4oabA_, 0.6891, 3.50, 0.213, 279, 244,  
4843, d3v5jA1, 0.6891, 3.06, 0.189, 239, 233, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 090
4844, d3lfaA_, 0.6891, 3.00, 0.187, 333, 230, HUMAN P38 MAP KINASE IN COMPLEX WITH DASATINIB
4845, d5d7vD1, 0.6890, 3.39, 0.215, 262, 242, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
4846, d4ztnC_, 0.6890, 3.67, 0.211, 284, 246, IRAK4-INHIBITOR CO-STRUCTURE
4847, d3mw1A_, 0.6890, 3.18, 0.197, 342, 234, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4848, d5d10B_, 0.6889, 2.96, 0.216, 247, 231, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL236
4849, d5c03A_, 0.6889, 3.38, 0.146, 260, 240, CRYSTAL STRUCTURE OF KINASE
4850, d2w96B_, 0.6889, 3.24, 0.179, 267, 235, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
4851, d2qu6B_, 0.6889, 3.05, 0.193, 260, 233, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
4852, d5owqB_, 0.6888, 3.30, 0.196, 254, 235, HUMAN STK10 BOUND TO DOVITINIB
4853, d5fxsA1, 0.6888, 3.41, 0.198, 307, 242, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
4854, d4z9lA_, 0.6888, 3.26, 0.204, 333, 235, THE STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE-PYRIMIDINE INHIBITOR
4855, d4ztnA_, 0.6887, 3.50, 0.198, 286, 243, IRAK4-INHIBITOR CO-STRUCTURE
4856, d3zsiA_, 0.6887, 2.93, 0.210, 326, 229, X-RAY STRUCTURE OF P38ALPHA BOUND TO VX-745
4857, d3zshA_, 0.6887, 3.12, 0.190, 331, 232, X-RAY STRUCTURE OF P38ALPHA BOUND TO SCIO-469
4858, d3hubA_, 0.6887, 3.12, 0.197, 335, 233, HUMAN P38 MAP KINASE IN COMPLEX WITH SCIOS-469
4859, d2bmcE_, 0.6887, 3.20, 0.183, 256, 235, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4860, d4d2rA_, 0.6886, 3.58, 0.204, 300, 245, HUMAN IGF IN COMPLEX WITH A DYRK1B INHIBITOR
4861, d4cqeB_, 0.6886, 3.11, 0.214, 248, 234, B-RAF KINASE V600E MUTANT IN COMPLEX WITH  A DIARYLTHIAZOLE B-RAF INHIBITOR
4862, d3qquB_, 0.6886, 3.57, 0.198, 288, 243, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
4863, d3coiA1, 0.6886, 3.40, 0.226, 342, 239, CRYSTAL STRUCTURE OF P38DELTA KINASE
4864, d2qodA_, 0.6886, 3.10, 0.161, 274, 236, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y602F MUTANT
4865, d5d7vC1, 0.6885, 3.35, 0.212, 262, 241, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
4866, d4joaA_, 0.6885, 3.48, 0.176, 250, 239, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 7-AZAINDOLE BASED INHIBITOR
4867, d3zfyA_, 0.6885, 3.17, 0.145, 260, 235, CRYSTAL STRUCTURE OF EPHB3
4868, d3tl8G_, 0.6885, 3.77, 0.181, 301, 248, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
4869, d3hv6A_, 0.6885, 2.90, 0.202, 331, 228, HUMAN P38 MAP KINASE IN COMPLEX WITH RL39
4870, d3a2cL_, 0.6885, 3.60, 0.176, 276, 239, CRYSTAL STRUCTURE OF A PYRAZOLOPYRIMIDINE INHIBITOR COMPLEX BOUND TO MAPKAP KINASE-2 (MK2)
4871, d5eknA_, 0.6883, 3.07, 0.210, 336, 233, CRYSTAL STRUCTURE OF MAPK13 COMPLEX WITH INHIBITOR
4872, d3c7qA_, 0.6883, 3.47, 0.207, 286, 241, STRUCTURE OF VEGFR2 KINASE DOMAIN IN COMPLEX WITH BIBF1120
4873, d5lpyA_, 0.6882, 3.53, 0.218, 282, 243, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH ATP FROM ARABIDOPSIS THALIANA
4874, d4ztmD_, 0.6882, 3.44, 0.199, 282, 241, IRAK4-INHIBITOR CO-STRUCTURE
4875, d4ibmB_, 0.6882, 3.37, 0.201, 294, 239, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH AN INHIBITOR IRFIN-1
4876, d2bmcD_, 0.6882, 3.18, 0.183, 256, 235, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4877, d5m53A1, 0.6881, 2.74, 0.186, 248, 226, NEK2 BOUND TO ARYLAMINOPURINE INHIBITOR 11
4878, d4ztlA_, 0.6881, 3.49, 0.203, 280, 241, IRAK4-INHIBITOR CO-STRUCTURE
4879, d4yp8C_, 0.6881, 3.48, 0.210, 287, 243, IRAK4-INHIBITOR CO-STRUCTURE
4880, d2w9fB_, 0.6881, 3.14, 0.175, 261, 234, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
4881, d2qoiA_, 0.6881, 3.10, 0.161, 274, 236, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F DOUBLE MUTANT
4882, d4lueA3, 0.6880, 3.14, 0.174, 261, 236, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH 7-[TRANS-4-(4- METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE (RESULTING FROM DISPLACEMENT OF SKF86002)
4883, d3fl4A_, 0.6880, 3.16, 0.194, 339, 232, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO5634
4884, d4l01A_, 0.6879, 3.70, 0.181, 274, 248, CRYSTAL STRUCTURE OF THE V658F APO JAK1 PSEUDOKINASE DOMAIN
4885, d3npcB_, 0.6879, 3.21, 0.219, 356, 233, CRYSTAL STRUCTURE OF JNK2 COMPLEXED WITH BIRB796
4886, d3a2cI_, 0.6879, 3.72, 0.175, 275, 240, CRYSTAL STRUCTURE OF A PYRAZOLOPYRIMIDINE INHIBITOR COMPLEX BOUND TO MAPKAP KINASE-2 (MK2)
4887, d3a2cG_, 0.6879, 3.63, 0.172, 273, 239, CRYSTAL STRUCTURE OF A PYRAZOLOPYRIMIDINE INHIBITOR COMPLEX BOUND TO MAPKAP KINASE-2 (MK2)
4888, d3a2cD_, 0.6879, 3.61, 0.171, 277, 240, CRYSTAL STRUCTURE OF A PYRAZOLOPYRIMIDINE INHIBITOR COMPLEX BOUND TO MAPKAP KINASE-2 (MK2)
4889, d3a2cB_, 0.6879, 3.58, 0.176, 277, 239, CRYSTAL STRUCTURE OF A PYRAZOLOPYRIMIDINE INHIBITOR COMPLEX BOUND TO MAPKAP KINASE-2 (MK2)
4890, d5y8uA_, 0.6878, 3.54, 0.189, 267, 243, CRYSTAL STRUCTURE OF THE C276S MUTANT OF MAP2K7
4891, d5t1tD_, 0.6878, 3.48, 0.198, 283, 242, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4892, d4ztlC_, 0.6878, 3.49, 0.191, 282, 241, IRAK4-INHIBITOR CO-STRUCTURE
4893, d3ttiA_, 0.6878, 3.27, 0.206, 341, 238, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-930 AN ORALLY ACTIVE ANTI-FIBROTIC JNK INHIBITOR
4894, d3ortA_, 0.6878, 3.19, 0.216, 271, 236, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 6)
4895, d2w5hA1, 0.6878, 3.06, 0.186, 257, 231, HUMAN NEK2 KINASE APO
4896, d2qofA_, 0.6878, 3.11, 0.161, 280, 236, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F MUTANT
4897, d4yfiA_, 0.6877, 3.50, 0.202, 268, 238, TNNI3K COMPLEXED WITH INHIBITOR 1
4898, d3g9nA_, 0.6877, 3.24, 0.207, 346, 237, JNK3 BOUND TO (Z)-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL)METHYL)-3- (HYDROXYIMINO)-4-PHENYLINDOLIN-2-ONE
4899, d4zjjC_, 0.6875, 3.40, 0.212, 276, 240, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
4900, d3tucA_, 0.6875, 3.15, 0.187, 257, 235, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-BENZYL-N-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
4901, d2qooA_, 0.6874, 3.11, 0.165, 273, 236, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:Y742F TRIPLE MUTANT
4902, d5wdyA_, 0.6873, 3.29, 0.203, 260, 236, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH 1-CYCLOHEXYL-N-({6-FLUORO-1- [2-(3-METHOXYPHENYL)PYRIDIN-4-YL]-1H-INDOL-3-YL}METHYL)METHANAMINE (COMPOUND 6)
4903, d5t1tB_, 0.6873, 3.49, 0.212, 280, 241, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4904, d3w18A_, 0.6873, 2.63, 0.187, 234, 224, STRUCTURE OF AURORA KINASE A COMPLEXED TO BENZOIMIDAZOLE-INDAZOLE INHIBITOR XIII
4905, d2r9sB_, 0.6873, 2.97, 0.207, 325, 232, C-JUN N-TERMINAL KINASE 3 WITH 35-DISUBSTITUTED QUINOLINE INHIBITOR
4906, d5tf9A_, 0.6872, 3.29, 0.200, 262, 235, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH MN2+AMPPNP AND WNK476
4907, p4h39A_, 0.6872, 3.12, 0.211, 340, 232, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH JIP1 PEPTIDE
4908, d2qlqB_, 0.6872, 3.00, 0.211, 248, 232, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN WITH COVALENT INHIBITOR RL3
4909, d4ztnD_, 0.6871, 3.51, 0.198, 285, 243, IRAK4-INHIBITOR CO-STRUCTURE
4910, d3oy1A_, 0.6871, 2.99, 0.213, 329, 230, HIGHLY SELECTIVE C-JUN N-TERMINAL KINASE (JNK) 2 AND 3 INHIBITORS WITH IN VITRO CNS-LIKE PHARMACOKINETIC PROPERTIES
4911, d3iw5A_, 0.6871, 3.03, 0.199, 336, 231, HUMAN P38 MAP KINASE IN COMPLEX WITH AN INDOLE DERIVATIVE
4912, d2xm9A_, 0.6871, 4.14, 0.205, 287, 244, STRUCTURE OF A SMALL MOLECULE INHIBITOR WITH THE KINASE DOMAIN OF CHK2
4913, d2oibB_, 0.6871, 3.36, 0.205, 278, 239, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
4914, d3k3jA_, 0.6870, 2.88, 0.198, 329, 227, P38ALPHA BOUND TO NOVEL DFG-OUT COMPOUND PF-00416121
4915, d2oj9A_, 0.6870, 3.58, 0.199, 295, 246, STRUCTURE OF IGF-1R KINASE DOMAIN COMPLEXED WITH A BENZIMIDAZOLE INHIBITOR
4916, d1ianA_, 0.6870, 2.84, 0.203, 328, 227, HUMAN P38 MAP KINASE INHIBITOR COMPLEX
4917, d5w85B_, 0.6869, 3.48, 0.208, 279, 240, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 9)
4918, d5kx8A_, 0.6869, 3.52, 0.198, 285, 243, IRAK4-INHIBITOR CO-STRUCTURE
4919, d5jt2B1, 0.6869, 3.24, 0.236, 250, 237, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
4920, d4gt4A_, 0.6869, 3.25, 0.151, 274, 238, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
4921, d3cpbB_, 0.6869, 3.11, 0.206, 263, 233, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BISAMIDE INHIBITOR
4922, d5d9hA_, 0.6868, 3.97, 0.187, 290, 251, CRYSTAL STRUCTURE OF SPAK (STK39) DIMER IN THE BASAL ACTIVITY STATE
4923, d4yffD_, 0.6868, 3.48, 0.197, 257, 239, TNNI3K COMPLEXED WITH INHIBITOR 2
4924, d1y8gB_, 0.6868, 3.13, 0.230, 292, 230, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: INACTIVE DOUBLE MUTANT WITH SELENOMETHIONINE
4925, p5lenB_, 0.6867, 2.84, 0.224, 346, 228, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_D12_10_47 IN COMPLEX WITH JNK1A1 AND JIP1 PEPTIDE
4926, d3dtcA_, 0.6867, 3.04, 0.212, 245, 231, CRYSTAL STRUCTURE OF MIXED-LINEAGE KINASE MLK1 COMPLEXED WITH COMPOUND 16
4927, p6f5eB_, 0.6866, 2.84, 0.224, 346, 228, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_D12_10_47 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
4928, d4riyC_, 0.6866, 3.48, 0.148, 275, 243, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
4929, d3rtpA_, 0.6866, 2.95, 0.218, 331, 229, DESIGN AND SYNTHESIS OF BRAIN PENETRANT SELECTIVE JNK INHIBITORS WITH IMPROVED PHARMACOKINETIC PROPERTIES FOR THE PREVENTION OF NEURODEGENERATION
4930, d5kx8D_, 0.6865, 3.50, 0.198, 283, 242, IRAK4-INHIBITOR CO-STRUCTURE
4931, d4kaoA_, 0.6865, 3.31, 0.200, 252, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-TERT- BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-(4-PYRIDIN-3- YL-PHENYL)-UREA
4932, d3f61A_, 0.6865, 3.31, 0.209, 271, 239, CRYSTAL STRUCTURE OF M. TUBERCULOSIS PKNB LEU33ASP/VAL222ASP DOUBLE MUTANT IN COMPLEX WITH ADP
4933, d5k76B_, 0.6864, 3.42, 0.213, 281, 239, IRAK4 IN COMPLEX WITH COMPOUND 28
4934, d5h2uB1, 0.6864, 3.41, 0.207, 261, 241, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
4935, p4d28D_, 0.6864, 3.04, 0.196, 271, 230, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
4936, d2bmcB_, 0.6864, 3.29, 0.186, 258, 237, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4937, d5bpyB1, 0.6863, 3.22, 0.160, 246, 237, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
4938, d5w85A_, 0.6862, 3.48, 0.213, 278, 239, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 9)
4939, d5h2uD1, 0.6862, 3.42, 0.212, 261, 241, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
4940, d3l8sA_, 0.6862, 3.03, 0.191, 334, 230, HUMAN P38 MAP KINASE IN COMPLEX WITH CP-547632
4941, d5flfE_, 0.6860, 3.11, 0.206, 258, 233, DISEASE LINKED MUTATION IN FGFR
4942, d4yo6D_, 0.6860, 3.59, 0.209, 285, 244, IRAK4-INHIBITOR CO-STRUCTURE
4943, d4czuD1, 0.6860, 3.60, 0.196, 296, 240, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270 T190D MUTANT
4944, d3hv7A_, 0.6860, 2.98, 0.211, 330, 228, HUMAN P38 MAP KINASE IN COMPLEX WITH RL38
4945, p5oktB2, 0.6858, 0.81, 0.990, 200, 200, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH IWP-2 
4946, d5da3A1, 0.6858, 3.43, 0.219, 261, 242, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN WITH INHIBITOR
4947, d3cpcB_, 0.6858, 3.12, 0.202, 262, 233, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
4948, d3a2cC_, 0.6858, 3.82, 0.170, 273, 241, CRYSTAL STRUCTURE OF A PYRAZOLOPYRIMIDINE INHIBITOR COMPLEX BOUND TO MAPKAP KINASE-2 (MK2)
4949, d4d4rB_, 0.6857, 3.53, 0.188, 270, 245, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4950, d4bdiA1, 0.6857, 4.19, 0.197, 289, 244, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4951, d3my0K_, 0.6857, 3.30, 0.187, 261, 235, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4952, d4riwC_, 0.6856, 3.52, 0.152, 275, 244, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
4953, d5h2uC1, 0.6855, 3.43, 0.212, 261, 241, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
4954, d4rixC_, 0.6855, 3.49, 0.148, 275, 243, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
4955, p4d28A_, 0.6855, 3.04, 0.203, 274, 231, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
4956, d3cs9D_, 0.6855, 3.31, 0.227, 263, 238, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
4957, d1y8gA_, 0.6855, 3.16, 0.230, 292, 230, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: INACTIVE DOUBLE MUTANT WITH SELENOMETHIONINE
4958, d5d9hB_, 0.6854, 4.02, 0.182, 293, 253, CRYSTAL STRUCTURE OF SPAK (STK39) DIMER IN THE BASAL ACTIVITY STATE
4959, d2r9sA_, 0.6854, 3.11, 0.210, 325, 233, C-JUN N-TERMINAL KINASE 3 WITH 35-DISUBSTITUTED QUINOLINE INHIBITOR
4960, d4yffC_, 0.6853, 3.53, 0.201, 258, 239, TNNI3K COMPLEXED WITH INHIBITOR 2
4961, d4eh5A_, 0.6853, 2.80, 0.200, 329, 225, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F4 AND RL87
4962, d4zjjD_, 0.6852, 3.71, 0.221, 274, 244, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
4963, d5kx7B_, 0.6850, 3.54, 0.198, 286, 243, IRAK4-INHIBITOR CO-STRUCTURE
4964, d2bmcA_, 0.6850, 3.26, 0.186, 256, 236, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4965, d4ztmC_, 0.6849, 3.39, 0.201, 282, 239, IRAK4-INHIBITOR CO-STRUCTURE
4966, d4xs2B_, 0.6849, 3.57, 0.216, 278, 241, IRAK4-INHIBITOR CO-STRUCTURE
4967, d4aa0A_, 0.6849, 2.91, 0.211, 328, 227, P38ALPHA MAP KINASE BOUND TO CMPD 2
4968, d3efwA_, 0.6849, 2.71, 0.194, 240, 227, STRUCTURE OF AURORAA WITH PYRIDYL-PYRIMIDINE UREA INHIBITOR
4969, d3iw8A_, 0.6848, 3.15, 0.190, 334, 232, STRUCTURE OF INACTIVE HUMAN P38 MAP KINASE IN COMPLEX WITH A THIAZOLE-UREA
4970, d3a2cA_, 0.6848, 3.55, 0.177, 274, 237, CRYSTAL STRUCTURE OF A PYRAZOLOPYRIMIDINE INHIBITOR COMPLEX BOUND TO MAPKAP KINASE-2 (MK2)
4971, d4auaA_, 0.6847, 2.79, 0.164, 256, 226, LIGANDED X-RAY CRYSTAL STRUCTURE OF CYCLIN DEPENDENT KINASE 6 (CDK6)
4972, d5c01B_, 0.6846, 3.45, 0.150, 260, 240, CRYSTAL STRUCTURE OF KINASE
4973, d4a9tA1, 0.6846, 4.16, 0.209, 288, 244, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4974, d2hwoA_, 0.6846, 3.00, 0.207, 251, 232, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR
4975, d4yp8A_, 0.6845, 3.60, 0.205, 284, 244, IRAK4-INHIBITOR CO-STRUCTURE
4976, d3ha8A_, 0.6845, 3.13, 0.193, 342, 233, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/COMPOUND 14B
4977, d5k75C_, 0.6844, 3.45, 0.212, 282, 240, IRAK4 IN COMPLEX WITH COMPOUND 1
4978, d5k72A_, 0.6844, 3.43, 0.218, 277, 239, IRAK4 IN COMPLEX WITH COMPOUND 21
4979, d4yr8C_, 0.6844, 2.94, 0.187, 318, 230, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
4980, d4ludA3, 0.6844, 3.20, 0.179, 261, 235, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
4981, d4e6cA_, 0.6844, 2.99, 0.197, 330, 229, P38A-PERIFOSINE COMPLEX
4982, d3zfyB_, 0.6844, 3.26, 0.144, 255, 236, CRYSTAL STRUCTURE OF EPHB3
4983, d3l8xA_, 0.6844, 2.83, 0.200, 326, 225, P38 ALPHA KINASE COMPLEXED WITH A PYRAZOLO-PYRIMIDINE BASED INHIBITOR
4984, d5o23B1, 0.6843, 3.61, 0.177, 276, 243, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE
4985, d3s4qA_, 0.6841, 2.85, 0.190, 326, 226, P38 ALPHA KINASE COMPLEXED WITH A PYRAZOLO-TRIAZINE BASED INHIBITOR
4986, d2yitA_, 0.6841, 3.90, 0.216, 286, 241, STRUCTURAL ANALYSIS OF CHECKPOINT KINASE 2 IN COMPLEX WITH PV1162 A NOVEL INHIBITOR
4987, d2wqmA_, 0.6841, 2.99, 0.202, 258, 233, STRUCTURE OF APO HUMAN NEK7
4988, d5uiqC_, 0.6840, 3.42, 0.192, 280, 240, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
4989, d3pj1A_, 0.6840, 2.94, 0.169, 241, 231, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 3-(26-DICHLORO- PHENYL)-7-[4-(2-DIETHYLAMINO-ETHOXY)-PHENYLAMINO]-1-METHYL-34- DIHYDRO-1H-PYRIMIDO[45-D]PYRIMIDIN-2-ONE
4990, d3my0X_, 0.6840, 3.30, 0.187, 257, 235, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4991, d3lfcA_, 0.6840, 2.99, 0.197, 334, 229, HUMAN P38 MAP KINASE IN COMPLEX WITH RL99
4992, d1zy5A1, 0.6839, 3.75, 0.150, 269, 246, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: R794G HYPERACTIVATING MUTANT COMPLEXED WITH AMPPNP.
4993, d5uitB_, 0.6838, 3.53, 0.198, 283, 242, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 14
4994, d1a06A_, 0.6838, 3.34, 0.167, 279, 234, CALMODULIN-DEPENDENT PROTEIN KINASE FROM RAT
4995, d4riyA_, 0.6836, 3.49, 0.153, 269, 242, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
4996, d3fc1X_, 0.6836, 2.89, 0.181, 330, 227, CRYSTAL STRUCTURE OF P38 KINASE BOUND TO PYRIMIDO-PYRIDAZINONE INHIBITOR
4997, d3daeB_, 0.6836, 3.21, 0.223, 246, 233, CRYSTAL STRUCTURE OF PHOSPHORYLATED SNF1 KINASE DOMAIN
4998, d2ewaA_, 0.6836, 2.99, 0.206, 330, 228, DUAL BINDING MODE OF PYRIDINYLIMIDAZOLE TO MAP KINASE P38
4999, d5n67A_, 0.6835, 2.82, 0.200, 327, 225, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9L
5000, d4ztmB_, 0.6835, 3.43, 0.223, 280, 238, IRAK4-INHIBITOR CO-STRUCTURE
